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Introductory	note	
This	 thesis	 focuses	 in	 the	 identification	 of	 new	 biomarkers	 of	 heart	 and	 kidney	
involvement	in	Fabry	disease,	not	only	of	the	very	early	pre-clinical	stages,	but	also	their	
prognostic	value.	
In	 the	 introduction	 section	 I	 present	 a	 brief	 overview	 of	 Fabry	 disease	
epidemiology,	 pathophysiology,	 clinical	 manifestations	 and	 treatment,	 with	 a	 special	
attention	 to	 the	 rational	 underlying	 the	 urgent	 need	 for	 better	 biomarkers	 in	 Fabry	
disease.	 Furthermore,	 I	 also	 review	 the	 biomarker	 concept	 and	 its	 usefulness	 in	 this	
disorder,	 as	well	 as	 the	 current	 state	of	 the	art	 in	 terms	of	 the	available	biomarkers	 in	
Fabry	disease.		Moreover,	an	overview	about	searching	new	biomarkers	and	the	available	
evidence	supporting	the	studied	biomarkers	related	to	myocardial	fibrosis	and	glomerular	
and	tubular	injury	is	also	presented.		
The	global	goals	of	this	thesis	are	enumerated	at	the	end	of	the	introduction	in	the	
aims	section	and	the	subsequent	sections	are	the	result	of	the	original	work	performed	
during	the	PhD:	
-	 The	 “cardiomyopathy	 study”	 was	 designed	 to	 understand	 the	 role	 of	 the	
biomarkers	 related	 to	 collagen	 metabolism,	 not	 only	 in	 the	 identification	 of	 the	 pre-
clinical	stage	of	Fabry	disease	cardiomyopathy,	but	also	their	prognostic	value	in	terms	of	
the	 identification	 of	 patients	 at	 greater	 risk	 of	 a	 progressive	 disorder	 (increase	 in	 left	
ventricular	mass).	Part	of	the	results	have	been	accepted	for	publication	in	the	Journal	of	
American	 Heart	 Association	 and	 another	 paper	 is	 being	 prepared	 with	 the	 remaining	
results.		
-	In	the	“nephropathy	study”	I	have	studied	several	biomarkers	of	glomerular	and	
tubular	 injury	 in	 terms	 of	 the	 identification	 of	 patients	 with	 incipient	 Fabry	 disease	
nephropathy	 and	 patients	 prone	 to	 a	 progressive	 decline	 in	 glomerular	 filtarion	 rate.	
Some	 results	 have	 been	 published	 in	 the	Molecular,	 Genetics	 and	Metabolism	 and	 the	
remaining	are	being	prepared	for	publication.		
Finally,	 I	 present	 the	 ongoing	 projects	 of	 biomarkers	 research	 and	 the	 future	
perspectives.		
All	the	publications	are	included	as	appendices.		
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Abstract	
Anderson-Fabry	 disease	 is	 an	 X-linked	 lysosomal	 storage	 disorder,	 causing	
significant	morbidity	and	premature	death;	cardiac	and	renal	involvements	are	the	major	
determinants	 of	 overall	 disease	 prognosis.	 Fabry	 cardiomyopathy	 is	 characterized	 by	 a	
hypertrophic	 phenotype,	 in	 the	 setting	 of	 histological	 cardiomyocyte	 hypertrophy	 and	
myocardial	fibrosis;	myocardial	fibrosis	is	an	irreversible	event	and	affects	the	prognosis.	
A	progressive	chronic	kidney	disease	characterizes	Fabry	disease	nephropathy;	however	it	
is	clinically	silent	 for	a	 long	period,	because	heavy	storage	may	occur	 in	renal	cells	with	
minimal	 or	 no	 changes	 on	 standard	 renal	 tests.	 Furthermore,	 accumulating	 evidence	
suggests	that	early	enzyme	replacement	therapy	is	effective	in	preventing	progression	of	
both	cardiomyopathy	and	nephropathy.	Therefore,	in	this	thesis	I	have	studied	two	linked	
research	questions	in	a	multicenter,	prospective,	 longitudinal	(evaluation	at	baseline,	12	
months	and	24	months)	and	diagnostic	test	study:		
1)	 Role	 of	 biomarkers	 related	 to	 collagen	 type	 I	metabolism	 in	 the	 diagnosis	 of	
incipient	and	prognosis	of	 Fabry	 cardiomyopathy,	 in	a	 cohort	of	60	patients	with	Fabry	
disease	and	20	healthy	controls,	according	to	subgroups	of	 increasing	disease	severity.	 I	
found	that	collagen	type	I	synthesis	is	increased	in	Fabry	disease	cardiomyopathy,	even	in	
the	earlier	stages	of	the	disease,	and	this	profibrotic	state	has	good	prognostic	value	for	
and	 is	 likely	 to	 be	 critical	 to	 the	 development	 of	 overt	 left	 ventricular	 hypertrophy.	
Moreover,	inhibition	of	enzymes	involved	in	collagen	type	I	cleavage	also	seems	crucial	to	
myocardial	collagen	deposition	and	is	related	to	risk	of	progressive	diastolic	dysfunction.	
2)	 Identification	 of	 early	 and	 prognostic	 biomarkers	 of	 Fabry	 nephropathy	 in	 a	
cohort	of	78	patients	with	Fabry	disease	and	25	healthy	controls,	according	to	subgroups	
of	 increasing	disease	severity.	 I	have	shown	that	 two	biomarkers	of	glomerular	damage	
(urinary	transferrin	and	collagen	type	IV	excretion)	and	three	biomarkers	of	tubular	injury	
(urinary	 α1-microglobulin,	 N-acetyl-β-D-glucosaminidase	 and	 alanine	 aminopeptidase	
excretion)	may	 overcome	 the	 limitations	 of	 albuminuria	 as	 a	 sensitive	marker	 of	 early	
renal	 dysfunction;	 furthermore	 N-acetyl-β-D-glucosaminidase	 presented	 the	 better	
prognostic	 value	 in	 the	 identification	 of	 patients	 at	 risk	 for	 chronic	 kidney	 disease	
progression.	 These	 biomarkers	 may	 also	 define	 novel	 early	 stages	 of	 nephropathy	
characterized	by	mesangial	expansion	and/or	tubular	damage.			
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Resumo	
A	Doença	 de	 Fabry	 é	 uma	doença	 lisossomal	 de	 sobrecarga	 com	um	padrão	 de	
hereditariedade	 ligado	 ao	 cromossoma	 X,	 que	 condiciona	 morbilidade	 significativa	 e	
mortalidade	precoce;	o	envolvimento	cardíaco	e	renal	são	os	principais	determinantes	do	
prognóstico	global.	A	cardiomiopatia	da	Doença	de	Fabry	é	caracterizada	por	um	fenótipo	
hipertrófico,	condicionado	pela	hipertrofia	dos	cardiomiócitos	e	fibrose	miocárdica;	esta	
última	 é	 irreversível	 e	 afecta	 o	 prognóstico.	 A	 doença	 renal	 crónica	 progressiva	
caracteriza	a	nefropatia	da	Doença	de	Fabry;	contudo,	esta	é	clinicamente	silenciosa	por	
um	longo	período,	na	medida	em	que	pode	ocorrer	extensiva	acumulação	de	substractos	
nas	células	renais	na	ausência	de	alterações	nos	testes	standard	de	avaliação	da	função	
renal.	Mais	ainda,	evidência	crescente	sugere	que	a	instituição	precoce	de	terapêutica	de	
substituição	 enzimática	 é	 efectiva	 na	 prevenção	 da	 progressão	 quer	 da	 cardiomiopatia	
quer	 da	 nefropatia.	 Por	 conseguinte,	 na	 presente	 tese	 eu	 abordei	 duas	 questões	
interrelacionadas,	 num	 estudo	 de	 testes	 de	 diagnóstico,	 multicêntrico,	 prospectivo	 e	
longitudinal	(avaliação	basal	e	aos	12	e	24	meses):	
1)	A	função	dos	biomarcadores	relacionados	com	o	metabolismo	do	colagénio	tipo	
I	no	diagnóstico	precoce	e	na	determinação	do	prognóstico	na	cardiomiopatia	da	Doença	
de	Fabry,	num	coorte	de	60	doentes	com	Doença	de	Fabry	e	20	controlos	saudáveis,	de	
acordo	 com	 subgrupos	 de	 gravidade	 crescente.	Demonstrei	 que	 a	 síntese	 de	 colagénio	
tipo	 I	 encontra-se	 aumentada	 na	 cardiomiopatia	 da	 Doença	 de	 Fabry,	 mesmo	 nos	
estádios	mais	 precoces	 da	 doença	 e	 que	 este	 estado	 profibrótico	 apresenta	 bom	 valor	
prognóstico	 para	 e	 parece	 ser	 essencial	 ao	 desenvolvimento	 de	 hipertrofia	 ventricular	
esquerda.	 Constei	 ainda	 que	 a	 inibição	 das	 enzimas	 envolvidas	 na	 degradação	 do	
colagénio	tipo	I	também	afigura-se	como	crucial	à	deposição	de	colagénio	no	miocárdio	e	
encontra-se	relacionada	com	o	risco	de	disfunção	diastólica	progressiva.				
2)	 Identificação	 de	 biomarcadores	 precoces	 e	 de	 prognóstico	 na	 nefropatia	 da	
Doença	 de	 Fabry	 num	 coorte	 de	 78	 doentes	 com	 Doença	 de	 Fabry	 e	 25	 controlos	
saudáveis,	 de	 acordo	 com	 subgrupos	 de	 gravidade	 crescente.	 Evidenciei	 que	 dois	
biomarcadores	 urinários	 de	 lesão	 glomerular	 (transferrina	 e	 colagénio	 tipo	 IV)	 e	 três	
biomarcadores	 urinários	 de	 dano	 tubular	 (α1-microglobulina,	 N-acetil-β-D-
glucosaminidase	 e	 alanina	 aminopeptidase)	 podem	 ultrapassar	 as	 limitações	 da	
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albuminuria	como	marcador	sensível	de	disfunção	renal	precoce;	mais	ainda,	a	excreção	
de	N-acetil-β-D-glucosaminidase	apresentou	melhor	valor	prognóstico	na	identificação	de	
doentes	 em	 risco	 de	 doença	 renal	 crónica	 progressiva.	 Estes	 biomarcadores	 também	
poderão	definir	novos	estádios	precoces	da	nefropatia	da	Doença	de	Fabry	caracterizados	
por	expansão	do	mesângio	e/ou	lesão	tubular.		
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Introduction	
1.	Anderson-Fabry	disease	
1.1	Aetiology,	genotype-phenotype	correlations	and	epidemiology	
Anderson-Fabry	 disease	 (FD)	 is	 an	 X-linked	 lysosomal	 storage	 disorder	 (LSD),	
independently	 first	 described	 by	 Johannes	 Fabry	 and	 William	 Anderson	 in	 1898,1	who	
reported	patients	with	“angiokeratoma	corporis	diffusum”,	the	red-purple	maculopapular	
skin	lesions	that	are	characteristic	of	the	disease.	It	was	only	in	1967	that	FD	was	found	to	
be	caused	by	mutations	 in	the	GLA	gene	(that	encodes	the	enzyme	α-galactosidase	A).2	
The	 deficiency	 of	 this	 enzyme	 leads	 to	 the	 lysosomal	 accumulation	 of	 neutral	
glycosphingolipids	 (mainly	 globotriaosylceramide	 [Gb3])	 in	 several	 cells,	 causing	 organ	
failure.	Involvement	of	the	heart,	kidney	and	brain	in	FD	causes	significant	morbidity	and	
premature	death.3,	4		
The	GLA	gene	was	mapped	to	the	q22.1	region	of	the	X	chromosome.	It	contains	
seven	 exons	 and	 the	 coding	 part	 of	 the	 gene	 consists	 of	 1290	 base	 pairs,	 encoding	 a	
polypeptide	of	429	amino	acids.5	A	total	of	672	mutations	/	variants	have	been	described,	
most	of	 them	(455)	missense	/	nonsense.6	The	great	majority	of	 the	GLA	mutations	are	
private	(each	family	has	its	own	mutation)	and	theoretical	considerations	point	to	3-10%	
of	patients	with	de	novo	mutations.7		
GLA	 gene	 encodes	 the	 lysosomal	 enzyme	 α-galactosidase	 A	 (a	 homodimeric	
molecule),	responsible	for	the	degradation	of	neutral	glycosphingolipids	with	terminal	α-
galactosyl	moieties	in	cells	throughout	the	body.	Its	main	substrate	is	Gb3,	but	there	are	
also	other	minor	substrates,	including	digalactosylceramide,	P1	antigen	and	blood	group	
B	 glycolipids.	 Gb3	 originate	 from	 metabolic	 turnover	 of	 membrane	 glycosphingolipids	
(like	 globoside	 [Gb4])	 present	 in	 large	 amounts	 in	 the	 kidneys,	 liver,	 vascular	
endothelium,	lungs	and	erythrocytes.5		
Despite	its	“monogenic”	origin,	FD	is	clinically	heterogeneous,	with	some	patients	
presenting	 a	 classical	 phenotype	 (full-blown	 clinical	 picture	 with	 “acroparesthesias”,	
angiokeratomas,	 hypohydrosis,	 corneal	 opacity	 and	 renal,	 cardiac	 and	 cerebrovascular	
involvement)	 and	 others	 a	 late-onset	 /	 attenuated	 form	 (mainly	 affecting	 the	 heart).8	
Genetic	factors	certainly	contribute	to	this	heterogeneity,	with	patients	exhibiting	out-of-
frame	short	length	rearrangements	and	splice-site	and	nonsense	mutations,	leading	to	a	
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premature	stop	codon	and	a	truncated	and	most	likely	non-functional	enzyme,	presenting	
a	 classical	 phenotype.5	 In	 patients	with	missense	mutations,	 enzymatic	 activity	may	 be	
variably	 affected:	 mutations	 in	 functionally	 important	 regions	 or	 leading	 to	 large	
structural	changes	show	the	classical	phenotype,	whereas	late-onset	forms	are	associated	
with	mutations	located	apart	from	the	active	site,	conditioning	small	structural	changes.9	
However,	 in	 patients	 within	 the	 same	 family	 or	 with	 the	 same	 mutation,	 the	 clinical	
picture	may	 vary	widely,	 thus	 other	 genetic,	 epigenetic	 and	 environmental	 factors	 also	
contribute	to	clinical	heterogeneity.			
Furthermore,	 unlike	many	 other	 X-chromosomal	 conditions,	 female	 FD	 patients	
may	show	signs	and	symptoms	commonly	seen	in	male	patients.	However,	disease	onset	
occurs	later	and	the	phenotype	tends	to	be	milder	(though	clinically	heterogeneous	with	
several	 patients	 with	 classic	 FD).10,	 11	 Thus,	 with	 this	 state	 of	 intermediate	 disease	
penetrance	in	female	FD	patients,	the	terms	“X-linked	recessive”	or	“X-linked	dominant”	
may	not	capture	the	wide	spectrum	of	variable	expression	in	heterozygotes	and	FD	may	
be	referred	to	as	“X-linked”.12	
Phenotype	and	penetrance	 in	FD	female	patients	may	be	explained	according	to	
the	principles	 of	 random	X	 chromosome	 inactivation	 (lionization),	 resulting	 in	 a	mosaic	
with	some	cells	expressing	“wild	type”	and	others	“mutant”	GLA	gene.13	The	celular	and	
tissue	levels	of	α-galactosidase	A	activity	will	depend	on	the	balance	between	“wild	type”	
and	 “mutant”	 X-inactivation,	 varying	 from	organ	 to	 organ	 and	with	 female	 FD	 patients	
exhibiting	skewed	X-inactivation	favouring	“mutant”	GLA	gene,	presenting	a	more	severe	
phenotype.14	 However,	 there	 is	 no	 correlation	 between	 plasma	 or	 leucocyte	 α-
galactosidase	A	activity	and	disease	severity,	and	cross	correction	of	the	metabolic	defect	
by	 uptake	 of	 the	 “wild	 type”	 enzyme	 by	 the	 cells	 with	 the	 “mutant”	 GLA	 gene	 would	
prevent	 females	 from	 developing	 clinically	 significant	 disease.15,	 16	 Thus,	 these	 findings	
suggest	 that	 cross	 complementation	 is	 impaired	 or	 insufficient	 in	 FD,	 possibly	 due	 to	
defective	 uptake,	 for	 reasons	 as	 yet	 unclear,	 of	 “wild	 type”	 enzyme	 by	 the	 “mutant”	
cells.16	Moreover,	“cross-induction”	of	the	defect	may	be	another	pathophysiological	link	
explaining	the	clinical	manifestations	in	female	FD	patients.	Lyso-Gb3,	a	deacylated	form	
of	Gb3,	is	increased	in	the	great	majority	of	female	FD	patients;	it	is	widely	diffusible	and	
has	the	capacity	to	inhibit	α-galactosidase	A	activity	in	“wild	type”	cells.17	Moreover,	lyso-
Gb3	may	have	a	direct	“toxic”	effect	on	the	disease	pathophysiology,	because	it	induces	
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smooth	 muscle	 cells	 proliferation	 (directly	 contributing	 to	 FD	 vasculopathy)	 and	
production	 of	 extracellular	 matrix	 proteins	 by	 podocytes	 (leading	 to	 glomerular	
damage).17,	18	
FD	 is	 pan-ethnic,	 but	 due	 to	 its	 rarity,	 it	 is	 difficult	 to	 determine	 its	 true	
prevalence.	Moreover,	in	most	countries,	there	are	various	diagnostic	centres,	making	it	
difficult	 to	collect	 the	diagnoses.	Three	main	studies	addressing	 the	birth	prevalence	of	
FD	 reported	 incidences	 ranging	 from	 1:117,000	 in	 Australia,	 to	 1:833,000	 in	 Northern	
Portugal.19-21	 In	 the	 Australian	 epidemiological	 study,	 no	 data	 was	 obtained	 on	
heterozygote	 females,	 but	 the	 incidence	 determined	 in	 hemizygote	 males	 could	 be	
extrapolated	to	give	a	combined	incidence	of	1	in	58,000.	However,	the	true	prevalence	
of	FD	 is	 likely	to	be	much	higher,	due	to	the	existence	of	 late-onset	 forms	/	attenuated	
phenotypes	 of	 the	 disease	 as	 identified	 by	 the	 screening	 of	 high-risk	 populations	 and	
newborns.	Several	newborn	screening	 initiatives	of	FD	 raised	 the	 incidence	of	FD	up	 to	
1:3,100	 male	 births	 in	 Italy	 or	 even	 1:1,250	 male	 births	 in	 Taiwan,	 with	 most	 of	 the	
identified	mutations	 associated	 with	 attenuated	 phenotypes	 with	 predominant	 cardiac	
involvement,	 giving	 an	 estimated	 ratio	 as	 high	 as	 11:1	 of	 attenuated	 to	 classic	
phenotypes.22,	23	 A	 summary	 of	 prevalence	 and	 newborn	 screening	 studies	 is	 shown	 in	
table	1.	
	
1.2	Pathology	and	pathophysiology	
1.2.1	Cardiomyopathy	
In	FD	cardiomyopathy,	glycosphingolipid	storage	(mainly	Gb3)	occurs	in	all	cardiac	
cell	 types,	 namely	 cardiomyocytes,	 conduction	 system	 cells,	 valvular	 fibroblasts,	
endothelial	 cells,	 vascular	 smooth	muscle	 cells	and	cardiac	nerves	 (including	autonomic	
nervous	 system).24-26	In	 female	FD	patients	 there	 is	 a	mosaic	pattern	of	 storage,	due	 to	
the	random	X-inactivation.27	However,	autopsy	studies	in	extremely	hypertrophied	hearts	
showed	that	Gb3	infiltration	of	the	myocardium	accounts	only	for	1-3%	of	the	wet	weight	
of	the	hypertrophic	heart	and	cannot	explain	its	degree,	which	indicates	that	activation	of	
several	pathological	pathways	and	other	histological	features	are	also	important.28	
Hence,	Gb3	storage	is	probably	a	primer	for	lysosomal	and	cellular	malfunctioning,	
triggering	 intracellular	 common	 signalling	 pathways	 leading,	 ultimately,	 to	
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cardiomyocytes	 hypertrophy,	 apoptosis	 and	 necrosis,	 followed	 by	 replacement	 fibrosis.	
These	 events	 are	 responsible	 for	 the	 diastolic	 dysfunction	 and	 contractility	 impairment	
seen	in	the	clinical	setting.28,	29	
	
Table	 1:	 Studies	 on	 prevalence	 of	 Fabry	 disease.	 LSD:	 lysosomal	storage	disorder;	FD:	Fabry	disease;	UK:	
United	Kingdom;	NL:	Netherlands;	USA:	United	States	of	America	(adapted	from	Germain	DP30).	
Methods	 Source	 Period	 Prevalence	 Country	reference	
Birth	 prevalence	 (pre	 and	 postnatal	
enzymatic	diagnosis	divided	by	number	
of	births)	
Two	 centres	 conducting	 all	 enzyme	
assays	in	Australia	
1980-1996	 1:117.000	 Australia19	
Birth	 prevalence	 (pre	 and	 postnatal	
enzymatic	diagnosis	divided	by	number	
of	births)	
One	 centre	 providing	 all	 pre	 and	
postnatal	diagnosis	in	Portugal	
1982-2001	 1:833.000	 Northern	
Portugal20	
Birth	 prevalence	 (cases	 born	 in	 a	
certain	period	divided	by	total	number	
of	live	births	in	the	same	period)	
All	 the	 laboratories	 making	 pre	 and	
postnatal	diagnosis	in	Netherlands	
1970-1996	 1:476.000	 NL21	
Birth	 prevalence	 (cases	 born	 in	 a	
certain	period	divided	by	total	number	
of	live	births	in	the	same	period)	
Two	main	reference	centres	providing	
enzyme	 assay	 for	 patients	 under	 5	
years	old	suspected	of	LSD	
1997-2002	 1:6.666.000	 Turkey31	
Prevalence	 Records	 from	 regional	 genetic	 units,	
enzyme	 reference	 laboratories	 and	
individual	doctors	
1980-1995	 1:370.000	 UK	(♂)3	
Prevalence	of	obligate	carriers	 By	 family	 history,	 from	 the	 UK	 FD	
register	
1980-1995	 1:345.000	 UK	(♀)4	
Neonatal	screening	 Northern	Italy	(males	only)	 2003-2005	 1:3,100	 Italy22	
Neonatal	screening	 Taiwan	(males	only)	 2006-2008	 1:1,250	 Taiwan23	
Neonatal	screening	 Austria	 2010	 1:3,900	 Austria32	
Neonatal	screening	 Hungary	 2010	 1:5,000	 Hungary33	
Neonatal	screening	 Washington	state	(males	only)	 	 1:7,800	 USA34	
Neonatal	screening	 Missouri	state	 2013	 1:2,900	 USA35	
	
	 The	 link	 between	 lysosomal	 storage	 and	 cellular	 dysfunction	 is	 not	 well	
understood,	 but	 energy	 depletion	 (related	 to	 respiratory	 chain	 enzymes	 dysfunction),	
abnormal	production	of	reactive	oxygen	species	(ROS),	ischaemia	and	circulating	growth-
promoting	factors	are	certainly	involved.		
Cellular	 energy	depletion,	 due	 to	 inefficient	 cardiomyocytic	 energy	utilization,	 is	
one	of	the	most	accepted	hypotheses.		It	has	been	proposed	as	a	common	mechanism	for	
several	types	of	metabolic	and	even	sarcomeric	hypertrophic	cardiomyopathy.36	A	study	
using	cultured	skin	 fibroblasts	 from	 four	FD	patients	and	 ten	controls	has	 shown,	 in	FD	
patients,	a	significant	reduction	of	the	activity	of	respiratory	chain	complexes	I+III,	IV	and	
V,	 as	 well	 as	 a	 significant	 decrease	 of	 cellular	 content	 of	 high-energy	 phosphate	
compounds	 (creatine	 phosphate	 [PCr]	 and	 adenosine	 diphosphate)	 and	 adenosine	
monophosphate.37	 Moreover,	 studies	 with	 cardiac	 phosphorus-31	 magnetic	 resonance	
spectroscopy	 (a	 non-invasive	 technique	 enabling	 in	 vivo	 determination	 of	 PCr	 and	
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adenosine	 triphosphate	 [ATP])	 in	FD	have	shown	a	 significant	decrease	 in	PCr,	ATP	and	
the	PCr	to	ATP	ratio,	as	well	as	a	significant	 inverse	correlation	between	the	PCr	to	ATP	
ratio	and	the	annual	increase	in	left	ventricular	(LV)	mass,	indicating	mitochondrial	energy	
depletion.38,	 39	 This	 mitochondrial	 dysfunction	 will	 lead	 to	 inefficient	 sarcomeric	 ATP	
utilization	 and	 impaired	 contractility,	 resulting	 in	 hypertrophy.	 The	 reason	 for	 the	
reduction	of	respiratory	chain	enzyme	activities	in	FD	remains	unclear.	However,	in	vitro,	
lysosphingolipids	may	have	direct	deleterious	effects	on	mitochondrial	function,	by	direct	
binding	to	mitochondrial	membranes	and	inhibition	of	oxidative	phosphorylation.40	
Several	studies	suggest	that	oxidative	stress	is	also	implicated	in	the	link	between	
lysosomal	 storage	 and	 cellular	 dysfunction	 in	 FD	 cardiomyopathy	 and	 vasculopathy.	 In	
cultured	 FD	 endothelial	 cells,	 incubation	 with	 increasing	 doses	 of	 Gb3	 increased	
intracellular	 ROS	 generation	 in	 a	 dose-dependent	 manner,	 which	 was	 significantly	
lowered	(even	in	the	cells	loaded	with	Gb3)	by	addition	of	an	antioxidant	(vitamin	C).	In	
the	 same	 study,	 incubation	 of	 the	 cell	 line	 with	 plasma	 from	 FD	 patients	 also	 led	 to	
increased	 ROS	 production,	 even	 if	 the	 endothelial	 cells	 were	 pre-treated	 with	 a	
glycosphingolipid	 synthase	 inhibitor	or	 recombinant	enzyme	 replacement	 therapy	 (ERT)	
to	 decrease	 Gb3	 loading,	 suggesting	 that	 other	 factors	 in	 FD	 patient	 plasma	may	 also	
contribute	 to	oxidative	 stress	 in	vascular	endothelial	 cells.41	This	data	was	confirmed	 in	
vivo	by	demonstration,	in	FD	patients	under	ERT,	of	reduced	glutathione	and	glutathione	
peroxidase	 activity	 and	 increased	 superoxide	 dismutase	 /	 catalase	 ratio	 in	 erythrocytes	
(leading	to	decreased	levels	of	antioxidant	defences),	as	well	as	oxidative	damage	of	lipid	
and	proteins	 (increased	 levels	of	malondialdehyde	 [a	product	of	 lipid	peroxidation]	and	
carbronyl	 group	 and	 dityrosine	 [both	 resulting	 from	 oxidative	 damage	 to	 proteins]).42	
Moreover,	oxidative	damage	to	deoxyribonucleic	acid	(DNA)	purines	is	significantly	higher	
in	FD	patients,	despite	efficient	DNA	repair.43	
Gb3	 loading	 may	 also	 cause	 a	 deregulation	 of	 nitric	 oxide	 (NO)	 pathway,	 with	
down-regulation	of	endothelial	NO	synthase,	up-regulation	of	inducible	NO	synthase	and	
enhanced	 cyclooxygenase-2	 expression	 in	 microvascular	 (but	 not	 in	 macrovascular)	
cardiac	 endothelial	 cells.44	 Moreover,	 FD	 causes	 increased	 nitrotyrosine	 expression	 in	
brain	tissue	from	FD	patients45	and	elevated	 levels	of	nitrotyrosine	 in	an	endothelial	FD	
cell	 line	 and	 in	 the	 plasma	 of	 FD	 patients,46	 attributable	 to	 endothelial	 NO	 synthase	
deregulation	and	production	of	nitrogen	reactive	species.		
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Regarding	cardiomyocytes	oxidative	damage,	 in	a	 study	 involving	18	FD	patients	
performing	endomiocardial	biopsies,	immunohistochemistry	has	shown	that	inducible	NO	
synthase	 and	 nitrotyrosine	 expression	 was	 increased	 in	 FD	 patients	 compared	 with	
hypertrophic	cardiomyopathy	due	sarcomere	protein	gene	mutations	(HCM)	and	normal	
controls.	 Oxidative	 damage	 to	 DNA,	 assessed	 by	 immunostaining	 for	 8-
hydroxydeoxyguanosine,	was	also	only	identifiable	in	FD	patients	(25%	of	cardiomyocyte	
nuclei)	and	not	 in	controls;	cardiomyocytes	apoptotic	cell	death	was	187-fold	greater	 in	
FD	patients	than	in	controls	and	only	detected	in	nuclei	with	oxidative	DNA	damage.47	
The	disease	pathophysiology	is	potentiated	by	ischaemia,	which	may	occur	even	in	
the	 absence	 of	 significant	 epicardial	 coronary	 artery	 disease.	 Elliott	 P	 et	 al.,	 in	 a	 study	
including	 10	 FD	 male	 patients	 (none	 had	 angiographically	 significant	 coronary	 artery	
disease),	showed	that	resting	and	hyperaemic	myocardial	blood	flow	and	coronary	flow	
reserve	 were	 significantly	 reduced	 in	 FD	 patients,	 with	 comparable	 resting	 coronary	
reserve,	 attributable	 to	 abnormal	 microvascular	 function.48	 This	 might	 be	 due	 to	
increased	 susceptibility,	 for	 unknown	 reasons,	 of	 microvascular	 endothelial	 myocardial	
cells	 to	 deregulation	 of	NO	pathway,44	 increased	 oxygen	 demand	of	 the	 hypertrophied	
muscle	 cells,	 decreased	 capillary	 density,	 increased	 diastolic	 filling	 pressures	 (impairing	
blood	flow	throughout	the	subendocardium)	and	sphingolipid	storage	within	endothelial	
and	vascular	smooth	muscle	cells	of	small	arterioles	and	capillaries.5	
Furthermore,	 incubation	 of	 FD	 patients	 plasma	 with	 mouse	 vascular	 smooth	
muscle	 cells	 and	 neonatal	 cardiomyocytes,	 suggests	 that	 there	 are	 circulating	 growth-
promoting	 factors	 inducing	 cell	 hypertrophy	and	proliferation,	 correlating	with	 LV	mass	
and	carotid	common	artery	intima-media	thickness.49	
Cellular	dysfunction	affects	myofilaments	and	cardiomyocyte	contractility;	there	is	
evidence	 of	myofilament	 proteolysis	 (revealed	 by	 presence	 of	 degradation	 products	 of	
troponin	 I	 and	 desmin)	 and	 dislodgement	 and	 disarray	 (partly	 due	 to	 intracellular	
glycosphingolipids	storage)	and	myofibrillolysis.	 In	 this	context,	 it	was	reported	that	 the	
active	 tension	 of	 cardiomyocytes	 was	 four	 times	 lower	 in	 Fabry	 cardiomyocytes	
compared	 to	 controls,	 and	 this	 correlated	 well	 with	 the	 extent	 of	 myofibrinolysis.	
Furthermore,	the	resting	tension	was	six	times	higher	than	in	controls,	which	was	shown	
to	correlate	with	tissue	Doppler	imaging	(TDI)	data,	suggesting	that	increased	stiffness	of	
cardiomyocytes	contributes	to	diastolic	dysfunction	in	FD	cardiomyopathy.29	
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Myofilament	dysfunction,	with	impaired	relaxation	and	contractility	and	increased	
cell	stress	may	trigger,	as	hypothesized	for	HCM,	expression	of	stress-responsive	trophic	
and	 mitotic	 factors	 (in	 an	 attempt	 of	 structural	 and	 functional	 cell	 repair),	 a	 possible	
direct	 cause	 of	 myocyte	 hypertrophy	 and	 disarray	 and	 increased	 interstitial	 collagen	
synthesis	(figure	1).50	
	
Figure	 1:	 Pathophysiology	 of	 Fabry	 disease	 cardiomyopathy.	 Glycosphingolipid	 storage	 is	
probably	the	main	trigger	to	the	activation	of	several	pathways,	ending	in	cellular	dysfunction	and	
increased	 cell	 stress;	 this	 will	 promote	 increased	 collagen	 synthesis	 and	 cardiomyocyte	
hypertrophy.	ROS:	reactive	oxygen	species.	
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Histologically,	 the	 most	 prominent	 feature	 in	 patients	 with	 advanced	 FD	
cardiomyopathy	 is	 the	 severe	 cardiomyocyte	 hypertrophy,	 mainly	 attributable	 to	
intracytoplasmic	 glycosphingolipids	 storage,	 appearing	 as	 perinuclear	 vacuoles	 in	 light	
microscopy	and	as	electron-dense	deposits	consisting	of	parallel	or	concentric	lamellae	in	
electron	 microscopy.24,	 29,	 51-53	 There	 is	 disarray	 and	 peripheral	 displacement	 of	 the	
myofibrils,	with	some	of	the	fibres	displaying	signs	of	disintegration	(being	surrounded	by	
small	collections	of	foamy	histiocytes).24,	28,	29		
Myocardial	fibrosis	 is	also	one	of	the	hallmarks	of	FD	cardiomyopathy.	Fibrosis	 is	
unequally	distributed	along	the	LV	wall,	being	more	prominent	within	the	mid-myocardial	
layers	and	the	posterolateral	segments	of	the	LV29,	51	and	ranging	from	mild	fibrosis	(with	
fibres	 embedded	 in	 loose	 fibrous	 tissues)	 in	 the	 interventricular	 septum	 (IVS),28,	 53	 to	
marked	fibrosis	(with	almost	no	myocardial	cells	observed)	in	the	base	of	the	LV	posterior	
wall	 (PW).54	Moreover,	 fibrosis	seems	to	be	predominantly	 interstitial	diffuse	(with	only	
focal	 areas	 of	 replacement	 fibrosis)	 and,	 in	 one	 study,	 it	 did	 not	 correlate	 with	 TDI	
measurements	of	systolic	or	diastolic	LV	function.29,	54	
Furthermore,	 massive	 accumulation	 of	 lipids	 is	 also	 present	 in	 the	 conduction	
tissue,	tricuspid	and	mitral	valves	and	endothelium	cells	of	the	myocardial	capillaries.24,	55	
In	 FD	 patients	 with	 attenuated	 phenotypes	 with	 predominant	 cardiac	 involvement,	 no	
lysosomal	inclusions	were	observed	in	cardiac	capillary	endothelial	cells.54		
Concluding,	 Gb3	 storage	 is	 probably	 the	 trigger	 for	 the	 activation	 of	 several	
signalling	 pathways	 leading	 to	 cellular	 dysfunction	 and,	 ultimately,	 to	 cardiomyocyte	
hypertrophy	 and	 fibrosis,	 in	 direct	 relationship	 with	 the	 clinical	 manifestations	 of	 LV	
hypertrophy	and	diastolic	dysfunction.		
	
1.2.2	Nephropathy	
	 As	mentioned	above	for	cardiomyopathy,	Gb3	storage	also	occurs	in	all	renal	cells,	
namely	 the	 endothelial,	 glomerular,	 interstitial	 and	 tubular	 cells,	 and	 the	 disease	
progression	 results	 in	 the	 development	 of	 glomerulosclerosis,	 tubular	 atrophy	 and	
interstitial	 fibrosis.56,	 57	 However,	 the	 pathophysiology	 of	 FD	 nephropathy	 and	 the	
relationship	 between	 Gb3	 storage	 and	 the	 aforesaid	 findings	 are	 not	 completely	
understood.	Podocyte	and	endothelial	damage,	as	well	as	other	mechanisms	may	play	an	
important	role	in	FD	nephropathy	pathogenesis.		
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	 Though	 present	 in	 all	 glomerular	 cells,	 Gb3	 storage	 is	 most	 abundant	 in	
podocytes.57-60	 Moreover,	 podocytes	 are	 unique	 neuron-like	 glomerular	 cells	 that	 are	
highly	differentiated,	with	only	 limited	potential	of	 self-renewal,	a	 fact	 that	could	make	
them	particularly	susceptible	to	damage	by	lysosomal	storage	disorders.	Podocyte	injury	
leads	 to	 loss	 of	 integrity	 of	 the	 glomerular	 filtration	 barrier	 and	 progression	 to	 chronic	
kidney	disease.61	Several	pathways	are	certainly	 involved	 in	podocytes	damage,	namely	
autophagy	dysregulation,	 cytoskeleton	disorganization	 (and	podocyturia)	 and	 activation	
of	fibrotic	and	inflammatory	pathways.	
Dysregulation	of	the	autophagic	pathway	is	one	of	the	contributors	to	podocytes	
damage.	In	vitro	studies	in	a	human	podocytes	cell	line,	a	FD	phenotype	was	established	
using	 small	 hairpin	 ribonucleic	 acids	 (RNA)	 to	 reduce	 α-galactosidase	 A	 expression	 and	
activity.	 In	 these	 α-galactosidase	 A	 deficient	 podocytes,	 Gb3	 accumulation	 was	
accompanied	 by	 an	 increase	 in	 autophagosomes	 and	 a	 down-regulation	 of	mammalian	
target	 of	 rapamycin	 (mTOR)	 signalling	 cascade	 (a	well-known	 inhibitor	 of	 autophagy).62	
This	data	was	confirmed	 in	kidney	biopsies	of	5	patients,	 showing	 increased	number	of	
autophagic	vacuoles	in	FD	kidney	tissue	(notably	in	podocytes),	which	decreased	in	renal	
biopsies	performed	after	three	years	of	ERT.63	Sphingolipid	storage	may	have	a	direct	role	
in	 the	 dysregulation	 of	 the	 autophagic	 pathway,	 since	 ceramide	 is	 an	 activator	 of	
autophagy.64		
Gb3	 overload	 in	 podocytes	 may	 also	 interfere,	 by	 mechanical	 stress,	 with	 the	
distribution	 of	 synaptopodin,	 an	 actin-associated	 protein	 highly	 expressed	 in	 podocyte	
foot	 processes	 that	 is	 involved	 in	 cytoskeletal	 reorganization.65	 Moreover,	 Gb3	 may	
interact	with	 F-actin	 causing	 cell	 contraction,	 slit	 diaphragm	widening	 and	 the	 coupling	
with	 integrins.65,	 66	 Integrins,	 mainly	 αvβ3	 (also	 known	 as	 vitronectin	 receptor),	 are	
essential	 to	anchor	podocytes	 to	 the	basement	membrane	and	 their	 activation	 triggers	
podocyte	contraction	and	migration	and,	ultimately,	detachment	from	the	glomerulus.	In	
FD	patients,	 increased	urinary	excretion	of	αvβ3	integrin	was	 found	 in	both	classical	and	
attenuated	phenotypes;	also	 its	 increased	expression	was	observed	 in	podocytes	of	 the	
kidney	 tissue	 from	a	patient	with	a	 classical	phenotype.67	 Therefore,	 integrin	activation	
seems	 to	be	 actively	 involved	 in	podocytes	detachment	 from	 the	 glomerular	basement	
membrane	in	FD.	This	phenomenon	will	lead	to	higher	levels	of	podocyturia,	as	previously	
shown	 in	 two	 studies	with	 FD	 patients,	 one	 of	 them	 reporting	 a	 significant	 correlation	
	 32	
between	podocyturia	and	albuminuria.66,	68	Podocytopenia	is	the	main	consequence,	and	
it	 is	 believed	 that	when	 each	 glomerulus	 loses	more	 than	 40%	of	 its	 500	 podocytes,	 it	
undergoes	obliteration.69		
In	 a	 human	 glomerular	 podocytes	 cell	 line,	 as	 lyso-Gb3	 increases,	 there	 is	
activation	of	fibrotic	pathways,	leading	to	the	expression	and	production	of	extracellular	
matrix	proteins	(fibronectin	and	collagen	type	IV	[ColIV]),	mediated	by	the	transforming	
growth	 factor-β1	 (TGF-β1)	 and	 Notch1	 pathways.	 Paricalcitriol	 and	 calcitriol,	 vitamin	 D	
receptor	 activators,	 prevented	 the	 up-regulation	 of	 these	mediators.	 This	 expansion	 of	
extracellular	matrix	is	certainly	involved	in	the	glomerulosclerosis	pathogenesis.18,	70		
Inflammatory	response	is	also	up-regulated	in	FD	glomerular	podocytes,	as	shown	
by	higher	urinary	excretion	of	CD80	in	FD	patients,	as	well	as	increased	CD80	messenger	
RNA	 expression	 in	 podocytes	 cultured	 with	 lyso-Gb3.71	 CD80	 (lymphocyte	 activation	
antigen	 7-1)	 is	 normally	 located	 in	 antigen	 presenting	 cells	 (not	 expressed	 by	 normal	
podocytes)	and	modulates	T	helper	and	T	cytotoxic	cells	activity.72	 Increased	expression	
of	CD74,	a	macrophage	migration	inhibitory	factor	receptor	that	regulates	the	expression	
of	lethal	cytokines,	had	also	been	shown.18	Furthermore,	Notch1	pathway,	a	key	mediator	
of	 proinflammatory	 response,	 was	 up-regulated	 in	 a	 podocytes	 cell	 line	 cultured	 with	
lyso-Gb3,	 with	 increase	 expression	 of	 chemokines	 MCP-1	 (Monocyte	 Chemoattractant	
Protein-1)	and	RANTES	(Regulated	on	Activation,	Normal	T	Cell	Expressed	and	Secreted),	
mediated	by	the	recruitment	of	 the	transcription	of	NFkB	(nuclear	 factor	kappa	B).	This	
data	 was	 confirmed	 in	 kidney	 biopsies	 from	 FD	 patients,	 with	 immunohistochemistry	
confirming	Notch1	expression	in	glomerular	podocytes	and	tubular	cells.70	
Vasculopathy	 is	 also	 certainly	 involved	 in	 FD	 nephropathy	 pathogenesis.	 As	
mentioned	 above	 for	 FD	 cardiomyopathy,	 production	 of	 ROS	 and	 dysregulation	 of	 NO	
pathway	are	major	contributors	to	endothelial	dysfunction.41,	42,	44-46	The	classical	theory	
emphasized	 and	 suggested	 that	 kidney	 fibrosis	 and	 advanced	 kidney	 lesions	 were	 a	
consequence	of	ischaemic	tissue	damage,	derived	from	microvascular	endothelial	disease	
and/or	necrosis	of	 vascular	 smooth	muscle	 cells.57,	60	 This	hypothesis	was	 supported	by	
pathological	 studies	 showing	 universal	 lipid	 deposits	 at	 a	 very	 early	 age,	 unlike	 the	
nonspecific	 changes	 (like	 glomerulosclerosis,	 tubular	 atrophy	 and	 interstitial	 fibrosis)	
which	were	age-related	and	firstly	involving	the	vessels.57	However,	these	are	nonspecific	
features	 of	 advanced	 kidney	 disease	 of	 any	 aetiology	 and	 are	 generally	 minimal	 in	
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patients	younger	than	25	years	old,	suggesting	that	they	are	secondary	features	and	not	
the	 early	 pathogenic	 event.	 Therefore,	 the	 current	 knowledge	 on	 the	 importance	 of	
podocyte	 injury	 in	 glomerulosclerosis	 pathogenesis	 indicates	 that	 vasculopathy	 is	
certainly	involved	in	FD	pathogenesis,	but	it	is	not	the	sole	or	even	the	main	pathogenic	
mechanism.		
Tubulointerstitial	injury	is	also	involved	in	FD	nephropathy	pathogenesis.	Gb3	may	
have	 direct	 toxic	 effects	 in	 tubular	 cells,	 causing	 focal	 tubular	 atrophy	 and	 interstitial	
fibrosis.	 Although	 there	 is	 weak	 evidence	 supporting	 this	 mechanism,	 the	 finding	 of	
glomerular	 enlargement	 in	 the	 early	 stages	 of	 glomerular	 and	 tubular	 injury	 could	
corroborate	that	the	glomeruli	upstream	of	affected	tubules	may	function	poorly	and	that	
other	 glomeruli	 may	 undergo	 hypertrophy	 to	 compensate.	 Hyperfiltration	 in	 these	
glomeruli	may	trigger	a	secondary	 form	of	 focal	segmental	glomerulosclerosis.60	Diffuse	
involvement	of	interstitial	cells,	with	electron	dense	inclusions,	has	also	been	reported.57,	
73	 By	 causing	 tubular	 injury,	 proteinuria	may	 have,	 as	 in	 other	 nephropathy	models,	 a	
direct	 role	 in	chronic	kidney	disease	 (CKD)	progression	and	may	provide	a	 link	between	
the	aforesaid	pathological	processes	and	the	development	of	tubulointerstitial	disease.74,	
75	
These	 abovementioned	 effects	 of	 storage	 in	 all	 renal	 cells	 will	 give	 rise	 to	
progressive	 nephropathy,	 characterized	 by	 nonspecific	 degenerative	 lesions,	 namely	
mesangial	widening,	 segmental	 and/or	 global	 glomerular	 sclerosis,	 tubular	 atrophy	 and	
interstitial	 fibrosis	 (figure	 2).56,	 57,	 60,	 73,	 76	 These	 well	 known	 histological	 findings	 in	
advanced	 FD	 nephropathy	 contrast	 with	 the	 limited	 knowledge	 about	 the	 histology	 of	
patient	with	incipient	nephropathy.		
Lipid	deposition	related	lesions	are	characteristic	of	FD	nephropathy.	As	ceramide	
tails	of	glycosphingolipids	are	dissolved	during	paraffin	embedding	of	kidney	 tissue,	 the	
most	characteristic	finding	in	routine	light	microscopy	of	kidney	biopsies	is	vacuolization.	
This	 is	particularly	prominent	 in	podocytes,	parietal	epithelial	cells	of	Bowman’s	capsule	
and	Henle’s	loop	and	distal	tubular	cells.56,	57,	60,	76	In	light	microscopy,	glycosphingolipids	
deposits	are	best	assessed	in	toluidine	blue	stained	semi-thin	sections	of	glutaraldehyde	/	
formaldehyde	fixed	and	epoxy-embedded	tissue.	 In	the	glomeruli	 the	 largest	amount	of	
lipid	 material	 is	 seen	 in	 podocytes	 followed	 by	 parietal	 epithelial,	 mesangial	 and	
glomerular	 endothelial	 cells.57,	 59,	 77	 Tubular	 inclusions	 are	 more	 prominent	 in	 distal	
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tubules,	 with	 relatively	 spared	 proximal	 tubules	 (mainly	 in	 females)	 and	 there	 is	 also	
peritubular	 capillary	 inclusions,	 including	 intimal	and	medial	 vascular	 inclusions,	 leading	
to	severe	medial	injury	and	necrosis,	with	arterial	hyalinosis.57,	59,	77	
	
	
Figure	 2:	 Pathophysiology	 of	 Fabry	 disease	 nephropathy.	Glycosphingolipids	 storage	 in	 several	
kidney	 compartments	 is	 the	 main	 trigger	 to	 the	 activation	 of	 several	 pathways,	 ending	 in	
glomerular	 sclerosis	 and	 tubulointerstitial	 fibrosis;	 these	 are	 the	 main	 findings	 leading	 to	
progressive	 chronic	 kidney	 disease.	 ECM:	extracellular	matrix;	GLS:	 glycosphingolipids;	NO:	nitric	oxide;	ROS:	
reactive	oxygen	species.	
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Under	electron	microscopy,	electron	dense	 cytoplasmic	granules	 (inclusions)	are	
found	 in	all	 renal	cells,	but	 their	 size,	 shape,	abundance	and	distribution	vary	 from	one	
type	of	cell	to	another.	Though	the	inclusions	are	more	abundant	and	larger	in	podocytes,	
Henle’s	 loop	 and	 distal	 convoluted	 tubules,	 they	 are	 present	 in	 all	 glomerular	 and	
interstitial	cells,	proximal	convoluted	tubules	and	arterial	endothelial	and	smooth	muscle	
cells.57,	76,	77	 In	contrast	to	the	earlier	reports	showing	normal	podocytes’	 foot	processes	
and	 glomerular	 basement	membranes,57	 several	 recent	 publications	 show	 foot	 process	
effacement	as	an	early	finding	in	FD	nephropathy.58,	77-80	
	 These	characteristic	 severe	 inclusions	 in	podocytes	and	distal	 tubules,	as	well	as	
segmental	 foot	 process	 effacement	 have	 been	 shown	 even	 at	 early	 stages	 of	 Fabry	
nephropathy,	in	paediatric	and	adult	patients	with	minimal	or	no	alterations	in	standard	
renal	 tests	 (namely,	 glomerular	 filtration	 rate,	 albuminuria	 or	 proteinuria).57,	 58,	 77,	 79-81	
Moreover,	mesangial	and	endothelial	cells	inclusions,	as	well	as	non-specific	degenerative	
lesions,	 such	 as	 mesangial	 widening,	 glomerulosclerosis,	 tubulointerstitial	 fibrosis	 and	
arteriopathy	have	also	been	described	in	this	group	of	patients.57,	77,	80	This	data	confirms	
that	 clinically	 silent	 deposition	 of	 Gb3	 begins	 in	 early	 childhood,	 long	 before	 overt	 FD	
nephropathy,	 with	 a	 wide	 variation	 in	 the	 individual	 progression	 of	 glomerulosclerosis	
and	interstitial	fibrosis	and	development	of	end-stage	renal	disease.82	
	 However,	 the	 importance	 of	 these	 pathological	 findings	 as	 potential	 surrogate	
markers	 for	 the	 progression	 of	 renal	 dysfunction	 (glomerular	 filtration	 rate	 [GFR])	 is	
uncertain	and	needs	to	be	further	studied	longitudinally.	In	contrast	to	semi-quantitative	
scoring	systems	for	intracellular	Gb3	inclusions,	using	light	microscopy,	that	has	failed	to	
show	any	 correlation	with	age,	proteinuria	and	GFR,57,	59,	77,	83	 a	 small	 study	with	14	FD	
patients,	 using	 quantitative	 stereological	 electron	 microscopy	 methods,	 has	 shown	
significant	 correlations	 between	 podocyte	 Gb3	 fractional	 volume	 of	 inclusions	 by	
cytoplasm	 or	 foot	 process	 width	 and	 age	 or	 proteinuria.58	 Contrariwise,	 some	 studies	
showed	 correlation	 between	 degenerative	 glomerular	 /	 tubulointerstitial	 lesions	 or	
arterial	 sclerosis	 scores	 and	 age	 or	 GFR.57,	 59,	 83	 Furthermore,	 under	 light	 microscopy,	
segmental	and/or	global	glomerulosclerosis	was	found	to	be	the	only	pathologic	correlate	
of	 proteinuria	 at	 early	 stages	 of	 Fabry	 nephropathy.84	 Thus,	 chronic	 nonspecific	
glomerular	and	tubulointerstitial	lesions	seen	in	kidney	biopsies	seems	to	correlate	better	
with	 the	 natural	 history	 and	 manifestations	 of	 FD	 nephropathy	 than	 renal	
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glycosphingolipids	accumulation.	
	
1.3	Clinical	manifestations	and	natural	history	
1.3.1	Cardiomyopathy	
As	 the	disease	progresses,	heart	 involvement	occurs	 in	 the	great	majority	of	 FD	
patients,	with	virtually	all	patients	presenting	cardiac	symptoms	in	the	seventh	decade	of	
life.10,	85	The	 incidence	of	cardiac	symptoms	seems	to	be	the	same	 in	both	genders,	but	
with	 a	 delayed	 mean	 age	 of	 onset	 in	 female	 patients	 (about	 seven	 years	 difference	
between	 genders).10,	 85	 The	 prevalence	 of	 cardiac	 events	 and	 interventions	 varies	
according	to	the	study	(given	the	distinct	definitions	of	event),	between	19	-	49%	and	14	-	
35%	for	male	and	 female	patients,	 respectively.11,	82,	85	Cardiac	events	seem	to	be	more	
prevalent	 and	 tend	 to	 occur	 at	 an	 earlier	 age	 in	 male	 patients.11,	 82,	 85	 Furthermore,	
probably	reflecting	the	improvement	in	the	management	of	renal	disease	in	FD,	the	most	
recent	studies	have	shown	cardiovascular	disease	as	the	main	cause	of	death	in	FD	and	a	
major	determinant	of	overall	disease	prognosis.86,	87	
In	 view	 of	 the	 ubiquitous	 deposition	 of	 Gb3	 in	 all	 cardiac	 cells,	 cardiac	
manifestations	/	complications	of	FD	 include	myocardial	hypertrophy,	 impaired	diastolic	
and/or	 systolic	 LV	 function,	 electrophysiological	 /	 conduction	abnormalities,	myocardial	
ischemia,	valve	disease	and	autonomic	neuropathy.	
LV	 hypertrophy	 is	 the	 hallmark	 of	 FD	 cardiomyopathy	 and	 the	 most	 common	
structural	 cardiac	 abnormality	 seen	 in	 FD.85	 It	 is	 characterized,	 in	 the	 early	 stages,	 by	
concentric	LV	remodelling	 (seen	 in	approximately	50%	of	adolescents	and	children	over	
the	age	of	10	years	old),	which	progresses	over	 time	to	hypertrophy.88,	89	Concentric	LV	
hypertrophy	 is	 the	 most	 typical	 pattern,	 but	 asymmetrical	 septal	 hypertrophy	 (more	
characteristically	 seen	 in	 HCM)	 is	 seen	 in	 5-10%	 of	 the	 cases	 with	 severe	 cardiac	
involvement,	usually	associated	to	LV	outflow	tract	obstruction.88,	90,	91		
Hypertrophic	changes	are	more	prevalent,	more	severe	and	occur	earlier	in	males	
than	 in	 females.85,	 88,	 91	 Its	 prevalence	 increases	 with	 age	 in	 both	 men	 and	 women	
(whether	 treated	 or	 not)85,	 88,	 91,	 92	 and	 LV	mass	 is	 inversely	 correlated	 with	 estimated	
GFR.85	The	presence	of	 LV	hypertrophy	 is	associated	with	 the	presence	of	 cardiac	 signs	
and	 symptoms,	 in	 particular	 dyspnoea,	 angina	 and	 palpitations.85,	 88	 There	 is	 limited	
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longitudinal	data	describing	the	progression	of	LV	hypertrophy	in	untreated	patients,	but	
in	a	study	with	serial	echocardiograms	in	39	male	and	39	female	untreated	patients,	the	
average	increase	in	LV	mass	was	significantly	higher	for	male	patients	(4.1	±	1.0g/m2.7	per	
year	against	2.3	±	0.8g/m2.7	per	year	in	females),	with	a	greater	rate	of	progression	when	
only	patients	with	baseline	LV	hypertrophy	were	analysed.91	
	 Cardiac	 hypertrophy	 is	 readily	 detectable	 by	 different	 techniques,	 namely	
electrocardiography,	echocardiography	and	magnetic	resonance	imaging	(MRI).	
	 LV	 hypertrophy	 by	 voltage	 criteria	 and	 ST-segment	 abnormalities	 and	 T-wave	
inversion	are	some	of	the	most	common	electrocardiographic	abnormalities	seen	in	FD.88,	
93	A	significant	correlation	between	Sokolow-Lyon	voltage	index	or	Romhilt–Estes	scores	
and	LV	mass	has	been	described,	as	well	as	a	high	prevalence	of	ST-segment	and	T	wave	
abnormalities	in	patients	with	LV	hypertrophy	or	remodelling	(83-93%).88,	93	Remarkably,	
repolarisation	abnormalities	may	be	seen	 in	about	a	quarter	of	patients	with	normal	LV	
morphology.88,	 93	 Therefore,	 repolarisation	 abnormalities	 or	 LV	 hypertrophy	 by	 voltage	
criteria,	in	the	absence	of	abnormal	cardiac	morphology,	may	be	the	first	manifestation	of	
Gb3	accumulation	in	cardiac	tissue.		
	 There	are	no	echocardiographic	pathognomonic	 features	of	 FD	 cardiomyopathy,	
but,	 as	noted	above,	 it	 is	 characterized	by	an	early	 stage	of	 concentric	 remodelling	 (an	
increase	in	relative	LV	wall	thickness,	with	normal	LV	mass),	which	progresses	over	time	
to	overt	symmetrical	LV	hypertrophy,88,	89,	92	characteristically	without	resting	LV	outflow	
tract	 obstruction	 (except	 in	 a	 small	 proportion	 of	 patients	 with	 asymmetrical	 LV	
hypertrophy),	 with	 some	 patients	 presenting	 exercise-induced	 LV	 outflow	 tract	
obstruction.88,	 90,	 91,	 94	 Probably	 due	 to	 the	 energy	 depletion	 in	 the	 cardiomyocytes,	
eccentric	 hypertrophy	 (indicated	 by	 an	 increase	 in	 end-diastolic	 LV	 diameter),	 may	 be	
seen	 in	a	 few	patients	 (less	 than	10%).88,	91	Another	 typical	aspect	 is	 the	prominence	of	
papillary	muscles	(present	in	up	to	75%	of	patients).95,	96		
As	a	lysosomal	storage	disorder,	FD	was	misleadingly	assumed	to	be	a	restrictive	
cardiomyopathy,	because	storage	of	Gb3	would	lead	to	a	stiff	left	ventricle	with	impaired	
passive	 diastolic	 filling	 (the	 hallmark	 of	 restrictive	 cardiomyopathy).97-99	 However,	 the	
hallmark	of	FD	cardiomyopathy	 is	LV	hypertrophy	(not	present	 in	most	restrictive	forms	
of	 cardiomyopathy)	 and	 severe	 diastolic	 dysfunction	 consistent	with	 a	 restrictive	 filling	
pattern	was	very	rare	in	several	studies,	with	up	to	100	FD	patients.88,	90,	100	Nevertheless,	
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mild	 diastolic	 dysfunction	with	 impaired	 LV	 relaxation	 is	 encountered	 in	 a	 quarter	 to	 a	
third	of	patients	and	a	smaller	proportion	(≈10%)	has	moderate	diastolic	dysfunction	with	
a	 pseudonormal	 filling	 pattern.90,	 100	 Conventional	measures	 of	 LV	 systolic	 function	 (LV	
ejection	 fraction	 and	 LV	 fractional	 shortening)	 are	 usually	 within	 the	 normal	 range,	
regardless	of	whether	or	not	 the	patient	has	 LV	hypertrophy.88,	101,	102	Nonetheless,	 the	
sole	small	study	evaluating	natural	history	of	systolic	function	in	FD	suggests	that	there	is	
a	 gradual	 deterioration	 in	 LV	 fractional	 shortening.101	 Moreover,	 studies	 using	 more	
sophisticated	non-invasive	measures,	like	TDI	and	strain	rate	(SR)	imaging,	demonstrated	
reductions	 in	 systolic	 performance	 at	 a	 very	 early	 stage	 of	 disease	 progression.103-108	
Dyspnoea	and	other	symptoms	of	heart	failure	are	mainly	caused	by	diastolic	dysfunction	
(more	rarely	by	systolic	dysfunction)	and	occur	 in	up	to	30%	of	patients,	with	the	same	
incidence	in	both	genders.85			
As	 myocardial	 lipid	 storage	 and	 fibrosis	 are	 hallmarks	 of	 FD	 cardiomyopathy,	
cardiac	 MRI	 provides	 complementary	 data	 to	 echocardiography	 through	 its	 ability	 to	
characterize	myocardial	tissue.	Focal	myocardial	replacement	fibrosis	can	be	visualized	by	
late	gadolinium-contrast	enhancement	(LGE)	in	cardiac	MRI.109	LGE	may	be	present	in	up	
to	50%	of	male	and	female	patients	and	is	located	particularly	in	the	posterolateral	basal	
LV	 wall	 (usually	 sparing	 the	 subendocardial	 layers).105,	 106,	 110-112	 The	 reason	 for	 this	
distribution	 of	 LGE	 is	 unknown,	 but	 it	 has	 been	 hypothesized	 that	 FD	 cardiomyopathy	
might	predispose	the	patient	to	subclinical	myocarditis	(causes	a	similar	pattern	of	LGE)	
or,	since	LV	work	load	is	highest	in	the	inferolateral	wall,	these	segments	may	be	prone	to	
myocardial	fibrosis	development	due	to	increased	local	wall	stress.105,	109	Female	patients	
seem	to	have	 lower	LGE	areas	and	a	higher	probability	of	LGE	presence	with	normal	LV	
mass.110,	113	Moreover,	LGE	correlates	with	abnormalities	in	regional	myocardial	function	
(assessed	 by	 SR	 or	 two-dimensional	 speckle-tracking	 imaging	 studies)105,	 114,	 115	 and	 is	
associated	with	 a	worse	 prognosis	 in	 terms	 of	 exercise	 capacity	 and	 risk	 for	malignant	
ventricular	arrhythmias.106,	116	
The	right	ventricle	(RV)	is	also	affected	by	storage,	with	about	30-70%	of	patients	
presenting	 RV	 hypertrophy.117-120	 RV	 hypertrophy	 prevalence	 increases	 with	 age	 and	
appears	similar	in	both	genders,	but	the	onset	seems	to	occur	later	in	females.118,	119	RV	
hypertrophy	occurs	predominantly	 in	 association	and	 is	paralleled	 to	 the	 severity	of	 LV	
hypertrophy.117-120	However,	in	cardiac	MRI,	myocardial	replacement	fibrosis	in	the	RV	is	
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absent,	even	in	the	end-stage	of	the	disease,	as	evidenced	by	two	studies	with	up	to	75	
patients.120,	121	Data	on	the	impact	of	FD	in	RV	systolic	function	is	contradictory,	but	the	
regional	function	of	RV	lateral	free	wall	(measured	by	RV	longitudinal	SR)	seems	reduced	
in	patients	with	 LV	 fibrosis.117-120	 Contrariwise,	RV	diastolic	 dysfunction	 seems	 frequent	
(mainly	 impaired	 RV	 relaxation)	 and	 predominantly	 affects	 patients	 with	 RV	
hypertrophy.118,	119	Nonetheless,	the	clinical	significance	of	RV	dysfunction	is	believed	to	
be	low,	as	isolated	right	ventricular	failure	rarely	complicates	the	course	of	the	disease.		
Up	to	50%	of	the	patients	with	FD,	regardless	of	gender	and	especially	those	with	
LV	 hypertrophy	 complain	 of	 pain	 suggestive	 of	 myocardial	 ischemia.82,	 85,	 88,	 90	
Nevertheless,	 the	 incidence	 of	 proven	 myocardial	 infarction	 or	 revascularization	
procedures	 is	 low,	 as	 well	 as	 epicardial	 coronary	 artery	 disease.3,	 82,	 85	 Thus,	 by	 the	
aforesaid	mechanisms	 in	cardiomyopathy	pathophysiology,	microvascular	angina,	 in	 the	
setting	 of	 reduced	 coronary	 flow	 reserve,	 may	 be	 responsible	 for	 these	 symptoms	 in	
some	patients;48,	122,	123	vasospastic	stimuli	may	also	be	involved.90,	124	As	mentioned,	large	
vessel	 coronary	 artery	 disease	 is	 rarer,	 but	 the	 risk	 of	 death	 due	 to	 it	 should	 not	 be	
underestimated;26	 it	 may	 be	 more	 correlated	 to	 classic	 risk	 factors,	 such	 as	 arterial	
hypertension	(HBP),	dyslipidaemia	and	CKD	and,	in	one	series,	despite	a	lack	of	significant	
large	vessel	disease,	diffuse	hypoechogenic	plaques,	assessed	by	intravascular	ultrasound,	
were	more	common	in	FD	compared	to	age-matched	controls.125		
Palpitations,	 the	 most	 frequent	 clinical	 symptom	 for	 underlying	 cardiac	
arrhythmias,	 are	 common	 in	male	and	 female	patients	with	FD,	but	 tend	 to	 start	at	an	
earlier	 age	 in	 males	 and	 its	 incidence	 is	 higher	 in	 patients	 with	 LV	 hypertrophy	 and	
increases	with	age.82,	85,	126	Furthermore,	arrhythmias	are	by	far	the	most	frequent	cardiac	
event	 reported	 in	 FD.82,	 87	 	 Supraventricular	 tachycardia	 is	 the	 most	 frequently	
encountered	 rhythm	 abnormality,	 mainly	 atrial	 fibrillation	 (paroxysmal	 or	 persistent	 /	
permanent),	 identified	 in	 almost	20%	of	patients	 in	 a	 cohort	of	 60	 FD	patients;126	 non-
sustained	 ventricular	 tachycardia	 was	 recognized,	 during	 24	 hour	 Holter	 recordings,	 in	
8.3%	 of	 the	 patients	 in	 the	 same	 series	 and	 are	 reported	 in	 cases	 of	 fatal	 malignant	
arrhythmias	 resistant	 to	 implantable	 cardioverter	 defibrillator.126,	 127	 This	 higher	 risk	 of	
both	 atrial	 and	 ventricular	 arrhythmias	 is	 related	 to	 glycosphingolipid	 deposition,	 atrial	
dilatation	 and	 ischemia	 secondary	 to	 LV	hypertrophy	 and	 fibrosis.	 A	 study	 including	 73	
patients	reported	an	annual	increase	in	cardiac	fibrosis	as	the	sole	independent	predictor	
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of	 malignant	 ventricular	 arrhythmias	 and	 non-sustained	 ventricular	 tachycardia	 and	
sudden	cardiac	death	occurred	only	in	the	group	of	patients	with	LGE	in	cardiac	MRI.55,	116,	
128	
Even	 the	 resting	 ECG	 is	 frequently	 abnormal.	 Early	 ECG	 manifestations	 of	 FD,	
occurring	in	younger	patients	with	normal	LV	mass,	include	a	short	PR	interval	(observed	
in	up	 to	40%	of	patients),	which	 is	 likely	due	 to	accelerated	atrioventricular	 (AV)	nodal	
conduction	 rather	 than	 by	 accessory	 pathways.90,	93,	126,	129,	130	With	 disease	 progression	
(development	of	LV	hypertrophy)	and/or	age	the	conduction	system	dysfunction	occurs	
and	the	PR	interval	may	change	and	patients	develop	bundle	branch	block,	AV	conduction	
delay	 (which	 can	 progress	 to	 high-grade	 AV	 block)	 and	 progressive	 sinus	 node	
dysfunction.88,	90,	126	Between	3%	and	12.5%	of	patients	require	pacemaker	 implantation	
for	complete	heart	block	or	symptomatic	bradycardia,	suggesting	that	bradyarrhythmias	
have	a	significant	impact	on	the	natural	history	of	FD.85,	126,	131	
FD	patients	may	have	dysfunction	of	autonomic	cardiac	control,	but	usually	do	not	
present	 clinically	 overt	 signs	 of	 orthostatic	 dysregulation.	 One	 of	 the	 first	 signs	 of	
cardiovascular	 system	 involvement	 in	 FD	 is	 depressed	 heart	 rate	 variability,	 which	 has	
been	 demonstrated	 in	 paediatric	 patients,	 mainly	 in	 boys,	 and	 may	 represent	 a	 pro-
arrhythmogenic	 electrophysiological	 substrate.89,	 132	 Moreover,	 most	 adult	 patients	
(mainly	males)	may	present	resting	bradycardia	and	chronotropic	incompetence,	as	well	
as	 reduced	 sympathetic	 activation	 and	 baroreflex	 sensitivity	 adjustment	 upon	
standing.133,	134	
As	in	other	LSDs,	massive	Gb3	accumulation	in	heart	valve	tissue	and	fibroblasts,	
with	secondary	fibrosis	and	calcification	may	cause	valvular	dysfunction.24,	135	Changes	are	
predominantly	 found	 in	 the	 left	 heart	 valves	 (mitral	 and	 aortic),	 probably	 due	 to	 the	
higher	haemodynamic	 stress	 in	 this	 side	of	 the	heart.88,	136	 In	early	 studies,	mitral	 valve	
prolapse	was	said	to	be	common	in	FD	patients,137,	138	but	subsequent	reports	were	not	
able	to	confirm	this	finding,	perhaps	due	to	the	novel	diagnostic	criteria	for	identification	
of	mitral	valve	prolapse.88,	136	Nevertheless,	minor	structural	abnormalities	in	both	mitral	
and	 aortic	 valves	 are	 frequently	 noted,	 with	 no	 difference	 in	 incidence	 between	
genders.85	 Mitral	 valve	 seems	 to	 be	 the	 first	 and	 the	 most	 frequently	 affected	 by	
structural	 changes,	 mainly	 leaflet	 thickening	 and	 redundancy,	 often	 accompanied	 by	
hypertrophy	 and	 hyperechogenicity	 of	 the	 papillary	 muscles	 and	 mild	 valvular	
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regurgitation.88,	 136	 Moreover,	 in	 patients	 with	 asymmetrical	 septal	 hypertrophy,	 the	
typical	 systolic	 anterior	 motion	 of	 the	 anterior	 mitral	 leaflet	 may	 contribute	 to	 mitral	
valve	dysfunction.90	Aortic	valve	abnormalities	seems	to	appear	at	an	older	age88	and	the	
aortic	root	dilatation,	found	in	the	advanced	stage	of	FD	cardiomyopathy,	may	contribute	
to	mild	aortic	valve	regurgitation.88,	136,	138,	139	Nonetheless,	valve	regurgitations	are	often	
mild	and	 irrelevant	 in	haemodynamic	 terms,	hence	 the	need	 for	 surgical	 valve	 repair	 is	
rare.85,	88,	136,	140	
	
1.3.2	Nephropathy	
Kidney	 involvement	 is	 common	 in	 FD	 disease,	 with	 a	 proportion	 of	 patients	
progressing	 to	 end-stage	 renal	 disease	 (ESRD).82,	83,	141	 In	 the	 past,	 before	 renal	 dialysis	
and	transplant	became	widely	available,	renal	failure	was	the	main	cause	of	death	in	male	
patients	with	FD.10,	86	More	recent	studies	have	shown	cardiovascular	disease	as	the	main	
cause	of	death.	However,	the	majority	of	patients	dying	from	cardiovascular	events	had	
previously	 received	 renal	 replacement	 therapy.86,	87	Therefore,	FD	nephropathy	 remains	
as	a	major	determinant	of	overall	disease	prognosis.	
As	noted	above,	accumulation	of	Gb3	occurs	in	all	renal	cells,	with	consequences	
on	glomerular	and	tubular	function,	reflected	in	the	clinical	and	laboratory	manifestations	
of	 FD	 nephropathy:	 proteinuria,	 impaired	 GFR,	 HBP,	 tubular	 dysfunction	 and	 urine	
sediment	abnormalities.	
Most	patients	(up	to	50%)	with	FD	develop	overt	proteinuria	(>300mg/day),	which	
is	more	prevalent	and	more	severe	in	males	than	in	females,	except	for	CKD	stages	4/5,	
where	 the	 incidence	 and	 degree	 of	 proteinuria	 is	 similar	 for	 both	 genders.82,	 141,	 142	
Moreover,	 its	prevalence	and	severity	 increases	 in	accordance	with	CKD	stage,	and	 it	 is	
believed	to	directly	contribute	to	the	progression	of	FD	nephropathy.82,	141,	142	Proteinuria	
(>150mg/day)	 and	 albuminuria	 A2	 (>30mg/day)	 are	 usually	 the	 first	 signs	 of	 renal	
involvement	 and	 may	 start	 as	 early	 as	 in	 the	 2nd	 decade	 of	 life	 in	 both	 genders,	 but,	
before	 the	 age	of	 18	 years	 old,	 they	 are	presente	only	 in	 a	minority	 of	 patients	 (up	 to	
15%)	of	both	genders.143-146	Thereafter,	there	is	a	progressive	increase	in	the	number	of	
patients	with	proteinuria,	with	50%	of	male	patients	developing	proteinuria	by	the	age	of	
35	years	old,	 and	all	 surviving	patients	presenting	proteinuria	by	 the	age	of	52	years.83	
Proteinuria	 seems	 to	 be	 often	 of	 glomerular	 origin	 (containing	 ≥	 50%	 albumin)83	 and	
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nephrotic	 range	proteinuria	 (>	3.5g/day)	 is	 relatively	uncommon,	being	present	 in	7.3	–	
18%	of	male	patients	and	in	3.6	–	7.5%	of	female	patients,	with	a	greater	prevalence	in	
more	 severe	 CKD	 stages.83,	 141,	 142	 Nonetheless,	 a	 full-blown	 nephrotic	 syndrome	 is	 not	
frequent,	 with	 only	 21%	 of	 the	 patients	 with	 nephrotic	 range	 proteinuria	 presenting	
serum	cholesterol	>	200mg/dL.83			
Progressive	 decline	 of	 GFR	 is	 a	 common	 complication	 of	 Fabry	 disease,	 with	
greater	 prevalence	 and	 decline	 in	 male	 compared	 with	 female	 patients.82,	 83,	 142	 As	 in	
other	nephropathies,	an	initial	hyperfiltration	state	of	glomerular	compensation	may	exist	
and	mask	the	early	impairment	of	renal	function,	until	the	damage	of	a	critical	number	of	
nephrons.	Actually,	several	studies	in	FD	paediatric	population	showed	that	most	children	
exhibited	 estimated	 GFR	 (estimated	 by	 Schwartz	 equation)	 higher	 than	 expected	 for	
healthy	 children	 and	 adolescents.143,	 145,	 147	 However,	 this	 data	 must	 be	 interpreted	
cautiously,	as	the	Schwartz	equation	may	overestimate	GFR	 in	patients	without	CKD,	as	
described	 in	 a	 population	 of	 30	 paediatric	 patients	with	 FD,	with	 a	mean	difference	 of	
18.0ml/min/1.73m2	 between	 estimated	 and	 measured	 GFR.81	 For	 adult	 populations,	 a	
similar	 issue	 is	 raised,	 as	 estimation	 of	 GFR	 may	 also	 be	 inaccurate	 for	 patients	 with	
higher	GFR,	mainly	with	Modification	of	Diet	in	Renal	Disease	(MDRD)	study	equation.148	
Nevertheless,	 there	 remain	 a	 few	 paediatric	 and	 adult	 patients	 with	 FD	 and	 true	
hyperfiltration	based	on	measured	GFR,	but	whether	hyperfiltration	presages	a	later	fall	
in	GFR	is	unknown.81,	149		
Regardless	of	this	hyperfiltration	stage,	only	a	minority	(up	to	3%)	of	FD	patients	
have	decreased	GFR	 (<	90ml/min/1.73m2)	before	 the	age	of	18	years	old	 (nonetheless,	
cases	of	ESRD	have	been	 reported	as	early	as	 in	 second	decade	of	 life).143,	145,	146,	150,	151	
However,	 thereafter	 the	 rate	 of	 GFR	 decline	 is	 heterogeneous	 (with	 several	 factors	
affecting	the	rate	of	decline),	but	can	be	as	high	as	12.2ml/min/year	in	male	patients	with	
serum	creatinine	>	1.5mg/dL,	with	a	mean	time	of	progression	to	ESRD	of	4	years	(range:	
1	to	13	years).83	 In	a	cohort	of	105	classically	affected	males,	23%	developed	ESRD,	at	a	
median	age	of	47	years	old,	and	with	all	the	patients	surviving	to	the	age	of	55	years	old	
developing	 ESRD.83	 In	 larger	 cohorts,	 including	 male	 and	 female	 patients,	 with	 both	
classical	and	late-onset	phenotypes,	the	prevalence	of	ESRD	was	13.7	–	17.6%	and	2.0	–	
4.8%,	 for	 male	 and	 female	 patients,	 respectively,	 with	 a	 similar	 median	 age	 of	
development	of	ESRD	for	both	genders	(between	the	end	of	the	fourth	and	the	beginning	
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of	the	fifth	decade	of	life).82,	150	The	incidence	of	ESRD	was	also	markedly	higher	in	male	
patients,	regardless	of	the	age	group.150		
As	mentioned	above,	 the	progression	of	FD	nephropathy	 is	heterogeneous,	with	
several	factors	influencing	the	rate	of	GFR	decline,	including	gender,	baseline	CKD	stage,	
degree	 of	 proteinuria	 and	 residual	 enzymatic	 activity.	 Regarding	 gender,	 there	 is	 a	
significant	 greater	 proportion	 of	 male	 patients	 achieving	 CKD	 stage	 ≥	 3	 (22.2	 -	 28.4%	
versus	13.1%	-	15.1%	for	male	and	female	patients,	respectively),	with	a	higher	mean	age	
of	 female	 patients	 in	 all	 CKD	 stages,	 except	 in	 CKD	 stages	 4	 /	 5,	 as	 well	 as	 a	 larger	
proportion	of	male	patients	with	a	loss	of	estimated	GFR	>	1ml/min/1.73m2/year.82,	141,	152	
In	 a	 large	 cohort	 of	 FD	 patients,	 the	 rate	 of	 GFR	 decline	 in	male	 patients	who	 did	 not	
develop	 ESRD	 was	 −2.9ml/min/1.73m2/year,	 compared	 with	 −1.02ml/min/1.73m2/year	
for	 female	 patients.82	 The	 progression	 rate	 is	 also	 greater	 for	 patients	 presenting	 CKD	
stage	≥	3	at	the	first	evaluation,	with	a	more	than	two-fold	greater	GFR	decline,	for	both	
male	 and	 female	 patients.82	 Proteinuria	 also	 seems	 to	 play	 an	 important	 role	 in	 FD	
nephropathy	 progression,	 because	 for	 both	 genders,	 the	 proportion	 of	 patients	 with	
overt	proteinuria	(>	300mg/day)	and	its	magnitude	and	the	prevalence	of	nephrotic	range	
proteinuria	 are	 higher	with	more	 advanced	 CKD	 stages.82,	141	Moreover,	 comparing	 the	
GFR	 decline	 stratified	 by	 baseline	 proteinuria,	 higher	 baseline	 proteinuria	 levels	 were	
associated	with	more	rapid	GFR	decline,	but	the	patients	with	higher	baseline	proteinuria	
were	also	older	and	with	 lower	baseline	GFR.82,	152	Notwithstanding	 this,	 in	one	study	a	
regression	model	 for	GFR	slope	retained	proteinuria	as	 the	most	 important	 indicator	of	
renal	 disease	 progression	 in	 adult	 FD	 patients.152	 Therefore,	 there	 seems	 to	 be	 an	
influence	 of	 proteinuria	 in	 nephropathy	 progression,	 although	 the	 magnitude	 of	 this	
influence	is	not	well	established,	as	several	studies,	with	both	male	and	females	patients,	
finding	 no	 relationship	 between	 the	 degree	 of	 proteinuria	 and	 the	 rate	 of	GFR	 decline	
and,	in	one	study,	11%	of	the	male	and	28%	of	the	female	patients	with	estimated	GFR	<	
60ml/min/1.73m2,	presented	no	overt	proteinuria.15,	83,	141	In	male	patients,	the	presence	
of	residual	α-galactosidase	A	activity	≥	1%	in	leucocytes	also	seems	to	be	associated	with	
better	 renal	 outcomes,	with	 a	 significantly	 older	 age	 of	 achieving	 a	 serum	 creatinine	 >	
1.5mg/dL,	compared	with	the	patients	with	undetectable	α-galactosidase	A	activity.83	
Data	 on	 HBP	 or	 blood	 pressure	 (BP)	 control	 in	 patients	 with	 FD	 is	 scarce.	 In	 a	
previous	 study,	 the	 prevalence	 of	 HBP	 was	 30%	 in	 a	 cohort	 of	 male	 FD	 patients.83	
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However,	contemporary	studies,	with	larger	cohorts,	showed	a	greater	overall	prevalence	
of	patients	with	systolic	BP	≥	130mmHg	and/or	diastolic	BP	≥	80mmHg,	between	57.1%	-	
58%	in	males	and	46.9%	-	52.5%	in	females.82,	153	This	contrasts	with	a	44.2%	prevalence	
of	HBP	among	the	general	European	population,	although	the	threshold	for	diagnosis	of	
HBP	 in	 this	 study	 (BP	 >	 140/90mmHg)	 differs.154	 	 Moreover,	 the	 prevalence	 of	 HBP	 is	
significantly	greater	in	FD	patients	with	GFR	<	60ml/min/1.73m2	(64	-	80%),	compared	to	
FD	patients	with	GFR	≥	60ml/min/1.73m2	 (45	–	52%)82,	141,	153	and,	 in	one	study,	65%	of	
the	hypertensive	FD	patients,	 the	HBP	appeared	concurrently	or	after	 serum	creatinine	
reached	 ≥	 1.5mg/dL.83	 Nevertheless,	 HBP	 seems	 less	 prevalent	 in	 FD	 with	 GFR	 <	
60ml/min/1.73m2	 than	 in	 the	 general	 CKD	 population	 at	 comparable	 levels	 of	 GFR.155	
Besides,	 systolic	 BP	 positively	 correlates	 with	 proteinuria	 in	 adult	 male	 and	 female	
patients	and	diastolic	BP	correlates	with	GFR	slope	in	adult	male	patients.141,	152		
As	noted	above,	tubular	inclusions	are	more	prominent	in	distal	than	in	proximal	
tubules,57,	 77	 but	 the	 aetiology	 of	 this	 preferential	 accumulation	 of	 Gb3	 is	 not	 well	
understood.	 Therefore,	 distal	 tubular	 function	 is	 particularly	 affected,	 resulting	 in	
impaired	 urinary	 concentration	 and	 isosthenuria,	 which	 was	 demonstrated	 even	 in	
patients	with	normal	GFR	and	may	be	 the	earliest	 apparent	 renal	 abnormality.83,	156,	157	
The	 involvement	 of	 distal	 tubules	 and	 collecting	 ducts	 may	 also	 result	 in	 nephrogenic	
diabetes	 insipidus,	 impaired	 tubular	 potassium	 reabsorption	 (and	 enhanced	 net	
potassium	excretion)	 and	defective	 renal	 acidifying	mechanisms	 (with	 reduced	net	 acid	
excretion).156,	 158,	 159	 Proximal	 tubule	 dysfunction	 has	 been	 reported	 more	 rarely,	 with	
reduced	 tubular	 reabsorption	 of	 glucose	 and	 amino	 acids	 and,	 occasionally,	 an	 overt	
Fanconi	syndrome.159,	160	
The	accumulation	of	neutral	glycosphingolipids	in	renal	parenchyma	is	reflected	in	
urine	composition	and	sediment.	Even	at	early	 stages	of	FD	nephropathy,	erythrocytes,	
leucocytes	and	hyaline	and	granular	 casts	 can	be	 found	 in	urine	 sediment.161	The	urine	
sediment	may	also	contain	oval	fat	bodies,	which	may	be	present	either	freely	or	within	
desquamated	tubular	/	uroepithelial	cells	or	cell	fragments	and	represent	lipid	inclusions.	
Under	 polarised	 light	 microscopy,	 these	 oval	 bodies	 are	 birefringent,	 with	 the	
characteristic	 “Maltese	 cross”	 configuration,	 with	 lamellar	 appearance.	 In	 electron	
microscopy,	they	match	the	typical	lamellar	osmiophilic	inclusions	in	urinary	cells.162,	163	
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1.4	Treatment	
As	 a	multi-system	 condition,	 a	 comprehensive	 therapy	 for	 FD	 is	warranted,	 not	
only	 including	 disease	 specific	 treatment,	 but	 also	 conventional	 medical	 treatment	 for	
complications	and	adjunctive	therapies.30,	164	Until	recently	the	former	was	not	available	
and	its	management	mainly	consisted	of	other	treatment	strategies.	However,	in	2001	a	
disease	specific	ERT	was	aprroved	as	the	gold	standard	in	the	treatment	of	FD	and,	more	
recently,	 in	 2017,	 European	 regulatory	 authorities	 approved	 the	 pharmacological	
chaperone	migalastat	for	treatment	of	FD	patients	with	amenable	mutations.		
In	Europe,	there	are	currently	two	commercially	available	ERT	preparations,	both	
based	 on	 the	 infusion	 of	 recombinant	 enzymes:	 agalsidase-α	 (Replagal®,	 Shire	
Pharmaceuticals,	 Lexington,	 Massachusetts),	 produced	 in	 a	 human	 cell	 line	 by	 gene	
activation	and	licensed	at	the	dose	of	0.2mg/Kg,	every	other	week	(EOW);165	agalsidase-β	
(Fabrazyme®,	Sanofi	Genzyme,	Cambridge,	Massachusetts),	produced	in	Chinese	hamster	
ovary	cells	by	recombinant	techniques	and	licensed	at	the	dose	of	1mg/Kg,	EOW.166	Both	
products	have	the	same	primary	amino	acid	sequence	(equivalent	to	the	wild-type	human	
enzyme),167	but	there	are	several	differences	in	post-translational	modification,	including	
glycosylation.168,	 169	 Post-translational	 modifications	 may	 have	 profound	 effects	 on	 the	
conformation	and	physicochemical	properties	of	proteins,	and	glycosylation	is	known	to	
have	an	impact	on	the	antigenicity	of	recombinant	proteins.170,	171	
Migalatat	 is	currently	available	 in	Europe	and	 it	 is	a	pharmacological	chaperone,	
which	binds	to	the	active	site	of	α-galactosidase	A	and	stabilizes	certain	mutant	enzymes	
(amenable	mutations),	thus	facilitatng	proper	trafficking	to	lysosomes,	where	dissociation	
of	 migalastat	 allows	 α-galactosidase	 A	 to	 catabolize	 accumulated	 substrates.172	 This	
treatment	 is	 an	 orally	 administred	 small-molecule,	 with	 apprently	 higher	 volume	 of	
distribution	 than	 ERT	 and	 does	 not	 present	 the	 burden	 of	 immunogenicity	 associated	
with	ERT.173		
New	 treatment	 strategies	 are	 currently	 under	 development	 in	 clinical	 trials,	
namely	 substrate	 reduction	 therapy	 (lucerastat)174	 and	modified	 forms	of	plant	derived	
ERT	(pegunigalsidase-α).175	
	
1.4.1	Cardiomyopathy	
The	gold	 standards	 in	 the	 treatment	of	 FD	cardiomyopathy	are	 the	ERT	and	 the	
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pharmacological	 chaperone	 migalastat,	 but	 adjunctive	 therapies	 directed	 at	 clinical	
manifestations	 (angina,	 arrhythmias,	 heart	 failure)	 and	other	 cardiovascular	 risk	 factors	
are	 also	 paramount.	 Nowadays,	 with	 15	 years’	 experience	 of	 available	 ERT,	 there	 is	
increasing	evidence	supporting	the	efficacy	of	ERT	in	several	cardiac	endpoints,	including	
histological,	intermediate	(clinical	and	imaging	parameters)	and	“hard”	outcomes	(cardiac	
events	and	death).		
Regarding	cardiac	Gb3	storage,	in	a	randomized,	double-blind,	placebo-controlled	
clinical	 trial	with	 agalsidase-α,	 there	was,	 over	 a	 6	month	 period,	 a	mean	 reduction	 of	
approximately	 20%	 in	 the	 myocardial	 Gb3	 content	 in	 the	 active	 treatment	 group,	
compared	with	a	mean	 increase	of	 approximately	10%	 in	 the	placebo	group,	but	 these	
findings	did	not	reach	statistical	significance.176		
In	the	phase	III	pivotal	clinical	trial	of	agalsidase-β,	after	a	20	weeks	period,	there	
was	 a	 significant	decrease	 in	 the	microvascular	 endothelial	 deposits	 score	 in	 the	 active	
treatment	group,	compared	with	the	placebo	group,	with	67%	of	the	patients	reaching	a	
0	 score;	 unfortunately,	 the	 cardiomyocyte	 storage	 was	 not	 described	 in	 this	 trial.166	
However,	 in	 the	 phase	 I/II	 agalsidase-β	 clinical	 trial,	 after	 5	 infusions,	 there	was	 also	 a	
reduction	 in	endothelial	deposits,	although	the	heart	Gb3	concentration	only	decreased	
slightly	 in	 4	 out	 of	 7	 patients	 and	 Gb3	 storage	 remained	 unchanged	 in	 the	
cardiomyocytes,	 pericytes	 and	 vascular	 smooth	muscle.177	Moreover,	 in	 the	 60	months	
open-label	extension	study	of	 the	aforementioned	agalsidase-β	phase	 III	 clinical	 trial,	 in	
the	 eight	 patients	 consenting	 to	 biopsies	 at	 the	 end	 of	 the	 study,	 the	 clearance	 in	
endothelial	 cells	 was	 maintained,	 but	 there	 was	 no	 clearance	 of	 Gb3	 in	 the	
cardiomyocytes.178,	179	Persistent	storage	in	cells	other	than	vascular	endothelial	cells	has	
also	 been	 identified	 in	 several	 case	 reports	 of	 patients	 treated	 with	 agalsidase-β.26,	 180	
Notably,	 in	 a	 study	 with	 5	 patients	 treated	 with	 agalsidase-β	 for	 one	 year,	 the	
glycosphingolipids	 deposits	 appeared	 unmodified,	 including	 in	 endothelial	 cells;	 these	
patients	were	older	 than	 the	ones	previously	 described	 and	probably	 had	more	 severe	
cardiac	 involvement).122	 Thus,	 the	 available	 evidence	 suggests	 that	 ERT	 has,	 at	 least	 in	
some	patients,	limited	access	to	non-vascular	cardiac	tissues	and	that	the	Gb3	clearance	
may	be	more	difficult	in	older	and	more	severe	patients.		
Several	 intermediate	endpoints	have	been	evaluated	 in	response	to	ERT,	namely	
cardiac	 structure	 and	 function	 or	 cardiac	 symptoms	 (angina	 and	 heart	 failure).	 In	
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summary,	 both	 ERT	 preparations	 have	 shown	 to	 improve	 myocardial	 remodelling	 and	
cardiac	 function,	 by	 decreasing	 LV	 wall	 thickness	 and	 mass103,	 106,	 176,	 181-190	 or	 the	
progression	 of	 LV	 mass	 index48,	 191-194	 and	 improving	 LV	 fractional	 shortening	 and	
strain.103,	106,	187	
The	effects	of	agalsidase-α	in	cardiac	structure	and	function	were	evaluated	in	the	
two	 randomized,	 double-blind,	 placebo-controlled	 clinical	 trials,	 with	 significant	
reductions	in	the	QRS	complex	duration165	and	LV	mass	index	assessed	by	cardiac	MRI,176	
compared	 to	 the	 placebo	 group,	 after	 6	 months	 of	 ERT,	 in	 a	 group	 of	 14	 and	 7	male	
patients,	respectively.	In	the	open-label	extension	of	the	second	trial,	including	10	of	the	
14	 recruited	 for	 the	original	 trial,	 the	 LV	mass	 remained	 stable	over	a	2	 year	 follow-up	
period,	 but	 there	 were	 significant	 reductions	 in	 LV	 posterior	 wall	 (LVPW)	 and	 IVS	
thickness,	suggesting	cardiac	remodelling	during	treatment.176	
The	effects	of	agalsidase-α	in	female	patients	have	also	been	assessed	in	a	4	year,	
prospective,	 open-label	 study,	 with	 36	 patients,	 69%	 of	 them	 with	 LV	 hypertrophy	 at	
baseline.	 There	 was	 a	 significant	 reduction	 in	 LV	 mass	 index	 (measured	 by	
echocardiography)	 after	 12	months	 of	 treatment	 in	 both	 patients	with	 and	without	 LV	
hypertrophy	at	baseline	 (of	 greater	extent	and	 significance	 in	patients	with	baseline	 LV	
hypertrophy),	 which	 was	 sustained	 throughout	 4	 years	 of	 treatment.	 Moreover,	 there	
was	 also	 a	 significant	 improvement	 in	 the	 New	 York	 Heart	 Association	 (NYHA)	 heart	
failure	functional	class.181,	184		
A	 pooled	 and	blinded	 analysis	 of	 all	 available	 echocardiograms	 from	4	 industry-
sponsored	 clinical	 studies	 (involving	male	 and	 female	 patients),	 including	 the	 aforesaid	
clinical	 trial,	 confirmed	 the	 positive	 effect	 of	 agalsidase-α	 in	 patients	 with	 baseline	 LV	
hypertrophy,	 with	 a	 significant	 decrease	 in	 LV	 mass	 index	 over	 a	 period	 of	 12	 to	 36	
months	(not	observed	in	the	group	of	patients	with	normal	LV	mass	at	baseline).182	This	
data	was	confirmed	in	a	single	centre,	based	on	long-term	retrospective	analysis	of	data	
from	 45	 patients,	 treated	 for	 approximately	 10	 years	 with	 agalsidase-α,	 showing	 a	
sustained	 significant	 decrease	 in	 LV	 mass	 index	 (maintained	 during	 the	 10	 years	 of	
treatment	in	male	patients)	in	patients	with	baseline	LV	hypertrophy	and	a	non-significant	
change	 in	 patients	 without	 baseline	 LV	 hypertrophy;	 this	 was	 accompanied	 by	 an	
improvement	 in	 heart	 failure	 and	 angina	 symptoms	 and	 stabilization	 of	 the	 ejection	
fraction.183	 The	 analysis	 of	 data	 extracted	 from	 the	 Fabry	Outcome	Survey	 (a	 registry	 /	
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database	for	FD	patients	who	are	receiving,	or	are	candidates	for,	ERT	with	agalsidase-α)	
confirmed	these	results	in	larger	cohorts	of	patients,	with	up	to	5	years	of	follow-up	and	
additionally	revealed	a	significant	 increase	in	midwall	fractional	shortening	of	the	LV.185-
187	It	 is	worth	mentioning	that	in	all	these	studies,	in	only	a	small	proportion	of	patients	
with	established	LV	hypertrophy,	the	LV	mass	falls	to	normal	range	with	ERT.	Moreover,	
in	 one	 observational	 study	 with	 76	 patients,	 33	 of	 whom	 were	 treated	 with	 ERT	
(agalsidase-α),	 it	was	found	that	ERT	significantly	prevented,	after	a	 follow-up	period	of	
approximately	 3	 years,	 the	 appearance	 of	 TDI	 abnormalities	 in	 FD	 patients	with	 no	 LV	
hypertrophy	or	TDI	abnormalities	at	baseline,	in	comparison	with	the	group	of	untreated	
patients.195	
The	effects	of	agalsidase-β	in	cardiac	structure	and	function	were	not	evaluated	in	
the	randomized,	double-blind,	placebo-controlled	clinical	trials.	However,	they	have	been	
reported	 in	several	non-controlled	studies.	Four	prospective,	open-label,	non-controlled	
studies	assessed	the	effects	of	agalsidase-β	on	LV	mass	by	cardiac	MRI;	all	evaluated	small	
cohorts	of	patients	(between	9	and	17	patients),	included	both	male	and	female,	and	the	
mean	 follow-up	 periods	 were	 between	 12	 and	 45	 months.103,	 188,	 191	 These	 reports	
presented	 conflicting	 results,	 with	 three	 studies	 showing	 a	 significant	 decrease	 in	 LV	
mass103,	 188,	 190	 and	 one	 displaying	 no	 change	 in	 LV	 mass	 after	 24	 months	 of	 ERT.191	
Remarkably,	 in	 the	 study	 evaluating	 17	 patients	 (follow-up	 time:	 12	 months),	 47%	 of	
these	 patients	 presented	 LGE	 in	 cardiac	MRI	 at	 the	 study	 baseline	 and,	 in	 this	 patient	
subgroup,	the	decrease	in	LV	mass	was	non-significant	and	the	improvement	of	regional	
function	was	 restricted	 to	myocardial	 segments	without	 LGE;	moreover,	 the	amount	of	
LGE	increased	significantly	during	ERT,	but	no	patient	without	LGE	developed	LGE	during	
ERT.190	
The	effects	of	agalsidase-β	in	cardiac	structure	and	function,	by	echocardiography,	
have	also	been	evaluated	in	several	small	(up	to	10	patients),	short/medium-term	studies	
(12-24	months),	including	patients	of	both	genders.	Significant	decreases	in	LV	mass	have	
been	reported	in	one	study,189	while	other	authors	reported	no	significant	changes	in	LV	
mass.48,	192,	193	 It	worth	noting	that	one	of	these	studies	was	conducted	 in	9	FD	patients	
undergoing	dialysis,	with	a	24	months	period	of	follow-up	and,	although	a	non-significant	
increase	in	LV	mass	was	observed,	there	was	an	almost	significant	decrease	in	the	mean	
slope	of	LV	mass	index	progression,	when	comparing	the	24	months	before	and	after	the	
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beginning	of	ERT.193	Moreover,	some	authors	reported	improvements	in	diastolic	function	
parameters189	 or	 in	 myocardial	 systolic	 strain	 (a	 more	 sensitive	 method	 to	 quantify	
regional	myocardial	function).103,	190	
Long-term	data	on	the	benefits	of	agalsidase-β	in	cardiac	structure	have	also	been	
reported.	In	an	open-label,	non-controlled	study	based	on	32	FD	patients	over	a	period	of	
3	years,	a	significant	and	sustained	reduction	in	LV	mass	(measured	by	echocardiography)	
was	observed	within	the	follow-up	period.	However,	comparing	the	subgroups	of	patients	
without	fibrosis,	with	mild	fibrosis	and	with	severe	fibrosis	(assessed	by	cardiac	MRI	with	
no	LGE,	LGE	in	one	segment	and	LGE	in	at	least	2	segments,	respectively)	the	reduction	in	
LV	 mass	 was	 more	 pronounced	 in	 patients	 without	 fibrosis	 (although	 significant	 in	 all	
subgroups);	moreover,	an	improvement	in	myocardial	function	(measured	by	myocardial	
systolic	strain)	and	exercise	capacity	(obtained	by	bicycle	stress	exercise)	was	only	evident	
in	the	subgroup	of	patients	without	fibrosis.106		
In	the	long-term	(10	years)	analysis	of	52	out	of	the	56	patients	originally	included	
in	the	pivotal	phase	III	clinical	trial	of	agalsidase-β,	there	was	a	slight	and	non-significant	
increase	of	LVPW	and	 IVS	 thicknesses.	However,	 it	was	more	pronounced	 (though	non-
significant)	 in	patients	with	high	renal	 involvement	 (defined	as	proteinuria	>0.5g/day	or	
≥50%	sclerotic	glomeruli	at	baseline)	and	there	was	a	significant	increase	in	wall	thickness	
in	 patients	 starting	 ERT	 at	 an	 age	 ≥40	 years	 old.194	 This	 influence	 of	 renal	 function	 in	
response	 to	 agalsidase-β	 had	 already	 been	 found	 in	 a	 previous	 study,	 where	 only	 the	
subgroup	 of	 patients	 with	 estimated	 GFR	 >90ml/min/1.73m2	 presented	 a	 significant	
decrease	in	LVPW	thickness	after	24	months	of	ERT;	moreover,	 in	the	same	study	there	
was	no	improvement	in	the	heart	failure	functional	class.196	
Limited	data	 is	 available	 regarding	 “hard”	outcomes,	 such	as	 cardiac	events	and	
death,	in	patients	treated	with	ERT.	A	composite	of	time	to	first	clinical	renal,	cardiac	or	
cerebrovascular	events	or	death	was	the	primary	endpoint	in	a	randomized,	double-blind,	
placebo-controlled	 clinical	 trial	 with	 agalsidase-β.	 The	 analysis	 of	 protocol-adherent	
patients	 (adjusted	 for	 imbalanced	 proteinuria	 at	 baseline)	 favoured	 agalsidase-β	 in	 the	
primary	endpoint,	with	a	hazard	ratio	of	0.39	(95%	confidence	interval	[CI]:	0.16	–	0.93).	
However,	 the	difference	 in	 cardiac	events	 (defined	 in	 the	 trial	 as	myocardial	 infarction;	
new	 symptomatic	 arrhythmia	 requiring	 antiarrhythmic	 medication,	 pacemaker,	 direct	
current	 cardioversion	 or	 defibrillator	 implantation;	 unstable	 angina	 accompanied	 by	
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electrocardiographic	 changes	 resulting	 in	 hospitalization;	 worsening	 congestive	 heart	
failure	requiring	hospitalization)	alone,	although	with	a	hazard	ratio	of	0.42,	did	not	reach	
statistical	significance.	Moreover,	patients	with	estimated	GFR	≥55ml/min/1.73m2	tended	
to	have	a	strong	treatment	effect	(on	the	primary	endpoint),	compared	to	patients	with	
GFR	 <55ml/min/1.73m2.197	 Furthermore,	 an	 analysis	 of	 the	 Fabry	 Registry	 (an	
international	 registry	of	FD	patients),	 including	1044	patients	 treated	with	agalsidase-β,	
showed	 that	 the	 incidence	 rate	 of	 various	 clinical	 events	 was	 maximal	 in	 the	 first	 6	
months	of	ERT,	significantly	decreasing	and	remaining	stable	thereafter.198	These	results	
contrast	with	the	findings	published	by	the	Würzburg	Fabry	Disease	Centre	(in	Germany),	
where	 the	 event	 rate,	 after	 a	 follow-up	 period	 of	 at	 least	 5	 years,	 was	 not	 different	
between	 the	 group	 of	 patients	 treated	 with	 agalsidase-β	 and	 the	 untreated	 (natural	
history)	group	of	the	Fabry	Registry.199	
Regarding	 the	 evaluation	 of	 “hard”	 cardiac	 outcomes	 with	 agalsidase-α,	 only	
indirect	 comparisons	 have	 been	 done	 between	 Fabry	 Outcome	 Survey	 treated	 cohort	
(677	patients)	and	historical	untreated	cohorts.	Moreover,	only	the	results	concerning	the	
composite	 endpoints	 of	 time	 to	 or	 age	 at	 the	 first	 clinical	 event	 (renal,	 cardiac	 or	
cerebrovascular	event	or	death)	have	been	 reported.	Nonetheless,	 treatment	appeared	
to	delay	the	time	to	as	well	as	the	age	at	the	first	event.200	
A	direct	comparison	between	ERT	preparations	in	terms	of	major	clinical	events	is	
currently	underway,	as	part	of	the	Canadian	Fabry	Disease	Initiative.	 In	the	most	recent	
published	data	from	this	study,	there	was	no	difference	between	ERT	preparations	in	the	
percentage	 of	 patients	 meeting	 the	 primary	 composite	 clinical	 endpoint	 (consisting	 of	
renal,	 cardiovascular	 or	 cerebrovascular	 events	 and	 death),	 but	 a	 specific	 analysis	 of	
cardiac	events	was	not	reported.201	
However,	the	effects	of	ERT	on	major	clinical	events,	including	cardiac	events,	are	
still	 debatable,	 given	 that	 in	 a	 comparison	 between	 the	 treated	 FD	 patients	 (including	
agalsidase-α	and	-β	treated	patients)	and	a	natural	history	cohort	(of	untreated	patients	
meeting	 criteria	 for	 ERT)	 in	 the	 Dutch	 FD	 population,	 there	 was	 no	 difference	 in	 the	
incidence	of	the	first	and	second	major	clinical	event.	202	Moreover,	major	cardiac	events	
continued	to	occur	 in	treated	patients,	mainly	 in	patients	with	advanced	disease	at	ERT	
beginning,	namely	patients	with	LV	hypertrophy,	severe	cardiac	fibrosis,	impaired	kidney	
function	and	heavy	proteinuria.187,	194,	196		
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In	 summary,	 although	 longer	 follow-up	 studies	 are	 needed	 to	 confirm	 the	
published	data	and	assess	the	effects	of	ERT	on	overall	prognosis,	 the	previous	 findings	
support	 that	 early	 treatment	 strategy	 may	 be	 more	 effective	 in	 preventing	 cardiac	
manifestations	 and	major	 cardiac	 events,	 because	 patients	 with	 myocardial	 fibrosis	 or	
kidney	dysfunction	may	have	experienced	irreversible	changes	in	cardiac	morphology	and	
do	not	fully	respond	to	ERT.	
The	pharmacologic	chaperone	migalastat	has	been	studied	in	two	phase	III	clinical	
trials,	one	in	naive	patients	(comparison	with	placebo)	and	another	in	patients	previously	
treated	 with	 ERT	 (comparison	 between	 switch	 patients	 and	 the	 ones	 mantained	 in	
ERT).172,	203	Although	 the	primary	objective	of	both	 trials	was	 renal	histology	/	 function,	
echocardiographic	assessment	was	a	secondary	endpoint.	In	the	placebo-controlled	trial,	
there	was	a	significant	decrease	in	LV	mass	index	in	patients	treated	with	migalastat	for	
up	to	24	months,	with	a	trend	toward	a	larger	reduction	in	patients	with	LV	hypetrophy	at	
baseline.172	In	the	switch	trial,	the	patients	switched	from	ERT	to	migalastat	presented	a	
significant	decrease	in	LV	mass	índex,	whereas	in	patients	remaining	on	ERT	there	was	a	
smaller,	 non-significant	 decrease.	 In	 the	 same	 trial	 the	 percentage	 of	 patients	 who	
experienced	 renal,	 cardiac	 or	 cerebrovascular	 events	 during	 the	 18-month	 treatment	
period	was	non-sigficantly	different	between	switch	and	ERT	groups.203		
	
1.4.2	Nephropathy	
The	treatment	of	FD	nephropathy	aims	to	slow	CKD	progression	to	a	loss	of	GFR	≤-
1.0ml/min/1.73m2/year.	 However,	 in	 order	 to	 achieve	 such	 an	 objective	 several	
treatment	strategies	should	be	applied,	namely:	ERT	/	chaperones,	antiproteinuric	drugs	
and	control	of	other	potentially	treatable	factors	that	may	contribute	to	progressive	loss	
of	 GFR	 (HBP,	 dyslipidaemia	 and	 smoking).	 As	 for	 cardiomyopathy,	 with	 15	 years	 of	
available	ERT,	we	have	increasing	evidence	supporting	the	efficacy	of	ERT	in	several	renal	
endpoints,	 including	 histological,	 intermediate	 (laboratorial	 parameters)	 and	 “hard”	
outcomes	(renal	events	and	death).		
In	the	pivotal	randomized,	double-blind,	placebo-controlled,	phase	III	clinical	trial	
of	 agalsidase-α,	 after	 24	 weeks	 of	 treatment	 there	 was	 a	 significant	 increase	 in	 the	
percentage	 of	 normal	 glomeruli	 and	 a	 significant	 decrease	 in	 the	 fraction	 of	 glomeruli	
with	 mesangial	 widening	 in	 the	 active	 treatment	 group,	 compared	 to	 the	 placebo	
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population.	 Furthermore,	 there	 was	 a	 significant	 decrease	 in	 glycolipid	 inclusion	 score	
within	 the	 vascular	 endothelium	 in	 the	 active	 treatment	 group,	 as	well	 as	 a	 21%	 non-
significant	decrease	in	kidney	Gb3	content.	However,	there	was	no	significant	change	in	
total	score	for	tubulointerstitial	pathology	or	for	the	total	Fabry	 inclusion	score	after	24	
weeks	of	treatment.165		
In	 the	agalsidase-β	drug	development,	both	phase	 I/II	and	phase	 III	 clinical	 trials	
had	histological	endpoints	as	the	main	efficacy	measures.166,	177	In	a	phase	I/II	open-label,	
dose-ranging	study,	there	was	mean	decrease	of	67.6%	in	kidney	Gb3	concentration	after	
5	infusions,	 in	5	five	patients	treated	with	agalsidase-β	in	a	doses	ranging	from	3mg/Kg,	
EOW	 to	 3mg/Kg,	 every	 other	 day.	Moreover,	 Gb3	 accumulation	 in	 the	 endothelium	 of	
interstitial	 and	 glomerular	 capillaries	 seemed	 to	 decline,	 as	 well	 as	 in	 mesangial	 and	
cortical	 interstitial	 cells,	 but	 the	 Gb3	 deposits	 in	 glomerular	 podocytes	 remained	
unchanged.177	 These	 results	were	 confirmed	 in	 the	 randomized,	 double-blind,	 placebo-
controlled,	phase	III	clinical	trial	(recruiting	58	patients),	with	a	mean	decrease	of	23.3%	in	
Gb3	concentration	in	kidney	tissues	and	a	significant	decrease	in	the	inclusion	score	in	the	
kidney	 microvascular	 capillary	 endothelial	 cells	 (with	 69%	 of	 the	 patients	 reaching	
complete	clearance)	after	20	weeks	of	active	treatment;	after	six	months	of	an	open-label	
extension	study,	98%	of	the	patients	had	complete	clearance	form	kidney	microvascular	
capillary	endothelial	cells.166	These	results	were	maintained	at	the	end	of	the	54	months	
open-label,	 extension	 study	 of	 this	 clinical	 trial	 (in	 8	 patients	 consenting	 to	 a	 kidney	
biopsy),	 with	 complete	 clearance	 of	 the	 endothelial,	 mesangial	 and	 distal	 convoluted	
tubule	/	collecting	duct	cells.	However,	in	this	long-term	period,	only	70%	of	the	patients	
reached	complete	clearance	of	interstitial	cells	and	none	of	the	patients	achieved	a	zero	
score	 in	 noncapillary	 smooth	 muscle	 cells	 and	 podocytes;	 there	 was	 only	 a	 one-point	
reduction	in	4	out	of	6	patients,	in	podocyte	Gb3	inclusion	score.178	
The	 long-term	 histological	 outcomes	 have	 also	 been	 evaluated	 in	 a	 small	
observational	 study,	with	 12	 young	 patients	 (aged	 between	 7	 and	 33	 years	 old),	 11	 of	
whom	were	treated	with	ERT	for	at	least	5	years.	After	5	years	of	ERT	there	was	complete	
clearance	 of	 inclusions	 in	 glomerular	 endothelial	 and	 mesangial	 cells	 in	 all	 patients.	
However,	the	clearance	of	inclusions	in	glomerular	podocytes	was	inconsistent	and	partial	
clearance	was	only	 observed	 in	 patients	 treated	with	 agalsidase-β	 at	 the	 licensed	dose	
and	agalsidase-α	at	the	dose	of	0.4mg/Kg,	EOW;	there	was	also	a	significant	correlation	
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between	the	cumulative	dose	of	ERT	(regardless	of	the	ERT	preparation)	received	and	the	
clearance	of	podocyte	Gb3.79	However,	this	study	was	carried	out	on	a	small	number	of	
patients	 and	 the	 clearance	 of	 Gb3	 from	 podocytes	 might	 have	 been	 affected	 by	
heterogeneity	 between	 patients	 in	 the	 expression	 levels	 of	 receptors	 (mannose-6-
phosphate	 receptor,	 sortilin	 and	 megalin)	 that	 are	 responsible	 for	 the	 uptake	 of	
recombinant	 α-galactosidase	 A	 into	 the	 lysosomes	 of	 podocytes;204	 thus,	 these	 results	
needs	to	be	confirmed	in	a	larger	cohort	of	patients.	Moreover,	electron	microscopy	was	
able	 to	 detect	 a	 significant	 decrease	 (average	 73%)	 in	 podocyte	 Gb3	 content	 after	 12	
months	of	ERT	with	agalsidase-β	 in	a	cohort	of	6	patients,	which	was	not	detectable	by	
light	microscopy	inclusion	scores.205		
However,	 the	 importance	 of	 the	 finding	 of	 persistent	 podocyte	 Gb3	 inclusions	
remains	 controversial,	 because	 its	 role	 as	 surrogate	 biomarker	 for	 the	 progression	 of	
renal	 dysfunction	 (GFR)	 in	 patients	 treated	 with	 ERT	 is	 not	 well	 established.	
Notwithstanding	 the	 significant	 correlation	between	 the	decrease	 in	urinary	albumin	 to	
creatinine	 ratio	 (ACR)	 and	 the	 decrease	 of	 podocyte	 Gb3	 inclusion	 score	 in	 the	
aforementioned	long-term	evaluation	of	histological	outcomes,	the	GFR	remained	stable	
in	all	patients,	regardless	of	the	decrease	in	podocyte	Gb3	inclusions.79	Similarly,	in	the	54	
months	 extension	 study	 of	 the	 agalsidase-β	 phase	 III	 clinical	 trial,	 despite	 persistent	
inclusion	 in	 podocytes	 in	 the	 6	 evaluated	 patients,	 only	 in	 one	 patient	 was	 there	
progressive	decline	in	GFR.178	Moreover,	as	mentioned	above,	even	in	untreated	patients	
there	 is	 no	 correlation	 between	 semi-quantitative	 scoring	 systems	 for	 intracellular	Gb3	
inclusions	and	GFR57,	59,	77,	83	and	only	a	small	study,	using	electron	microscopy,	has	shown	
significant	correlations	between	podocyte	Gb3	content	and	age	or	proteinuria.58		
	 Regarding	 intermediate	 endpoints,	 ERT	 has	 been	 shown	 to	 slow	 or	 halt	 the	
deterioration	of	 renal	 function	and	proteinuria	 in	patients	with	mild	 to	moderate	 renal	
impairment.149,	165,	166,	178,	181,	183,	185,	187,	194,	196,	197,	199,	200,	206-209	The	effects	of	agalsidase-α	in	
renal	 function	 (GFR)	was	originally	evaluated	 in	 the	 randomized,	double-blind,	placebo-
controlled	phase	III	clinical	trial	(including	only	male	patients)	and,	after	6	months,	there	
was	 a	 3	 fold	 greater	 (although	 non-significant)	 decrease	 in	 measured	 GFR	 (by	 inulin	
clearance)	in	the	placebo	group	compared	with	the	active	treatment	group.	The	change	in	
estimated	 GFR	 by	 creatinine	 clearance	 was	 significantly	 different	 between	 groups,	
increasing	and	decreasing	in	the	active	treatment	and	placebo	groups,	respectively.165	In	
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the	 48	 to	 54	months	 extension,	 open-label	 study	 of	 this	 clinical	 trial,	 there	was	 only	 a	
slight,	though	significant,	decline	in	estimated	GFR,	which	was	mainly	driven	by	the	group	
of	four	patients	with	CKD	stage	≥3	at	baseline,	where	there	was	decrease	at	an	average	
rate	of	5.2ml/min/1.73m2/year;	there	was	no	significant	change	in	proteinuria	during	the	
follow-up	period.206		
	 In	 a	 pooled	 analysis	 of	 the	 three	 6	months	 randomized,	 double-blind,	 placebo-
controlled	clinical	trials	(including	the	aforementioned	clinical	trial)	with	agalsidase-α	and	
their,	 open-label,	 extension	 studies	 for	 up	 to	 12	 to	 48	months,	 including	 108	male	 FD	
patients,	 the	 mean	 decline	 in	 measured	 GFR	 was	 -2.9ml/min/1.73m2/year	 (excluding	
hyperfiltrators:	GFR	>135ml/min/1.73m2),	significantly	different	from	no	change,	but	also	
much	lower	than	the	figure	for	placebo	groups	(-7.0ml/min/1.73m2/year).	There	was	no	
significant	 change	 in	 proteinuria	 during	 the	 follow-up,	 but	 the	 rate	 of	GFR	 decline	was	
much	 higher	 in	 patients	 with	 baseline	 proteinuria	 ≥1g/day	 (-6.4ml/min/1.73m2),	
compared	 with	 the	 ones	 with	 proteinuria	 <1g/day	 (-2.1ml/min/1.73m2)	 and	 also	
predicted	by	the	baseline	GFR.149	
	 The	 effects	 of	 agalsidase-α	 in	 female	 patients	 were	 evaluated	 in	 the	 study	
described	 above	 with	 36	 women	 and	 4	 years	 follow-up.	 The	 estimated	 GFR	 remained	
unchanged	during	the	entire	follow-up,	but	there	was	a	significant	decrease	in	estimated	
GFR	 in	 the	 subgroup	 of	 patients	 who	 were	 hyperfiltrators	 (estimated	 GFR	 >	
135ml/min/1.73m2)	 at	 baseline	 and	 a	 significant	 increase	 in	 estimated	 GFR	 in	 the	 CKD	
stage	2	 subgroup.	 In	 the	overall	 cohort,	 the	observed	decrease	 in	proteinuria	was	non-
significant,	but	 in	 the	subgroup	of	11	patients	with	proteinuria	 in	excess	of	300mg/day,	
mean	protein	excretion	declined	significantly	after	4	years	of	treatment.181		
	 The	analysis	of	data	extracted	from	the	Fabry	Outcome	Survey	registry	confirmed	
these	results	 in	 larger	cohorts	of	patients,	 in	progressively	 longer	follow-up	periods,	the	
last	one	with	a	mean	follow-up	of	7.4	years,	in	a	cohort	of	208	treated	adult	patients.	In	
the	 longer	 follow-up	studies	 the	annualized	decline	 in	estimated	GFR	was	between	-2.2	
and	-3.17ml/min/1.73m2	and	between	-0.7	and	-0.89ml/min/1.73m2	for	male	and	female	
patients,	respectively	and	was	partially	driven	by	a	greater	decline	 in	the	hyperfiltrators	
subgroup;	there	was	no	significant	changes	in	proteinuria,	but	the	rate	of	estimated	GFR	
decline	was	significantly	greater	in	patients	with	higher	baseline	proteinuria	(>1g/day).185,	
187,	207-209	In	a	recent	report	from	the	Fabry	Outcome	Survey,	comparing	treated	patients	
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(mean	 follow-up	 5.2years)	 with	 an	 untreated	 historical	 cohort,	 the	 rate	 of	 decline	 in	
estimated	 GFR	 was	 lower	 compared	 to	 untreated	 patients,	 regardless	 of	 the	 baseline	
GFR,	proteinuria	and	gender.200		
	 In	 the	 longer	 follow-up	 study	 (approximately	 10	 years)	 with	 agalsidase-α,	 in	 a	
cohort	 of	 45	 patients,	 the	 estimated	 GFR	 remained	 stable	 over	 the	 entire	 follow-up	
period,	except	for	a	significant	improvement	in	estimated	GFR	in	the	first	3	to	5	years	of	
ERT,	 in	 both	 male	 and	 female	 patients,	 with	 baseline	 estimated	 GFR	 <	
90ml/min/1.73m2.183	
	 Regarding	agalsidase-α	dosing	frequency,	in	a	small	cohort	of	11	patients	showing	
a	 continuous	 decline	 in	 estimated	 GFR	 ≥5ml/min/1.73m2/year,	 switching	 from	 EOW	 to	
weekly	dosing	was	 found	 to	 significantly	decrease	 the	 rate	of	decline	of	estimated	GFR	
from	 -7.92	 to	 3.84ml/min/1.73m2/year	 after	 up	 to	 10	 years	 of	 follow-up,	 with	 an	
estimated	average	delay	to	ESRD	of	13.8	years.210,	211		
	 The	 effects	 of	 agalsidase-β	 in	 renal	 function	 were	 also	 evaluated	 in	 the	
randomized,	 double-blind,	 placebo-controlled	 phase	 III	 clinical	 trial,	 in	 a	 cohort	 of	 58	
patients.	 Estimated	 GFR	 remained	 stable	 in	 both	 active	 treatment	 and	 placebo	 groups	
after	20	weeks	of	treatment,	as	well	as	in	the	six	month,	open-label,	extension	study.166	
Long-term	follow-up	of	these	patients	has	been	reported	after	54	months	and	10	years	of	
ERT.178,	 194	 After	 10	 years	 of	 ERT	 (available	 data	 for	 52	 of	 the	 initially	 recruited	 58	
patients),	there	was	a	significant	decline	in	estimated	GFR,	which	was	greater	in	patients	
with	high	renal	involvement	(defined	as	proteinuria	>0.5g/day	or	≥50%	sclerotic	glomeruli	
at	 baseline)	 than	 in	 the	 remaining	 patients:	 -6.82ml/min/1.73m2/year	 and	 -
1.89ml/min/1.73m2/year,	respectively;194	proteinuria	remained	stable	within	the	first	54	
months	 of	 the	 extension	 study.178	 In	 the	 other	 randomized,	 double-blind,	 placebo-
controlled	 trial	 with	 agalsidase-β,	 after	 a	median	 follow-up	 of	 18	months,	 the	 authors	
reported	 that	estimated	GFR	and	proteinuria	did	not	change	significantly	 in	both	active	
treatment	and	placebo	groups.197		
	 Two,	 open-label	 studies	 with	 agalsidase-β	 measured	 GFR	 by	 clearance	 of	
Technetium-99m.	In	a	cohort	of	25	patients,	with	a	mean	follow-up	period	of	23	months,	
there	was	 a	 declining	 trend	 in	 GFR,	 but	 which	was	 only	 significant	 in	 the	 subgroup	 of	
patients	with	measured	 GFR	 <90ml/min/1.73m2;	 proteinuria	was	 significantly	 higher	 in	
this	 subgroup	of	patients,	but	does	not	change	significantly	 in	any	 subgroup	during	 the	
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follow-up	 period.196	 After	 at	 least	 5	 years	 of	 follow-up,	 in	 a	 cohort	 of	 40	 patients	
(including	 the	 25	 patients	 of	 the	 previous	 study),	 the	 mean	 decline	 in	 GFR	 was	 -
2.3ml/min/year	(-2.4	and	-1.9ml/min/year	in	male	and	female	patients,	respectively).199	
	 The	 analysis	 of	 a	 cohort	 of	 patients	 from	 the	 Fabry	 Registry,	 treated	 with	
agalsidase-β	 for	 at	 least	 2	 years	 showed	 that,	 in	 multivariate	 regression	 analysis,	
proteinuria	≥1g/g	and	a	longer	time	from	symptom	onset	and	treatment	were	the	most	
important	factors	associated	with	renal	disease	progression.212	
	 The	 few	studies	evaluating	“hard”	outcomes	were	described	 in	 the	treatment	of	
FD	 cardiomyopathy,	 but	 often	 also	 evaluated	 renal	 events,	 mainly	 defined	 as	 a	 33%	
increase	 in	 serum	 creatinine	 level	 or	 ESRD	 requiring	 long-term	 dialysis	 or	 kidney	
transplantation.	 In	 the	 aforementioned	 randomized,	 double-blind,	 placebo	 controlled	
clinical	 trial	 with	 agalsidase-β,	with	 a	 primary	 endpoint	 of	 a	 composite	 of	 time	 to	 first	
renal,	cardiac	or	cerebrovascular	events	or	death,	most	events	were	renal,	consisting	 in	
all	cases	of	a	33%	increase	 in	serum	creatinine	 levels.	However,	the	difference	between	
active	treatment	and	placebo	in	renal	events,	although	with	a	hazard	ratio	of	0.49,	did	not	
reach	statistical	significance.	Moreover,	proteinuria	was	significantly	associated	with	any	
renal	event	(hazard	ratio	1.4	[95%	CI:	1.2	to	1.8].197	None	of	the	other	studies	reporting	
clinical	 events,	previously	described	 in	 the	 treatment	of	 cardiomyopathy,	described	 the	
effect	 of	 ERT	 specifically	 on	 renal	 outcomes,	 in	 comparison	 with	 no	 treatment.199-202	
However,	 renal	manifestations	are	significant	 risk	 factors	 for	any	clinical	event,	namely:	
proteinuria,	≥50%	sclerotic	glomeruli	and	decreased	GFR.194,	196,	199	
To	conclude,	because	of	the	heterogeneous	disease	presentation,	no	evidence	 is	
available	to	support	the	optimal	timing	of	ERT.	However,	it	appears	that	if	a	threshold	of	
renal	 disease	 (CKD	 stage	 ≥3,	 proteinuria	 >1g/day	 and	 ≥50%	 of	 glomerular	 sclerosis)	 is	
exceeded,	 the	 benefits	 of	 ERT	 may	 be	 limited,	 with	 a	 self-propagation	 of	 end-stage	
pathology.	 Furthermore,	 these	 results	 emphasize	 the	 need	 to	move	 towards	 combined	
therapy	with	ERT	and	antiproteinuric	drugs.	
	 Actually,	as	described,	proteinuria	is	major	risk	factor	for	decline	in	GFR	and	major	
clinical	 events,	 but	 ERT	does	not	 seem	 to	 reduce	proteinuria	 (mainly	 in	male	patients).	
Thus,	 antiproteinuric	 therapies	 may	 play	 a	 role	 in	 stabilization	 of	 kidney	 function.	
Nonetheless,	 the	 evidence	 supporting	 the	 use	 of	 angiotensin-converting	 enzyme	
inhibitors	 (ACEi)	and/or	angiotensin	 receptor	blockers	 (ARB)	 in	Fabry	disease	 is	 scant.	A	
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first,	 open-label	 study	 in	 a	 small	 cohort	 of	 patients	 treated	 with	 ACEi	 and/or	 ARB	 in	
conjunction	with	agalsidase-β,	reported	promising	results	with	reductions	 in	proteinuria	
and	 stabilization	of	 estimated	GFR	 (slope	 -0.23ml/min/1.73m2/year)	 in	 a	 subgroup	of	 6	
patients	with	CKD	stage	≥3,	within	30	months	of	follow-up.213	However,	these	promising	
results	 have	 not	 been	 confirmed	 in	 a	 larger	 (24	 patients,	 treated	 with	 agalsidase-β),	
multicenter	 study,	 with	 21	 months	 of	 follow-up.	 In	 this	 study,	 18	 out	 of	 24	 patients	
reached	proteinuria	<0.5g/g,	with	estimated	GFR	slopes	significantly	better	 than	 the	six	
who	 did	 not	 achieve	 this	 value	 (-3.6	 and	 -7.0ml/min/1.73m2/year,	 respectively).	
Nevertheless,	 even	 in	 the	 subgroup	 of	 18	 patients	 with	 proteinuria	 <0.5g/g,	 12	 still	
progressed	with	an	estimated	GFR	slope	<-2ml/min/1.73m2/year.214		
	 The	 two	 phase	 III	 clinical	 trials	 with	 migalastat	 had	 as	 primary	 endpoints:	
clearance	 of	 Gb3	 inclusions	 from	 the	 kidney	 interstitial	 capillaries	 and	 effect	 on	 renal	
function.	In	the	placebo-controlled	trial,	after	6	months	of	migalastat,	in	the	subgroup	of	
patients	with	suitable	mutations	there	was	a	significantly	greater	reduction	in	the	mean	
number	 of	 Gb3	 inclusion	 per	 kidney	 interstitial	 capillary	 than	 was	 in	 placebo	 group;	
moreover,	there	was	a	qualitative	decrease	in	Gb3	in	glomerular	podocytes,	endothelial	
cells	and	mesangial	cells	in	22%,	26%	and	48%	of	the	patients,	respectively.172	These	data	
were	 further	 confirmed	with	 a	 significant	 decrease	 in	 the	 quantitative	 analysis	 of	 Gb3	
inclusions	 in	 podocytes	 after	 6	 months	 of	 migalastat.215	 Measured	 and	 estimated	 GFR	
remained	essentially	stable	for	up	to	24	months	of	treatment.172,	203	
	
2.	Biomarkers	
2.1	Definition	and	application	in	Fabry	disease	
Biological	markers	or	biomarkers	are	defined,	according	to	the	National	Institutes	
of	Health	Biomarkers	Definitions	Working	Group,	 as	 “a	 characteristic	 that	 is	 objectively	
measured	 and	 evaluated	 as	 an	 indicator	 of	 normal	 biological	 processes,	 pathogenic	
processes,	or	pharmacologic	responses	to	a	therapeutic	intervention”.216	Biomarkers	may	
have	greatest	value	in	several	clinical	applications,	namely:	as	a	diagnostic	tool,	staging	or	
classifying	the	extent	of	the	disease,	disease	progression	and	prognosis,	in	prediction	and	
monitoring	of	clinical	response	to	an	intervention	and	early	efficacy	and	safety	evaluation	
in	clinical	 trials.216	However,	rigorous	validation	of	the	relationship	between	a	proposed	
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biomarker	and	disease	activity	and	outcome	is	of	key	importance.	
Candidate	 biomarkers	 for	 LSDs	 are	 mainly	 analytes	 and	 imaging	 techniques.	
Analytes	may	 range	 from	simple	metabolites	 to	complex	proteins	and,	 for	LSDs,	 can	be	
divided	into	two	categories:	molecules	that	accumulate	in	tissues	and	body	fluids	directly	
due	to	enzymatic	defect;	and	molecules	produced	by	the	cells	 in	response	to	 lysosomal	
storage.217			
One	 of	 the	 most	 urgent	 needs	 in	 FD	 is	 for	 reliable	 and	 validated	 biomarkers,	
ideally	 measured	 by	 non-invasive	 testing.	 This	 urgency	 is	 mainly	 related	 to	 the	
characteristics	 of	 and	 pitfalls	 in	 FD:	 diagnosis,	 determination	 of	 phenotype	 (classical	 vs	
attenuated),	monitoring	and	evaluation	of	treatment	response.		
The	diagnosis	of	FD	is	based	mainly	on	the	enzymatic	activity	of	α–galactosidase	A	
and	GLA	gene	sequencing,	but	both	methods	have	limitations	that	need	to	be	addressed.	
Due	 to	 random	 X	 chromosome	 inactivation,	 female	 patients	 may	 present	 significant	
residual	 enzymatic	 activity	 and	 about	 one	 third	 may	 have	 α–galactosidase	 A	 activity	
within	 the	normal	 range	 for	general	population,	 thus	 the	diagnosis	 can	only	be	 reliably	
performed	 by	 GLA	 sequencing.218	 Moreover,	 in	 male	 patients	 with	 residual	 enzymatic	
activity	(>	5%	of	normal),219,	220	definitive	diagnosis	of	FD	may	only	be	confirmed	by	GLA	
gene	mutation	analysis.221	However,	GLA	gene	 sequencing	may	not	provide	a	definitive	
diagnosis	 for	 several	 reasons:	 most	 GLA	 mutations	 found	 in	 FD	 patients	 are	 novel	 /	
”private”,	 there	 are	 various	mutations	of	 unknown	 significance	 and	 routine	 sequencing	
can	 only	 identify	 a	 mutation	 in	 97%	 of	 male	 patients	 with	 FD.221,	 222	 Hence,	 reliable	
biomarkers	may	help	diagnosis	in	these	situations.	
	 Furthermore,	 FD	 is	 clinically	 heterogeneous	 (in	 presentation	 and	 rate	 of	
progression),10,	15,	82,	83	with	genetic	factors	and	gender	certainly	contributing	to	this	fact.9,	
14	However,	the	clinical	picture	may	vary	widely	even	in	patients	within	the	same	family	
or	with	the	same	mutation,	thus	other	genetic,	epigenetic	and	environmental	factors	also	
contribute	to	clinical	heterogeneity.	Therefore,	the	identification	of	prognosis	biomarkers	
and	biomarkers	with	value	determining	 the	 likely	phenotype	 (classical	 vs	attenuated)	 is	
paramount	to	the	identification	of	patients	at	increased	risk	of	a	progressive	disorder.				
	 As	 previously	 described,	 although	 the	 optimal	 timing	 of	 ERT	 beginning	 is	 not	
known,	 increasing	 evidence	 suggests	 that	 an	 early	 treatment	 strategy	 may	 be	 more	
effective	to	prevent	cardiac	and	renal	manifestations	and	major	clinical	events.	However,	
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currently	 the	 European	 recommendations	 for	 ERT	 initiation	 are	 based	 on	 functional	 or	
structural	manifestations.223	Nonetheless,	 as	mentioned	above,	 there	 is	 a	 long	 clinically	
silent	 period	 before	 overt	 major	 organ	 manifestations,	 characterized	 by	 histological	
changes	 (often	 irreversible	 lesions)	 or	 in	 the	 transcriptional	 profile,	 whose	 detection	
depends	on	invasive	procedures.	Consequently,	identification	of	non-invasive	biomarkers	
of	pre-clinical	 involvement	of	the	organs	may	have	a	profound	impact	on	the	treatment	
decisions.	
	 Finally,	FD	is	a	relatively	slowly	progressive	disorder,	with	major	events	occurring	
mainly	 in	 adulthood.	 This	 fact	 constitutes	 a	 major	 difficulty	 in	 the	 design	 of	 clinical	
trials,165,	166,	176	because	long	follow-up	periods	are	required	to	demonstrate	the	benefits	
of	any	therapeutic	 intervention.	Therefore,	the	identification	of	surrogate	biomarkers	of	
response	 to	 treatment,	with	 rigorous	 correlations	with	 clinical	outcomes,	 is	 essential	 in	
the	evaluation	of	the	therapeutic	strategies	that	are	available	or	under	development.	
	
2.2	Fabry	disease	biomarkers	used	in	the	clinical	practice	
There	 is	 currently	 no	 proper	 or	 well	 established	 /	 validated	 plasma	 or	 urinary	
biomarkers	 for	 FD.	 However,	 there	 are	 several	 biomarkers	 (imaging	 techniques	 and	
analytes	[metabolites	related	to	lipid	abnormalities	or	proteins])	that	are	used	in	clinical	
practice	with	 some	 limitations	 (a	 summary	 is	 shown	 in	 table	2).	 These	biomarkers	may	
reflect	the	total	body	burden	of	storage	cells	or	manifestations	in	a	particular	organ.		
	
2.2.1	Total	disease	burden	
FD	 is	 characterized	 by	 disruption	 in	 glycosphingolipids	 metabolism,	 so	 lipid	
abnormalities	 have	 been	 studied	 as	 potential	 biomarkers.	 For	 a	 long	 time,	 the	 primary	
accumulating	 substrate	 Gb3	 has	 been	 considered	 a	 surrogate	 marker	 for	 FD	 and	 its	
reduction	 in	 the	 endothelium	 has	 served	 as	 an	 indicator	 for	 the	 development	 and	
registration	of	ERT	with	agalsidase-β.166,	177	Actually,	Gb3	is	not	only	found	inside	the	cells,	
but	 it	has	been	recognized	 for	a	 long	 time	that	 its	concentration	 is	 increased	 in	plasma	
and	 urine	 in	 FD	 male	 patients.224	 Plasma	 and	 urine	 Gb3	 values	 are	 more	 strikingly	
elevated	 in	 FD	males	 and	plasma	Gb3	 is	 elevated	 in	only	 a	 small	 percentage	of	 female	
patients	 (15-30%),	and	urinary	Gb3	may	even	be	within	 the	normal	 range	 in	8-13%	and	
12-20%	of	male	and	 female	patients,	 respectively.225,	226	 There	 is	 a	 correlation	between	
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types	 of	mutations	 and	 urinary	 Gb3	 excretion,	 with	 patients	 with	missense	mutations,	
mainly	 those	 associated	 with	 late-onset	 phenotypes,	 presenting	 lower	 values,	 most	 of	
which	within	the	normal	range;	in	patients	with	mutations	associated	with	an	attenuated	
phenotype,	plasma	Gb3	 is	usually	within	 the	normal	 range,	even	 in	male	patients.226-228	
Thus,	the	added	value	of	Gb3	for	diagnostic	purposes	is	at	least	questionable.		
	
Table	 2:	 Fabry	 disease	 biomarkers	 used	 in	 clinical	 practice.	 ERT:	 enzyme	 replacement	 therapy;	 Gb3:	
globotriaosylceramide;	 eGFR:	 estimated	 glomerular	 filtration	 rate;	 PCR:	 protein	 to	 creatinine	 ratio;	 ACR:	 albumin	 to	
creatinine	 ratio;	 LV:	 left	 ventricular;	MSSI:	Mainz	 Severity	 Score	 Index;	WML:	white	matter	 lesions;	HR:	hazard	 ratio;	
HCM:	 hypertrophic	 cardiomyopathy	 due	 sarcomere	 protein	 gene	 mutations;	 LGE:	 late	 gadolinium-contrast	
enhancement;	 MRI:	 magnetic	 resonance	 imaging;	 NT-proBNP:	 N-terminal	 fragment	 of	 the	 pro-hormone	 of	 brain	
natriuretic	peptide;	TDI:	tissue	Doppler	imaging;	LA:	left	atrial;	FD:	Fabry	disease;	CKD:	chronic	kidney	disease.	
Biomarker	 Diagnosis	 Clinical	correlations	 ERT	monitoring	
Gb3	(plasma	/	urine)	 Not	useful	 Poor:	
• Plasma	 Gb3	 with	 cerebral	
complications	(♂)	
• Urinary	 Gb3	 with	 eGFR,	
PCR	and	ACR	
Decrease	during	ERT:	
• Correlation	 with	 clinical	
endpoints	not	established	
	
	
Lyso-Gb3	(plasma)	 Added	 value	 (cautious	
interpretations	of	results)	
• ♀:	LV	mass	and	MSSI	
• ♂:	WML	
Decrease	during	ERT:	
• ♀: correlation	 with	 â	LV	
mass	and	HR	to	WML	
Cardiac	troponin	 Differentiate	 HCM	 versus	
infiltrative	cardiomyopathy	
• LV	wall	thickness	
• LGE	volume	in	cardiac	MRI	
	
Not	useful:		
• High-sensitivity	 troponin	 T	
increases	during	ERT	
NT-proBNP	 Not	evaluated	 Diastolic	 dysfunction	
parameters	and	LV	mass	
Not	evaluated	
Echocardiogram	(TDI)	 Superior	 to	 conventional	
echocardiography	 in	 the	
detection	 of	 early	 cardiac	
involvement	
LV	wall	thickness	 ERT	 successfully	 prevented	
appearance	 of	 abnormal	 TDI	
velocities	
Echocardiogram	
(speckle-tracking)	
	
Better	 sensitivity	 than	 TDI	 in	
detecting	 early	 diastolic	
dysfunction	
• LGE	in	cardiac	MRI	
• Functional	status	
ERT	improves:	
• Systolic	 strain	 and	 strain	
rate	(?)	
• LA	peak	positive	strain	
Cardiac	MRI	(LGE)	 Characteristic	 pattern	 of	 LGE	
distribution	 (distinguish	 from	
HCM)	
LGE	amount	correlates	with:	
• LV	mass	
• Regional	 myocardial	
function	
• Risk	 of	 ventricular	
arrhythmias	
Not	useful:	
• LGE	 amount	 increase	
during	ERT	
• Major	 predictor	 of	
response	to	ERT	
	
Cystatin	C	 Better	 diagnostic	 accuracy	
than	 creatinine	 in	 detecting	
early	renal	involvement	
Better	 correlation	 of	 cystatin	
C	 and	 creatinine-based	
equations	 with	 measured	
GFR	(?)	
More	 sensitive	 than	
creatinine	 in	detecting	minor	
decline	in	GFR	during	ERT	(?)	
Proteinuria	
Albuminuria	
Earlier	 biomarker	 of	 FD	
nephropathy	(limitations)	
Good	 correlation	 with	 GFR	
decline	 (there	 are	 several	
patients	 with	 CKD	 stage	 ≥3	
without	overt	proteinuria)	
Does	not	respond	to	ERT	
	
	
The	 correlation	 with	 clinical	 manifestations	 and	 its	 added	 value	 to	 monitor	
progression	of	FD	is	also	poor.	In	a	Dutch	cohort	of	63	male	and	female	FD	patients,	there	
	 61	
was	no	correlation	between	plasma	or	urinary	Gb3	with	age,	most	of	clinical	parameters	
and	total	disease	severity	(measured	by	Mainz	Severity	Score	Index	[MSSI]);229	however,	
plasma	 Gb3	 was	 significantly	 higher	 in	 male	 patients	 with	 cerebral	 complications	
(compared	with	 those	without)	 and	 urinary	Gb3	 significantly	 correlates	with	 estimated	
GFR,	 urine	 protein	 to	 creatinine	 ratio	 and	 ACR	 (in	 a	 cohort	 with	 male	 and	 female	
patients).225,	 230	 Finally,	 there	 was	 significant	 decrease	 in	 plasma	 and/or	 urine	 Gb3	 in	
patients	treated	under	the	clinical	trials	of	both	ERT	preparations;165,	166,	178,	206	however,	
the	 correlation	 between	 this	 decrease	 and	 the	 therapeutic	 outcome	 in	 terms	 of	
“intermediate”	or	“hard”	endpoints	 is	not	established.226,	228,	231	Moreover,	 in	one	study	
the	occurrence	of	antibodies	anti	ERT	was	accompanied	by	a	blunted	decrease	in	urinary	
Gb3,	 but	 the	 clinical	 significance	 of	 this	 remains	 unclear.232	 The	 limitations	 of	 Gb3	 in	
terms	of	predictive	value	for	FD	manifestations	are	not	surprising,	given	that	prominent	
Gb3	 has	 been	 noted	 in	 placental	 tissues	 of	 FD	 male	 patients,233,	 234	 with	 the	 onset	 of	
clinical	complications	occurring	only	several	years	later,	thus,	as	mentioned	above,	other	
factors	in	addition	to	Gb3	may	participate	in	pathogenesis.	
Given	the	limitations	of	Gb3	as	biomarker,	research	on	Gb3	metabolites	identified	
a	product	of	Gb3	deacetylation,	globotriaosylsphingosine	(lyso-Gb3),	which	is	hydrophilic	
and	 highly	 diffusible	 and	 whose	 plasma	 levels	 in	 FD	 patients	 are	 markedly	 increased	
(exceeding	 those	of	Gb3	by	more	 than	one	order	of	magnitude	and	most	prominent	 in	
male	patients).17	In	this	first	study	all	male	and	female	patients	presented	very	high	levels	
of	plasma	lyso-Gb3,	except	for	a	young	(6	year-old)	and	asymptomatic	female	patient.17	
These	 results	 were	 confirmed	 in	 larger	 cohorts	 of	 patients	 (with	 up	 to	 92	 patients),	
showing	that	even	male	patients	with	attenuated	phenotypes	presented	increased	lyso-
Gb3	levels	(though	in	lower	magnitude	than	patients	with	classical	phenotype).228,	235,	236	
However,	 the	 discriminative	 power	 in	 male	 and	 female	 patients	 with	 mutations	 of	
unknown	 significance,	 namely	 p.R112H	 and	 p.P60L,	 seems	 limited,	 as	 lyso-Gb3	 is	 not	
increased	 in	 this	 group	of	 patients	 (even	 in	 patients	with	 histological	 demonstration	of	
Gb3	 storage	 in	 podocytes).235,	 237	 Nonetheless,	 recently	 nano-liquid	 chromatography-
tandem	 mass	 spectrometry	 (a	 technique	 enabling	 the	 detection	 of	 extremely	 low	
concentrations	 of	 lyso-Gb3,	 with	 greater	 sensitivity	 than	 conventional	 techniques),	 in	
patients	with	mutations	of	unknown	significance	(p.R112H	and	p.M296I),	demonstrated	
that	lyso-Gb3	was	lower	than	in	classical	and	attenuated	phenotypes	FD	patients	having	
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other	mutations,	but	higher	than	 in	those	with	functional	variants	(p.E66Q)	and	healthy	
subjects.238	Urinary	 lyso-Gb3	 performance	 as	 a	 diagnostic	 tool	 seems	 similar	 to	 that	 of	
plasma	 lyso-Gb3,	with	 only	 a	minority	 of	 patients	 excreting	 undetectable	 amounts	 and	
with	patients	presenting	missense	mutations	having	significantly	lower	excretion	of	lyso-
Gb3.230	Thus,	 lyso-Gb3	seems	to	be	a	promising	diagnostic	biomarker,	with	added	value	
for	 diagnosis	 in	 specific	 situations,	 but	 evaluation	 of	 pathogenicity	 of	mutations	 based	
solely	in	this	parameter	should	be	cautious.	
Various	 correlations	 have	 been	 found	 between	 plasma	 lyso-Gb3	 and	 clinical	
manifestations.	 In	 male	 patients,	 lyso-Gb3	 does	 not	 increase	 with	 age	 (with	 markedly	
increased	 values	 even	 in	 neonates)	 and	 consequently	 does	 not	 correlate	 strictly	 with	
disease	severity	indexes	or	clinical	manifestations,	except	for	a	significant	correlation	with	
the	 presence	 of	 white	 matter	 lesions.17,	 235	 In	 contrast,	 in	 females	 lyso-Gb3	 tends	 to	
increase	 progressively	 with	 age	 and	 significant	 correlations	 have	 been	 found	 between	
lyso-Gb3	 and	 MSSI,	 LV	 mass	 and	 carotid	 intima	 media	 thickness.17,	 235,	 239	 There	 is	 no	
established	correlations	between	plasma	lyso-Gb3	and	kidney	function	parameters,	but	a	
significant	correlation	between	urinary	 lyso-Gb3	and	urine	protein	to	creatinine	ratio	or	
ACR	has	been	observed;	however,	this	correlation	was	performed	in	a	cohort	of	male	and	
female	patients	and	no	adjustment	for	gender	was	reported.230	As	lyso-Gb3	seems	to	be	a	
risk	 factor	 directly	 implied	 in	 FD	 pathogenesis,	 lifetime	 exposure	 to	 plasma	 lyso-Gb3	
(estimated	 product	 of	 lyso-Gb3	 concentration	 by	 age)	 should	 correlate	 better	 with	
disease	 (mainly	 in	male	patients,	 showing	very	high	values	 from	birth)	 than	 the	current	
lyso-Gb3	level.	Therefore,	both	in	male	and	female	patients	plasma	lyso-Gb3	exposure	is	
significantly	 correlated	with	disease	 severity	 and	with	 the	 cold	detection	 threshold	and	
thermal	 sensory	 limen	 of	 the	 upper	 limb	 (both	 signs	 of	 characteristic	 FD	 small	 fibre	
neuropathy).235,	240		
Lyso-Gb3	decreases	significantly	with	ERT,	but	does	not	reach	normal	values,	even	
in	 female	patients,	 independently	of	ERT	preparation.17,	228,	236,	241	Moreover,	 in	patients	
developing	 anti-ERT	 neutralizing	 antibodies,	 reduction	 of	 plasma	 lyso-Gb3	 is	 relatively	
poor,	mainly	in	patients	treated	with	agalsidase-α	(with	a	significant	difference	between	
patients	with	 and	without	 anti-drug	 antibodies).17,	236,	241	 The	 reduction	 in	 plasma	 lyso-
Gb3	during	ERT	was	found	to	correlate	with	correction	of	LV	mass	in	female	patients	and	
with	a	 lower	hazard	ratio	for	developing	new	cerebral	white	matter	 lesions	 in	male	and	
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female	patients.241	The	potentially	prognostic	value	of	plasma	lyso-Gb3	reduction	during	
ERT	 for	 clinical	 outcome	 clearly	 needs	 further	 investigation	 in	 larger	 cohorts	 of	 FD	
patients.	
Finally,	 as	 previously	 described,	 lyso-Gb3	 may	 play	 a	 direct	 role	 in	 disease	
pathogenesis:	it	has	the	capacity	to	inhibit	α-galactosidase	A	activity	in	“wild	type”	cells,	
contributing	 to	 the	 “cross-induction”	 of	 the	 defect	 in	 female	 patients;17	 “in	 vitro”,	 it	
induces	smooth	muscle	cell	proliferation	(directly	contributing	to	FD	vasculopathy);17,	242	
it	 induces	 expression	 and	 production	 of	 extracellular	matrix	 proteins	 by	 podocytes,	 via	
the	TGF-β1	and	Notch1	pathways.18,	70	
Research	 of	 potential	 protein	 biomarkers	 for	 FD	 showed	 a	 lack	 of	 prominent	
plasma	 protein	 abnormalities.	 However,	 several	 biomarkers	 mainly	 related	 to	
inflammation	 and	 endothelial	 dysfunction	 have	 been	 studied,	 but	 not	widely	 validated	
and,	consequently,	are	not	currently	used	in	clinical	practice.	A	brief	description	of	these	
protein	 biomarkers	 will	 be	 given	 in	 the	 section	 “Experimental	 biomarkers	 in	 Fabry	
disease”.	
	
2.2.2	Fabry	disease	cardiomyopathy	
Currently,	imaging	techniques	are	the	most	commonly	used	biomarkers	of	cardiac	
injury	in	FD,	but	some	biochemical	biomarkers	are	also	used	in	clinical	practice.		
Cardiac	 troponins	 are	 well-validated	 biomarkers	 of	 cardiomyocyte	 injury.	 New	
generation	 /	 high-sensitivity	 assays	 for	 cardiac	 troponin	 T	 enable	 the	 identification	 of	
minimal	 cardiac	 injury	 and	 have	 been	 associated	 with	 poor	 outcomes	 in	
cardiomyopathies	 other	 than	 ischemic	 heart	 disease.243,	244	 Two	 studies,	 evaluating	 the	
performance	 of	 troponin	 I	 as	 biomarker	 of	 FD	 cardiomyopathy	 have	 shown	 that	 this	
analyte	 was	 elevated	 (≥0.04ng/mL)	 in	 21	 –	 37%	 of	 the	 patients,	 with	 a	 very	 high	
diagnostic	 accuracy	 for	 LV	 hypertrophy	 or	 LGE	 in	 cardiac	 MRI.245,	 246	 High-sensitivity	
troponin	 T	 was	 evaluated	 in	 a	 large	 cohort	 of	 75	 patients	 and	 found	 to	 be	 elevated	
(>14ng/L)	 in	40%	of	the	cohort,	97%	of	whom	had	evidence	of	LGE	in	cardiac	MRI	(LGE-
positive	myocardial	volume	was	the	only	 factor	 independently	associated	with	 troponin	
elevation	 in	multivariate	 logistic	 regression	analysis).	 In	 the	 same	study,	 the	correlation	
between	 troponin	 and	 IVS	 wall	 thickness	 was	 also	 significant	 and	 in	 a	 retrospective	
analysis,	over	a	follow-up	period	of	3.9	years,	patients	with	elevated	troponin	at	baseline	
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had	significantly	increasing	replacement	fibrosis.247	Moreover,	high-sensitivity	troponin	T	
may	 help	 to	 differentiate	 between	 patients	 with	 HCM	 and	 infiltrative	 cardiomyopathy	
(amyloidosis	and	FD),	which	share	phenotypic	features,	being	significantly	more	elevated	
in	patients	with	infiltrative	aetiologies.248	
Brain	 natriuretic	 peptide	 and	 the	 N-terminal	 fragment	 of	 its	 pro-hormone	 (NT-
proBNP)	 have	 an	 established	 role	 in	 determining	 the	 diagnosis	 and	 prognosis	 of	 heart	
failure.249,	250	NT-proBNP	was	evaluated	as	a	biomarker	of	early	cardiac	involvement	in	FD	
in	 two	 relatively	 large	 cohorts	 of	 89	 and	 117	 FD	 patients.	 In	 both	 studies	 a	 significant	
correlation	was	 found	between	NT-proBNP	and	parameters	of	diastolic	dysfunction	and	
LV	 wall	 thickness;	 moreover,	 it	 has	 good	 diagnostic	 accuracy	 in	 predicting	 abnormal	
echocardiographic	 findings	and	may	be	a	sensitive	marker	 in	detecting	early	changes	 in	
cardiac	involvement,	such	as	diastolic	dysfunction.251,	252	
Nonetheless,	cardiac	imaging	techniques	are	the	mainstay	in	the	assessment	of	FD	
cardiomyopathy.	 Conventional	 two-dimensional	 and	 Doppler	 echocardiography	 is	 the	
standard	 imaging	 tool	 in	 the	 identification	 and	 staging	 of	 cardiac	 involvement	 in	 FD	
disease,	but	it	is	not	suitable	to	detect	subtle	myocardial	dysfunction	in	the	early	course	
of	FD	cardiomyopathy.138,	139	Therefore,	advanced	echocardiography	techniques,	 like	TDI	
and	 strain	 and	 SR	 speckle-tracking	 based	 echocardiography	 have	 been	 used	 in	 early	
cardiac	involvement	that	precedes	overt	LV	hypertrophy	and	appearance	of	replacement	
myocardial	fibrosis.	
There	are	several	studies,	such	as	in	HCM	and	other	inherited	cardiomyopathy,253	
demonstrating	the	added	value	of	TDI	in	the	early	detection	of	FD	cardiomyopathy.102,	104,	
195,	254-257	In	the	first	study	on	the	evaluation	of	TDI	in	FD	cardiomyopathy	(10	FD	patients	
with	LV	hypertrophy,	10	FD	patients	without	LV	hypertrophy	and	10	healthy	controls),	it	
was	 reported	 that	 echocardiography	 did	 not	 show	 any	 difference	 between	 FD	 patients	
without	LV	hypertrophy	and	controls	in	conventional	parameter	of	diastolic	dysfunction,	
but	 there	 was	 a	 significant	 decrease	 in	 myocardial	 systolic	 and	 diastolic	 velocities	
(evaluated	 by	 TDI),	 even	 in	 FD	 patients	 without	 LV	 hypertrophy	 (although	 of	 lesser	
magnitude	than	 in	patients	with	overt	LV	hypertrophy).	Furthermore,	 in	the	histological	
analysis,	even	in	the	FD	group	without	LV	hypertrophy,	in	some	patients’	interstitium	was	
slightly	 widened	 due	 to	 intercellular	 fibrosis	 and	 there	 were	 also	 tiny	 areas	 of	 fibrous	
replacement.104	These	results	were	further	confirmed	in	several	small	cohorts	of	patients	
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(with	 up	 to	 19	 FD	 patients).102,	 254,	 255	 Abnormalities	 of	 systolic	 velocities	 in	 the	 RV,	
measured	by	TDI	have	also	been	recently	described.258	
The	 sensitivity	 of	 various	 parameters	 to	 detect	 early	 diastolic	 dysfunction	 have	
been	compared	in	two	studies:	a	study	with	81	echocardiographic	examinations	showed	
that	 early	 diastolic	mitral	 annular	 velocity	 (E’)	measured	 by	 TDI	 has	 significantly	 better	
diagnostic	 accuracy	 to	 detect	 diastolic	 dysfunction	 (defined	 by	 the	 LV	 filling	 patterns	
obtained	 using	 standard	 Doppler	 indexes)	 than	 colour	 M-mode	 flow	 propagation	
velocity.256	 Another	 study	 including	 59	 FD	 patients	 (none	 of	 them	under	 ERT)	 not	 only	
confirmed	 the	 results	 of	 impaired	 TDI	 parameters	 even	 in	 FD	 patients	 without	 LV	
hypertrophy	 (including	myocardial	 systolic	 and	diastolic	 velocities,	 but	 also	a	 significant	
increase	 in	 isovolumic	 relaxation	 time	 [IVRT]	 and	 a	 significant	 decrease	 in	 isovolumic	
contraction	 time),	 but	 also	 demonstrated	 a	 significant	 inverse	 correlation	 between	
systolic	mitral	annular	velocity	(S’)	or	E’	and	IVS	or	LVPW	thickness	and	a	significant	direct	
correlation	between	IVRT	and	LV	wall	thickness.	Moreover,	comparison,	between	several	
TDI	parameters,	of	the	diagnostic	accuracy	to	detect	early	preclinical	cardiac	involvement	
(defined	as	absent	 cardiac	 symptomatology	and	 semiology	and	normal	echocardiogram	
and	ECG)	was	maximal	for	isovolumic	contraction	time	(area	under	the	curve	[AUC]	0.97),	
but	also	significant	for	IVRT	and	E’.257	
The	effects	of	ERT	in	the	prevention	of	early	cardiac	involvement	(defined	by	the	
presence	of	TDI	abnormalities)	was	evaluated	in	a	study	with	66	FD	patients,	33	of	whom	
were	 treated	with	agalsidase-α	over	a	 follow-up	period	of	around	3	years.	Agalsidase-α	
successfully	 prevented	 the	 appearance	 of	 abnormal	 TDI	 velocities	 in	 the	 group	 of	 29	
patients	with	 normal	 echocardiograms	 at	 baseline	 (80%	 of	 the	 patients	 not	 under	 ERT	
progressed	 to	 abnormal	 TDI	 velocities	 during	 follow-up,	 whereas	 this	 progression	 only	
occurred	 in	33%	of	patients	under	ERT).195	The	appearance	of	TDI	abnormalities	before	
overt	 LV	 hypertrophy	 is	 not	 surprising:	 bioptic	 studies	 have	 shown	 ultrastructural	
evidence	of	myofibrillolysis	correlated	with	a	far	lower	active	tension	coupled	with	higher	
resting	 tension	 of	 cardiomyocytes	 in	 FD.29	 Furthermore,	 increased	myocardial	 stiffness,	
due	to	mild	interstitial	fibrosis	and	tiny	areas	of	replacement	fibrosis	has	even	been	found	
in	 FD	 patients	 without	 LV	 hypertrophy,	 but	 has	 a	 negative	 effect	 on	 contraction	 and	
relaxation	 velocities.104	 Concluding,	 reduction	 in	 myocardial	 contraction	 and	 relaxation	
velocities	 in	 TDI	 are	 detectable	 before	 the	 development	 of	 LV	 hypertrophy	 or	 even	
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abnormalities	 in	 the	 traditional	 parameters	 of	 diastolic	 function	 and	 can	 enable	 the	
recognition	of	preclinical	cardiac	damage.	
	 New	 tools	 like	 strain	 and	 SR	 speckle-tracking	 based	 echocardiography	 (a	 TDI-
derived	 technique),	 which	 enables	 measurement	 of	 myocardial	 systolic	 and	 diastolic	
strains,	seems	superior	and	more	sensitive	than	myocardial	velocities	(measured	by	TDI)	
in	 quantifying	 changes	 of	myocardial	 systolic	 function,	 because	 it	 is	 less	 influenced	 by	
overall	cardiac	motion.259	Decreased	systolic	strain	and	SR	of	the	LV	has	been	reported	in	
FD	patients,	compared	with	healthy	controls.107,	108,	260,	261	These	alterations	in	myocardial	
systolic	strains	are	detectable	even	in	the	early	stages	of	FD	cardiomyopathy:	 in	a	study	
comparing	19	FD	patients	with	 LV	hypertrophy,	21	FD	patients	without	 LV	hypertrophy	
and	 40	 healthy	 controls,	 there	 was	 a	 significant	 reduction	 in	 both	 global	 systolic	
longitudinal	 and	 circumferential	 strains,	 as	 well	 as	 an	 absence	 of	 the	 normal	 regional	
base-to-apex	circumferential	strain	gradient,	even	in	the	subgroup	of	patients	without	LV	
hypertrophy.261	These	results	were	further	confirmed	in	another	study	comparing	22	FD	
with	LV	hypertrophy,	22	patients	without	LV	hypertrophy	and	22	controls.107		
	 Decreased	LV	diastolic	strain	and	SR	was	also	reported	in	FD.108,	260	In	a	cohort	of	
16	patients	(9	of	whom	with	LV	hypertrophy),	a	significant	decrease	in	longitudinal	early	
diastolic	 SR	 and	 in	 SR	 during	 isovolumic	 relaxation	 period	 was	 reported,	 even	 in	 the	
subgroup	of	patients	without	LV	hypertrophy	(for	SR	during	isovolumic	relaxation	period).	
Moreover,	the	sensitivity	to	detect	diastolic	dysfunction	was	higher	with	speckle-tracking	
imaging	 than	with	 TDI	 early	 diastolic	 velocities,	 and	 the	diastolic	 parameter	 considered	
the	 best	 predictor	 for	 FD	 was	 SR	 during	 isovolumic	 relaxation	 period	 (AUC	 0.953,	
compared	with	0.753	for	E’).108	Left	atrial	(LA)	systolic	and	diastolic	strain	and	SR	is	also	
decreased	 in	 FD	 patients,	 with	 a	 significant	 decrease	 of	 systolic	 SR	 even	 in	 patients	
without	LV	hypertrophy.262,	263	
	 Speckle-tracking	 based	 echocardiography	 may	 also	 be	 a	 non-invasive	 tool	 for	
detection	 of	 myocardial	 fibrosis	 in	 FD.114,	 190	 In	 a	 study	 with	 101	 patients,	 global	
longitudinal	systolic	strain	was	lower	in	patients	with	LGE	in	cardiac	MRI,	compared	with	
those	 without	 LGE,	 with	 a	 significant	 correlation	 between	 global	 longitudinal	 systolic	
strain	 and	 the	 amount	 of	 LGE;	 furthermore,	 segmental	 strain	 values	 were	 particularly	
decreased	in	the	LGE	positive	basal	posterior	and	lateral	segments	and	the	strain	in	these	
wall	 segments	 shows	 the	 best	 diagnostic	 accuracy	 to	 detect	 myocardial	 LGE	 (AUC	
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0.913).114	 Moreover,	 LV,	 RV	 and	 LA	 strains	 are	 inversely	 linked	 to	 the	 heart	 failure	
functional	 class260	 and	 LA	 strain	 parameters	 are	 associated	 with	 atrial	 fibrillation	 and	
stroke.264		
The	effect	of	ERT	in	myocardial	systolic	and	diastolic	strains	is	still	controversial:	in	
a	study	with	16	patients	treated	with	agalsidase-β,	there	was	a	significant	increase	in	both	
longitudinal	 and	 radial	 peak	 systolic	 SR	 and	 systolic	 strain	 after	 12	 months	 of	
treatment;103	while	 in	another	study,	for	a	cohort	of	13	patients,	treated	with	ERT	for	a	
mean	 period	 of	 3.1	 years,	 there	 was	 no	 change	 in	 global	 systolic	 longitudinal	 or	
circumferential	 strain.261	 The	 improvement	 in	 systolic	 SR	 may	 be	 influenced	 by	 the	
presence	 and	 amount	 of	 myocardial	 fibrosis	 at	 ERT	 initiation,	 with	 a	 study	 showing	 a	
significant	increase	in	radial	systolic	SR	occurring	only	in	the	subgroup	of	patients	without	
fibrosis;	 systolic	 SR	 remained	 essentially	 unchanged	 in	 patients	 with	 mild	 fibrosis,	 but	
rather	 decreased	 in	 the	 severe	 fibrosis	 subgroup.106	 ERT	 also	 seems	 to	 improve	 LA	
function,	by	an	increase	in	LA	peak	positive	strain.264	
	 Cardiac	 MRI	 plays	 a	 critical	 role	 in	 evaluating	 the	 differential	 diagnosis	 of	
cardiomyopathy	 and	 is	 the	 diagnostic	 standard	 for	 assessing	 cardiac	 morphology	 and	
function,	with	high	spatial	resolution	and	low	observer	variability,	in	patients	with	FD.265	
Cardiac	 MRI,	 as	 noted	 above	 in	 cardiomyopathy	 treatment,	 can	 reliably	 evaluate	 the	
beneficial	effects	of	ERT	on	LV	mass	in	FD	patients.103,	176,	188,	190,	191,	266	Furthermore,	 it	 is	
essential	 for	 the	 comprehensive	 segmental	 analysis	 of	 LV	 regional	 morphology	 and	
function	in	FD.	In	patients	with	LGE,	the	regional	function	is	severely	restricted,	mainly	in	
the	 segments	 displaying	 LGE,	 but	 also	 in	 the	 non-enhanced	 segments.190	 Likewise,	
segmental	LV	wall	thickness	is	higher	in	patients	with	LGE	and	significantly	correlates	with	
the	 segmental	 volume	of	 the	 LGE,	 and	wall	motion	 in	 patients	with	 LGE	 is	 significantly	
impaired	in	some	segments,	compared	with	patients	without	LGE	and	the	distribution	of	
hypokinetic	 segments	 followed	 that	 of	 hypertrophic	 segments.267	 ERT,	 in	 a	 study	 with	
agalsidase-β	administered	for	12	months,	seems	to	improve	segmental	LV	wall	thickness	
and	 wall	 motion	 (with	 a	 significant	 decrease	 in	 hypokinetic	 segments),	 but	 only	 in	
patients	without	LGE	at	ERT	initiation.267		
	 LGE	 imaging	 techniques	 using	 cardiac	MRI	 is	 the	 gold	 standard	 for	 non-invasive	
detection	 of	 focal	 replacement	 fibrosis	 in	 the	 myocardium.	 The	 intercellular	 space	 is	
increased	 in	 the	 areas	 with	 replacement	 myocardial	 fibrosis	 and	 chelated	 gadolinium	
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diffuses	 into	 this	 space	 and	 is	 unable	 to	 cross	 the	 cell	 membrane;	 therefore,	 the	
distribution	kinetic	is	slower	and	a	higher	relative	concentration	of	gadolinium	is	found	in	
myocardial	areas	with	replacement	fibrosis	compared	to	unaffected	myocardium.110		
	 As	noted	above,	between	31%	and	77%	of	patients	with	FD	disease	may	present	
LGE,	 with	 a	 characteristic	mid-myocardial	 distribution	 (sparing	 the	 subendocardium)	 in	
the	inferolateral	basal	and	mid	basal	segments	of	the	LV	wall,	that	seems	to	be	specific	of	
FD	 cardiomyopathy	 (differentiating	 it	 from	 other	 causes	 of	 hypertrophic	
cardiomyopathy).105,	106,	110-112,	190,	268	Additionally,	in	FD	LGE	was	correlated	with	histologic	
findings	 (myocardial	collagen	deposition)	 from	autopsy.109	A	greater	proportion	of	male	
patients	presents	larger	amounts	of	LGE	in	cardiac	MRI;110,	112	it	was	reported	previously	
that	only	female	patients	might	present	LGE	with	normal	LV	mass	(in	one	study,	10	out	of	
the	19	 female	patients	with	LGE	did	not	present	LV	hypertrophy),113	but	 recent	 reports	
have	demonstrated	that	a	significant	proportion	of	male	patients	without	LV	hypertrophy	
may	also	present	LGE.112,	269	
	 Several	studies	reported	a	significant	correlation	between	the	amount	of	LGE	and	
LV	mass110,	112,	190,	267,	270	 and,	as	mentioned	above,	 LGE	correlates	with	abnormalities	 in	
regional	 myocardial	 function	 assessed	 by	 speckle-tracking	 imaging	 studies.105,	 113-115,	 190	
However,	 the	sensitivity	of	LGE	to	detect	early	cardiac	 involvement,	as	expected	due	to	
the	 identification	 of	 irreversible	 replacement	 fibrosis,	 is	 limited.	 In	 a	 study	with	 20	 FD	
patients,	none	of	the	patients	without	LV	hypertrophy,	but	with	abnormal	TDI	velocities,	
presented	 LGE	 in	 cardiac	MRI.271	Moreover,	 in	 a	 study	with	 73	patients,	 followed	 for	 a	
mean	period	of	4.8	years,	logistic	regression	analysis	revealed	that	the	annual	increase	in	
LGE	 during	 the	 follow-up	was	 the	 only	 independent	 predictor	 of	malignant	 ventricular	
arrhythmias	(sudden	cardiac	deaths	only	occurred	in	the	group	of	patients	with	LGE).116	
ERT	 does	 not	 seem	 to	 have	 any	 effect	 on	 LGE:	 the	 amount	 of	 LGE	 significantly	
increased	in	patients	treated	for	12	months	with	agalsidase-β	(no	patients	without	LGE	at	
baseline	developed	LGE	during	ERT)	and	LV	mass	only	significantly	decreased	in	patients	
without	LGE	at	baseline.190	These	results	were	 further	confirmed	with	 longer	 treatment	
periods,	also	showing	some	patients	developing	LGE	even	during	treatment	with	ERT.116	
Moreover,	 as	 previously	mentioned,	 the	presence	of	 LGE	 is	 one	of	 the	most	 important	
predictors	of	response	to	ERT	in	terms	of	myocardial	function	and	exercise	capacity.106	
	 Nevertheless,	LGE	has	several	limitations	as	an	imaging	biomarker:	it	only	detects	
	 69	
irreversible	 tissue	 damage	 with	 focal	 replacement	 fibrosis	 (with	 limited	 resolution:	
theoretical	 limit	 of	 about	 0.2g,	 probably	 higher	 in	 the	 clinical	 setting	 of	 infarction	
studies);272,	273	it	may	not	detect	early,	potentially	reversible,	diffuse	fibrosis;274	although	
possible,	 there	 is	no	universally	accepted	technique	to	quantify	 fibrosis	volume	and	the	
intra-	 and	 inter-observer	 variability	 is	 in	 the	 range	of	20-40%	of	 the	 LGE	amount.275,	276	
These	limitations	may	be	paramount	in	FD:	in	a	study	with	20	FD	patients,	10	with	and	10	
without	LV	hypertrophy,	the	interstitium	was	mildly	widened	in	some	patients	without	LV	
hypertrophy	due	to	intercellular	fibrosis	and	tiny	areas	of	fibrous	replacement	were	also	
detected	 in	 this	 subgroup	 of	 patients;	 in	 patients	with	 LV	 hypertrophy	 the	 interstitium	
was	moderately	 to	 severely	 increased	 because	 of	 scar	 tissue;	 however,	 none	 of	 these	
patients	 presented	 LGE	 in	 cardiac	MRI,	 depicting	 the	 limited	 resolution	 and	 inability	 to	
detect	diffuse	interstitial	fibrosis	of	LGE	based	techniques.104	
	 A	novel	technique,	T1	mapping,	enables	the	measurement	of	native	myocardial	T1	
(non-contrast	myocardial	T1)	and	T1	after	administration	of	gadolinium	contrast.	Native	
T1	allows	for	a	better	characterization	of	the	myocardium	content,	with	increased	values	
in	 the	 setting	 of	 fibrosis,	 oedema	 or	 amyloid	 deposits	 and	 decreased	 values	 in	 iron	
overload	 or	 lipid	 storage.	 Measurement	 of	 T1	 with	 extracellular	 gadolinium	 based	
contrast	 agents	 gives	 additional	 information	 about	 the	 extracellular	 volume	 fraction,	
which	is	particularly	valuable	for	diffuse	diseases	that	are	usually	more	difficult	to	detect	
using	conventional	LGE	and	has	been	studied	for	assessment	of	diffuse	fibrosis,	with	good	
histological	 correlations.274	 However,	 in	 FD	 it	 has	 been	more	 extensively	 studied	 as	 an	
imaging	biomarker	 for	 early	 detection	of	 cardiac	 involvement	 and	 for	 distinguishing	 FD	
from	other	aetiologies	of	concentric	 remodelling	and	hypertrophy	 (due	 to	 lipid	storage,	
yielding	low	native	T1	[correlative	biopsy	data	is	not	yet	available]),	than	for	evaluation	of	
diffuse	fibrosis.277-281	
	 In	a	cohort	of	63	FD	patients,	low	septal	native	T1	was	evidenced	in	around	90%	of	
the	patients	with	LV	hypertrophy	and	in	48%	of	the	patients	without	LV	hypertrophy	(this	
subgroup	 had	 lower	 global	 longitudinal	 strain	 by	 speckle	 tracking	 and	 higher	 LV	 filling	
pressure).	 This	data	suggests	that	 low	T1	 is	a	possible	marker	of	cardiac	 involvement	 in	
early	 stages	 of	 hypertrophy	 and	 fibrosis	 and	 4	 phases	 of	myocardial	 involvement	were	
proposed:	phase	1:	no	 involvement;	phase	2:	 low	T1	and	early	myocardial	dysfunction;	
phase	3:	LV	hypertrophy	with	low	T1;	phase	4:	“pseudonormalization”	of	T1,	fibrosis	and	
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heart	failure	(as	extensive	fibrosis	and	scarring	present	high	T1	values).278	
	
2.2.3	Fabry	disease	nephropathy	
Reproducible	 and	 accurate	 estimates	 of	 renal	 function	 are	 essential	 in	 the	
management	of	 FD.	 There	 are	 limitations	 in	 all	 current	 equations	 to	 estimate	GFR,	 but	
MDRD	 equation282	 is	 not	 validated	 in	 patients	 with	 higher	 GFR	 (knowing	 that	 an	
hyperfiltration	 stage	 have	 been	 described	 in	 FD	 nephropathy)	 and	 seems	 less	 accurate	
than	Chronic	Kidney	Disease	Epidemiology	Collaboration	(CKD-EPIcreatinine2009)	equation.148	
Thus,	CKD-EPIcreatinine2009	equation	is	the	recommended	equation	to	estimate	GFR	in	adults	
with	 FD.283,	 284	 However,	 given	 that	 measured	 GFR	 by	 iohexol	 plasma	 clearance	 and	
isotopic	 methods	 is	 more	 accurate,	 depending	 on	 local	 availability,	 the	 precise	
measurement	 of	 the	 GFR	 is	 recommended	 for	 FD	 patients	 if	 the	 estimated	 GFR	 is	
>60ml/min/1.73m2.284	
Cystatin	 C	 is	 a	 protease	 inhibitor,	 produced	 at	 a	 constant	 rate	 by	 all	 nucleated	
cells,	freely	filtered	through	the	glomeruli	and	completely	reabsorbed	and	broken	down	
by	 the	 proximal	 tubules;	 therefore,	 its	 serum	 concentration	 is	 constant	 and	 it	 was	
proposed	 as	 a	 reliable	marker	 of	 renal	 function.285	 Cystatin	 C	 has	 been	 compared	with	
creatinine	in	the	evaluation	of	renal	function,	in	a	cohort	of	21	patients	starting	treatment	
with	agalsidase-α,	with	a	follow-up	period	of	up	to	4	years.	During	follow-up	under	ERT	
there	was	no	significant	change	 in	creatinine	or	 in	creatinine-based	estimated	GFR,	but	
there	 was	 a	 significant	 increase	 (just	 after	 only	 one	 year	 of	 ERT)	 in	 cystatin	 C	 and	 a	
concurrent	decrease	in	estimated	GFR	by	Hoek	equation286	(using	cystatin	C	values).	The	
authors	concluded	that	cystatin	C	was	an	early	marker	for	the	decline	of	GFR,	but	no	gold	
standard	precise	measurement	of	GFR	was	used	to	support	this	conclusion.287	This	data	
was	 corroborated	 by	 another	 study	 including	 89	 patients,	 showing	 that	 the	 diagnostic	
accuracy	 of	 cystatin	 C	 to	 detect	 mild	 renal	 damage	 and	 minor	 decreases	 in	 GFR	 was	
superior	to	diagnosis	based	on	creatinine.252	
Cystatin	 C-based	 estimation	 of	 GFR	 was	 compared	 with	 measured	 GFR	 in	 a	
relatively	 small	 validation	 study	 (including	 several	 cystatin	 and	 creatinine-based	
equations),	 including	 136	 GFR	 measurements	 in	 a	 population	 of	 36	 FD	 patients.	 In	
contrast	 to	 that	 previously	 mentioned,	 Hoek	 equation	 was	 less	 accurate	 than	 CKD-
EPIcreatinine2009	equation	 in	 detecting	GFR	 decline	 during	 ERT,	 but	 Stevens’	 equation288	 (a	
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creatinine	and	cystatin	C-based	formula)	was	the	one	that	most	closely	approximated	to	
the	 measured	 GFR.289	 However,	 Stevens’	 equation	 development	 was	 based	 on	 serum	
cystatin	C	assays	in	adults	that	were	not	traceable	to	standard	reference	material,	and	are	
no	longer	recommended	by	international	CKD	guidelines.283		
	 Total	 urinary	 protein	 and	 albumin	 excretion	 can	 be	 considered	 as	 important	
biomarkers	 in	FD	nephropathy.	As	previously	mentioned,	proteinuria	 (>150mg/day)	and	
albuminuria	 A2	 are	 usually	 the	 first	 signs	 of	 renal	 involvement.143-146	 The	 sensitivity	 of	
albuminuria	 seems	 superior	 to	 that	of	 total	urinary	protein	excretion	 in	detecting	early	
renal	 involvement	 in	 FD.141	 Thus,	 albuminuria	 remains	 as	 the	 best	 existing	 marker	 to	
detect	 early	 renal	 involvement,	 but	 the	 relevance	 of	 albuminuria	 A2	 as	 a	 biomarker	 is	
largely	 based	 on	 validation	 studies	 in	 the	 earlier	 stages	 of	 other	 nephropathy	 models	
(diabetic	 and,	 to	 a	 lesser	 extent,	 hypertensive	 renal	 disease).	 Moreover,	 in	 FD	
nephropathy	albuminuria	may	not	 result	 only	 from	glomerular	damage	of	 the	 filtration	
barrier,	 but	 also	 from	 tubular	 involvement	 with	 decreased	 reabsorption	 of	 filtered	
albumin.		
However,	the	usefulness	of	albuminuria	and/or	proteinuria	to	identify	incipient	FD	
nephropathy	is	questionable.	Though	the	significant	correlation	between	urinary	protein	
excretion	 rates	 and	 foot	 process	 width	 and	 fractional	 volume	 of	 Gb3	 inclusions	 in	 the	
podocytes,58	 FD	 nephropathy,	 as	 noted	 above,	 is	 clinically	 silent	 for	 a	 long	 period	 and	
significant	histological	changes	(not	only	the	characteristic	inclusions,	but	also	nonspecific	
degenerative	 lesions,	 like	 mesangial	 widening,	 glomerulosclerosis,	 tubulointerstitial	
fibrosis	 and	 arteriopathy)	 may	 occur	 without	 pathological	 albuminuria	 and/or	
proteinuria.57,	 58,	 77,	 79-81	 In	 incipient	 stages	 of	 FD	 nephropathy,	 tubular	 reabsorption	 of	
albumin	may	overcome	its	increased	excretion,	limiting	the	sensitivity	of	this	biomarker.	
Furthermore,	proteinuria	seems	also	to	play	an	important	role	in	FD	nephropathy	
progression,	even	 in	patients	 treated	with	ERT,	because	 it	 is	an	 independent	 risk	 factor	
affecting	 the	 extent	 of	 renal	 decline	 and	 is	 one	 of	 the	 determinants	 of	 the	 success	 of	
ERT.82,	141,	149,	152,	194,	196,	197,	207,	212	However,	the	magnitude	of	the	influence	of	proteinuria	
in	FD	progression	 is	not	well	established,	as	 some	studies	 find	no	 relationship	between	
the	degree	of	proteinuria	and	the	rate	of	GFR	decline,	and	several	FD	patients	with	CKD	
stage	 ≥3	may	 not	 present	 overt	 proteinuria.15,	83,	141	 Finally,	 as	 already	mentioned,	 ERT	
does	not	seem	to	reduce	proteinuria	(mainly	in	male	patients),	so	this	biomarker	is	not	a	
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good	biomarker	of	response	to	ERT;	actually,	reduction	in	proteinuria	is	the	objective	and	
guides	the	use	of	ACEi	and	ARB,	indicating	the	effectiveness	of	these	drugs.	
	
2.3	Searching	for	new	biomarkers	
Searching	for	new	biomarkers	in	Fabry	disease	is	paramount:	as	an	illustration,	no	
proper	or	well-established	plasma	or	urinary	biomarkers	are	available	in	clinical	practice	
to	 aid	 the	 diagnosis,	 early	 detection	 of	 major	 organ	 involvement,	 monitoring	 and	
evaluation	 of	 treatment	 response.	Moreover,	 the	 sensitivity	 of	 imaging	 techniques	 for	
cardiac	evaluation	seems	limited	in	the	detection	of	early	events	 in	FD	cardiomyopathy.	
However,	biomarkers	discovery	remains	a	very	challenging	task	due	to	the	complexity	of	
the	 samples	 (body	 fluids	 or	 tissues)	 and	 the	 wide	 dynamic	 range	 of	 molecule	
concentrations	in	a	heterogeneous	disease.		
There	are	two	main	approaches	to	discover	new	plasma	/	urine	biomarkers	in	FD:	
“angling”,	a	one	by	one	approach,	which	involves	the	study	of	candidate	biomarkers	(for	
example,	 tubular	 proteins	 or	 inflammatory	 mediators)	 where	 laboratory	 studies	 have	
suggested	 a	 pathological	 link	 or	 with	 proven	 value	 in	 a	 similar	 pathological	 model;	
“trawling”,	 based	 on	 “omics”	 medicine,	 where	 biological	 fluid	 /	 tissue	 is	 screened	 for	
disease-associated	 molecules	 (for	 example,	 proteins	 or	 metabolites)	 using	 an	 array	 of	
technologies,	predominantly	based	on	mass	spectrometry.	
	 One	 by	 one	 approach	 has	 been	 widely	 used	 and	 several	 biomarkers	 with	 clear	
pathological	correlation	have	been	found;	moreover,	 the	 interpretation	of	 the	data	and	
correlation	with	the	clinical	variables	/	disease	heterogeneity	is	easier	with	this	approach.	
However,	most	 of	 the	 serum	 and	 urine	 biomarker	 studies	 performed	 to	 date	 seem	 to	
have	 converged	 on	 a	 set	 of	 proteins	 and	metabolites	 that	 are	 repeatedly	 identified	 in	
many	 studies	 and	 that	 represent	 only	 a	 small	 fraction	 of	 the	 entire	 proteome	 /	
metabolome,	 so	 the	added	value	of	 the	one	by	one	approach	 in	deepening	 knowledge	
about	the	disease	pathophysiology	is	limited.290	
	 In	 contrast,	 omics-based	 applications	make	 available	 a	 formidable	 technological	
resource	 to	 further	 expand	 our	 knowledge	 on	 the	 complexities	 of	 human	 disease.	
However,	 if	 reliable	 and	 useful	 inferences	 with	 potential	 for	 translation	 into	 clinical	
practice	are	to	be	achieved,	omics	techniques	require:	understanding	inherent	biological	
variables,	 rigorous	 methodology	 and	 analytical	 chemistry	 tools,	 the	 use	 of	
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instrumentation	that	ensures	high	data	quality,	and	consistent	and	transparent	analysis	of	
the	generated	data.291	In	proteomics	and	metabolomics	there	are	several	challenges	and	
limitations	that	need	to	be	overcome	so	as	not	 lag	behind	and	achieve	clinical	practice:	
complexity	 of	 proteome	 (large	 number	 of	 structural	 and	 biochemical	 differences	 of	
proteins),	 very	 wide	 range	 in	 protein	 concentration,	 complex	 sample	 preparation	 and	
data	 analysis	 (most	 reported	 biomarkers	 remain	 unidentified)	 and	 limited	 sensitivity.	
Moreover,	 capacity	 for	 quantitative	 measurements	 is	 not	 yet	 at	 a	 level	 required	 by	
routine	 diagnostics	 in	 a	 clinical	 setting.	 It	 is	 also	 unclear	 how	 clinicians	 will	 use	 this	
sensitive	data	since	even	small	changes	in	physiology,	such	as	food	ingestion	or	going	up	a	
flight	of	stairs,	can	have	significant	impact	on	the	metabolome.292	
	
2.3.1	Experimental	biomarkers	in	Fabry	disease	
Several	protein	and	lipid	experimental	biomarkers	are	under	investigation	in	Fabry	
disease,	 mainly	 related	 to	 inflammation,	 endothelial	 dysfunction,	 cardiac	 fibrosis,	
glomerulosclerosis	and	tubulointerstitial	fibrosis.	Furthermore,	there	are	also	few	reports	
on	proteomic	and	metabolomics	analysis.	
As	mentioned	above,	 FD	 is	 characterized	by	 vasculopathy	 related	 to	 endothelial	
dysfunction	 and	 leucocyte	 activation,	 leading	 to	 a	 low	 grade	 inflammatory	 disorder.293	
Thus,	few	inflammatory	biomarkers	have	been	studied	in	FD	patients:	the	classic	marker	
of	 an	 inflammatory	 response,	 C-reactive	 protein,	 generated	 conflicting	 results	 in	 three	
large	cohorts	of	FD	patients,	with	two	studies	showing	no	increase	and	the	other	showing	
a	marked	increase,	but	not	correlated	with	disease	severity	and	not	responsive	to	ERT.294-
296	Nonetheless,	pro-inflammatory	cytokines,	including	interleukin	6	(IL-6),	are	elevated	in	
patients	 with	 FD	 cardiomyopathy	 and	 decrease	 during	 ERT	 (IL-6	 decrease	 significantly	
correlated	with	 the	decrease	 in	 lyso-Gb3	and	 the	 improvement	 in	 LV	mass);297	Another	
study	 evaluating	 an	 IL-6	 promoter	 polymorphism	 (c.-174G>C),	 with	 IL-6	 C/C	 genotype	
associated	with	susceptibility	of	cerebral	arteries	to	IL-6-mediated	inflammatory	damage,	
revealed	 that	 FD	 patients	 with	 CC	 genotype	 was	 associated,	 in	 both	male	 and	 female	
patients,	with	a	significant	 increase	 in	neurological	subscore	and	total	MSSI	and	with	all	
the	 6	 (out	 of	 56)	 patients	 who	 had	 suffered	 a	 strike	 during	 follow-up	 with	 this	 same	
genotype.294	Two	other	inflammatory	markers,	myeloperoxidase	and	chitotriosidase,	are	
also	significantly	increased	in	FD	males	(but	not	in	females):	the	former	seems	to	predict	
	 74	
the	risk	of	vasculopathy–related	events,	but	does	not	decrease	during	ERT;295	the	second	
does	 not	 correlate	 with	 clinical	 manifestations,	 but	 significantly	 decreases	 during	 ERT	
(with	an	hampered	response	in	patients	developing	neutralizing	antibodies).298		
In	 the	 same	 model	 of	 a	 systemic	 vasculopathy	 and	 prothrombotic	 state,293,	 299	
several	studies	focused	on	the	identification	of	biomarkers	of	coagulation	and	endothelial	
activation.	 Laboratory	 investigations	 in	 this	 field	 gave	 conflicting	 and	 disappointing	
results:	first	studies,	in	a	cohort	of	25	FD	patients,	showed	a	significant	increase	in	soluble	
adhesion	 molecules	 (soluble	 intercellular	 adhesion	 molecule-1,	 soluble	 vascular	 cell	
adhesion	 molecule-1	 (sVCAM-1)	 and	 soluble	 P-selectin),	 a	 significant	 decrease	 of	 the	
coagulation	 factor	 thrombomodulin	 (TM,	 an	 anti-thrombotic	 factor)	 and	 an	 increased	
expression	 of	 the	 integrin	 Macrophage-1	 antigen	 (a	 cell	 surface	 adhesion	 molecule),	
consistent	 with	 a	 prothrombotic	 state.293	 However,	 in	 subsequent	 studies	 only	 a	
significant	 increase	 in	 sVCAM-1	 was	 confirmed	 in	 one	 investigation	 and	 other	 studies	
reported	 only	 minimal	 and	 inconsistent	 abnormalities	 in	 markers	 of	 platelet	 and	
coagulation	 activation.296,	 300,	 301	 Endothelial-derived	 NO,	 produced	 by	 endothelium-
derived	 NO	 synthase,	 is	 also	 a	 key	 regulator	 of	 endothelium	 and	 vessel	 wall	 function.	
Polymorphisms	 of	 the	 gene	 encoding	 the	 enzyme	 endothelium-derived	 NO	 synthase,	
associated	with	a	higher	risk	for	cardiovascular	diseases	in	general	population,	influenced	
the	 LVPW	 thickness	 of	 the	 heart	 in	 one	 study	 with	 FD	 patients.302	 An	 increase	 in	
homocystein	level	was	found	in	2	separate	studies	(with	9	and	12	FD	patients)	and	one	of	
them	 reported	 that	 all	 the	 patients	 presenting	 cerebrovascular	 disease	 had	
hyperhomocysteinemia.300,	301	
Finally,	 regarding	the	biomarkers	related	with	vasculopathy,	one	study	 identified	
another	 soluble	 factor,	 apart	 from	 lyso-Gb3,	 promoting	 vascular	 smooth	 muscle	 cell	
proliferation,	 sphingosine-1	 phosphate;	 its	 levels	 are	 significantly	 increased	 in	 male	
patients	 with	 FD	 (but	 not	 in	 females)	 and	 correlate	 with	 carotid	 artery	 intima-media	
thickness	and	LV	mass	index.303	
Given	the	aforementioned	limitations	of	albuminuria	/	proteinuria	as	biomarkers	
of	renal	involvement	in	FD,	other	biomarkers	of	glomerular	and	tubular	injury	have	been	
studied.	 As	 previously	 described,	 the	massive	 Gb3	 storage	 in	 the	 podocytes	 translates	
into	early	podocytopathy,	with	increased	podocyturia	(podocyte	count	in	urine	sediments	
is	 a	 time-consuming	 procedure	 and	 it	may	 be	 technically	 challenging	 to	 obtain	 reliable	
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data	because	the	reading	is	observer-dependent).	A	few	studies	evaluated	podocyturia	in	
FD,	 showing	 that	 it	 is	 already	 increased	 in	 patients	 without	 albuminuria	 and	 overt	
nephropathy,	but	a	significant	correlation	with	albuminuria	/	proteinuria	was	inconsistent	
between	the	studies	and	an	inverse	correlation	with	estimated	GFR	was	only	found	in	one	
of	them	(and	only	in	male	patients),	and	the	added	value	against	albuminuria,	in	terms	of	
diagnostic	 accuracy,	 nephropathy	 prognosis	 and	 response	 to	 ERT	 has	 not	 been	
established.66,	 68,	 304,	 305	 Some	 tubular	 injury	 biomarkers	 have	 been	 also	 studied:	 a	
decreased	urinary	excretion	of	uromodulin	has	been	reported	and	immunohistochemical	
analysis	 revealed	 aberrantly	 processed	 uromodulin,	 abnormal	 uromodulin	 localization	
and	expression	inversely	proportional	to	the	degree	of	storage	(these	abnormal	patterns	
normalized	under	ERT	in	all	patients).306	In	a	cohort	of	13	female	patients	under	ERT	for	
more	 than	 one	 year,	 a	 decrease	 in	 proximal	 tubular	 damage	markers	 α1-microglobulin	
and	 retinol-binding	 protein	 excretion	 was	 found.307	 A	 significant	 increase	 in	 urinary	
excretion	of	bikunin,	a	 serine	protease	 inhibitor,	has	been	 reported	 in	FD	patients	with	
renal	impairment	(but	not	in	those	without	overt	nephropathy);	however,	bikunin	origin	
and	the	mechanisms	by	which	its	urine	levels	are	elevated	remains	unclear	and	deserve	
further	evaluation.308	
Next	to	targeted	analysis	of	potential	lipids	and	proteins	candidates,	the	search	for	
biomarkers	of	FD	has	been	extended	to	analysis	of	the	entire	metabolome	and	proteome.	
A	metabolomics	approach	has	been	employed	using	tandem	mass	spectrometry	and	has	
identified	 several	metabolites	 over-expressed	 in	 FD	patients,	 all	 of	 them	Gb3,	 lyso-Gb3	
and	 galabiosylceramide	 isoforms	 /	 analogues.	 In	 plasma	 it	 was	 possible	 to	 identify	
analogues	/	isoforms	of	Gb3	and	lyso-Gb3	(the	magnitude	of	increase	was	lower	for	all	of	
them,	compared	with	lyso-Gb3),	all	of	them	significantly	more	elevated	in	male	patients	
(compared	with	female	patients)	and	most	of	them	showing	a	significant	decrease	during	
ERT.309,	 310	 Urinary	metabolomics	 studies	 were	 able	 to	 show	 an	 increased	 excretion	 of	
lyso-Gb3	 (whose	 differences	 relied	 mainly	 on	 the	 sphingosine	 moiety),	 Gb3	 and	
galabiosylceramide	 isoforms	 /	 analogues,	 also	with	 a	more	 prominent	 increase	 in	male	
patients	and	a	significant	decrease	during	ERT.	 Interestingly,	all	but	one	of	the	 lyso-Gb3	
analogues	 have	 relative	 concentrations	 that	 are	 higher	 than	 lyso-Gb3	 (up	 to	 17	 times	
higher	 than	 lyso-Gb3)	 and	 the	 types	 and	 relative	 proportion	 of	 galabiosylceramide	
structural	variants	present	some	significant	differences	to	their	Gb3	counterparts,	raising	
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some	 questions	 about	 possible	 different	 synthesis	 or	 degradation	 pathways.311,	 312	
Despite	 the	 promising	 results	 of	 these	 studies,	 the	 candidate	 biomarkers	 still	 need	 to	
prove	 that	 they	overcome	 the	 lyso-Gb3	 limitations:	 the	need	 to	 test	mutations	 carriers	
known	to	cause	 little	 increase	 in	metabolites	concentration	and	correlation	with	clinical	
manifestations	and	treatment	response.	
The	proteomic	approach	has	also	been	applied	in	the	search	for	biomarkers	of	FD	
in	 plasma,	 peripheral	 blood	 mononuclear	 cells	 and	 urine.	 The	 first	 study	 with	 plasma	
proteomics	compared	the	plasma	of	13	children	with	FD,	prior	and	after	ERT	and	was	able	
to	 show	 a	 decrease	 in	 5	 proteins	 during	 treatment.313	 Subsequently,	 another	 study	
identified,	 in	 plasma,	 an	 eight-protein	 biomarker	 panel	 that	 was	 very	 specific	 and	
sensitive	for	diagnose	of	male	FD	patients;	in	female	patients,	a	nine-biomarker	panel	of	
proteins	was	identified,	with	only	three	proteins	(apolipoprotein	E,	haemoglobin	α-2	[up-
regulated	in	females	and	down-regulated	in	males,	when	compared	to	matched	controls]	
and	peroxiredoxin	2),	common	to	both	genders,	suggesting	a	gender-specific	alteration	in	
plasma	biomarkers	in	patients	with	FD.314	
Proteomic	 analysis	 of	 peripheral	 blood	 mononuclear	 cells	 was	 performed	 in	 a	
small	 cohort	 of	 8	 FD	 patients	 and	 6	 controls	 and	 all	 proteins	 that	were	 found	 to	 have	
significant	expression	differences	(either	up	or	down-regulation)	play	roles	in	mechanisms	
that	may	be	associated	with	the	pathophysiology	of	FD.315	
Urinary	proteome	is	the	most	extensively	studied	in	FD,	with	a	few	studies	with	up	
to	 23	 patients	 reporting	 several	 proteins	 with	 altered	 expression.316-320	 The	 most	
consistent	alterations	found	were	the	up-regulation	of	prostaglandin	H2	D-isomerase	and	
prosaposin	(the	latter	 including	in	paediatric,	pre-symptomatic	patients),	both	known	to	
play	roles	in	processes	that	might	be	involved	in	FD	pathophysiology.	These	proteins	also	
enabled	 discriminating	 female	 FD	 patients	 from	 controls	 and	 their	 levels	 significantly	
reduced	 during	 ERT318-320	 In	 another	 study	 with	 35	 treatment-naive	 female	 patients	 a	
diagnostic	 biomarker	 pattern	 (composed	 of	 64	 proteins)	 exhibited	 high	 diagnostic	
accuracy	when	validated	in	an	independent	FD	cohort	and	remained	highly	specific	when	
applied	 to	 cohorts	with	a	variety	of	other	 renal,	metabolic	and	cardiovascular	diseases.	
Several	of	the	 identified	diagnostic	biomarkers	showed	correlation	with	disease	severity	
and	most	of	them	responded	to	ERT	(8	out	of	the	11	treated	patients	scored	negative	for	
FD	in	the	diagnostic	model).317	
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3.	Circulating	biomarkers	of	myocardial	fibrosis	
3.1	Myocardial	fibrosis:	relevance	and	available	circulating	candidate	biomarkers	
In	 the	 heart,	 a	 complex	 extracellular	matrix	 (mainly	 composed	 of	 type	 I	 fibrillar	
collagen)	 connects	 cardiomyocytes,	 fibroblasts	 and	 vascular	 cells	 and	 is	 paramount	 for	
preserving	structural	integrity	and	plasticity	of	the	heart.	In	the	diseased	heart,	the	matrix	
undergoes	structural	and	subcellular	changes	that	progressively	influence	heart	function,	
playing	a	major	role	in	progression	of	the	cardiac	disease,	in	a	vicious	circle.321	
Myocardial	 fibrosis	 is	 characterized	 by	 dysregulated	 collagen	 turnover,	 with	 a	
predominance	of	increased	synthesis	of	type	I	and	type	III	collagen	over	an	unchanged	or	
decreased	 degradation.322	 Two	 distinct	 patterns	 of	 collagen	 can	 be	 distinguished	 in	
myocardial	 fibrosis:	 replacement	 fibrosis,	 which	 is	 focal	 and	 forms	 scars	 in	 order	 to	
replace	 dead	 cardiomyocytes;	 and	 interstitial	 /	 reactive	 fibrosis,	 which	 is	 diffuse	 and	
occurs	 in	 the	 interstitial	 space	 without	 notable	 cells	 loss.323	 In	 interstitial	 /	 reactive	
fibrosis	 the	 accumulation	 of	 type	 I	 collagen	 (highly	 cross-linked,	 large-diameter	 fibres)	
prevails	over	 type	 III	 collagen	 (non-cross-linked,	 small-diameter	 fibres),	which	enhances	
myocardial	 stiffness	 and	 the	 resistance	 of	 collagen	 fibres	 to	 degradation	 by	 matrix	
metalloproteinases	(MMP).	Moreover,	collagen	alignment	is	disrupted,	which	impairs	the	
transmission	of	the	strength	generated	by	the	cardiomyocytes	to	the	ventricular	chamber	
and	has	a	detrimental	effect	on	myocardial	contractility.324,	325					
Therefore,	 the	 quantitative	 and	 qualitative	 aspects	 myocardial	 fibrosis,	 as	
evaluated	in	biopsy	samples,	disrupt	myocardial	architecture	and	have	been	shown	to	be	
associated	with:	mechanical	impairment	portrayed	by	increased	LV	stiffness	and	diastolic	
dysfunction	 and	 impaired	 LV	 contraction	 and	 systolic	 dysfunction;326,	 327	 electrical	
instability	 leading	 to	 arrhythmias;328,	 329	 and	 vasomotor	 dysfunction	 with	 impaired	
coronary	blood	flow.330	Moreover,	the	amount	of	myocardial	fibrosis,	in	biopsy	samples,	
influence	long-term	prognosis	in	patients	with	heart	failure,	not	only	in	terms	of	cardiac	
events,	but	also	all-cause	mortality331,	332	and	predict	the	effectiveness	of	long-term	heart	
failure	therapy.333	Consequently,	the	assessment	of	myocardial	fibrosis	is	crucial	not	only	
for	better	pathophysiological	understanding	of	the	clinical	picture,	but	also	to	help	in	the	
determination	of	the	prognosis	and	appropriate	treatment.		
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In	this	setting,	the	search	for	biomarkers	of	structural	myocardial	remodelling	and	
fibrosis	has	evolved	at	a	remarkable	pace	in	the	last	decade.	However,	histopathological	
analysis	of	endomyocardial	biopsy	specimens	remains	as	the	gold	standard	for	diagnosis	
and	assessment	of	cardiac	fibrosis.	Thus,	any	candidate	biomarker	of	myocardial	fibrosis	
must	be	compared	with	 the	gold	standard	and	 its	blood	 levels	 should	directly	correlate	
with	quantitative	parameters	used	to	define	fibrosis	in	endomyocardial	biopsy	specimens,	
namely	 myocardial	 collagen	 volume	 fraction	 and	 the	 determination	 of	 the	 proportion	
occupied	by	either	collagen	type	I	or	III	fibres.334	Moreover,	due	to	the	patchy	distribution	
of	myocardial	fibrosis,	the	analysis	of	several	tissue	fragments	is	important	for	diagnostic	
accuracy	and	interpretation.		
A	number	of	molecules,	detectable	in	either	human	serum	or	plasma,	have	been	
proposed	 as	 biomarkers	 of	 myocardial	 fibrosis,	 namely:	 molecules	 related	 to	 collagen	
metabolism	(described	in	detail	in	the	next	sections),	molecules	related	to	the	regulation	
of	 collagen	 turnover	 and	molecules	 integrating	 cardiac	 stress	 injury,	 inflammation	 and	
fibrosis.	However,	in	most	cases	validation	against	the	histological	gold	standard	is	lacking	
or	remains	inconclusive	(a	summary	is	shown	in	table	3).335,	336	Cardiac	MRI	is	emerging	as	
a	 technique	 that	 enables	 non-invasive	 evaluation	 of	 the	 myocardial	 interstitial	 space	
through	 the	 measurement	 of	 myocardial	 extracellular	 volume	 with	 T1	 mapping.	 This	
measure	seems	to	correlate	with	myocardial	collagen	volume	fraction,	but	still	 requires	
methodological	 standardization	 and	 further	 investigation	 (if	 it	 can	 serve	 as	 a	 surrogate	
parameter	of	myocardial	fibrosis	for	validation	purposes).337		
In	 recent	 years,	 interest	 /	 research	 on	 some	 of	 the	 presented	 candidate	
biomarkers	had	increased	substantially.	In	brief,	some	of	the	results	related	to	microRNAs	
and	gallectin-3	are	described	as	follows.	MicroRNAs	are	small	non-coding	RNA	molecules	
able	to	regulate	gene	expression	at	 the	post-transcriptional	 level	and	are	key	players	 in	
heart	 development	 and	 myocardial	 conditions.338	 Over	 the	 last	 few	 years,	 abundant	
literature	has	accumulated	suggesting	 that	aberrant	expression	of	various	microRNAs	 is	
crucial	in	cardiac	fibrosis	and	heart	failure.	MicroRNAs	may	regulate	fibrotic	response	via	
various	 distinct	 mechanisms:	 acting	 as	 an	 essential	 downstream	 intermediate	 in	 the	
signalling	pathway;	fine-tuning	critical	components	of	the	signalling	pathways;	repressing	
or	 amplifying	 the	 fibrotic	 signal	 by	 participating	 in	 negative	 or	 positive	 feedback	 loops,	
respectively.339	 Myocardial	 fibrosis	 in	 patients	 with	 diverse	 cardiac	 disease	 is	
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accompanied	by	the	increased	expression	of	profibrotic	microRNAs	such	as	microRNA-21	
and	microRNA-499-5p340,	341	and	decreased	expression	of	antifibrotic	microRNAs	such	as	
microRNA-29,	microRNA-122	and	microRNA-133a.342-344	
	
Table	 3:	 Potential	 circulating	 biomarkers	 for	 assessment	 of	 cardiac	 fibrosis.	 HCM:	 hypertrophic	
cardiomyopathy	 due	 sarcomere	 protein	 gene	 mutations;	 ECM:	 extracellular	 matrix;	 RAAS:	 renin–angiotensin–
aldosterone	system	(adapted	from	López	B336).	
Candidate	biomarker	 Role	an	correlation	to	fibrosis	 Histological	evidence	
 Related	to	collagen	metabolism	 	 	
C-terminal	propeptide	of	procollagen	type	I		 Cleaved	enzymatically	from	procollagen	I		
(collagen	biosynthesis)	
Yes	
N-terminal	propeptide	of	procollagen	type	I	 Cleaved	enzymatically	from	procollagen	I		
(collagen	biosynthesis)	
Unknown	
N-terminal	propeptide	of	procollagen	type	III	 Cleaved	enzymatically	from	procollagen	III		
(collagen	biosynthesis)	
Yes	
C-terminal	telopeptide	of	collagen	type	I	 Cleaved	by	matrix	metalloproteinase-1		
(collagen	I	degradation)		
Inconclusive	
Matrix	metalloproteinase-1	 Degrades	collagens	I,	II,	and	III	 No	
Matrix	metalloproteinase-2	 Degrades	collagens	I,	III,	IV	and	V	 Unknown	
Matrix	metalloproteinase-3		 Degrades	collagens	II,	III,	IV,	IX	and	X	 Unknown	
Matrix	metalloproteinase-8		 Degrades	collagens	I,	II,	and	III	 Unknown	
Matrix	metalloproteinase-9		 Degrades	collagens	I,	IV	and	V	 Unknown	
Tissue	inhibitor	of	metalloproteinases-1	 Inhibits	several	matrix	metalloproteinases	 No	
Tissue	inhibitor	of	metalloproteinases-4	 Inhibits	several	matrix	metalloproteinases	 Unknown	
Related	to	the	regulation	of	collagen	turnover	 	 	
microRNA-21	 Correlation	with	fibrosis	in	aortic	stenosis	 Inconclusive	
microRNA-29b	 Correlation	of	plasma	levels	with	hypertrophy	and	
fibrosis	in	HCM,	reduced	cardiac	expression	
Unknown	
microRNA-122	 Targets	and	inhibits	transforming	growth	factor-β1	 Unknown	
microRNA-133a	 Regulatory	effects	on	the	expression	of	Col1α1	 Unknown	
microRNA-499-5p	 Blocks	cardiomyocyte	differentiation	 Unknown	
Transforming	growth	factor-β1	 Promotes	 myofibroblast	 transactivation	 and	 ECM	
synthesis,	deactivates	macrophages	
Inconclusive	
Growth	differentiation	factor-15	 Predictor	of	atrial	fibrosis	 Inconclusive	
Connective	tissue	growth	factor	 Modulating	the	activity	of	growth	factors	in	the	ECM	 Inconclusive	
Osteopontin	 Matricellular	 protein	 involved	 in	 macrophage	
regulation	
No	
Osteoglycin	 Regulate	collagen	assembly	 Unknown	
Syndecan-1	 Regulates	transforming	growth	factor-β1	 Unknown	
Syndecan-4	 Regulates	 mechanical	 stress-induced	 cardiac	
fibroblast	differentiation	
Unknown	
Integrating	inflammation	and	fibrosis	 	 	
Galectin-3	 Galactosamine	 binding	 protein	 associated	 with	
collagen	deposition	of	fibroblasts	
Inconclusive	
Cardiotrophin-1	 Cytokine	associated	with	cardiac	fibrosis	 No	
Soluble	ST2	 A	 "decoy"	 receptor	 for	 IL-33,	 inhibiting	 IL-33/ST2	
signalling	
Unknown	
Mid-regional	pro-atrial	natriuretic	peptide	 Stable	marker	for	the	release	of	ANP,	which	induces	
natriuresis	and	inhibition	of	RAAS	
Unknown	
Myostatin	 Activation	 of	 the	 TAK-1-MKK3/6-p38	 signalling	
pathway	
Unknown	
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	 Galectin-3	 is	 a	 galactoside-binding	 protein	 that	 is	 released	 to	 the	 circulation	 by	
fibroblasts	and	inflammatory	cells.345,	346	Galectin-3	is	up-regulated	by	angiotensin	II	and	
aldosterone347,	 348	 and	 turns	 quiescent	 fibroblasts	 into	 active	 myofibroblasts	 producing	
structural	matrix	proteins.346	 In	heart	 failure	patients,	 serum	 levels	of	galectin-3	predict	
hospitalization	 for	 acute	 heart	 failure	 and	 death	 and	 have	 an	 inverse	 correlation	 with	
estimated	GFR.349,	350	 Although	 serum	 levels	 of	 galectin-3	may	 be	 reliably	 assayed	 by	 a	
commercially	 available	 enzyme-linked	 immunosorbent	 assay	 (ELISA),	 recent	 reports	
showed	 that	 there	 is	a	 significant	correlation	between	myocardial	galectin-3	expression	
and	the	histological	amount	of	fibrosis	in	patients	with	idiopathic	dilated	cardiomyopathy	
(DC),	but	there	are	no	correlations	between	the	myocardial	galectin-3	expression	or	the	
myocardial	fibrosis	volume	and	the	serum	levels	of	galectin-3,	questioning	the	circulating	
galectin-3	as	a	reliable	biomarker	of	myocardial	fibrosis.351,	352		
	
3.1.1	Circulating	candidate	biomarkers	related	to	collagen	metabolism	
Molecules	 related	 to	 collagen	 metabolism	 are	 the	 best	 characterized	 group	 of	
circulating	biomarkers	of	myocardial	fibrosis.	As	mentioned	above,	myocardial	collagen	is	
primarily	 composed	 of	 collagen	 types	 I	 and	 III,	 the	 former	 prevailing	 in	 processes	 of	
interstitial	 myocardial	 fibrosis.324	 Fibrillar	 collagen	 types	 I	 and	 III	 synthesis	 and	
degradation,	 as	well	 as	 its	 regulatory	 control	mechanisms	 are	 similar	 and	 occur	 in	 the	
following	 steps:	 procollagen	 synthesis,	 post-synthetic	 procollagen	 processing,	 post-
translational	collagen	cross-linking	and	collagen	degradation	(figure	3).				
Collagen	 is	 synthesized	 as	 a	 procollagen	 molecule	 primarily	 in	 myocardial	
fibroblasts,	 beginning	 with	 the	 synthesis	 of	 procollagen	 α-chain	 monomeric	 proteins,	
which	then	form	the	triple-helical	structure	of	a	procollagen	molecule.353	Afterwards,	it	is	
secreted,	as	a	 soluble	molecule	with	an	amino	 (N)	and	carboxy	 (C)	 terminal	propeptide	
attached,	 into	 the	extracellular	matrix	 space	 for	 sequential	 post-synthetic	processing	 in	
order	 to	 create	 mature	 insoluble	 collagen	 fibril.354-357	 Removal	 of	 the	 terminal	
propeptides	by	specific	proteinases	 is	 the	 initial	of	a	number	of	essential	 steps	of	post-
synthetic	processing.		
First,	 enzymatic	 cleavage	 of	 the	 C-terminal	 propeptide	 by	 bone	 morphogenic	
protein-1	(enhanced	by	procollagen	C-proteinase	enhancer)	is	required.355,	358	A	100-KDa	
procollagen	type	I	C-terminal	propeptide	(PICP)	is	released	into	the	bloodstream	after	this	
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first	enzymatic	step	during	the	synthesis	of	fibril-forming	collagen	type	I.	A	stoichiometric	
ratio	of	1:1	exists	between	the	number	of	collagen	type	I	molecules	produced	and	that	of	
PICP	 released,	with	 PICP	 cleared	 from	 the	 blood	 by	 the	 liver.359	 The	 second	 enzymatic	
step	 is	 the	 cleavage	 of	 the	 N-terminal	 propeptide	 by	 the	 A	 Disintegrin-like	 and	
Metalloproteinase	 Domain	 with	 Thrombospodin	 Type	 Motif	 (ADAMST)-2/3	 enzyme;	
however,	 the	 70-KDa	 procollagen	 type	 I	 N-terminal	 propeptide	 (PINP),	 which	 is	 also	
cleared	 from	 the	blood	by	 the	 liver,	 is	not	 completely	 cleaved	during	 this	 cleavage	and	
may	remain	in	the	final	fibres,	where	they	can	be	released	during	fibre	degradation.360,	361	
During	collagen	type	III	processing,	equivalent	procollagen	type	III	C-terminal	propeptide	
and	procollagen	type	III	N-terminal	propeptide	(PIIINP)	are	released,	but	it	is	unknown	if	
the	 former	 reaches	 the	 bloodstream.336	 Like	 PINP,	 the	 42-KDa	 PIIINP	 is	 also	 not	
completely	cleaved	during	the	conversion	of	procollagen	type	III	to	collagen	type	III	and	is	
cleared	from	the	blood	via	hepatobiliary	elimination.362,	363	
After	 the	 cleavage	 of	 C	 and	 N	 terminal	 propeptides,	 the	 resulting	 collagen	
molecules	undergo	covalent	cross-linking	to	form	insoluble	fibrils;	initially,	cross-linking	is	
formed	 spontaneously	 by	 oxidized	 reactive	 aldehydes	 on	 lysine	 and	 hydroxylysine	
catalysed	 by	 the	 enzymes	 lysil	 and	 hydroxylysyl	 oxidase,	 but	 additional	 non-enzymatic	
cross-links	 can	 be	 formed	 by	 glycation	 end	 product	 formation.364-366	 A	 number	 of	
matricellular	proteins	 such	as	 Secreted	Protein	Acidic	and	Rich	 in	Cysteine	 (SPARC)	and	
thrombospondin-2	 are	 also	 critical	 in	 the	 regulation	 of	 procollagen	 processing	 by	
facilitating	fibril	assembly,	formation	and	collagen	deposition	to	insoluble	ECM.356,	357,	367	
Myocardial	 fibrillar	 collagen	 type	 I	degradation	begins	with	catalytic	 cleavage	by	
MMP-1	(the	rate-limiting	step);	MMP-1	cleaves	all	three	alpha	chains	of	collagen	type	I	by	
hydrolysing	 a	 peptide	 bond	 following	 a	 glycine	 residue	 located	 at	 a	 distance	 of	 three-
fourths	of	the	collagen	molecule	length	from	the	N	terminus,	resulting	in	36-KDa	and	12-
KDa	 telopeptides	 (which	 maintain	 their	 helical	 structure).	 The	 larger	 telopeptide	
spontaneously	 denatures	 into	 non-helical	 gelatine	 derivatives,	 which	 are	 completely	
degraded	 by	 the	 gelatinases	 MMP-2	 and	 MMP-9.368	 The	 final	 fragments	 of	 these	
derivatives	or	matrikines,	like	tripeptide	glycyl-histidyl-lysine	(GHL)	may	regulate	collagen	
metabolism,	 stimulating:	 new	 collagen	 synthesis	 by	 fibroblasts	 and	 in	 vitro	 MMP-2	
expression	 and	 secretion	 by	 fibroblasts.369,	 370	 GHL	 can	 found	 in	 plasma,	 but	 its	
stoichiometry	 relative	 to	 the	 degradation	of	 collagen	 type	 I	 is	 unknown.371	 The	 smaller	
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telopeptide,	collagen	type	I	C-terminal	telopeptide	(CITP),	 is	released	immunochemically	
intact	 into	 the	 blood	 stream	 (in	 a	 stoichiometric	 ratio	 of	 1:1	 between	 the	 number	 of	
collagen	 type	 I	 molecules	 degraded	 and	 that	 of	 CITP	 released)	 and	 cleared	 from	 the	
circulation	 via	 glomerular	 filtration.372	 MMPs	 are	 regulated	 by	 tissue	 inhibitor	 of	
metalloproteinases	 (TIMP),	 which	 bind	 to	 active	 MMPs	 and	 inactivate	 their	 protease	
activity,	leading	to	a	reduction	in	collagen	degradation.373	
Figure	 3:	 Steps	 involved	 in	 the	 synthesis	 and	 degradation	 of	 collagen	 type	 I	 fibrils.	 Several	
peptides	released	during	this	process	reach	the	bloodstream	and	may	be	measured	in	serum.	PINP:	
procollagen	 type	 I	 amino-terminal	 propeptide;	 PICP:	 procollagen	 type	 I	 carboxy-terminal	 propeptide;	 BMP:	 bone	
morphogenic	 protein;	 PCOLCE:	 procollagen	 carboxy-proteinase	 enhancer;	 ADAMST:	 a	 disintegrin-like	 and	
metalloproteinase	domain	with	 thrombospodin	 type	motif;	 LOX:	 lysil	 oxidase;	AGE:	 advanced	 glycation	 end	product;	
SPARC:	secreted	protein	acidic	and	rich	in	cysteine;	TP:	thrombospondin;	MMP:	matrix	metalloproteinase;	TIMP:	tissue	
inhibitor	 of	 matrix	 metalloproteinases;	 CITP:	 collagen	 type	 I	 carboxy-terminal	 telopeptide;	 GHL:	 tripeptide	 glycyl-
histidyl-lysine.	
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Each	 protein	 and	 peptide	 referred	 to	 above	 can	 be	 measured	 in	 the	 plasma	 /	
serum	and	can	be	used	as	a	biomarker	to	assess	collagen	synthesis	and	degradation	rates.	
Thus,	 PICP,	 PINP	 and	 PIIINP	 are	 candidate	 surrogate	 biomarkers	 of	 collagen	 type	 I	 and	
collagen	type	III	synthesis	and	high	serum	levels	may	reflect	ongoing	tissue	fibrosis.374,	375	
Instead,	CITP,	MMP-1,	MMP-2,	MMP-9	and	TIMP-1	may	be	used	as	biomarkers	related	to	
the	intensity	of	the	degradation	of	collagen	type	I	fibrils.372	However,	myocardial	collagen	
content,	composition	and	geometry	are	the	result	of	the	balance	between	synthesis	and	
degradation	 of	 collagen,	 which	 determines	 its	 turnover	 (estimated	 at	 80	 to	 120	 days);	
thus,	 the	 ratio	 of	 propeptides	 to	 telopeptides	 reflects	 the	 collagen	 turnover	 rate,	with	
higher	ratios	resulting	in	a	net	increase	in	collagen	content	and	fibrosis.376					
Nonetheless,	as	noted	above,	because	biomarkers	of	collagen	metabolism	present	
in	 blood	 are	 not	 cardiac	 specific,	 the	 serum	 levels	 of	 any	 candidate	 biomarker	 of	
myocardial	 fibrosis	must	be	compared	with	 the	gold	 standard	quantitative	measures	of	
fibrosis	in	endomyocardial	biopsy	specimens.334	The	evidence	supporting	the	association	
between	biomarkers	 related	 to	collagen	metabolism	and	myocardial	 fibrosis	 is	variable,	
according	 to	 the	 biomarker.336	 Among	 the	 many	 proposed	 circulating	 biomarkers	 of	
myocardial	fibrosis	(see	Table	3),	only	2	biomarkers	related	to	collagen	metabolism	have	
been	shown	to	be	associated	histologically	to	myocardial	fibrosis:	PICP	and	PIIINP.	
PICP	 is	 the	 circulating	 biomarker	 most	 extensively	 validated	 against	 the	
histological	gold	standard.	In	a	study	with	65	hypertensive	patients	with	LV	hypertrophy	
(31	 of	 them	 with	 heart	 failure),	 the	 concentration	 of	 peripheral	 blood	 PICP	 was	
significantly	 lower	compared	with	that	in	the	coronary	sinus,	but	there	was	a	significant	
direct	correlation	between	peripheral	and	coronary	PICP	and	between	peripheral	blood	
PICP	and	the	collagen	volume	fraction	or	the	extent	of	collagen	type	I	deposition	 in	the	
myocardium.326	 The	 direct	 correlation	 between	 peripheral	 blood	 PICP	 and	 collagen	
volume	fraction	of	the	myocardium	was	further	confirmed	in	patients	with	hypertensive	
heart	 disease	 with	 and	 without	 heart	 failure,	 patients	 with	 chronic	 heart	 failure	 (of	
diverse	 aetiologies).352,	 377-379	 Moreover,	 PICP	 levels	 and	 collagen	 fractional	 volume	
changed	 in	 parallel	 in	 response	 to	 diverse	 treatments:	 in	 one	 study	 torasemide	 was	
compared	 with	 furosemide	 in	 the	 ability	 to	 decrease	 myocardial	 fibrosis	 and	 collagen	
fractional	volume,	as	well	as	PICP,	which	only	decreased	in	the	torasemide	group,	with	a	
direct	 correlation	between	 the	 change	 in	 both	 variables.377	Another	 study	 showed	 that	
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after	12	months	of	 treatment	with	 losartan,	 there	was	a	parallel	 significant	decrease	of	
collagen	volume	fraction	and	PICP	in	the	subgroup	of	patients	with	severe	fibrosis	(>6%	of	
the	 total	myocardium),	whereas	 in	 the	 subgroup	of	patients	without	 severe	myocardial	
fibrosis	 there	was	 only	 a	 non-significant	 trend	 of	 decrease	 in	 both	 variables.380	 Similar	
results	 were	 found	 in	 patients	 with	 idiopathic	 DC	 treated	 with	 spironolactone	 for	 12	
months.381	 In	 this	 last	 study,	 a	 significant	 correlation	 between	 PICP	 to	 CITP	 ratio	 and	
collagen	 volume	 fraction	 was	 found,	 both	 before	 and	 after	 treatment	 with	
spironolactone.381		
There	is	conflicting	evidence	supporting	the	correlation	between	serum	PIIINP	and	
the	histological	gold	standard.	 In	a	study	 in	17	patients	with	DC,	 there	was	a	significant	
correlation	between	PIIINP	and	myocardial	collagen	type	III	fractional	area;382	moreover,	
after	12	months	of	treatment	with	spironolactone,	the	reduction	of	the	collagen	volume	
fraction	of	the	myocardium	was	paralleled	by	a	reduction	in	serum	PIIINP.381	However,	2	
further	 studies	 did	 not	 confirm	 this	 histological	 validation:	 in	 38	 patients	 with	
hypertensive	 cardiomyopathy	 and	 heart	 failure,	 a	 correlation	 between	 PIIINP	 and	
collagen	volume	fraction	was	not	found	(but	the	collagen	type	III	fractional	area	was	not	
analysed).379	In	another	study	with	39	patients	with	heart	failure,	there	was	no	significant	
correlation	 between	 PIIINP	 and	 collagen	 volume	 fraction	 or	 collagen	 type	 III	 fractional	
area.352	
The	evidence	 regarding	 the	 relationship	between	CITP	and	myocardial	 fibrosis	 is	
controversial.	 In	 the	 aforementioned	 study	 with	 17	 patients	 with	 DC,	 a	 significant	
correlation	was	identified	between	CITP	and	myocardial	collagen	type	I	fractional	area.382	
However,	 in	 another	 study	 in	 patients	 with	 idiopathic	 DC,	 CITP	 levels	 were	 lower	 in	
patients	with	severe	fibrosis	(compared	with	the	remaining	patients)	and	increased	after	
12	 months	 of	 spironolactone,	 whereas	 collagen	 volume	 fraction	 in	 the	 myocardium	
decreased	 in	 the	 same	 subgroup	of	patients.381	Moreover,	 in	 the	previously	mentioned	
study	comparing	torasemide	and	furosemide,	CITP	remained	unchanged	after	treatment	
in	both	groups	 (collagen	volume	fraction	significantly	 reduced	 in	 the	 torasemide	group)	
and	no	correlation	was	 found	between	serum	CITP	and	collagen	volume	fraction	of	 the	
myocardium.377	 Serum	 CITP	 was	 inversely	 associated	 with	 insoluble	 (cross-linked)	
collagen	volume	fraction	in	one	study.379	
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Higher	concentrations	of	MMP-1	and	TIMP-1	were	found	in	coronary	sinus	blood	
compared	with	 peripheral	 blood,	 but	 a	 significant	 correlation	 between	both	 sources	 of	
blood	was	 found	 for	 the	 two	molecules.	 Nonetheless,	 correlations	 between	MMP-1	 or	
TIMP-1	and	myocardial	fibrosis	are	intriguing,	because	no	correlation	was	found	between	
MMP-1	 or	 TIMP-1	 and	 collagen	 volume	 fraction	 in	 patients	 with	 hypertensive	 heart	
disease	and	heart	failure;	however,	it	is	noteworthy	that	the	patients	with	higher	values	
of	 serum	MMP-1	 exhibited	 reduced	 levels	 of	 perimysial	 and	 endomysial	 collagen.	 This	
finding	suggests	that	these	molecules	may	be	related	more	to	the	loss	of	the	physiological	
mysial	collagen	scaffold	than	to	the	accumulation	of	pathologic	non-mysial	collagen.383	
No	 data	 is	 available	 in	 the	 literature	 on	 the	 association	 between	 the	 remaining	
circulating	candidate	biomarkers	related	to	collagen	metabolism	and	myocardial	collagen	
content.	
Apart	the	histological	validation	of	the	candidate	biomarkers,	the	interpretation	of	
their	 serum	 levels	 may	 be	 complex	 due	 to	 several	 aspects	 influencing	 their	 clinical	
evaluation,	 namely:	 immunoassay	 method	 of	 detection,	 elimination	 of	 circulating	
biomarkers	 from	 the	 circulation,	 patient	 demographics,	 presence	 of	 comorbidities	 and	
effects	of	pharmacological	treatment.	
The	 abovementioned	molecules	may	 be	measured	 in	 serum	 or	 plasma	 samples	
easily,	 reproducibly	 and	 inexpensively	 using	 commercially	 available	 ELISA	 or	
radioimmunoassay	kits;	however,	several	kits	are	available	for	the	same	biomarker	(with	
various	 antibodies	 and	 standards)	 and	 it	 is	 important	 to:	 standardize	 these	
determinations	before	applying	them	to	routine	clinical	practice	and	take	this	aspect	into	
account	when	comparing	results	provided	by	different	studies.	Moreover,	whereas	most	
of	the	peptides	generated	during	the	processing	of	procollagen	types	I	and	III	are	found	as	
one	antigen	form	in	serum,	PINP	appears	in	two	different	forms:	one	form	corresponding	
to	the	whole	propeptide	and	a	smaller	form	that	is	the	product	of	its	degradation.	Thus,	it	
is	 important	 to	 use	 assays	 that	 can	 identify	 the	 intact	 molecule	 as	 the	 biomarker	 of	
interest.384	Remarkably,	 all	 propeptide	antigens	are	 very	 stable	 in	 serum	 if	 samples	are	
taken,	 handled	 and	 stored	 according	 to	 good	 clinical	 laboratory	 practice	 (there	 are	 a	
number	 of	 reports	 in	 the	 literature	 on	 the	 analysis	 of	 PINP,	 PICP	 or	 PIIINP	 in	 frozen	
samples	that	were	collected	several	years	previously).385	
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Other	 potentially	 confounding	 factors	 in	 the	 interpretation	 of	 blood	
concentrations	 of	 the	 biomarkers	 are:	 their	 rate	 of	 release,	 how	 they	 reach	 the	 blood	
(cardiac	lymph	versus	venous	drainage),	their	volume	of	distribution	and	the	pathway	of	
elimination.363	PICP,	PINP	and	PIIINP	are	cleared	from	the	circulation	by	the	liver	and	CITP	
is	 cleared	 through	 the	 kidneys,	 thus	 chronic	 liver	 insufficiency	 and	 CKD	 (GFR	
<50ml/min/1.73m2)	may	cause	increase	in	their	serum	concentrations,	respectively.359,	360,	
362,	 372	 The	 mechanism	 for	 the	 clearance	 of	 MMPs	 and	 TIMPs	 in	 not	 fully	 known,	 but	
various	 pathways	 have	 been	 implied:	 own	 autoproteolysis,	 direct	 clearance	 via	 low-
density	 lipoprotein-related	 scavenger	 receptor	 and	 entrapment	 in	 a	 complex	 with	 α2-
macroglobulin.386-388	
Demographic	/	physiological	parameters	may	also	affect	the	serum	concentration	
of	some	biomarkers:	PICP	is	increased	in	infants,	children	and	adolescents	up	to	18	years	
old	 (with	a	peak	before	3	months	of	age)	and	correlates	with	growth	velocity;389	PIIINP	
and	 TIMP-1	 increase	 both	 with	 age	 and	 body	 mass	 and	 the	 second	 biomarker	 is	 also	
higher	in	males.390,	391	
Due	to	the	ubiquitous	distribution	of	collagen	type	I	(bone,	tendon,	ligament,	skin,	
cornea	and	others)	and	collage	type	III	(skin,	blood	vessels	and	others),	the	lack	of	cardiac	
specificity	 of	 the	 circulating	 biomarkers	 related	 to	 collagen	 metabolism	 is	 one	 of	 the	
major	concerns	in	their	clinical	applicability.354	Taking	into	account	this	diversity	of	tissue	
sources	of	collagen	biomarkers,	change	 in	their	blood	 levels	may	be	related	not	only	to	
the	 myocardial	 collagen	 network,	 but	 also	 to	 alterations	 in	 other	 organs.	 Even	 in	
cardiovascular	 diseases,	 like	 HBP,	 arterial	 stiffness	 was	 directly	 correlated	 with	 serum	
PICP	or	CITP	in	elderly	patients	and	inversely	associated	to	plasma	MMP-1.	Although	no	
cardiac	 parameters	 were	 included	 in	 a	 multiple	 regression	 analysis	 and	 no	 cardiac	
histological	 evaluation	 was	 performed,	 alterations	 in	 these	 circulating	 biomarkers	 may	
reflect	disturbances	of	collagen	metabolism	that	occur	not	just	at	the	myocardial	but	also	
at	the	arterial	wall	level.392,	393		
Moreover,	 the	 presence	 of	 concomitant	 non-cardiovascular	 diseases	 affecting	
collagen	matrix	 turnover	 can	 also	 affect	 the	 circulating	 levels	 of	 these	 biomarkers	 and	
must	be	excluded	 in	the	patients	under	study.	This	 issue	 is	paramount	concerning	bone	
disorders,	 because	 bone	 is	 one	 of	 the	 main	 sources	 of	 collagen	 type	 I	 in	 the	 body.	
Metabolic	bone	diseases,	like	osteoporosis,	increase	collagen	type	I	synthesis	biomarkers	
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(PICP	 and	 PINP)	 and	 post-menopausal	 women	 present	 an	 increase	 of	 about	 20%	 in	
PICP;394,	 395	 osteolytic	 metastatic	 bone	 disease	 and	 multiple	 myeloma	 increased	 the	
biomarkers	of	collagen	type	I	degradation,	namely	CITP.396	To	minimize	this	confounding	
factor,	 in	one	study	evaluating	collagen	biomarkers	 in	HCM,	the	 investigators	measured	
specific	markers	 of	 bone	metabolic	 activity	 (like	 bone-specific	 alkaline	 phosphatase	 [B-
AP])	and	normalized	biomarkers	to	this	analyte.397	Chronic	liver	disease	and	CKD	may	also	
affect	 the	 levels	 of	 the	 biomarkers	 related	 to	 collagen	metabolism,	 not	 only	 impairing	
their	elimination,	and	also	to	the	hepatic	fibrosis	(increases	PIIINP	and,	to	a	lesser	extent,	
PICP)	 and	 to	 the	 kidney-related	 bone	 disease	 (increases	 PICP	 and	 CITP).398,	 399	 Other	
fibrogenic	 diseases,	 like	 diffuse	 fibrosing	 lung	 disease,	 may	 also	 increase	 the	
concentration	of	the	metabolites	related	to	collagen	type	I	metabolism	(PICP	and	CITP).400	
Finally,	 inflammatory	 (for	 example,	 rheumatoid	 arthritis)	 and	 endocrine	 (for	 example,	
thyroid	 disorders)	 diseases	 can	 also	 affect	 bone	 metabolism	 and	 consequently	 may	
increase	collagen	metabolism	biomarkers.401,	402		
As	noted	above,	long-term	pharmacological	treatment	of	cardiovascular	disorders	
may	decrease	 collagen	 volume	 fraction	of	 the	myocardium	and	modify	 serum	 levels	 of	
the	biomarkers	of	 collagen	metabolism:	ACEi	and	ARB	decreases	 the	 levels	of	PICP	and	
the	PICP	to	CITP	ratio	and	increases	the	levels	of	CITP	and	MMP-1;380,	403-406	aldosterone	
antagonists	 have	 a	 similar	 effect	 on	PICP,	 PICP	 to	CITP	 ratio	 and	CITP,	 but	 a	 significant	
decrease	 in	 PIIINP	was	 also	 reported.381,	407-410	 As	 previously	 described,	 treatment	with	
torasemide	 also	 decreased	 PICP	 blood	 levels.377	 Moreover,	 CITP	 decreases	 in	
hypercholesterolaemic	 patients	 treated	 with	 statins.411	 The	 administration	 of	
bisphosphonates,	 glucocorticoids	 or	 hormone	 replacement	 therapy	 in	 post-menopausal	
women	decreases	PICP,	PINP	and	CITP	levels.395,	412		
	
3.2	Biomarkers	related	to	collagen	metabolism	in	cardiac	diseases:	state	of	the	art	
3.2.1	Fabry	disease	
	 The	 body	 of	 knowledge	 about	 the	 circulating	 candidate	 biomarkers	 related	 to	
collagen	 metabolism	 in	 FD	 is	 limited.	 A	 study	 evaluating	 extracellular	 matrix	 turnover	
(MMP-9,	 TIMP-1	 and	 TIMP-2),	 including	 29	 FD	 patients	 (15	 males,	 16	 on	 ERT)	 and	 21	
controls,	reported:	significantly	increased	levels	of	MMP-9	in	FD	patients	compared	with	
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controls;	 significant	 inverse	 correlation	 between	 MMP-9	 and	 endocardial	 or	 midwall	
fractional	shortening	of	the	LV	(independent	of	age	and	sex);	significant	direct	correlation	
between	MMP-9	 and	QRS	 duration	 or	 total	MSSI	 (but	 not	MSSI	 cardiac	 subscore);	 and	
there	was	no	correlation	between	MMP-9	and	LV	mass	index	or	LV	cavity	dimension.	No	
difference	was	found	in	levels	of	TIMP-1	and	TIMP-2	between	FD	patients	and	controls.413	
	 Another	 study	 based	 on	 73	 FD	 patients	 (57	 receiving	 ERT),	 followed	 by	 a	mean	
time	of	4.8	 years	 reported	an	 increase	 in	PICP,	PIIINP	and	CITP,	without	any	 significant	
difference	 between	 treated	 and	 untreated	 FD	 patients	 or	 among	 patients	 with	 and	
without	 LGE	 in	 cardiac	 MRI;	 moreover,	 no	 significant	 change	 between	 baseline	 and	
follow-up	measurements	was	found,	regardless	of	ERT	status.116	
	
3.2.2	Hypertrophic	cardiomyopathy	due	sarcomere	protein	gene	mutations	
HCM	 is	 caused	 by	 mutations	 in	 genes	 encoding	 sarcomere	 proteins,	 being	 the	
most	 common	 monogenic	 cardiac	 disorder	 (prevalence	 of	 1:500	 in	 the	 general	
population).414	HCM	share	some	features	with	FD	cardiomyopathy,	namely:	they	are	both	
monogenic	 cardiac	 disorders	 (though	 with	 different	 patterns	 of	 inheritance);415	
heterogeneous	 phenotype,	 with	 mutation	 carriers	 not	 presenting	 overt	 hypertrophic	
phenotype	 (however	 at	 high	 risk	 of	 development),	 but	 often	 exhibiting	 early	
manifestations	 that	 precede	 the	 pathological	 remodelling	 of	 the	 overt	 disease	 (for	
example,	 impairment	 of	 LV	 relaxation);416-418	 histological	 evidence	 of	 diffuse	 interstitial	
and	focal	replacement	myocardial	fibrosis	in	overt	disease	(the	latter	emerging	as	LGE	in	
cardiac	MRI).419,	420	
A	few	studies	evaluated	circulating	biomarkers	related	to	collagen	metabolism	in	
patients	with	HCM,	not	only	their	sensitivity	to	detect	early	cardiac	involvement,	but	also	
their	 clinical	 correlations,	 prognostic	 value	 and	 response	 to	 treatments.	 A	 study	
evaluating	77	patients	with	pathogenic	sarcomere	mutations	associated	with	HCM,	38	of	
them	with	overt	LV	hypertrophy	(defined	as	LV	wall	thickness	≥12mm)	and	39	without	LV	
hypertrophy	 (though	 presenting	 lower	 average	 E’	 than	 healthy	 controls),	 reported	 a	
significant	increase	in	PICP	(biomarker	of	collagen	type	I	synthesis)	even	in	the	subgroup	
of	patients	without	overt	LV	hypertrophy	(in	comparison	with	healthy	controls),	although	
significantly	lower	than	in	subgroup	of	patients	with	overt	LV	hypertrophy.	This	significant	
increase	remained	after	adjustment	for	bone	turnover	(ratio	of	PICP	to	B-AP).	There	was	
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no	significant	difference	in	circulating	biomarkers	of	collagen	degradation	MMP-1,	TIMP-1	
and	CITP	(except	a	significant	increase	of	MMP-1	in	the	subgroup	of	patients	without	LV	
hypertrophy	 in	 comparison	with	 controls),	 but	 a	 progressive	 and	 significant	 increase	 in	
PICP	to	CITP	ratio	(reflects	the	balance	between	collagen	synthesis	and	degradation)	was	
observed,	 comparing	 controls	 and	patients	without	 LV	hypertrophy,	 as	well	 as	 patients	
without	and	with	LV	hypertrophy.	 In	 the	same	study	71%	of	 the	patients	with	overt	 LV	
hypertrophy	presented	LGE	in	cardiac	MRI,	whereas	LGE	was	not	evidenced	in	any	patient	
without	 LV	 hypertrophy.	 However,	 there	were	 no	 significant	 correlations	 between	 LGE	
and	levels	of	PICP,	CITP,	MMP-1	or	TIMP-1,	and	nor	was	PICP	correlated	significantly	with	
natriuretic	 peptides,	 cardiac	 troponin	 or	 any	 echocardiographic	 variables.397	 In	 another	
study	 of	 23	 patients	 with	 established	 HCM	 and	 16	 patients	 at	 risk,	 a	 clear	 trend	 was	
identified	of	increased	MMP-9	in	the	subgroup	of	patients	at	risk	(compared	with	healthy	
controls),	but	it	was	only	significant	in	patients	with	established	HCM.421	
No	 other	 studies	 evaluated	 patients	 without	 overt	 phenotype.	 Nonetheless,	
further	studies	confirmed	increased	levels	in	PICP	and	no	change	in	CITP	in	patients	with	
overt	HCM.	Moreover	a	significant	decrease	in	MMP-1	and	a	significant	increase	in	TIMP-
1,	MMP-2	and	MMP-9	were	reported	in	patients	with	established	HCM.422,	423	Conflicting	
results	 were	 reported	 by	 one	 study	 showing	 a	 non-significant	 increase	 in	 PICP	 and	 a	
significant	 decrease	 of	 CITP	 in	 patients	with	 overt	HCM;424	 another	 study	 described	 no	
clear	difference	between	HCM	and	controls	in	the	levels	of	PINP,	CITP	and	PIIINP.425	
However,	 some	 other	 studies	 demonstrated	 significant	 correlations	 between	
circulating	 collagen	biomarkers	 and	parameters	 of	 diastolic	 function:	 significant	 inverse	
correlation	between	PICP	or	PINP	and	the	difference	between	the	duration	of	transmitral	
forward	wave	 (A	 dur)	 and	 the	 duration	 of	 the	 pulmonary	 venous	 retrograde	wave	 (Ar	
dur);	significant	direct	correlation	between	free	MMP-1	or	active	MMP-2	and	A	dur	–	Ar	
dur;	lower	S’	and	higher	E’	and	ratio	of	peak	velocity	of	early	LV	filling	(E)	to	E’	(an	indirect	
estimate	 of	 LV	 filling	 pressure)	 in	 patients	 with	 higher	 PINP	 to	 ICTP	 ratio.426,	 427	 These	
results	 support	 the	hypothesis	 that	 the	observed	 increase	 in	collagen	 I	 synthesis	with	a	
concurrent	 suppression	 of	 catabolic	 enzymes	 leads	 to	 diastolic	 dysfunction.	 One	 study	
evaluating	 diastolic	 dysfunction	 during	 exercise	 in	 patients	 with	 HCM	 was	 not	 able	 to	
identify	any	correlation	with	circulating	biomarkers	related	to	collagen	metabolism.424,	427		
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A	small	number	of	studies	showed	significant	correlations	between	PICP	and	 IVS	
thickness	 or	 between	 PINP	 and	 maximal	 LV	 wall	 thickness	 and	 a	 significant	 inverse	
correlation	 between	 CITP	 and	 IVS	wall	 thickness.422,	 424	 In	 other	 studies,	 no	 correlation	
between	collagen	biomarkers	and	 severity	of	 LV	hypertrophy	or	 the	amount	of	 LGE	 (or	
the	post-contrast	myocardial	 T1	 time	 in	 one	 study)	 in	 cardiac	MRI	was	 found.423,	425,	426	
Only	 in	one	 	study	with	54	patients	with	overt	HCM,	was	a	significant	correlation	found	
between	MMP-9	and	the	amount	of	LGE	in	cardiac	MRI	(and	only	in	female	patients).428	
Nonetheless,	 in	one	 study	based	on	28	patients	with	HCM,	11	of	 them	at	an	advanced	
stage	 characterized	 by	 LV	 wall	 thinning,	 LV	 dilatation	 and	 systolic	 dysfunction,	 a	
significant	increase	in	MMP-2	and	TIMP-2	was	reported	only	in	the	subgroup	of	patients	
with	 advanced	 HCM	 (with	 no	 difference	 between	 the	 remaining	 patients	 and	 the	
controls);	 moreover,	 MMP-2	 concentrations	 significantly	 increased	 as	 the	 NYHA	
functional	 class	 increased	 (another	 study	 further	 confirmed	 this	 inverse	 correlation	
between	MMP-2,	as	well	as	MMP-9	and	exercise	capacity).423,	429	An	 inverse	correlation	
between	CITP	and	NYHA	class	has	been	also	reported.422	
The	 correlation	 between	 the	 levels	 of	 the	 circulating	 biomarkers	 related	 to	
collagen	metabolism	 and	 cardiac	 events,	 like	 malignant	 ventricular	 arrhythmias,	 is	 not	
well	 established,	with	 two	 studies	 identifying	 a	 significant	 correlation	 between	MMP-3	
and	 ventricular	 arrhythmias	 (in	 multivariate	 regression	 analysis),428,	 430	 while	 other	
authors	were	not	able	to	show	any	correlation.424		
In	patients	with	HCM,	data	on	the	response	of	the	circulating	biomarkers	related	
to	 collagen	 metabolism	 to	 treatments	 is	 sparse.	 In	 a	 small	 cohort	 of	 23	 patients,	 11	
treated	with	losartan	and	12	non	treated	with	ARB	or	ACEi,	there	was,	after	12	months	of	
treatment,	 a	 significant	 decrease	 in	 PICP	 in	 the	 subgroup	 of	 patients	 treated	 with	
losartan,	while	 in	 the	other	 subgroup	 it	 remained	unchanged;	 in	 the	 same	 study	PIIINP	
levels	were	not	influenced	by	the	treatment.405			
	
3.2.3	Dilated	cardiomyopathy	and	hypertensive	heart	disease		
Non	ischemic	DC	is	characterized	by	LV	dilatation	and	impaired	systolic	function,	
associated	with	 profound	morphological	 and	 histological	 changes,	 including	myocardial	
fibrosis,431	which	may	predispose	patients	to	both	atrial	and	ventricular	arrhythmias.432	A	
few	 studies	 have	 evaluated	 circulating	 biomarkers	 related	 to	 collagen	 metabolism	 in	
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patients	 with	 DC	 and	 the	 results	 are	 conflicting.	 Nevertheless,	 a	 consistent	 pattern	 of	
increased	collagenase	expression	and	activity,	increased	collagen	type	I	degradation	and	a	
shift	toward	an	increased	synthesis	of	collagen	type	III	was	reported,433-435	as	evidenced	
by:	 one	 study	 recruiting	 43	 DC	 patients	 showed	 a	 non-significant	 trend	 of	 increased	
collagen	 synthesis	 (measured	 by	 PICP)	 and	 a	 significant	 increase	 in	 CITP,	 MMP-1	 and	
TIMP-1;436	other	studies	corroborated	the	increase	in	CITP	and	demonstrated	a	significant	
increase	 in	 PIIINP	 levels	 (even	 in	 the	 paediatric	 population).382,	 437	 However,	 diverging	
results	 were	 found	 in	 another	 study	 recruiting	 73	 patients	 with	 mild	 to	 moderate	 DC	
(NYHA	class	 I	or	 II),	where	a	significant	decrease	 in	PINP	and	PIIINP	and	a	no	significant	
difference	in	CITP	were	found	in	DC	patients	(in	comparison	with	healthy	controls).	This	
finding	was	attributed	by	the	authors	to	the	mild	phenotype	and	to	the	use	of	ACEi	/	ARB	
and	 aldosterone	 antagonists	 (as	 noted	 above,	 known	 to	 decrease	 collagen	 synthesis	
biomarkers).	Moreover,	in	the	same	study,	LA	size	was	directly	correlated	with	CITP	or	the	
PIIINP	to	PINP	ratio	and	negatively	correlated	with	PINP.438	
PIIINP	was	also	directly	correlated	with	diastolic	dysfunction	 in	patients	with	DC,	
predicting	 mitral	 inflow	 pattern	 independently	 of	 the	 haemodynamic	 variables.439	
Regarding	 systolic	 function:	 free	 MMP-1	 presented	 a	 direct	 correlation	 with	 LV	 end	
diastolic	 diameter	 and	 an	 inverse	 correlation	with	 cardiac	 index,	 and	 CITP	was	 directly	
correlated	 with	 LV	 end	 diastolic	 diameter;436	 PIIINP	 showed	 a	 significant	 direct	 and	
inverse	correlations	with	NYHA	functional	classes	and	cardiac	output,	respectively.382	
The	prognostic	value	of	circulating	biomarkers	related	to	collagen	metabolism	 in	
patients	with	 DC	was	 highlighted	 in	 a	 study	 involving	 70	 patients	 during	 12	months	 of	
follow-up.	 During	 this	 follow-up	 period	 14	 patients	 implanted	 cardiac	 devices	 for	
prevention	of	sudden	cardiac	death	and	the	baseline	 levels	of	CITP,	MMP-1	and	TIMP-1	
were	 significantly	 higher	 in	 this	 subgroup	 of	 patients	 (CITP	 showing	 better	 diagnostic	
accuracy	to	predict	malignant	arrhythmic	event).440	The	prognostic	significance	of	CITP,	in	
terms	 of	 overall	 survival,	was	 corroborated	 in	 another	 study.382	Moreover,	 few	 studies	
identified	PIIINP	as	a	significant	predictor	of	overall	survival	during	follow-up.382,	439,	441	
Hypertensive	 heart	 disease	 is	 one	 of	 the	 most	 common	 aetiological	 conditions	
predisposing	 to	 heart	 failure	 and	 is	 characterized	 by	 complex	 changes	 in	 myocardial	
structure:	 enhanced	 cardiomyocyte	 growth	 and	 apoptosis,	 accumulation	 of	 interstitial	
and	 perivascular	 collagen	 fibres	 and	 disruption	 of	 endomysial	 and	 perimysial	 collagen	
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network.442	Several	circulating	biomarkers	of	myocardial	 remodelling	have	been	studied	
in	hypertensive	heart	disease,	particularly	those	related	to	collagen	metabolism.		
As	 mentioned	 above,	 PICP	 is	 the	 sole	 circulating	 biomarker	 related	 to	 collagen	
metabolism	has	been	consistently	validated	against	the	histological	gold-standard	(mainly	
in	 patients	 with	 hypertensive	 heart	 disease).326,	 352,	 378	 Several	 authors	 reported	 that	
serum	 PICP	 is	 increased	 in	 hypertensive	 patients	 (in	 comparison	 with	 normotensive	
patients).326,	 377,	 378,	 380,	 404,	 443-447	 No	 significant	 differences	 in	 serum	 PICP	 were	 found	
between	hypertensive	patients	with	and	without	LV	hypertrophy,	but	patients	with	overt	
heart	 failure	presented	 significantly	 higher	 levels	 of	 PICP	 compared	with	 the	 remaining	
patients.326,	 404,	 446	 Actually,	 PICP	 seems	 to	 be	 associated	 with	 increasing	 severity	 of	
myocardial	 fibrosis,	 as	 shown	 by	 its	 diagnostic	 accuracy	 to	 detect	 severe	 myocardial	
fibrosis	in	hypertensive	patients	with	LV	hypertrophy.378	
The	 increase	 in	 PICP	 parallels	 the	 increase	 of	 LV	 stiffness	 and	 filling	 pressures,	
suggesting	a	correlation	with	diastolic	dysfunction	(due	to	accumulation	of	collagen	fibres	
within	 the	myocardium.380,	 447	Moreover,	 a	 significant	 correlation	 between	 serum	 PICP	
concentration	and	LV	mass	index	has	also	been	identified.404,	443		
There	 is	 also	 histological	 validation	 that	 the	 decrease	 of	 PICP	 during	 anti-
hypertensive	treatments	parallels	the	changes	in	the	amount	of	myocardial	fibrosis,	with	
significant	 decreases	 in	 PICP	 reported	 in	 two	 studies,	 with	 a	 follow-up	 period	 of	 12	
months,	of	patients	treated	with	losartan	and	torasemide.377,	380		
An	 elevated	 serum	 concentration	 of	 PIIINP	 was	 also	 found	 in	 hypertensive	
patients,	 which	 was	 significantly	 higher	 in	 patients	 with	 heart	 failure,	 compared	 with	
asymptomatic	 patients.443,	 446,	 448	 PIIINP	 levels	 were	 also	 directly	 correlated	 with	 the	
severity	of	diastolic	dysfunction,443,	446	as	well	as	with	systolic	dysfunction	(measured	by	
LV	strain)	and	NYHA	functional	class.449	Moreover,	PIIINP	decreased	significantly	to	levels	
of	normotensive	population	in	patients	treated	with	lisinopril.443		
Regarding	markers	of	 collagen	degradation,	 the	 serum	MMP-1	 toTIMP-1	 ratio	 is	
abnormally	increased	in	patients	with	hypertensive	cardiomyopathy	and	heart	failure	and	
is	 abnormally	 decreased	 in	 both	 asymptomatic	 patients	 with	 and	 without	 LV	
hypertrophy.383,	406	Furthermore,	this	ratio	is	higher	in	hypertensive	patients	with	systolic	
heart	failure	than	in	patients	with	diastolic	hear	failure,	and	is	associated	with	a	decrease	
in	 ejection	 fraction	 and	 an	 increase	 in	 LV	 end-diastolic	 volume.383	 MMP-1	 was	 also	
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identified	 as	 an	 independent	 predictor	 of	 cardiac	 events	 or	 death	 in	 a	 hypertensive	
population,	with	a	median	follow-up	period	of	5.5	years.450	
There	are	few	reports	about	CITP	in	hypertensive	heart	disease,	but	an	increase	in	
CITP	levels	was	identified	in	hypertensive	populations,	which	is	of	greater	magnitude	and	
directly	 correlated	 with	 systolic	 dysfunction	 (measured	 by	 LV	 strain)	 in	 patients	 with	
worse	NYHA	functional	classes.448,	449	
 
4.	Urinary	biomarkers	of	glomerular	injury	
4.1	Glomerular	physiology:	rational	for	the	categorization	of	biomarkers	
The	 glomerulus	 is	 the	 filtering	 unit	 of	 the	 kidney	 and	 a	 unique	 and	 specialized	
bundle	 of	 capillaries	 situated	 between	 two	 resistance	 vessels	 (contained	 within	 the	
Bowman’s	capsule),	enabling	the	formation	of	primary	glomerular	filtrate.	The	glomerular	
filter	 is	 composed	 of	 various	 structures:	 endothelium,	 basement	 membrane,	 visceral	
epithelial	 cells	 (podocytes)	 and	 mesangium.	 The	 integrity	 of	 all	 these	 components	 is	
essential	for	normal	charge	and	size	selectivity	of	the	glomerular	filter,	as	demonstrated	
by	 the	 fact	 that	 disruption	 of	 any	 of	 these	 components	 leads	 to	 proteinuric	 disease	
states.451	
The	glomerular	endothelium	represents	the	first	layer	in	the	glomerular	filtration	
barrier	 and	 is	 in	 direct	 contact	 with	 the	 blood;	 it	 is	 a	 flattened	 and	 fenestrated	
endothelium,	 characterized	 by	 the	 presence	 of	 individual	 fenestrae	 of	 the	 order	 of	 70-
100nm	 in	diameter,	 permitting	high	 flow	of	water	 and	 small	 solutes.	 It	 is	 covered	by	 a	
glycocalyx	that	 likely	restricts	the	passage	of	 large	molecules	and	is	 important	 in	charge	
selectivity	 (due	 to	 its	 negatively	 charged	 components),	 but	 our	 knowledge	 about	 its	
components	and	functions	in	humans	is	limited.452	Moreover,	the	maintenance	of	normal	
endothelial	structure	seems	to	depend	on	a	paracrine	factor	secreted	by	podocytes,	the	
vascular	endothelial	growth	factor	(VEGF).453				
The	second	layer	of	the	filter	is	the	glomerular	basement	membrane	(GBM),	which	
is	thin	(250	to	400nm)	and	formed	by	the	fusion	of	basement	membranes	from	both	the	
endothelial	and	epithelial	cells	and	contains,	morphologically,	a	dense	inner	layer	(lamina	
densa),	flanked	by	the	inner	laminae	rara	interna	and	rara	externa.	It	is	a	complex	mash	
of	 extracellular	 proteins	 (ColIV,	 laminin,	 nidogen,	 fibronectin	 and	 proteoglycans),	
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providing	 structural	 support	 for	 the	 glomerular	 capillaries	 and	 harbouring	 ligands	 for	
receptors	on	the	surface	of	the	adjacent	endothelial	cells,	podocytes	and	mesangial	cells.	
Moreover,	the	GBM	also	contributes	to	glomerular	charge	and	size	selective	permeability,	
restricting	 the	 passage	 of	 plasma	 proteins	 across	 the	 glomerular	 filtration	 barrier.454	
However,	the	exact	mechanism	by	which	GBM	allows	such	high	rates	of	water	flow	while	
restricting	 the	 flow	 of	 large	 molecules	 and	 yet	 remains	 functional	 and	 “unclogged”	 is	
unknown.	Studies	suggest	that	GBM	acts	more	 like	a	gel	 than	a	simple	 filter	 in	that	the	
size-selective	 properties	 of	 the	 glomerular	 filter	 are	 determined	 by	 permeation	 and	
diffusion	properties	of	the	GBM.451	
The	distal	layer	of	the	glomerular	filter	is	composed	of	podocytes,	which	are	both	
morphologically	and	functionally	unique.	Podocytes	may	serve	as	support	to	help	sustain	
the	 integrity	 of	 the	 freestanding	 capillary	 loops,	 but	 their	 main	 function	 is	 related	 to	
filtration.	 Long	 intricate	 extensions,	 or	 primary	 processes,	 lead	 to	 secondary	 or	 foot	
processes,	which	 form	a	complex	 interdigitating	 structure	with	 the	 foot	processes	 from	
adjacent	 podocytes.	 The	 serpentine	 cell–cell	 junction	 known	 as	 the	 slit	 diaphragm	 that	
bridges	 these	 podocytes	 can	 be	 considered	 a	 modified	 adherens	 junction	 with	 some	
unique	additional	molecular	components	and	 is	essential	 for	the	normal	function	of	the	
filtration	 barrier.455	 The	 normal	 structure	 and	 function	 of	 the	 podocytes	 and	 slit	
diaphragms	 depend	 on	 transmembrane	 proteins	 (like	 nephrin	 and	 podocin,	 which	 are	
podocyte	 limited	 in	 their	 expression),456	 proper	 function	 of	 the	 actin	 cytoskeletal	
apparatus457	and	efficient	communication	and	signalling	between		slit	diaphragm	proteins	
and	the	cytoskeleton.458	Moreover,	the	integrity	of	signalling	pathways	(like	small	GTPase	
signalling)	and	autophagy	are	critical	to	podocyte	function.459,	460		
The	mesangium	refers	to	the	mesangial	cells	(third	cell	type	in	the	glomerular	tuft)	
and	 the	matrix	 they	 produce.	Mesangial	 cells	 provide	 support	 to	 the	 adjacent	 capillary	
loops;	moreover,	 the	mesangial	 processes	 are	 filled	with	 bundles	 of	 actin	 and	myosin-
based	microfilaments	 that	extend	 to	contact	 the	GBM	(in	which	 they	bind	 laminin)	and	
seems	 to	 provide	 protection	 against	 glomerular	 pressure	 and	may	 regulate	 glomerular	
capillary	 flow	 via	 contractile	 properties.461,	 462	 The	 mesangial	 matrix	 produced	 by	
mesangial	 cells	 is	 composed	 of	 a	 diverse	 group	 of	 proteins,	 including	 ColIV,	 heparan	
sulphate	proteoglycans,	and	elastic	fibre	proteins	including	fibronectin,	laminin,	entactin	
and	fibrillin-1;	accumulation	of	the	mesangial	matrix	is	a	feature	commonly	observed	in	a	
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number	of	glomerular	diseases.	
The	 ultimate	 function	 of	 the	 glomerular	 filter	 is	 the	 production	 of	 the	 primary	
filtrate,	according	to	the	size	and	the	charge	selectivity	of	the	filtered	molecules.	Studies	
using	dextran	molecules	of	varying	sizes	and	charge	demonstrated	that	neutral	particles	
with	 a	 molecular	 radius	 4.2nm	 are	 restricted	 from	 the	 urinary	 space,	 whereas	 anion	
particles	3.4	nm	have	a	fractional	clearance	that	approaches	zero.463		
The	 key	 features	 of	 glomerular	 damage	 in	 any	 nephropathy	 are	 the	 changes	 in	
glomerular	permeability	and	structure	that	occur	as	a	result	of	injury	to	any	of	the	major	
components	 of	 the	 aforementioned	 components	 of	 the	 glomerular	 filtration	 barrier	
apparatus.	 Thus,	 urinary	 biomarkers	 of	 glomerular	 damage	 represent	 either	 increased	
permeability	to	plasma	proteins	or	increased	excretion	of	intra	or	extracellular	proteins	of	
the	 glomerular	 structures.464,	 465	 Increased	 permeability	 may	 result	 from:	 loss	 of	
glomerular	 charge	 selectivity,	 loss	 of	 glomerular	 size	 selectivity	 or	 increased	
intragomerular	 pressure;	 for	 example,	 urinary	 excretion	 of	 albumin	 or	 transferrin	 are	
biomarkers	of	 increasing	permeability.466,	467	Some	biomarkers	are	constitutive	elements	
of	 the	 glomerulus,	 whose	 excretion	 increase	 with	 glomerular	 damage,	 for	 example:	
nephrin	 and	 podocalyxin	 from	 the	 podocytes;468	 collagen	 and	 laminin	 from	 the	
mesangium	 and	 GMB;469	 VEGF	 from	 the	 endothelial	 cells.470	 Actually,	 proteins	 derived	
from	 the	 mesangium	 and	 GBM,	 like	 ColIV,	 laminin	 and	 fibronectin	 are	 high	 molecular	
weight	 proteins	 that	 are	 not	 normally	 filtered	 through	 the	 glomerulus;	 thus,	 their	
excretion	in	urine	may	reflect	the	synthesis	/	degradation	in	damaged	kidneys	and	may	be	
surrogate	biomarkers	of	mesangial	matrix	expansion	and	GBM	thickening.469,	471	
	
4.2	Urinary	transferrin	excretion	
4.2.1	Rational	and	pathophysiology	
Transferrin	 is	a	plasma	glycoprotein	synthesized	primarily	 in	the	liver,	but	also	in	
the	 eyes,	 brain,	 testis	 and	 placenta.472-475	 Its	 half-life	 is	 approximately	 7	 days	 and	 its	
plasma	 levels	 are	 mainly	 regulated	 by	 iron	 availability	 (increasing	 in	 iron	 deficiency	
states),	but	are	also	 influenced	by	physiological	 states,	 like	pregnancy	and	ageing.476,	477	
Transferrin	 is	 metabolized	 in	 the	 liver	 and	 excreted	 by	 the	 kidney	 and	 the	 bowel	
mucosa.477	Transferrin	 is	 the	main	 iron-binding	protein	 in	plasma	and	carries	 ferric	 iron	
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from	 the	 intestine,	 reticuloendothelial	 system	 and	 liver	 parenchymal	 cells	 to	 all	
proliferating	 cells	 in	 the	 body.477,	 478	 Furthermore,	 transferrin	 also	 has	 antimicrobial	
properties	and	regulates	cell	growth,	proliferation	and	apoptosis.479		
Transferrin	 has	 a	 molecular	 weight	 (76.5KDa)	 and	 radius	 (4.0nm)	 only	 slightly	
greater	than	albumin	(66.5KDa	and	3.6nm,	respectively);	moreover,	It	is	less	anionic	than	
albumin	with	an	 isoelectric	point	 that	 is	one	unit	higher	 and	 therefore,	 expected	 to	be	
filtered	more	 readily	 through	 the	glomerular	barrier.480,	481	However,	glomerular	 sieving	
coefficients	of	endogenous	plasma	proteins,	estimated	in	patients	with	Fanconi	syndrome	
(characterized	by	a	“knock-out”	of	renal	tubular	protein	reabsorption,	causing	“tubular”	
proteinuria)	 is	 slightly	 greater	 for	 albumin	 than	 for	 transferrin.482	 After	 entering	 the	
glomerular	filtrate,	transferrin	is	retrieved	by	specific	receptor-mediated	uptake	(through	
cubilin	 and	 transferrin	 receptors)	 in	 the	 kidney	 tubular	 system,	mainly	 in	 the	 proximal	
tubules.483,	 484	 In	 the	 proximal	 tubular	 cells,	 divalent	 metal	 transporter	 (DMT)-1,	
expressed	in	late	endosomal	/	lysosomal	membranes,	processes	the	apically	sequestered	
transferrin.485	 Resorption	 of	 transferrin	 in	 the	 tubular	 system	 seems	 to	 be	 important	
because:	it	is	an	essential	growth	factor	in	the	development	of	kidney	and	differentiation	
of	 tubule	and	may	be	 the	major	mechanism	by	which	proximal	 tubule	cells	acquire	 the	
iron	 that	 they	 need.485,	 486	 After	 resorption	 in	 the	 tubular	 system,	 the	 quantity	 of	
transferrin	in	normal	urine	is	approximately	0.32	to	0.47mg/day.487	It	is	noteworthy	that	
there	is	no	correlation	between	the	quantity	of	transferrin	in	the	blood	and	the	urine.488-
490	 Thus,	 transferrin	 is	 not	 only	 a	 biomarker	 of	 glomerular	 injury,	 but	 also	 of	 tubular	
proximal	dysfunction.	
Nonetheless,	transferrin	may	also	be	a	mediator	of	tubular	toxicity;	in	the	setting	
of	increased	glomerular	permeability	to	transferrin,	its	concentration	in	tubules	increases	
and	 the	 resorption	 and	 degradation	 capacity	 in	 the	 tubular	 proximal	 cells	 is	 exceeded,	
leading	 to	 rupture	 of	 the	 lysosomes	 and	 release	 of	 free	 iron	 and	 formation	 of	 free	
hydroxyl	radicals	in	the	tubular	cells,	triggering	up-regulation	of	pro	inflammatory	and	pro	
fibrotic	cytokines,	which	causes	mononuclear	cells	 infiltrate,	tubular	and	interstitial	cells	
ischemia	 and,	 eventually,	 tubulointerstitial	 fibrosis.490-492	 This	 detrimental	 effect	 of	
increased	urinary	transferrin	excretion	(UTE)	in	tubular	interstitial	injury	was	evidenced	in	
a	 study	 involving	45	 type	2	diabetic	patients,	where	 the	UTE	was	 significantly	higher	 in	
patients	with	albuminuria	A2	with	tubular	interstitial	lesions,	in	comparison	with	patients	
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with	 albuminuria	 A2	without	 lesions	 or	 patients	with	 albuminuria	 A1;	moreover,	 there	
was	a	significant	correlation	between	UTE	and	the	degree	of	 interstitial	 fibrosis,	 tubular	
atrophy	and	inflammatory	cells	infiltrate	in	the	interstitium.493	
	
4.2.2	Urinary	transferrin	excretion	in	renal	diseases:	state	of	the	art		
UTE	 has	 been	 evaluated	 as	 biomarker	 of	 kidney	 dysfunction	 mainly	 in	 type	 2	
diabetes	mellitus	(T2DM)	and	diabetic	nephropathy.	In	FD,	it	has	been	only	measured	in	a	
small	cohort	of	17	female	patients,	13	of	them	treated	with	ERT,	where	there	was	a	non-
significant	trend	of	a	decrease	in	UTE	in	treated	patients	after	a	mean	follow-up	period	of	
6	years;	an	opposite	trend	of	an	increase	in	UTE	was	observed	in	the	untreated	patients	
after	a	mean	follow-up	period	of	5	years.307	
However,	 FD	nephropathy	and	diabetic	nephropathy	 share	 some	characteristics,	
as	both	are	proteinuric	nephropathies	of	metabolic	origin,	characterized	by	a	progressive	
decrease	 of	 renal	 function	 to	 an	 end-stage	 CKD,	 requiring	 dialysis	 or	 transplantation.		
Although	the	metabolic	environments	of	 the	two	diseases	are	considerably	different,	 in	
diabetes	 high	 glucose	 and	 in	 FD	 lyso-Gb3	 and	 other	 mediators,	 both	 may	 result	 in	
recruitment	 of	 secondary	mediators	 of	 injury	 on	 target	 organ	 cells,	which	will	 result	 in	
kidney	fibrosis	(to	which	ischemia	is	also	a	contributor	in	FD).	In	both	diseases	GBM	and	
tubular	 basement	 membrane	 thickening	 depends	 on	 increased	 production	 of	 extra-
cellular	matrix	by	glomerular	epithelial	podocytes	and	 tubular	epithelial	 cells	 injured	by	
the	metabolic	 defect;	 this	 is	 followed	by	 recruitment	of	 activated	 fibroblasts,	 focal	 and	
segmental	glomerular	fibrosis	and	sclerosis	and	interstitial	fibrosis.494	
In	T2DM	several	studies,	based	on	up	to	157	patients,	showed	an	increase	in	UTE	
comparing	 patients	 with	 T2DM	 and	 healthy	 controls,	 even	 in	 diabetic	 patients	 with	
albuminuria	 A1	 (between	 21	 -	 61%	 of	 the	 normoalbuminuric	 patients	 presented	 an	
increase	in	UTE).480,	488,	495-500	For	example,	in	a	study	of	60	T2DM	patients	(30,	19	and	11	
patients	with	albuminuria	A1,	A2	and	A3,	 respectively),	33.3%	of	 the	normoalbuminuric	
patients	presented	high	UTE,	whereas	all	patients	with	albuminuria	A2	and	A3	presented	
high	UTE.488	 In	 type	1	diabetes	mellitus	 (T1DM),	 two	studies	demonstrated	a	significant	
increase	of	UTE	in	diabetic	patients,	in	comparison	with	healthy	controls.	Moreover,	one	
of	the	studies	reported	an	increase	in	UTE	in	77.8%	of	the	normoalbuminuric	patients	and	
a	 significant	correlation	between	UTE	and	albuminuria.489,	501-503	Therefore,	UTE	may	be	
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more	sensitive	than	albuminuria	to	 identify	early	diabetic	nephropathy,	as	corroborated	
in	a	recent	systematic	review	of	the	available	evidence.504	
A	 significant	 direct	 correlation	 between	 UTE	 and	 albuminuria	 was	 shown	 in	
several	studies	in	patients	with	both	T1DM	and	T2DM	(documenting	a	similar	glomerular	
leak	 and	 tubule	 handling	 for	 these	 two	 proteins),488,	 490,	 496,	 498,	 499,	 505-508	 as	 well	 as	 a	
significant	 inverse	correlation	between	UTE	and	creatinine	clearance.488	The	correlation	
between	 the	UTE	 and	 the	 degree	 of	 histological	 glomerular	 lesions	was	 evaluated	 in	 a	
study	involving	60	T2DM	patients	and	the	UTE	showed	a	significant	increase	with	respect	
to	 the	 progress	 of	 glomerular	 diffuse	 lesions;	 moreover,	 UTE	 was	more	 sensitive	 than	
albuminuria	in	detecting	early	pathological	alterations	of	diabetic	nephropathy.488	
The	prognostic	value	of	UTE	was	evaluated	in	longitudinal	studies,	where	the	risk	
of	subsequent	development	of	albuminuria	A2,	in	normoalbuminuric	patients	with	T2DM,	
was	significantly	greater	in	patients	with	increased	UTE	at	baseline,480,	509	with	the	largest	
study	evaluating	117	normoalbuminuric	T2DM	patients,	for	a	follow-up	period	of	5	years	
and	 showing	 that	 UTE	 was	 significantly	 higher	 (more	 than	 double)	 in	 the	 patients	
progressing	 to	albuminuria	A2	and	 that	35.3%	of	 the	progressors	had	 increased	UTE	at	
baseline	(versus	only	9%	of	the	non-progressors).509		
The	correlation	between	UTE	and	blood	pressure	was	explored	in	several	studies	
and	a	 significant	correlation	seems	 to	exist	between	UTE	and	systolic	or	diastolic	blood	
pressure.498,	510,	511	Even	the	diurnal	changes	in	blood	pressure	significantly	correlate	with	
diurnal	changes	in	UTE	in	normoalbuminuric	diabetic	patients	(an	influence	not	found	for	
albuminuria).	Additionally,	 in	the	same	study,	UTE	was	 influenced	(whereas	albuminuria	
was	not)	by	enhanced	GFR	after	acute	protein	loading,	which	causes	increased	glomerular	
capillary	 pressure	 due	 to	 afferent	 arterioles	 dilation,	 mimicking	 diabetic	 intra-renal	
haemodynamics.	 Thus,	 UTE	 may	 be	 a	 more	 sensitive	 indicator	 of	 glomerular	 capillary	
pressure	 change	 than	 albuminuria	 in	 normoalbuminuric	 diabetic	 patients.510	 These	
findings	 were	 further	 corroborated	 by	 other	 studies	 showing	 a	 greater	 magnitude	 of	
increase	 in	 UTE	 (in	 comparison	 with	 urinary	 albumin	 excretion)	 after	 exercise.507,	 512	
However,	the	effect	of	diabetes	in	UTE,	in	comparison	with	HBP,	seems	to	be	of	greater	
magnitude,	 as	 demonstrated	 in	 a	 study	with	 270	 patients	with	HBP,	 180	 of	 them	with	
T2DM,	where	 after	 controlling	 for	 systolic,	 diastolic	 and	mean	 arterial	 blood	pressures,	
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greater	than	expected	proportions	of	diabetic	subjects	(than	if	they	were	just	additive	risk	
factors	for	UTE)	were	found	to	have	elevated	excretion	ratios	of	transferrin.513	
There	 is	 conflicting	 evidence	 concerning	 the	 correlation	 between	 UTE	 and	 the	
degree	 of	 glycaemic	 control	 (measured	 by	 glycated	 haemoglobin	 [HbA1c])	 in	 diabetic	
patients,	 with	 one	 study	 showing	 a	 direct	 significant	 correlation	 between	 both	
variables,488	 while	 others	 not.498,	 499	 Furthermore,	 the	 correlation	 between	 UTE	 and	
duration	of	diabetes	was	inconstant,	with	one	study	reporting	a	significant	correlation,496	
but	 a	 few	 studies	 did	 not	 find	 any	 correlation.498,	 499	 However,	 one	 study	 recruited	 40	
newly	diagnosis	 diabetic	patients	 starting	hypoglycaemic	 agents	 and,	 after	 12	weeks	of	
follow-up,	 there	was	a	significant	decrease	 in	HbA1c,	as	well	as	 in	albuminuria	and	UTE	
(at	baseline	53%	of	the	patients	had	elevated	UTE,	whereas	after	12	weeks	of	treatment	
only	20%	presented	elevated	UTE).508	
There	 is	 little	 evidence	 about	 the	 effect	 of	 antiproteinuric	 treatment	 in	 UTE.	
However,	in	a	small	study	based	on	19	T2DM	patients	with	high-normal	/	grade	1	HBP	and	
33	 T2DM	 normotensive	 patients,	 the	 administration	 of	 an	 ARB	 for	 18	 months	 in	 the	
former	 group	 was	 associated	 to	 normalization	 of	 HBP	 after	 only	 2	 months	 of	 active	
treatment	and	to	a	stabilization	in	both	albuminuria	and	UTE;	in	the	group	of	33	patients,	
not	treated	with	ARB,	there	was	a	significant	increase	in	both	albuminuria	and	UTE	after	
18	months	of	follow-up.514	In	another	cohort	of	11	patients	treated	with	ARB	for	8	weeks,	
there	 was	 a	 significant	 reduction	 of	 UTE	 during	 the	 treatment	 period,	 whereas	 the	
albumin	excretion	remained	unchanged.515		
The	 evidence	 supporting	 the	 usefulness	 of	 UTE	 in	 patients	 with	 primary	
glomerulonephritis	 is	 scant	 in	 comparison	with	 that	 available	 for	diabetic	 nephropathy.	
However,	the	few	published	studies	reported	a	significant	direct	correlation	between	UTE	
and	albumin	excretion.516-518	Moreover,	in	a	study	of	17	patients	with	glomerulonephritis	
and	albuminuria	A2,	35	T2DM	patients	with	albuminuria	A2	and	38	healthy	controls,	the	
UTE	was	comparable	between	glomerulonephritis	and	T2DM	subgroups	and	significantly	
higher	than	in	the	controls.516		
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4.3	Urinary	collagen	type	IV	excretion	
4.3.1	Rational	and	pathophysiology	
ColIV	is	a	large,	non-fibrillar	and	distinct	form	of	collagen	found	only	in	basement	
membranes,	constituting	their	major	 insoluble	scaffold.	ColIV	consists	of	a	 family	of	six,	
genetically	 distinct	 isoforms:	 α1	 to	 α6	 chains,	 which	 associate	 to	 form	 distinct	 ColIV	
molecules	 (together	with	many	 additional	 components,	 like	 laminin	 and	proteoglycans,	
highlighting	 the	 complexity	 and	 variability	 between	 basement	 membranes	 in	 different	
organs).519	The	epithelial	cells	produce	ColIV	as	an	approximately	400nm	long	monomer,	
composed	of:	large	globular	non-collagenous	domain	at	the	C	terminus	(NC1	domain);	an	
extended	collagenous	domain	of	350nm	(monomers	have	numerous	interruptions	in	their	
regular	 Glycine-X-Y	 sequence	 repeats,	 which	 make	 them	 more	 flexible	 than	 the	
monomers	 of	 the	 fibrillar	 collagens);	 a	 short	 non-collagenous	 N-terminal	 domain	 (7S	
domain).	These	monomers	are	assembled	in	trimers	when	their	3	α-chains	come	together	
through	 associations	 among	 their	 non-collagenous	 domains,	 followed	 by	 folding	 of	 the	
collagenous	domains	 into	triple	helices;	these	newly	assembled	ColIV	monomers	do	not	
undergo	processing	before	 incorporation	 into	 the	basement	membrane	matrix.520,	521	 In	
the	basement	membrane	matrix	these	triple-helical	molecules	further	associate	to	form	
supramolecular	networks	by	dimerization	at	the	C	terminus	through	NC1	domains	and	by	
formation	 of	 tetramers	 at	 the	 N	 terminus	 (7S	 domain).522,	 523	 This	 protomeric	 network	
serves	as	a	network	scaffold	for	other	basement	membrane	proteins,	but	ColIV	may	also	
bind	various	cells	via	surface	receptors	such	as	integrins.524	
In	the	kidney,	differences	in	ColIV	composition	may	hint	towards	specific	roles	of	
specialized	 basement	 membranes.525	 In	 adults,	 the	 human	 renal	 tubular	 basement	
membrane	that	surrounds	proximal	tubules	consists	exclusively	of	α1	and	α2	protomers,	
whereas	distal	tubules	also	contain	some	α3	through	α6	chains.526	In	GBM,	two	networks	
with	distinct	chain	composition	have	been	 identified:	an	α1	and	α2	network	assembled	
first	 in	 the	 embryonic	 glomerulus	 and	 a	 more	 cross-linked	 α3,	 α4	 and	 α5	 network	
(appearing	 after	 a	 developmental	 switch),	 characterized	 by	 loops	 and	 supercoiling	 that	
forms	the	GBM	of	the	mature	glomerulus	in	humans.527,	528	
The	 specific	 enzymes	 responsible	 for	 basement	 membrane	 dissolution	 and	 the	
processing	 of	 ColIV	 are	 not	 well	 known,	 and	 nor	 is	 the	 route	 of	 elimination	 of	 the	
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products	of	 its	catabolism.	MMP-2	and	MMP-9	were	 initially	called	type	IV	collagenases	
due	 to	 their	 ability	 to	 degrade	 this	 abundant	 component	 of	 basement	 membranes	 in	
vitro.529,	530	However,	this	concept	has	been	challenged	by	the	weak	MMP-2	and	MMP-9	
collagenolytic	 activity	 in	 vivo	 and	 by	 the	 fact	 that	 the	 double-null	 mice	 for	MMP-2	 or	
MMP-9	 remain	 viable,	 with	 no	 basement	 membrane	 defects.531,	 532	 Besides,	 bioactive	
fragments	 released	 by	 	 the	 proteolytic	 cleavage	 of	 ColIV	 (called	 matricryptins)	 are	
involved	 in	 the	 regulation	 of	 several	 physiological	 and	 pathological	 processes	 such	 as	
development,	 angiogenesis,	 tumour	 growth	 and	 metastasis,	 with	 antiangiogenic	 and	
antitumoural	 activity.533	Nevertheless,	 given	 the	high	molecular	weight	of	ColIV	 trimers	
(approximately	540-KDa),	they	are	not	filtered	through	the	glomerulus	and	their	urinary	
excretion	of	ColIV	seems	to	be	only	marginally	affected	by	the	serum	levels;	 thus,	since	
ColIV	 is	 the	main	 component	 of	 GBM	 and	mesangial	matrix,	 its	 urinary	 excretion	may	
reflect	the	rate	of	matrix	turnover	(degradation).534-539		
The	 major	 characteristics	 of	 diabetic	 nephropathy	 include	 tubular	 hypertrophy,	
thickening	 of	 tubular	 basement	 membrane,	 interstitial	 fibrosis,	 GBM	 thickening,	
mesangial	expansion	and	hypertrophy	and	accumulation	of	extracellular	matrix	proteins	
such	as	ColIV	and	fibronectin.540	Thus,	ColIV	is	one	of	mediators	in	diabetic	nephropathy	
pathophysiology,	 contributing	 to	 the	 progression	 of	 glomerulosclerosis	 and	
tubulointerstitial	fibrosis.	Actually,	several	experiments	have	demonstrated	that	elevated	
glucose	levels	up-regulates	transcription	of	TGF-β1	in	multiple	renal	cell	types,	 including	
mesangial	and	tubular	cells.541,	542		
In	 the	 glomeruli,	 TGF-β1	 exerts	 pleiotropic	 effects,	 inducing	 hyperplasia	 and	
hypertrophy	 of	 mesangial	 cells	 and	 apoptosis	 and	 detachment	 of	 podocytes.543,	 544	
Moreover,	 TGF-β1	 increases	 deposition	 of	 extracellular	matrix,	 not	 only	 by	 stimulating	
synthesis	 of	 individual	 matrix	 components	 (like	 fibronectin	 and	 ColIV),	 but	 also	 by	
blocking	 matrix	 degradation	 (decreasing	 the	 synthesis	 of	 proteases	 and	 increasing	 the	
levels	 of	 protease	 inhibitors).542	 As	 mentioned	 above,	 in	 FD	 there	 is	 also	 evidence	 of	
activation	 of	 the	 TGF-β1	 pathway	 and	 increased	 synthesis	 of	 ColIV	 and	 fibronectin,	 as	
demonstrated	in	human	podocytes	cultured	with	lyso-Gb3.18	
The	role	of	the	TGF-β1	pathway	in	tubulointerstitial	fibrosis	is	not	well	established,	
but	 ColIV	 is	 one	 of	 the	 key	 mediators	 of	 fibrosis	 in	 the	 interstitial	 compartment	 and	
tubular	 atrophy.	 The	 TGF-β1	 not	 only	 induces	 collagen	 production	 by	 interstitial	
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fibroblasts,	but	also	promotes	tubular	epithelial	cell	 injury	and	apoptosis;	moreover,	the	
TGF-β1	 per	 se	 and	 changes	 in	 ColIV	 structure	 and	 architecture	 of	 tubular	 basement	
membrane	 promote	 epithelial-mesenchymal	 transdifferentiation	 of	 tubular	 epithelium	
into	 a	 more	 fibroblast-like	 phenotype,	 increasing	 the	 expression	 of	 collagen	 and	
fibronectin.521,	541		
As	the	mesangial	matrix	and	GBM	seem	to	be	the	source	of	ColIV,	 it	may	reflect	
the	 mesangial	 expansion	 and	 GBM	 thickening	 observed	 in	 diabetic	 nephropathy,	
corroborated	by	histological	correlation	studies,	showing	significant	correlations	between	
urinary	ColIV	excretion	and	mesangial	expansion	or	tubulointerstitial	injury	scores,	as	well	
between	 urinary	 ColIV	 excretion	 and	 glomerular	 or	 tubulointerstitial	 ColIV	 expression	
areas.545,	546			
	
4.3.2	Urinary	collagen	type	IV	excretion	in	renal	diseases:	state	of	the	art		
For	the	aforementioned	reasons,	urinary	ColIV	excretion	has	been	evaluated	as	a	
biomarker	of	diabetic	nephropathy	in	numerous	studies.	In	FD	nephropathy	there	are	no	
published	 studies	 evaluating	 the	 diagnostic	 and	 prognostic	 value	 of	 urinary	 ColIV	
excretion.	
In	 patients	 with	 T2DM	 there	 are	 several	 reports,	 evaluating	 up	 to	 698	 diabetic	
patients,	showing	a	significant	increase	in	urinary	ColIV	in	diabetic	patients,	in	comparison	
with	healthy	controls.469,	497,	534,	537-539,	546-554	Furthermore,	a	few	studies	have	reported	an	
increase	in	urinary	ColIV	even	in	normoalbuminuric	diabetic	patients,	in	comparison	with	
healthy	 controls	 or	 the	 established	 normal	 range	 (between	 26	 -	 49%	 of	 T2DM	 with	
albuminuria	A1	 presented	 an	 increase	 in	 urinary	 ColIV).469,	497,	534,	536-538,	547,	549,	550,	552-556	
The	value	of	urinary	ColIV	as	an	early	biomarker	of	diabetic	nephropathy	is	clearly	shown	
in	 a	 study	 based	 on	 82	 T2DM	 patients	 (with	 albuminuria	 A1	 and	 normal	 urinary	 ColIV	
excretion),	in	a	longitudinal	study	during	6	months.	After	the	follow-up	period	there	was	a	
significant	 increase	 in	 both	 urinary	 ColIV	 and	 albuminuria,	 but	while	 urinary	 ColIV	was	
above	the	reference	value	 in	62.2%	of	 the	patients	at	 the	end	of	 the	study,	only	32.9%	
presented	 albuminuria	 A2;	 in	 the	 subgroup	 of	 patients	 with	 HBP	 at	 baseline,	 a	
significantly	higher	proportion	of	patients	developed	urinary	ColIV	or	albumin	above	the	
reference	range.547	Moreover,	high	urinary	ColIV	excretion	was	also	reported	as	early	 in	
normoalbuminuric	patients	with	impaired	glucose	tolerance.535	
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However,	 in	 one	 study	 the	 urinary	 ColIV	 excretion	was	 similar	 between	 healthy	
controls	 and	 normoalbuminuric	 T2DM	 patients.546	 Moreover,	 a	 variable	 percentage	
(between	33	-	42%)	of	patients	with	evidence	of	increased	albuminuria	did	not	show	an	
increase	in	urinary	ColIV	excretion.469,	536,	555	
A	 significant	 correlation	 between	 urinary	 ColIV	 excretion	 and	 albuminuria	 was	
found	 in	most	 of	 the	 studies,469,	534,	536,	537,	547,	550,	552-557	 as	well	 as	with	 other	mesangial	
matrix	 proteins	 excretion,	 like	 laminin.469	 In	 one	 study	 including	 T1DM	 and	 T2DM	
patients,	 a	 significant	 inverse	 correlation	was	 found	between	 the	urinary	ColIV	and	 the	
reciprocal	 of	 serum	 creatinine	 (there	 was	 no	 correlation	 between	 albuminuria	 and	
reciprocal	of	serum	creatinine),	but	there	was	no	significant	correlation	between	urinary	
ColIV	and	albuminuria.558	 This	 result	was	 further	 confirmed	 in	a	 few	other	 studies	with	
T2DM	patients	that	demonstrated	a	significant	inverse	correlation	between	urinary	ColIV	
and	creatinine	clearance	or	estimated	GFR.539,	546,	554	
Various	authors	have	documented	the	prognostic	value	of	urinary	ColIV	excretion:	
in	 a	 group	of	 normoalbuminuric	 T2DM	patients,	 after	 1	 year	 of	 follow-up,	 there	was	 a	
significant	 increase	 in	 urinary	 ColIV	 in	 the	 patients	 progressing	 to	 albuminuria	 A2,	
whereas	 there	 was	 a	 significant	 decrease	 in	 urinary	 ColIV	 in	 the	 non-progressors;536		
another	 1-year	 follow-up	 study	 showed	 that	 76.8%	 of	 the	 normoalbuminuric	 T2DM	
patients	in	the	high	urinary	ColIV	group	developed	albuminuria	A2,	as	opposed	to	22.6%	
patients	 in	the	normal	urinary	ColIV	group	(in	multivariate	analysis	urinary	ColIV	was	an	
independent	 risk	 factor	 for	 progression	 to	 albuminuria	 A2);556	 in	 a	 large	 cohort	 of	 254	
T2DM	patients	(with	albuminuria	A1	and	A2),	after	a	median	follow-up	of	8	years,	urinary	
ColIV	was	 the	strongest	predictor	 (in	multivariate	 regression	analysis)	of	estimated	GFR	
annual	decline	 (albuminuria	was	not	a	significant	predictor	 in	 the	same	model)	and	 the	
patients	 above	median	 cut-off	 level	 presented	 significantly	 higher	 decline	 in	 estimated	
GFR	(in	comparison	with	those	below),	regardless	of	the	baseline	albuminuria;557	similar	
results	were	 observed	 in	 a	 cohort	 of	 30	 patients	with	 overt	 proteinuria,	where	 after	 a	
follow-up	period	of	4.2	years,	baseline	urinary	ColIV	excretion	was	negatively	correlated	
with	the	subsequent	GFR	change.559	
The	prognostic	value	of	urinary	ColIV	was	also	corroborated	in	T1DM	patients,	in	a	
study	involving	231	patients	(with	albuminuria	A1	or	A2	at	baseline),	with	a	mean	follow-
up	period	of	7.4	years.	Urinary	ColIV	excretion	presented	a	significant	inverse	correlation	
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with	estimated	GFR	annual	change	 in	multivariate	 regression	analysis;	moreover,	 in	 the	
subgroup	of	patients	with	albuminuria	A1,	only	urinary	ColIV	(and	not	albuminuria)	was	
significantly	correlated	with	estimated	GFR	decline,	and	the	rate	of	estimated	GFR	decline	
was	significantly	higher	in	patients	presenting	elevated	urinary	ColIV	(in	comparison	with	
those	 with	 normal	 urinary	 ColIV).560	 Another	 study	 based	 on	 225	 normoalbuminuric	
T1DM	patients,	followed	by	a	median	period	of	8.8	years,	 identified,	 in	multivariate	Cox	
proportional	 hazards	 analysis,	 high	 urinary	 ColIV	 as	 the	 only	 significant	 risk	 factor	 for	
development	of	albuminuria	A2.561	
Most	studies	reported	no	evidence	of	correlation	between	urinary	ColIV	and	blood	
pressure,	 duration	 of	 diabetes	 or	 glycaemic	 control	 (mainly	 in	 multivariate	 regression	
analysis).469,	536,	547,	550,	558	However,	 two	 studies	 reported	 a	 significant	 direct	 correlation	
between	 urinary	 ColIV	 and	 HbA1c	 and	 another	 between	 urinary	 ColIV	 and	 duration	 of	
diabetes.534,	537,	549	Furthermore,	another	study	reported	a	significant	correlation	between	
urinary	 ColIV	 and	 diastolic	 blood	 pressure,	 as	 well	 a	 significantly	 higher	 excretion	 of	
urinary	ColIV	in	patients	with	HBP.557	
Urinary	ColIV	excretion	 seems	 to	be	distinctively	affected	by	different	 classes	of	
agents	 for	 treatment	 of	 T2DM.	 In	 a	 study	 with	 T2DM	 patients	 (with	 albuminuria	 A2),	
comparing	13	patients	treated	with	an	agonist	of	glucagon-like	peptide-1	with	18	patients	
treated	with	a	sulfonylurea,	after	16	weeks	of	treatment,	there	was	a	similar	decrease	in	
HbA1c	 in	 both	 groups,	 but	 only	 the	 subgroup	 of	 patients	 treated	 with	 an	 agonist	 of	
glucagon-like	peptide-1	showed	a	significant	decrease	in	albuminuria,	urinary	TGF-β1	and	
urinary	 ColIV.562	 A	 thiazolidinedione	 was	 also	 compared	 with	 a	 sulfonylurea	 in	 T2DM	
patients	with	albuminuria	A2	or	A3;	as	mentioned	above,	after	12	months	of	treatment,	
sulfonylurea	did	not	influence	albuminuria	or	urinary	ColIV,	but	in	thiazolidinedione	group	
a	significant	decrease	in	albuminuria	and	urinary	ColIV	was	only	observed	in	the	subgroup	
of	patient	with	albuminuria	A2.563	However,	 in	another	study	 (recruiting	T2DM	patients	
with	 proteinuria	 >	 500mg/day)	 a	 thiazolidinedione	 derivative	 significantly	 decreased	
proteinuria,	urinary	TGF-β1	and	urinary	ColIV,	in	comparison	with	placebo,	after	12	weeks	
of	treatment.564	
	 The	effect	 of	 antiproteinuric	 treatment	 in	 urinary	ColIV	 excretion	has	only	 been	
evaluated	 in	a	 few	 longitudinal	studies,	with	different	designs.	One	of	 them,	 in	patients	
with	T2DM,	enrolled	43	patients	to	receive	an	ACEi	and	88	control	patients	(not	treated	
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with	an	ACEi),	with	a	 follow-up	period	of	24	months.	 In	 the	control	group	urinary	ColIV	
significantly	 increased	 time-dependently,	 whereas	 in	 the	 ACEi	 group	 there	 was	 no	
change,	 thus	 in	 the	 ACEi	 group	 the	 urinary	 ColIV	 was	 significantly	 lower	 than	 in	 the	
control	group	at	24	months.565	Other	study	assigned	22	T2DM	patients	to	receive	an	ARB	
for	6	months	and,	although	a	 significant	decrease	 in	urinary	TGF-β1	was	noted,	urinary	
ColIV	 was	 not	 significantly	 altered	 by	 the	 treatment.566	 Finally,	 a	 study	 compared	 the	
effects	of	ACEi	and	ARB,	after	a	follow-up	period	of	11	months,	and	a	significant	decrease	
in	albuminuria	was	found	in	both	groups,	but	urinary	ColIV	only	significantly	decreased	in	
the	ARB	group.567		
	 Concerning	patients	with	other	non-diabetic	renal	diseases,	there	is	little	evidence	
supporting	the	use	of	urinary	ColIV.	In	most	of	the	studies	urinary	ColIV	has	been	used	for	
differential	 diagnosis	 between	 diabetic	 and	 non-diabetic	 nephropathies,	 because	 a	
significant	 increase	 in	urinary	ColIV	was	reported	(in	comparison	with	healthy	controls),	
but	 the	 magnitude	 of	 the	 increase	 or	 the	 urinary	 ColIV	 to	 albuminuria	 ratio	 was	
significantly	lower	in	comparison	with	the	diabetic	population.469,	537	Moreover,	in	one	of	
the	 studies	 there	 was	 no	 significant	 correlation	 between	 urinary	 ColIV	 excretion	 and	
albuminuria	in	patients	with	chronic	glomerulonephritis.537	These	results	were	confirmed	
in	a	study	with	527	biopsy-proven	non-diabetic	renal	diseases,	but	this	study	highlighted	
that	urinary	ColIV	was	distinctively	higher	in	the	subgroups	of	patients	with	membranous	
nephropathy	and	anti-neutrophil	cytoplasmic	antibody-associated	glomerulonephritis,	 in	
comparison	with	the	other	 forms	of	non-diabetic	 renal	disease	 (however,	even	 in	 these	
subgroups	 the	 magnitude	 of	 increase	 was	 lower	 in	 comparison	 to	 the	 diabetic	
population).568	 Contrariwise,	 in	 another	 report	 the	 level	 of	 urinary	 ColIV	 was	 similar	
between	healthy	controls	and	patients	with	non-diabetic	glomerular	diseases.546	
	
5.	Urinary	biomarkers	of	tubular	injury	
5.1	Tubular	physiology	and	pathology:	rational	for	the	categorization	of	biomarkers	
The	kidney	 is	 the	principal	organ	that	maintains	 the	amount	and	composition	of	
extracellular	 fluid,	 essential	 for	 cell	 viability.	Most	 of	 this	 function	 occurs	 in	 the	 kidney	
tubule,	 whose	 components	 are:	 proximal	 convoluted	 tubule,	 thin	 limbs	 of	 the	 loop	 of	
Henle,	thin	ascending	limb	of	the	loop	of	Henle	and	distal	convoluted	tubule.	
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Proximal	convoluted	tubule	function	is	critical	for	body	haemostasis,	because	it	is	
a	 tour	 de	 force	 of	 reabsorption	 of	 the	 160-170L	 of	 primary	 glomerular	 ultrafiltrate	
produced	each	day.	The	proximal	 tubule	 fulfils	most	of	 the	 reabsorptive	 role	 for	water,	
sodium	chloride	and	sodium	bicarbonate,	leaving	the	fine-tuning	to	the	distal	nephron;	it	
also	 completes	 the	 reabsorption	of	 glucose,	 amino	acids,	 phosphate	and	 citrate.569	 The	
proximal	tubule	also	performs	metabolic	functions:	conversion	of	vitamin	D	to	active	and	
inactive	 forms	and	gluconeogenesis.570,	571	Normal	proximal	 tubular	 function	 is	essential	
for	reabsorption	of	filtered	proteins;	these	molecules	are	reabsorbed	and	catabolized	to	
amino	 acids	 in	 the	 proximal	 tubular	 cells	 in	 complex	 transport	 processes,	 that	 are	
essential	 to	 provide	 the	 nitrogen	 and	 carbon	 skeleton	 required	 to	 support	 renal	
gluconeogenesis	 and	 ammoniagenesis;	 moreover,	 proximal	 tubular	 cells	 promote	
secretion	 of	 several	 organic	 compounds,	 including	 proteins,	 to	 the	 tubular	 lumen,	 by	
active	transport	mechanisms.569		
The	main	 function	of	 the	 thin	and	 thick	portions	of	 the	 loop	of	Henle	 is	urinary	
concentration,	promoting	the	generation	of	a	gradient	of	increasing	osmolality	along	the	
medulla;	 moreover,	 they	 also	 participate	 in	 calcium	 and	 magnesium	 homeostasis,	
bicarbonate	 and	 ammonium	 homeostasis	 and	 urinary	 protein	 composition.572,	 573	 The	
distal	convoluted	tubule	plays	a	critical	 role	 in	 sodium	chloride	reabsorption,	potassium	
secretion	and	calcium	and	magnesium	handling;	furthermore,	it	has	a	unique	capacity	to	
adapt	to	changes	in	hormonal	stimuli	and	the	contents	of	the	tubular	lumen.574	
In	 the	 pathogenesis	 of	 diabetic	 nephropathy,	 glomerular	 pathophysiology	 has	
attracted	the	attention	of	research	for	many	years.	However,	the	correlation	between	the	
degree	of	glomerular	injury	and	GFR	decline	is	far	from	perfect,	and	tubular	atrophy	and	
interstitial	fibrosis	are	apparent	before	overt	proteinuria	and	more	clearly	associated	with	
the	prognosis	of	kidney	function.575,	576	Thus,	there	is	increasing	research	about	the	role	of	
tubulointerstitial	 injury	 in	 the	 pathogenesis	 of	 diabetic	 nephropathy;	 hyperglycaemia,	
advanced	 glycosylation	 end	 products	 and	 oxidative	 stress	 are	 some	 of	 the	 triggering	
factors	pathophysiological	activating	pathways,	leading	to	tubular	toxicity	and	interstitial	
fibrosis.577-579	 Early	 tubulointerstitial	 damage	 may	 be	 the	 trigger	 for	 subsequent	
glomerular	 injury	 in	 the	 hyperfiltration	 stages	 of	 diabetic	 nephropathy,	 known	 as	 the	
tubular	 hypothesis	 of	 glomerular	 filtration;	 moreover,	 tubular	 atrophy	 can	 promote	
increased	 intraglomerular	 pressure	 and	 subsequent	 glomerular	 injury.580	 Nonetheless,	
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proteinuria	resulting	from	glomerular	damage	may	promote	direct	toxicity	to	the	tubular	
cells,	in	a	vicious	circle	of	progression	in	diabetic	nephropathy.581		
Therefore,	 searching	 for	 biomarkers	 reflecting	 tubular	 injury	 is	 paramount	 for	
early	 identification	 of	 tubulointerstitial	 pathology.	 There	 are	 two	 main	 categories	 of	
urinary	markers	of	tubular	damage:	low	molecular	weight	proteins	and	urinary	enzymes,	
both	 characterizing	 tubular	proteinuria.	 Low	molecular	weight	proteins	 (lower	 than	40-
KDa),	like	retinol-binding	protein	(RBP),	α1-microglobulin	(A1MG)	or	β2-microglobulin	are	
freely	 filtered	 through	 the	 glomerular	membrane	 and	 depend	 on	 proximal	 tubular	 cell	
integrity	 to	 be	 reabsorbed.	 Thus,	 in	 the	 context	 of	 proximal	 tubular	 injury,	 their	
reabsorption	is	impaired,	increasing	their	urinary	concentration.582	Urinary	enzymes,	like	
N-acetyl-β-D-glucosaminidase	 (NAG)	 and	 alanine	 aminopeptidase	 (AAP)	 are	 high	
molecular	weight	proteins,	so	they	are	not	filtered	through	the	glomerulus;	they	originate	
in	 renal	 tubular	 cells	 (mainly	 located	 in	 brush-border	 membranes,	 lysosomes	 and	
cytoplasm)	and	are	excreted	 in	urine,	 increasing	their	secretion	from	tubular	cells	 if	 the	
tubules	are	damaged.583		
	
5.2	Urinary	α1-microglobulin	excretion	
5.2.1	Rational	and	pathophysiology	
A1MG	 is	a	 low	molecular	weight	 (27-KDa)	plasma	glycoprotein,	belonging	 to	 the	
lipocalin	 superfamily.584	 This	 glycoprotein	 is	 synthesized	 in	 the	 liver,	 by	 a	 unique	 gene	
encoding	both	A1MG	and	bikunin,	which	has	no	known	relation	to	A1MG	other	than	co-
synthesis.	Subtilisin-like	proprotein	convertases	are	involved	in	the	intracellular	cleavage	
of	inactive	precursor	proteins,	still	in	the	hepatocyte.585-587	
After	secretion	to	blood,	the	protein	exists	in	free	form,	as	well	as	in	a	variety	of	
high	 molecular	 weight	 complexes:	 approximately	 50%	 forms	 a	 1	 to	 1	 complex	 with	
monomeric	 immunoglobulin	 A,	 approximately	 7%	 are	 linked	 to	 albumin	 and	 1%	 to	
prothrombin.588,	 589	 Tissue	 distribution	 studies	 showed	 that	 A1MG	 is	 found	 in	 most	
tissues,	with	the	exception	of	the	central	nervous	system,	but	liver,	plasma	and	kidney	are	
major	sites	of	localization	(reflecting	the	major	phases	of	the	metabolism	of	A1MG).587,	590	
A1MG	 plays	 an	 important	 physiological	 role,	 because	 A1MG	 deficiency	 has	 not	 been	
reported	in	any	species	(suggesting	that	its	absence	is	lethal);	however,	its	function	is	not	
	 108	
well	 established,	 being	 certainly	 involved	 in	 immunosuppression	 and	 control	 of	
inflammation,	as	well	as	in	protection	against	oxidative	agents.591			
Plasma	levels	of	A1MG	are	apparently	very	stable,	even	in	pathological	conditions,	
like	 neoplasms,	 central	 nervous	 system	 disorders,	 infections	 and	 rheumatoid	 arthritis;	
thus,	A1MG	does	not	met	 the	description	of	 an	 acute	phase	 reactant.592,	593	 Therefore,	
altered	total	plasma	or	serum	A1MG	concentration	is	usually	related	to	impaired	liver	or	
kidney	function;	A1MG	is	synthesized	in	the	liver,	so	severe	liver	insufficiency	leads	to	a	
decrease	 in	 serum	 level;	 free	 A1MG	 is	 freely	 filtered	 through	 the	 glomerulus,	 so	 its	
plasma	 concentration	 is,	 in	 contrast	 to	 A1MG	 bound	 to	 immunoglobulin	 A,	 mainly	
determined	by	GFR,	increasing	proportionally	to	decreasing	creatinine	clearance.587,	594	
As	mentioned	above,	 free	A1MG	 is	cleared	 from	plasma	by	 the	kidney,	where	 it	
passes	 relatively	 freely	 through	 the	 glomerular	membranes	 out	 into	 the	 primary	 urine;	
afterwards	 it	 is	 99%	 reabsorbed	 by	 the	 proximal	 tubules,	 via	 the	 endocytic	 receptor	
megalin,	where	catabolization	occurs.595,	596	Normal	urine	contains	a	very	small	amount	of	
free	 A1MG	 and	 none	 of	 the	 complexes	 can	 be	 detected.597-599	 Therefore,	 in	 conditions	
with	disturbed	tubular	function,	reabsorption	of	A1M	is	reduced	and	increased	amounts	
are	found	in	urine,	making	it	a	marker	for	renal	tubular	disorders.	
One	 of	 the	 advantages	 of	 A1MG	 as	 biomarker	 is	 its	 stability	 in	 human	 urine	ex	
vivo,	at	different	pHs.600,	601	Furthermore,	A1MG	is	stable	in	urine	stored	with	or	without	
preservative	at	 room	temperature	 for	7	days	or	 for	 longer	periods	at	 -4,	 -20	and	 -70ºC	
and	 the	addition	of	 a	preservative	 solution	preserves	A1MG	at	 -20ºC	 for	more	 than	12	
months.602,	603	
	
5.2.2	Urinary	α1-microglobulin	excretion	in	renal	diseases:	state	of	the	art		
Urinary	 A1MG	 excretion	 has	 been	 evaluated	 as	 a	 biomarker	 in	 several	 kidney	
disorders,	 including	diabetic	nephropathy.	A	small	study	 in	FD,	recruiting	17	women	(13	
of	 them	 under	 ERT)	 reported,	 after	 a	 mean	 follow-up	 period	 of	 6	 years,	 a	 significant	
decrease	 in	 A1MG	 in	 the	 treated	 patients;	 an	 opposite	 trend	 of	 an	 increase	 in	 urinary	
A1MG	 was	 observed	 in	 the	 untreated	 patients	 after	 a	 mean	 follow-up	 period	 of	 5	
years.307	
In	 patients	 with	 T2DM,	 several	 studies,	 evaluating	 up	 to	 590	 diabetic	 patients,	
reported	higher	urinary	A1MG	excretion	in	diabetic	patients	(increasing	with	the	severity	
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of	 the	 nephropathy)	 than	 in	 healthy	 controls.469,	578,	579,	604-610	 In	 the	 subgroup	of	 T2DM	
patients	with	albuminuria	A1,	there	are	reports	showing	an	increase,	in	comparison	with	
controls	or	reference	values,	of	urinary	A1MG	in	12.3	–	33.6%	of	the	patients,558,	578,	579,	
607,	608,	611,	612	but	there	is	also	studies	showing	similar	levels	in	normoalbuminuric	patients	
and	healthy	controls605	and	patients	with	albuminuria	A2	or	A3	(between	44.8	–	49.4%)	
presenting	A1MG	within	 the	normal	 range.469,	607	For	example,	 in	a	study	recruiting	590	
patients	 with	 T2DM,	 urinary	 A1MG	 excretion	 increased	 according	 to	 the	 severity	 of	
albuminuria;	however,	33.6%	of	the	normoalbuminuric	patients	presented	urinary	A1MG	
above	 the	 reference	 values,	 although	 44.8%	 of	 the	 patients	 presenting	 albuminuria	 A2	
and	 A3	 had	 urinary	 A1MG	 within	 the	 reference	 range	 (in	 the	 group	 of	 patients	 with	
normal	 A1MG,	 27.6%	 had	 albuminuria	 A2	 or	 A3).607	 One	 study,	 recruiting	 T1DM	 and	
T2DM	 patients	 and	 healthy	 volunteers,	 showed	 that	 urinary	 A1MG	 had	 a	 diagnostic	
accuracy	of	89.0%	in	identifying	diabetic	patients.613	These	results	suggest	urinary	A1MG	
as	 a	 marker	 of	 renal	 dysfunction	 that	 may	 complement	 markers	 of	 glomerular	
dysfunction	such	as	albumin	rather	than	outperform	them.	
These	results	were	also	corroborated	in	T1DM,	in	a	few	studies	involving	up	to	285	
patients	(adults	and	children)	there	was	a	significant	increase	in	urinary	A1MG	excretion	
in	 the	 diabetic	 population	 (in	 comparison	 with	 healthy	 controls),614,	 615	 even	 in	
normoalbuminuric	patients.616-619	
Surprisingly,	 in	 a	 group	 of	 53	 T2DM	 patients	 with	 albuminuria	 A2,	 undergoing	
A1MG	 urinary	 measurement	 and	 kidney	 biopsy,	 the	 increase	 of	 urinary	 A1MG	 was	
significantly	 higher	 in	 the	 subgroup	 of	 patients	with	 “typical”	 diabetic	 glomerulopathy,	
than	 in	 the	 subgroup	 of	 patients	 with	 absent	 or	 mild	 diabetic	 glomerular	 changes,	
associated	with	disproportionately	severe	tubulointerstitial	lesions.620	
The	 correlation	 between	 urinary	 A1MG	 excretion	 and	 biomarkers	 of	 glomerular	
damage	 seems	 significant,	 because	 only	 one	 study	 reported	 no	 correlation	 with	
albuminuria,617	whereas	others	reported	not	only	a	correlation	with	albuminuria,	but	also	
with	 other	 biomarkers	 of	 glomerular	 injury	 (namely,	 UTE,	 urinary	 ColIV	 and	 podocyte	
nephrin).469,	508,	578,	579,	607,	611,	614,	615,	619,	621	 In	 one	 study,	 urinary	 A1MG	was	 significantly	
correlated	with	a	pathophysiological	mediator	of	diabetic	nephropathy,	TGF-β1.615	There	
is	 little	 evidence	 regarding	 the	 correlation	 between	 urinary	 A1MG	 excretion	 and	 GFR,	
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with	two	studies	showing	a	significant	 inverse	correlation	with	estimated	GFR578,	579	and	
another	demonstrating	no	correlation	between	urinary	A1MG	and	serum	creatinine.614		
There	 is	 conflicting	 evidence	 concerning	 the	 correlation	 between	 urinary	 A1MG	
and	 diabetes	 duration,	 with	 a	 few	 studies	 showing	 an	 increase	 according	 to	 diabetes	
duration,607,	 611,	 614,	 616,	 618	 while	 other	 not.617	 No	 correlation	 with	 blood	 pressure	 was	
shown	in	various	studies.607,	614	Only	two	studies	reported	higher	values	of	urinary	A1MG	
in	male	patients,	as	well	as	with	increasing	age.607,	608	
A	 significant	 correlation	 between	 urinary	 A1MG	 levels	 and	 glycaemic	 control	
(measured	 by	 HbA1c)	 was	 reported	 in	 several	 studies.508,	 607,	 611,	 614,	 615,	 617,	 618,	 622	
Moreover,	 in	 newly	 diagnosed	 T2DM	 patients,	 A1MG	 significantly	 decrease	 with	 the	
treatment	with	antidiabetic	agents.508,	618,	622	Different	classes	of	antidiabetic	agents	seem	
to	distinctively	affect	urinary	A1MG	excretion.	 In	a	 study	with	normoalbuminuric	T2DM	
patients,	 comparing	 17	 patients	 treated	 with	 a	 thiazolidinedione	 derivative	 with	 17	
patients	treated	with	a	sulfonylurea,	urinary	A1MG	was	elevated	at	the	beginning	of	the	
study	(and	significantly	correlated	with	albuminuria),	with	no	difference	between	groups,	
whereas	 after	 12	 months	 of	 treatment	 urinary	 A1MG	 was	 significantly	 lower	 in	 the	
thiazolidinedione	 group	 compared	 to	 the	 sulfonylurea	 group.623	 These	 results	 were	
further	confirmed	in	another	study	with	the	same	classes	of	antidiabetic	agents.624		
Treatment	with	a	calcium	channel	blocker	or	an	ACEi	 for	12	months	significantly	
decreased	 the	 urinary	 A1MG	 excretion	 in	 a	 cohort	 of	 20	 patients	 with	 T1DM	 and	
albuminuria	A2.625	
Several	 studies	 evaluated	 urinary	 A1MG	 as	 biomarker	 in	 other	 nephropathies,	
namely	 caused	 by	 intoxication	 with	 heavy	 metals,	 primary	 glomerulopathies,	 Balkan	
nephropathy	and	acute	pyelonephritis	and	vesicoureteral	reflux.626,	627		Urinary	A1MG	has	
been	used	to	 identify	early	nephropathy	due	to	occupational	exposure	to	heavy	metals,	
like	cadmium,	lead	and	mercury.628-630	In	a	longitudinal	study,	evaluating	54	patients	with	
various	primary	glomerulopathies,	with	a	 follow-up	period	of	49	months,	urinary	A1MG	
excretion	 had	 a	 significant	 correlation	 with	 biomarkers	 of	 glomerular	 damage	
(albuminuria	 and	 urinary	 immunoglobulin	 G	 excretion)	 and	 an	 inverse	 correlation	with	
creatinine	 clearance;	 moreover,	 during	 follow-up	 urinary	 A1MG	 did	 not	 change	
significantly,	but	its	change	was	significantly	correlated	with	urinary	immunoglobulin	G.631	
Another	study	 in	patients	with	 idiopathic	membranous	nephropathy	demonstrated	 that	
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excretion	 of	 immunoglobulin	 G	 and	 A1MG	 was	 associated	 with	 the	 extent	 of	
tubulointerstitial	 damage,	 but	 only	 A1MG	 excretion	 was	 associated	 with	 global	
glomerular	sclerosis	and	arteriolar	hyalinosis;	excretion	of	 immunoglobulin	G	and	A1MG	
had	 a	 predictive	 value	 for	 both	 remission	 and	 progression	 and	 was	 useful	 to	 identify	
patients	at	risk	of	progression	and	for	whom	immunosuppressive	therapy	is	indicated.632	
	
5.3	Urinary	N-acetyl-β-D-glucosaminidase	excretion	
5.3.1	Rational	and	pathophysiology	
NAG	is	a	high	molecular	weight	(140-KDa)	lysosomal	enzyme	(also	known	as	β-N-
acetylhexosaminidase	 or	 β-hexosaminidase),	 belonging	 to	 the	 group	 of	 exoglycosidases	
(that	 catalyse	 sequential	 removal	 of	 terminal,	 non-reducing	 sugar	 units	 from	 the	
oligosaccharide	component	of	a	variety	of	large	molecules).633	This	enzyme	is	ubiquitously	
synthesized	and	is	a	dimeric	enzyme	(composed	of	two	polypeptide	chains	/	subunits:	α	
and/or	 β),	 thus	 three	 main	 NAG	 isoenzymes	 are	 recognized:	 A	 (heterodimeric	 αβ),	 B	
(homodimeric	 ββ)	 and	 S	 (homodimeric	 αα,	 which	 is	 unstable	 and	 has	 limited	 catalytic	
activity).634	α	and	β	subunits	are	encoded	in	different	chromosomes	and	protein	moiety	is	
synthesized	 in	 rough	endoplasmic	 reticulum	as	pre-propolypeptide	α	and	β,	 afterwards	
undergoing	post-translational	modifications	 (glycosylation,	 phosphorylation,	 proteolysis,	
folding	 and	 formation	 of	 disulfide	 bonds)	 and	 dimerization,	 forming	 stable	 NAG	
isoenzymes	that	are	delivered	to	lysosomes.635	
The	 main	 function	 of	 NAG	 is	 the	 cleavage	 of	 glycosidic	 linkages	 of	 the	 non-
reducing,	 terminal	 β-D-N-acetylglucosamine	 or	 β-D-N-acetylgalactosamine	 residues	 in	
glycolipids,	 glycoproteins	 and	 glycosaminoglycans;	 β-hexosaminidase	 deficiency	 impairs	
the	hydrolysis	of	GM2	gangliosides	and	is	the	biochemical	defect	 in	GM2	gangliosidosis:	
Tay-Sachs	 disease	 (mutation	 in	 α	 subunit)	 and	 Sandhoff	 disease	 (mutation	 in	 β	
subunit).636	 Nowadays,	 NAG	 is	 being	 increasingly	 associated	 with	 other	 pathological	
conditions,	like	liver	diseases,	multiple	sclerosis	and	neoplasms.635	
In	kidneys,	NAG	is	distributed	along	the	whole	nephron,	but	with	very	high	activity	
in	 lysosomes	 of	 proximal	 tubule	 (mainly	 the	 straight	 portion).637	 NAG’s	 high	molecular	
size	precludes	filtration	through	the	glomerulus,	even	in	glomerular	diseases	(analysis	of	
isoenzymes	of	NAG	demonstrated	that	the	increased	urinary	excretion	of	this	enzyme	is	
	 112	
due	 to	 an	 increased	 release	 by	 the	 renal	 tubular	 cells	 and	 not	 to	 increased	 filtration	
across	the	damaged	glomerular	capillary	wall),	so	urinary	NAG	is	derived	from	the	renal	
tubule.633,	 638	 Isoenzyme	 A	 is	 a	 part	 of	 soluble	 intralysosomal	 compartment	 and	 is	
secreted	 in	urine	by	exocytosis,	 thus	 its	urinary	activity	reflects	 the	secretory	activity	of	
tubular	 cells	 (functional	 isoenzymuria);	 isoenzyme	 B	 is	 intralysosomal	 and	 membrane	
bound	 and	 is	 released	 in	 urine	 together	 with	 disrupted	 lysosomal	 membranes,	 so	 its	
urinary	 activity	 reflects	 breakdown	 of	 tubular	 cells	 (lesional	 type	 isoenzymuria).639	
However,	 increased	 urinary	 NAG	 excretion	may	 not	 only	 occur	 in	 tubular	 damage,	 but	
also	 in	 a	 situation	 of	 increased	 lysosomal	 turnover	 and	 may	 be	 a	 measure	 of	 tubular	
function.640	
Due	 to	 aforementioned	 reasons,	 urinary	 NAG	 has	 emerged	 as	 a	 biomarker	 of	
tubular	 injury;	 moreover,	 it	 has	 other	 qualities	 as	 a	 biomarker:	 stability	 in	 urine	 and	
storage	at	4ºC	for	2	days	or	at	-20ºC	for	several	months	without	degradation.633	
	
5.3.2	Urinary	N-acetyl-glucosaminidase	excretion	in	renal	diseases:	state	of	the	art	
Urinary	NAG	excretion	was	evaluated	as	a	biomarker	of	 tubular	 injury	 in	several	
nephropathies,	 mainly	 in	 diabetic	 nephropathy.	 There	 is	 only	 unpublished	 evidence	 of	
increased	urinary	NAG	excretion	in	FD.641	
In	 patients	with	 T2DM,	 a	 few	 studies,	 based	 on	 up	 to	 672	 patients,	 reported	 a	
significant	 increase	 in	 urinary	 NAG	 excretion,	 in	 comparison	 with	 healthy	 controls;	
moreover,	 this	 increase	 was	 progressive	 according	 to	 the	 increase	 in	 the	 severity	 of	
diabetic	 nephropathy	 and	 occurred	 even	 in	 normoalbuminuric	 patients	 (between	 25	 -	
62%	 of	 the	 patients	 in	 this	 group	 had	 increased	 urinary	 NAG).604,	 605,	 611,	 642-654	 For	
example,	 in	 one	 study	 with	 70	 T2DM	 patients,	 urinary	 NAG	 was	 the	 most	 sensitive	
biomarker	 and	 with	 best	 diagnostic	 accuracy	 to	 identify	 patients	 with	 early	 renal	
involvement	 (albuminuria	 A2).642	 However,	 two	 studies	 showed	 an	 increase	 of	 urinary	
NAG	in	T2DM	patients,	but	not	 in	normoalbuminuric	patient,	where	NAG	excretion	was	
similar	 to	 that	of	healthy	 controls.655,	656	Moreover,	 in	another	 study	 comparing	urinary	
NAG	 excretion	 between	 T2DM	patients	with	 glomerular	 hyperfiltration,	 T2DM	patients	
with	normal	GFR	and	healthy	controls,	although	a	trend	of	its	increased	excretion	in	the	
two	T2DM	subgroups	in	comparison	with	the	controls	was	observed,	the	difference	was	
not	statistically	significant.657	
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Similar	results	were	found	in	patients	with	T1DM,	with	studies	based	on	up	to	659	
patients	showing	an	increase,	in	comparison	with	healthy	controls,	in	urinary	NAG	(with	a	
progressive	 increase	 according	 to	 nephropathy	 severity),	 even	 in	 normoalbuminuric	
patients.650,	658-661	
There	 is	conflicting	evidence	regarding	the	correlation	between	urinary	NAG	and	
albuminuria	 /	 proteinuria	 or	 GFR.	 Most	 studies	 showed	 a	 significant	 correlation	 with	
albuminuria	 and/or	 a	 significant	 inverse	 correlation	 with	 estimated	 GFR	 /	 creatinine	
clearance;642,	 643,	 646,	 647,	 649,	 654,	 661-665	 however,	 two	 studies	 reported	 no	 significant	
correlation	between	urinary	NAG	and	proteinuria	or	creatinine	clearance;657,	660	
The	 prognostic	 value	 of	 urinary	 NAG	 regarding	 nephropathy	 progression	 was	
established	in	several	studies.	A	longitudinal	study	including	296	T1DM	with	albuminuria	
A2,	 followed	 for	 2	 years,	 reported	 that	 albuminuria	 A2	 regressed	 to	 albuminuria	 A1	 in	
24%	of	the	patients,	progressed	to	albuminuria	A3	 in	12.5%	and	remained	stable	 in	the	
others.	In	comparison	with	the	other	subgroups,	urinary	NAG	excretion	was	significantly	
lower	in	the	regression	subgroup	and	39%	of	the	patients	who	regressed	to	albuminuria	
A1	were	in	the	lower	quartile	of	urinary	NAG	excretion	(with	a	significant	and	progressive	
decrease	in	this	percentage	across	the	patients	in	higher	quartiles,	even	after	adjustment	
for	other	variables).658	 	Another	two	studies	corroborated	these	results	 in	other	cohorts	
of	T1DM	patients,	one	of	them	not	only	showing	higher	urinary	NAG	excretion	in	patients	
progressing	 from	 albuminuria	 A1	 to	 A2	 or	 A3,	 but	 also	 identifying	 this	 biomarker	 as	 a	
significant	predictor	(with	a	slightly	higher	odds	ratio	than	albuminuria)	for	development	
of	albuminuria	A2	or	A3.666,	667	
Several	 studies	 reported	 a	 significant	 correlation	 between	 urinary	 NAG	 and	
glycaemic	 control	 (HbA1c).642-644,	646,	647,	649,	659,	660	 Only	 3	 studies	 showed	 no	 correlation	
between	 urinary	 NAG	 and	 HbA1c.648,	 656,	 663	Moreover,	 glycaemic	 control	with	 diet	was	
associated	with	a	significant	decrease	in	urinary	NAG	excretion.646,	647,	668	
The	 correlation	 between	 urinary	 NAG	 and	 diabetes	 duration	 was	 inconsistent,	
with	 a	 few	 studies	 showing	 a	 significant	 correlation,642	 while	 others	 not.660	 One	 study	
showed	that	urinary	NAG	excretion	rises	in	the	third	year	of	diabetes,	plateaux	until	the	
tenth	year	and,	afterwards,	increases	rapidly.653	
In	 one	 study	 no	 difference	 in	 urinary	 NAG	 excretion	 was	 identified	 between	
patients	 with	 and	 without	 HBP,669	 while	 in	 another	 there	 was	 a	 significant	 correlation	
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between	urinary	NAG	and	blood	pressure.645	 In	a	 study	comparing	T2DM	patients,	HBP	
patients	 (without	 diabetes)	 and	 healthy	 controls,	 urinary	 A1MG	was	 similar	 in	 patients	
with	HBP	and	healthy	 controls.652	Nonetheless,	 in	another	 study	patients	with	HBP	had	
significantly	higher	NAG	excretion	than	healthy	controls.670	
Urinary	 NAG	 excretion	 in	 primary	 glomerulopathies	 was	 evaluated	 in	 a	 study	
enrolling	 136	 patients	 with	 idiopathic	 membranous	 nephropathy,	 primary	 focal	 and	
segmental	 glomerulosclerosis	 or	 minimal	 change	 disease.	 A	 significant	 correlation	 was	
identified	 between	 urinary	 NAG	 and	 a	 biomarker	 of	 glomerular	 damage	 (urinary	
immunoglobulin	G),	and	urinary	NAG	was	significantly	higher	 in	patients	with	nephrotic	
range	 proteinuria,	 in	 comparison	 with	 the	 remaining	 patients.	 In	 43	 patients	 with	
nephrotic	 range	 proteinuria	 performing	 kidney	 biopsy,	 a	 non-significant	 increase	 in	
urinary	 NAG	 was	 found	 in	 patients	 with	 higher	 scores	 of	 tubulointerstitial	 damage.	
Furthermore,	 urinary	NAG	was	 the	most	 significant	 predictor	 of	 remission,	 progression	
and	response	to	therapy,	after	a	mean	follow-up	of	42	months,	in	patients	with	idiopathic	
membranous	 nephropathy	 and	 primary	 focal	 and	 segmental	 glomerulosclerosis.671	 This	
increased	urinary	NAG	excretion	and	the	correlation	with	tubular	atrophy	and	interstitial	
fibrosis	 was	 further	 confirmed	 in	 another	 study	 in	 patients	 with	 glomerulonephritis.672	
The	prognostic	value	of	urinary	NAG	to	predict	progression	and	remission	in	patients	with	
idiopathic	membranous	glomerulonephritis	was	also	confirmed	in	an	additional	study.673	
Another	study	showed	a	significant	increase	in	urinary	NAG,	in	comparison	with	controls,	
in	patients	with	non-diabetic-CKD.646	
In	 patients	 with	 tubular	 injury	 due	 to	 various	 insults,	 like	 drugs,	 heavy	 metals,	
rhabdomyolysis	 and	 poisoning	 by	 chemicals,	 there	 is	 an	 increase	 in	 urinary	 NAG;	
however,	urinary	NAG	excretion	seems	less	sensitive	than	low	molecular	weight	protein	
biomarkers	in	the	identification	of	tubular	damage	in	such	patients.674	 Increased	urinary	
NAG	 excretion	 has	 been	 observed	 in	 some	 urological	 abnormalities	 in	 children,	 like	
hydronephrosis	and	vesicoureteral	reflux.675	
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5.4	Urinary	alanine	aminopeptidase	excretion	
5.4.1	Rational	and	pathophysiology	
AAP	 is	 a	 microsomal	 exopeptidase	 that	 catalyses	 the	 splitting	 of	 an	 N-terminal	
amino	acid,	mainly	alanine,	from	a	peptide,	amide	or	arylamide.	Human	kidney	AAP	is	a	
high	molecular	weight	 (240-KDa)	glycoprotein,	 composed	of	 two	subunits.	 In	urine	AAP	
can	 be	 found	 in	 two	 different	 forms,	 a	 soluble	 and	 a	 particulate	 AAP,	 which	 can	 be	
separated	by	ultracentrifugation	and	electrophoresis.		
AAP	 is	 localized	on	the	tubules’	brush	border	membrane,	mainly	 in	the	proximal	
straight	 tubules;	normally	present	 in	urine	 in	 small	quantities,	possibly	owing	 to	 simple	
avulsion	 caused	 by	 laminar	 flow	 within	 the	 tubules.	 In	 injured	 tubules,	 brush	 border	
membrane	may	be	damaged,	 losing	microvilli;	 these	alteration	 in	the	membrane	causes	
an	increase	in	urinary	AAP	activity	originating	from	microsomes	and	cytosol.676	
The	determination	of	urinary	AAP	should	account	for	a	few	characteristics:	seems	
to	 undergo	 an	 infradian	 rhythm	 with	 a	 cycle	 of	 around	 10	 days;677	 has	 an	 inverse	
correlation	with	 age,	with	higher	 activity	 in	 healthy	 children;678,	679	 no	 apparent	 gender	
difference	in	excretion	when	expressed	in	relation	with	urinary	creatinine.680	
The	 specific	 activity	 of	 AAP	 in	 urine	 may	 be	 measured	 by	 various	 methods:	
spectrophotometrically	 by	 using	 L-alanine-4-nitroanilide	 and	 its	 derivatives	 as	 the	
substrates,	 and	 kinetic	 fluorimetric	 assay	with	 the	 substrate	 L-alanine-β-naphthylamide	
and	ELISA.681	AAP	is	stable	for	only	4	hours	after	urine	collection,	which	limits	its	clinical	
utility;	moreover,	 filtration	 through	a	chromatographic	column	 is	advisable	 to	eliminate	
interfering	 substances	 including	 low	molecular	 weight	 AAP	 inhibitors,	 like	 amino	 acids	
and	ammonia.682	
	
5.4.2	Urinary	alanine	aminopeptidase	excretion	in	renal	diseases:	state	of	the	art	
The	evidence	supporting	the	utilization	of	AAP	as	a	biomarker	of	tubular	injury	is	
limited	 in	 comparison	 to	 the	 previously	mentioned	 biomarkers.	 In	 FD,	 in	 the	 literature	
review	AAP	has	never	been	studied.	
Several	 studies,	 recruiting	 T2DM	and/or	 T1DM	patients,	 reported	an	 increase	 in	
urinary	AAP	excretion,	 in	comparison	with	healthy	controls;604,	645,	646,	683-687	moreover,	a	
progressive	 increase	 in	 AAP	 excretion	 according	 to	 the	 severity	 of	 the	 diabetic	
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nephropathy	was	 identified	 in	 some	 studies688	 and/or	an	 increase	 in	normoalbuminuric	
patients	(in	up	to	22.4%	of	these	patients)	was	also	demonstrated	in	few	studies.645,	684,	685	
However,	 in	 a	 study	 evaluating	 30	 T2DM	 male	 patients,	 6	 of	 them	 with	
albuminuria	A2	and	the	remaining	with	albuminuria	A1,	urinary	AAP	excretion	was	similar	
comparing	 T2DM	 patients	 and	 healthy	 controls.	 Moreover,	 after	 6	 months	 of	 aerobic	
exercise	 5	 out	 of	 the	 6	 patients	with	 albuminuria	 A2	 regressed	 to	 albuminuria	 A1,	 but	
urinary	AAP	did	not	 change.689	Another	 study	based	on	T1DM	patients	also	 showed	no	
increase	in	urinary	AAP	in	diabetic	patients,	in	comparison	with	healthy	controls.690		
A	 few	 studies	have	demonstrated	a	direct	 correlation	between	urinary	AAP	and	
albuminuria	/	proteinuria,685,	686	as	well	as	an	inverse	correlation	between	AAP	excretion	
and	estimated	GFR.646,	685	
Concerning	 the	correlation	between	urinary	AAP	and	glycaemic	control	 (HbA1c),	
various	 studies	 showed	 conflicting	 result,	 with	 some	 demonstrating	 a	 significant	
correlation,688	 while	 others	 not.646,	 684	 Moreover,	 glycaemic	 control	 with	 diet	 did	 not	
change	 the	 urinary	 AAP	 excretion.646	 Two	 studies	 reported	 no	 significant	 correlation	
between	AAP	excretion	and	blood	pressure.684,	688		
In	 patients	 with	 primary	 glomerulonephritis,	 urinary	 AAP	 excretion	 was	
significantly	 increased,	 in	 comparison	 with	 healthy	 controls	 and	 correlated	 with	
histological	tubular	atrophy	and	interstitial	fibrosis.672	Nonetheless,	in	another	study	AAP	
excretion	in	controls	was	similar	to	that	in	patients	with	membranous	glomerulonephritis,	
immunoglobulin	 A	 nephropathy	 and	 lupus	 nephritis.683	 A	 similar	 result	 was	 found	 in	
another	study	in	patients	with	non-diabetic	CKD.646	
It	was	 reported	 that	 occupational	 exposure	 to	 heavy	metals	 (arsenic,	 cadmium,	
lead)	and	tobacco	as	well	as	exposure	to	low	levels	of	environmental	cadmium	induces	an	
elevation	of	AAP	activity	in	the	urine	of	copper	smelter	workers	and	the	urine	of	studied	
residents,	respectively.691,	692	
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Aims	
Stemming	from	the	urgent	need	for	better	and	reliable	biomarkers	and	bearing	in	
mind	the	theoretical	background	established	in	the	introduction,	my	main	key	goal	is	the	
identification	of	serum	and	urinary	biomarkers	to	detect	cardiac	and	renal	 involvement,	
respectively,	in	patients	with	FD.		
Concerning	serum	biomarkers	of	cardiac	injury	/	fibrosis,	I	will	evaluate	molecules	
related	to	collagen	metabolism;	urinary	biomarkers,	beyond	urinary	albumin	excretion,	of	
glomerular	and	tubular	injury	will	be	assessed	for	kidney	injury.	
For	 each	 biomarker	 I	 will	 try	 to	 establish	 its	 added	 value	 in	 three	 fields:	
identification	 of	 FD	 patients	 and	 distinction	 from	 healthy	 individuals;	 recognition	 of	
incipient	 organ	 involvement,	 in	 comparison	 with	 the	 current	 gold	 standards	 to	 assess	
early	 FD	 cardiac	 or	 renal	 damage;	 definition	 of	 the	 prognosis	 in	 terms	 of	 the	
cardiomyopathy	or	nephropathy	progression.		
Therefore,	 I	 define	 as	 primary	 endpoint	 comparison	 of	 the	 biomarkers	 between	
healthy	controls	and	patients	with	FD.		
As	 secondary	 endpoints	 I	 will:	 1)	 compare	 the	 biomarkers	 among	 subgroups	 of	
Fabry	 disease	 patients	 with	 increasing	 severity	 of	 heart	 or	 kidney	 involvement;	 2)	
evaluate	 the	 longitudinal	 variation	 of	 these	 biomarkers	 and	 their	 correlation	 with	 the	
progression	of	the	organ	involvement.	
As	 exploratory	 endpoint,	 I	 will	 try	 to	 identify	 the	 effect	 of	 therapeutic	
interventions	 (ERT	 and	 inhibitors	 of	 the	 renin-angiotensin-aldosterone	 system)	 in	 the	
biomarkers.	
To	achieve	these	objectives,	I	will	perform	a	two-year	follow-up	study,	with	annual	
evaluation	 of	 the	 biomarkers	 and	 the	 organ	 involvement.	With	 this	 design	 I	 expect	 to	
establish	the	role	and	value	of	these	biomarkers	in	the	three	aforementioned	aspects.	
The	 overarching	 hypothesis	 throughout	 this	 thesis	 is	 that	 the	 increase	 in	 these	
biomarkers	heralds	 the	development	of	 functional	or	 structural	manifestations	of	Fabry	
disease	and,	 consequently,	 can	be	a	new	paradigm	 in	 the	 identification	of	pre-clinical	 /	
silent	 involvement	of	 the	heart	and	the	kidney	 in	Fabry	disease,	with	stronger	evidence	
for	earlier	therapeutic	intervention	in	order	to	prevent	the	later	major	organ	events.	
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In	 particular,	 I	 hypothesise	 that	 the	 biomarkers	 related	 to	 collagen	 type	 I	
metabolism	may	rise	in	serum	before	the	development	of	any	other	cardiac	abnormalities	
(including	the	first	signs	of	diastolic	dysfunction)	and	may	predict	the	appearance	of	overt	
cardiomyopathy.	Moreover,	I	postulate	that	some	of	the	studied	urinary	biomarkers	may	
outperform	albuminuria	as	early	and	prognostics	biomarkers	of	renal	involvement.		
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Materials	and	methods	
1.	Research	design	
Aiming	the	identification	of	biomarkers	of	FD	cardiomyopathy	and	nephropathy,	I	
developed	 two	 parallel	 studies,	 hereinafter	 designated	 as	 “cardiomyopathy	 study”	 and	
“nephropathy	 study”,	 both	 designed	 as	 multicenter	 (international),	 longitudinal,	
prospective	and	diagnostic	test	studies.	
FD	 patients	 and	 healthy	 controls	 were	 recruited	 in	 three	 centres:	 1)	 Centro	
Hospitalar	 Lisboa	Norte	 (Lisbon,	 Portugal);	 2)	 Hospital	 Senhora	 da	Oliveira	 (Guimarães,	
Portugal);	 3)	 Royal	 Free	 London	 NHS	 Foundation	 Trust	 (London,	 United	 Kingdom),	
between	 February	 2013	 and	 June	 2014.	 FD	 patients	 and	 healthy	 controls	 could	 be	
enrolled	in	both	studies.	
Both	studies	had	the	same	prospective	and	longitudinal	design:	each	recruited	FD	
patient	 was	 evaluated	 at	 baseline	 (enrolment)	 and	 after	 one	 and	 two	 years;	 healthy	
controls	were	evaluated	only	twice	(at	recruitment	and	after	one	year).	
In	 the	 cardiomyopathy	 study,	 I	 assessed	 biomarkers	 related	 to	 collagen	
metabolism	 (PICP,	 PINP,	 PIIINP,	 CITP,	 MMP-1,	 MMP-2,	 MMP-3	 and	 TIMP-1)	 in	 an	
population	 of	 60	 FD	 patients	 and	 20	 healthy	 controls,	 according	 to	 predefined	 criteria	
described	in	the	next	section.		
In	the	nephropathy	study,	I	evaluated	two	biomarkers	of	glomerular	damage	(UTE,	
urinary	 ColIV	 excretion)	 and	 five	 biomarkers	 of	 tubular	 injury	 (urinary	 RBP	 excretion,	
urinary	 κ	 and	 λ	 free	 light	 chains	 [FLC]	 excretion,	 urinary	 A1MG	 excretion,	 urinary	NAG	
excretion	 and	 urinary	 AAP	 excretion)	 in	 an	 estimated	 cohort	 of	 75	 FD	 patients	 and	 25	
healthy	 controls,	 whose	 inclusion	 and	 exclusion	 criteria	 will	 be	 described	 in	 the	 next	
section.	
Given	 the	 limited	 knowledge	 about	 the	 studied	 biomarkers	 in	 FD,	 these	
longitudinal	 studies	 were	 preceded	 by	 two	 pilot	 /	 proof	 concept	 studies:	 a	
cardiomyopathy	pilot	study	and	nephropathy	pilot	study.	 In	both	studies	10	FD	patients	
and	10	healthy	controls	were	recruited	and	the	corresponding	aforesaid	biomarkers	were	
measured;	only	the	differentially	expressed	biomarkers	(between	FD	patients	and	healthy	
controls)	were	evaluated	 in	 the	main	 longitudinal	 studies.	 FD	patients	 recruited	 for	 the	
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pilot	studies	were	also	enrolled	in	the	longitudinal	studies.	A	schematic	representation	of	
the	research	design	is	given	in	Figure	4.	
Figure	 4:	 Research	 design.	 Two	 parallel	 studies	 were	 developed	 with	 a	 main	 objective	 of	
searching	for	new	biomarkers	of	FD	cardiomyopathy	and	nephropathy,	where	each	FD	patient	or	
healthy	control	could	be	enrolled	in	any	study.	C:	healthy	controls;	FD:	Fabry	disease	patients.	
	
According	 to	 the	 aims	 of	 the	 research	 and	 the	 presented	 design,	 I	 did	 not	
anticipate	any	major	possible	biases.	Nonetheless,	the	possible	biases	were	sorted	out	as	
following:	
• selection	bias:	the	selection	of	the	patients	with	FD	for	the	study.	To	avoid	this	
bias,	all	the	consecutive	patients	until	the	n	defined	for	the	study	were	enrolled.	
• re	 selection	 bias:	 as	 consecutive	 patients	 were	 recruited,	 family	 groups	
attending	together	presented	the	same	mutation,	which	may	influence	the	results	
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of	 the	 biomarkers	 measurements	 (e.g.	 families	 presenting	 with	 mutations	
associated	with	attenuated	phenotypes).		
• information	 bias:	 the	 biomarkers	 measurements	 could	 be	 influenced	 by	 the	
severity	of	the	organ	involvement.		To	override	this	bias,	those	responsible	for	the	
laboratory	 analysis	 of	 the	 biological	 samples	 were	 blinded	 for	 any	 information	
about	the	patient	or	control.			
	
2.	Population	
2.1	Cardiomyopathy	study	
The	 FD	 population	 was	 recruited	 according	 to	 the	 following	 inclusion	 and	
exclusion	criteria.	For	FD	patients	the	only	inclusion	criteria	were	diagnosis	of	FD	and	age	
≥18	 years	 old.	 FD	 was	 defined	 in	 males	 as	 low	 α-galactosidase	 A	 activity	 (<5%	 of	 the	
normal	α-galactosidase	A	activity)	and/or	identification	of	a	proven	pathogenic	mutation	
in	the	GLA	gene	and	in	females	as	the	presence	of	a	proven	pathogenic	mutation	in	the	
GLA	gene.	
The	exclusion	criteria	defined	for	FD	patients	included	any	conditions,	other	than	
the	 usual	 manifestations	 of	 FD	 cardiomyopathy,	 potentially	 affecting	 cardiac	 collagen	
metabolism,	as	well	as	other	diseases	or	medication,	previously	mentioned	(introduction:	
section	3.1.1),	affecting	the	serum	levels	of	these	biomarkers,	namely:	
• HCM	or	other	cardiomyopathy;	
• previous	myocardial	infarction;	
• moderate	or	severe	valvular	heart	disease;	
• previous	heart	surgery;	
• cardiac	device	implanted	in	the	previous	6	months;	
• surgery	or	major	trauma	within	the	previous	6	months;	
• inflammatory	or	fibrotic	diseases;	
• active	cancer;	
• chronic	liver	disease;	
• thyroid	disorders;	
• drugs	affecting	bone	turnover:	bisphosphonates,	steroids	and	post-menopausal	
hormone	replacement	therapy.	
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The	control	group	included	healthy	individuals,	aged	≥18	years	old,	with	a	normal	
echocardiogram	(as	defined	below)	and	not	taking	any	drugs.	
In	 order	 to	 enrol	 60	 FD	 patients	 representative	 of	 the	 entire	 spectrum	 of	 FD	
cardiomyopathy	severity,	the	recruitment	was	made	according	to	subgroups	of	increasing	
severity	 of	 FD	 cardiomyopathy	 (aiming	 at	 a	 specific	 number	 of	 patients),	 defined	 by	
echocardiogram:			
• group	 1:	 FD	 patients	 without	 any	 evidence	 of	 cardiac	 involvement:	 no	 LV	
hypertrophy	or	TDI	abnormalities,	as	defined	bellow	(20	patients);		
• group	 2:	 FD	 patients	 with	 TDI	 abnormalities	 (defined	 by	 at	 least	 one	 of	 the	
following	 abnormalities:	 S’	 <6cm/s;	 E’	 <10cm/s,	 <8cm/s	 or	 <6cm/s	 at	 the	 septal	
corner	of	the	mitral	annulus,	 in	patients	≤40	years	old,	between	41	and	60	years	
old	and	>60	years	old,	respectively;	E’	<14cm/s,	<12cm/s	or	<6cm/s	at	the	lateral	
corner	of	 the	mitral	annulus	 in	patients	≤40	years	old,	between	41	and	60	years	
old	and	>60	years	old,	respectively)	and	no	LV	hypertrophy	(20	patients);		
• group	 3:	 FD	 patients	 with	 LV	 hypertrophy,	 defined	 as	 diastolic	 IVS	 or	 PW	
thickness	≥12	mm	(20	patients).	
	 The	 control	 group	 was	 age	 and	 sex-matched	 with	 the	 less	 severe	 FD	 subgroup	
(group	1).	
	 As	noted	above,	this	 longitudinal	study	was	preceded	by	a	pilot	study,	recruiting	
the	 following	groups	 (enrolled	according	 to	 the	aforementioned	 inclusion	and	exclusion	
criteria):	
• 10	healthy	controls,	with	a	normal	echocardiogram	(as	defined	previously),	age	
and	sex-	matched	with	the	following	group;		
• 10	FD	patients	with	LV	hypertrophy	(as	defined	above)	in	echocardiogram.	
	
2.2	Nephropathy	study	
	 In	the	nephropathy	study,	the	inclusion	criteria	for	FD	patients	were	the	same	as	
for	the	cardiomyopathy	study.	
	 The	 exclusion	 criteria	 defined	 for	 the	 FD	 patients	 included	 other	 diseases	 with	
potential	kidney	involvement,	namely:	
• diabetes:	defined	as	fasting	glucose	≥126mg/dL	or	use	of	antidiabetic	drugs;	
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• glomerular	diseases:	nephritic	or	nephrotic	syndrome;	
• immunoglobulin	A	nephropathy;	
• systemic	vasculitis;	
• systemic	lupus	erythematosus;	
• hepatitis	C;	
• amyloidosis;	
• multiple	myeloma.		
The	control	group	included	healthy	individuals,	aged	≥18	years	old,	with	a	normal	
kidney	function	(defined	as	estimated	GFR	≥60ml/min/1.73m2	and	ACR	<30mg/g)	and	not	
taking	any	drugs.	
	 To	ensure	the	entire	spectrum	of	severity	of	FD	nephropathy,	the	recruitment	of	
75	 FD	 patients	 was	 made	 according	 to	 subgroups	 of	 increasing	 severity	 of	 FD	
nephropathy	(aiming	at	a	specific	number	of	patients),	namely:			
• group	 1:	 FD	 patients	 without	 any	 evidence	 of	 kidney	 involvement:	 ACR	
<30mg/g	and	GFR	≥60ml/min/1.73m2	(25	patients);		
• group	 2:	 FD	 patients	 with	 ACR	 30-299mg/g	 and	 GFR	 ≥60ml/min/1.73m2	 (20	
patients);		
• group	 3:	 FD	 patients	 with	 ACR	 ≥300mg/g	 and	 GFR	 ≥60ml/min/1.73m2	 (10	
patients);	
• group	4:	FD	patients	with	CKD	stage	≥3	(according	to	Kidney	Disease	Improving	
Global	 Outcomes	 [KDIGO]	 guidelines),283	 defined	 as	 GFR	 <60ml/min/1.73m2	 (20	
patients).	
	 The	 control	 group	 was	 age	 and	 sex-matched	 with	 the	 less	 severe	 FD	 subgroup	
(group	1).	
	 As	 mentioned	 above,	 this	 longitudinal	 study	 was	 preceded	 by	 a	 pilot	 study,	
recruiting	the	following	groups	(enrolled	according	to	the	aforementioned	inclusion	and	
exclusion	criteria):	
• 10	healthy	controls,	with	a	normal	kidney	function	(as	defined	previously),	age	
and	sex-	matched	with	the	following	group;		
• 10	FD	patients	with	GFR	<60ml/min/1.73m2.	
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3.	Recruitment	and	compliance	
	 The	local	or	national	Ethical	Committees	of	each	participating	centre	approved	the	
study	 protocol	 and	 the	 study	was	 conducted	 in	 accordance	with	 this	 protocol	 and	 the	
ethical	principles	of	the	Declaration	of	Helsinki.			 	
	 All	consecutive	patients	until	the	n	defined	for	the	study	were	enrolled	when	they	
attended	their	care	team	for	FD	in	their	routine	follow-up.	Given	that	the	study	does	not	
present	any	harm	or	scheduled	visits	outside	 the	 routine	 follow-up,	 I	did	not	anticipate	
difficulties	in	enrolment	of	the	eligible	patients.	Written	informed	consent	was	obtained	
from	all	participants	before	any	study	procedures.	
	 Given	 that	 there	was	no	 recruitment	of	patients	 younger	 than	18	 years	old	 and	
with	 cognitive	 impairment	 or	 mentally	 ill,	 no	 specific	 arrangements	 were	 provided	 for	
these	special	populations.	
	 The	 controls	 were	 identified	 and	 recruited	 at	 Centro	 Hospitalar	 Lisboa	 Norte	
(Lisbon)	and	Hospital	Senhora	da	Oliveira	 (Guimarães),	within	the	healthy	population	of	
health	care	providers.	
	 As	the	patients	were	evaluated	during	their	routine	follow-up,	 I	did	not	organize	
any	specific	arrangement	to	record	the	compliance	of	the	patients.	For	patients	missing	
their	 routine	 follow-up	visits,	 the	usual	procedures	of	each	hospital	were	performed	 to	
recall	the	patient.	
	
4.	Clinical	data	
4.1	General	clinical	data	
	 As	 described	 in	 the	 research	 design,	 each	 patient	 had	 three	 scheduled	 visits:	
baseline	and	after	one	and	two	years.	General	clinical	data	was	collected	at	baseline	and	
after	 each	 visit,	 irrespective	 of	 the	 inclusion	 in	 a	 cardiomyopathy	 and/or	 nephropathy	
study,	namely:	
• 	identification:	age	at	enrolment	and	gender;	
• FD	diagnosis:	age	at	diagnosis,	plasma	α-galactosidase	A	activity	and	GLA	gene	
mutation;	
• current	medications:	ACEi,	ARB,	aldosterone	antagonists	and	β-blockers;	
• ERT:	drug,	dose	and	duration;	
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• FD	 clinical	 manifestations	 in	 the	 heart,	 kidney,	 central	 nervous	 system,	
peripheral	and	autonomic	nervous	system,	gastro-intestinal	system,	eye,	ear	and	
skin,	 in	 order	 to	 calculate	 the	 severity	 indices:	 MSSI	 and	 Fabry	 International	
Prognostic	Index	(FIPI);229,	693	
• cardiac	 laboratorial	 and	 imaging	 evaluation:	 NT-proBNP,	 echocardiogram	 and	
cardiac	MRI	(detailed	in	the	next	sections)	
• kidney	function	tests:	GFR,	creatinine,	albuminuria	and	proteinuria	(detailed	in	
the	next	sections)	
Plasma	 collected	 during	 the	 research	 project	 was	 also	 used	 to	measure	 plasma	
lyso-Gb3.	 Plasma	 lyso-Gb3	 was	 quantified	 by	 liquid	 chromatography	 tandem-mass	
spectrometry	(Agilent,	ultra	performance	liquid	chromatography	[UPLC]	triple	quadrupole	
[QqQ]	electrospray	ionization	[ESI]).	The	quantification	was	achieved	by	multiple	reaction	
monitoring	 (MRM)	 of	 the	 transitions	mass-to-charge	 ratios	 (m/z)	 786,4→282,3	 and,	 as	
internal	 standard	 1-β-D-glucosylsphingosine	 (GSG),	 460.5→280.3.	 The	 result	 was	
extrapolated	from	the	calibration	curve	obtained	from	responses	of	calibrators	of	known	
concentrations	versus	the	internal	standard.	
Data	collected	from	the	control	group	included	only	age	at	enrolment,	gender	and	
exclusion	of	comorbidities	and	medication.		
	
4.2	Cardiomyopathy	study	
	 In	the	cardiomyopathy	study,	I	compared	the	results	of	the	biomarkers	related	to	
collagen	metabolism	(index	tests)	with	the	gold	standard	 imaging	techniques	(reference	
tests)	 in	 the	evaluation	of	cardiac	 function	and	structure	 in	FD,	namely	echocardiogram	
and	 cardiac	MRI.	 The	 usefulness	 of	 the	 biomarkers	 was	 tested	 in	 the	 identification	 of	
specific	outcomes	in	the	reference	tests.	
	 Healthy	controls	also	performed	echocardiograms	to	exclude	any	cardiac	disorder	
and	guarantee	that	they	do	not	present	any	abnormality	defined	as	an	outcome.	They	did	
not	perform	cardiac	MRI.	
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4.2.1	Echocardiogram	
Echocardiogram	(LV	mass	and	TDI	abnormalities)	was	used	as	one	of	the	reference	
tests	to	compare	with	index	tests,	as	it	is	considered	the	gold	standard	in	the	evaluation	
of	early	cardiac	dysfunction	in	FD.	
Data	 from	 the	 M-mode,	 2-dimensional	 and	 Doppler	 transthoracic	
echocardiographic	 study	 was	 collected	 for	 each	 patient	 and	 control.	 FD	 patients’	
echocardiograms	were	executed	in	a	Vivid	7	(General	Electrics®)	ultrasound	system	in	all	
recruitment	sites.	The	controls	evaluation	was	performed	in	Vivid	7	(General	Electrics®)	or	
Toshiba	Xario	(model	SSA-660A)	ultrasound	systems.	The	average	of	three	cardiac	cycles	
was	used	for	measurement	of	cardiac	dimensions,	mitral	inflow	pattern,	pulmonary	veins	
flow	and	myocardial	velocities	at	the	corners	of	the	mitral	annulus.	
LV	 dimensions	 (interventricular	 septum,	 posterior	 wall	 and	 LV	 end-diastolic	
diameter)	 were	 assessed	 from	 the	 long-axis	 view	 and	 ventricular	 mass	 was	 calculated	
according	 to	 the	 Devereux	 formula	 and	 normalized	 for	 height	 (g/m2.7).	 LV	 hypertrophy	
was	 defined	 as	 LV	 mass	 ≥50g/m2.7.	 Left	 atrium	 area	 was	 obtained	 in	 the	 apical	 four-
chamber	view	and	expressed	in	cm2.	
Mitral	 inflow	pattern	(rapid	filling	[E]	and	atrial	contraction	[A]	peak	velocities,	E	
wave	 decelerating	 time,	 A	 dur	 and	 isovolumic	 relaxation	 time)	 were	 obtained	 at	 the	
mitral	 level	 by	 Doppler	 echocardiography	 in	 the	 apical	 four-chamber	 view.	 Retrograde	
flow	velocity	(Ar	vel)	and	Ar	dur	were	acquired	from	the	pulmonary	veins	also	by	Doppler	
echocardiography	in	the	same	view.	
Myocardial	velocities	during	systole	(S’)	and	early	diastole	(E’)	were	collected	from	
TDI	at	lateral	and	septal	corner	of	the	mitral	annulus	in	the	apical	four-chamber	view.	TDI	
abnormalities	 were	 defined	 as	 mentioned	 above.	 The	 ratio	 between	 E	 and	 E’	 average	
(septal	and	lateral)	was	used	to	estimate	left	ventricular	end-diastolic	pressure.	
Echocardiographic	 studies	 were	 performed	 and	 reported	 by	 persons	 who	 were	
blinded	 to	 the	measurement	 of	 collagen	 turnover	 biomarkers	 (index	 tests)	 and	 clinical	
data.	
Since	 echocardiogram	 is	 an	 observer	 dependent	 technique,	 evaluation	 of	 inter-
observer	 variability	 was	 anticipated.	 However,	 as	 the	 echocardiograms	 were	 executed	
during	 routine	 follow-up	 in	 echocardiography	 laboratories	 in	 each	 recruiting	 centre,	 by	
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various	 echocardiography	 technicians	 or	 cardiologists,	 it	 was	 not	 possible	 to	 test	 this	
variation	and	this	is	a	limitation	of	the	study.			
	
4.2.2	Cardiac	magnetic	resonance	imaging	
Cardiac	MRI	was	used	as	a	reference	test,	as	it	is	the	gold	standard	technique	for	
non-invasive	detection	of	replacement	myocardial	fibrosis.	
Data	 on	 cardiac	MRI	 was	 collected	 only	 when	 it	 was	 performed	 as	 part	 of	 the	
follow-up	 protocol.	 Cardiac	 MRI	 studies	 were	 performed	 in	 a	 3.0-T	 system	 (Philips®	
Intera).	 LGE	 is	 the	 standard	 for	 detection	 of	 focal	myocardial	 replacement	 fibrosis	 and	
was	 defined	 in	 the	 study	 as	 greater	 than	 2	 standard	 deviations	 above	 the	mean	 signal	
intensity	of	 the	distant	myocardium.	Due	to	 limited	access	 to	 the	cardiac	MRI	 images,	 I	
was	not	able	to	calculate	the	extent	of	LGE,	in	terms	of	total	volume	and	as	proportion	of	
the	total	LV	mass;	this	is	another	limitation	of	this	research	project.			
	
4.2.3	Outcomes	
To	 test	 the	 value	 of	 the	 biomarkers	 related	 to	 collagen	 metabolism	 in	 the	
identification	 of	 incipient	 FD	 cardiomyopathy,	 the	 correlation	 with	 cardiomyopathy	
severity	and	as	a	predictor	of	cardiomyopathy	prognosis,	several	outcomes	related	to	the	
reference	tests	were	defined:	
• comparison	 of	 the	 biomarkers	with	 TDI	 abnormalities	 in	 the	 identification	 of	
patients	with	FD;	
• correlation	of	 the	biomarkers	with	 the	severity	of	LV	hypertrophy	 (defined	as	
indexed	LV	mass	 in	 the	echocardiogram)	and	of	diastolic	dysfunction	(defined	as	
TDI	E’	values	in	the	echocardiogram);	
• diagnostic	 accuracy	 of	 the	 biomarkers	 to	 identify	 TDI	 abnormalities	 (as	
previously	 defined),	 LV	 hypertrophy	 (as	 previously	 defined)	 and	 LGE	 in	 cardiac	
MRI;	
• correlation	 of	 the	 longitudinal	 change	 of	 echocardiographic	 aforementioned	
measures	of	LV	hypertrophy	and	diastolic	dysfunction,	with	the	biomarkers	at	the	
baseline;	
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• correlation	of	the	variation	of	the	biomarkers	between	baseline	and	24	months	
of	 follow-up	 with	 the	 variation	 of	 the	 echocardiographic	 variables	 at	 the	 same	
time	points;	
• evaluation	of	the	prognostic	value	of	the	biomarkers,	expressed	as	their	ability	
to	 identify	 patient	 progression	 in	 terms	 of	 LV	 hypertrophy	 and	 diastolic	
dysfunction	along	the	observation	period.	LV	mass	progression	was	defined	as	an	
increase	 in	 LV	mass	 ≥10g/m2.7	 between	 the	 first	 and	 last	 evaluation	 within	 the	
study.	 Diastolic	 dysfunction	 progression	 was	 defined	 as	 an	 increase	 in	 LV	 end-
diastolic	 pressure	 (LVEDP),	 i.e.	 an	 increase	 ≥1.5	 in	 the	 E	 to	 E’	 average	 ratio,	
associated	with	TDI	abnormalities	between	baseline	and	last	follow-up	visit;	
• exploratory	sub-analysis	by	gender;		
• exploratory	 sub-analysis	 of	 the	 effect	 of	 ERT	 or	 ACEi	 /	 ARB	 on	 biomarker	
longitudinal	variation.	
	
4.3	Nephropathy	study	
	 In	 the	nephropathy	 study,	 I	 defined	 as	 the	 reference	 tests	 to	 compare	with	 the	
results	 of	 the	biomarkers	of	 glomerular	 and	 tubular	 damage,	 the	 gold	 standards	 in	 the	
evaluation	 of	 FD	 nephropathy:	GFR	 and	 albuminuria.	 The	 usefulness	 of	 the	 biomarkers	
was	also	tested	in	the	identification	of	specific	outcomes	in	the	reference	tests.	
	 Healthy	 controls	 also	 underwent	 kidney	 evaluation,	 with	 the	 measurement	 of	
albuminuria	and	serum	creatinine.			
	
4.3.1	Albuminuria	
Albuminuria	(ACR)	was	used	as	one	of	the	reference	tests,	as	 it	 is	considered,	as	
mentioned	 in	 the	 introduction,	 to	be	 the	gold	 standard	and	a	 sensitive	marker	of	early	
renal	dysfunction	in	FD	nephropathy.	
ACR	was	quantified	from	spot	urine,	in	random	urine	samples.	In	FD	patients	this	
was	 determined	 by	 the	 available	 laboratory	 method	 in	 each	 recruiting	 centre	
(immunonephelometry	 methods).	 In	 the	 control	 group	 it	 was	 evaluated	 by	
immunoturbidimetry	 (Siemens	 Healthcare	 Diagnostics,	 Germany).	 Increased	 ACR	 was	
defined	as	≥30mg/g,	according	to	KDIGO	guidelines.283			
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4.3.2	Serum	creatinine	and	glomerular	filtration	rate	
Glomerular	filtration	rate	is	the	gold	standard	for	diagnosis	and	staging	of	CKD.	As	
mentioned	 in	 the	 introduction	 it	 may	 be	 measured	 or	 estimated	 according	 to	 serum	
creatinine	and/or	cystatin.		
In	 FD	 patients,	 serum	 creatinine	 was	 assessed	 during	 routine	 follow-up	 in	 the	
Hospital	 laboratory	 by	 the	 modified	 Jaffe’s	 method	 (photometric	 assay)	 and	 it	 was	
collected	on	 the	 same	day	 as	 the	urine	used	 to	determine	ACR	and	 the	biomarkers.	 In	
controls,	 serum	 creatinine	 was	 determined	 by	 a	 compensated	 kinetic	 Jaffé	 method	
(Siemens	Healthcare	Diagnostics,	Germany).	GFR	was	estimated	by	the	CKD-EPIcreatinine2009	
equation,	according	to	KDIGO	guidelines.148,	283		
In	a	single	recruiting	centre	GFR	is	often	measured	using	Cr-51	EDTA	clearance	in	
FD	 patients.	 CKD	 staging	 by	 GFR	 categories,	 in	 agreement	 with	 KDIGO	 guidelines,	 was	
based	on	estimated	GFR,	except	in	patients	for	whom	radioisotopic	measurement	of	GFR	
was	available.283	
Laboratories	assessing	kidney	 function	were	blinded	 to	 the	measurement	of	 the	
biomarkers	of	glomerular	and	tubular	injury	(index	tests)	and	clinical	data.		
	
4.3.3	Outcomes	
To	 test	 the	 biomarkers	 correlation	 with	 incipient	 FD	 nephropathy	 and	
nephropathy	 severity	 and	 as	 predictors	 of	 nephropathy	 prognosis,	 several	 outcomes	
related	to	the	reference	tests	were	defined:	
• comparison	of	biomarkers	with	ACR	in	the	identification	of	patients	with	FD;	
• correlation	 of	 the	 biomarkers	 with	 the	 severity	 of	 CKD	 (defined	 as	 the	
estimated	GFR	and	the	CKD	stage);	
• diagnostic	accuracy	of	the	biomarkers	to	identify	CKD	stage	≥2;	
• correlation	 of	 the	 longitudinal	 change	 of	 GFR,	 with	 the	 concentration	 of	 the	
biomarkers	at	the	baseline;	
• correlation	of	the	longitudinal	variation	of	the	biomarkers	with	the	longitudinal	
variation	of	the	GFR;	
• definition	of	the	prognostic	value	of	the	biomarkers,	expressed	as	their	ability	
to	 identify	patient	progression	 in	 terms	of	ACR	and	GFR.	An	ACR	progressor	was	
defined	as	a	patient	with	an	increase	≥1.5	times	of	ACR	between	its	first	and	last	
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evaluation	 within	 the	 study,	 for	 at	 least	 ≥30mg/g	 or	 as	 a	 change	 between	
albuminuria	A1	and	A2	or	A2	and	A3.	GFR	progression	was	defined	as	a	decrease	
≥5ml/min/1.73m2	in	estimated	GFR	between	baseline	and	last	follow-up	visit,	for	
at	least	a	GFR	<90ml/min/1.73m2;	
• exploratory	sub-analysis	by	gender;	
• exploratory	 sub-analysis	 of	 the	 effect	 of	 ERT	 or	 ACEi	 /	 ARB	 on	 biomarker	
longitudinal	variation.	
	
4.4	Data	handling	and	archiving	
	 As	an	 international,	multicenter	study,	the	collected	data	was	handled	according	
to	the	ethical	requirements	in	the	participating	country,	in	order	to	protect	personal	data	
during	transmission	between	the	participating	countries.	
	 Patient	 personal	 data	was	 anonymised	 and	 securely	 stored	 in	 filling	 cabinets	 in	
rooms	with	 limited	 access.	 The	 electronic	 files	 of	 the	 processed	 data	 (all	 anonymised)	
were	 stored	 on	 the	 hospital	 computers	 where	 the	 study	 developed,	 with	 appropriate	
access	controls	to	store	the	confidential	research	information.	A	numeric	code	was	used	
to	anonymise	each	recruited	patients	and	the	numeric	code	key	was	only	known	by	the	
research	team	and	securely	stored	on	the	hospital	computers	used	in	the	research.	
	 Anonymised	data	was	appropriately	transferred	between	the	centres	 in	Portugal	
and	 the	United	Kingdom	 for	processing	and	 statistical	 analysis.	 The	data	 transferred	by	
laptop	 computers	 was	 encrypted.	 An	 international	 carrier	 of	 biological	 products	
transported	the	anonymised	biological	samples	to	Portugal.	
	 The	 research	documents	and	 files	will	be	stored	 in	each	centre	according	 to	 the	
requirements	at	each	institution:	for	20	years	at	the	Royal	Free	London	NHS	Foundation	
Trust	 and	 for	 5	 years	 at	 both	 Portuguese	 centres.	 After	 this	 period	 the	 data	 will	 be	
removed	from	the	computers	using	appropriate	data	destruction	software.	
	
5.	Biomarkers	assessment	
5.1	Cardiomyopathy	study		
	 As	 described	 in	 the	 research	 design,	 to	 assess	 myocardial	 collagen	 turnover,	 I	
measured	biomarkers	related	to	collagen	metabolism,	either	of	collagen	synthesis	(PICP,	
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PINP,	PIIINP)	or	degradation	(CITP,	MMP-1,	MMP-2,	MMP-3	and	TIMP-1).	Moreover,	we	
calculated	 the	 PICP	 to	 CITP	 ratio	 as	 an	 index	 reflecting	 the	 balance	 between	 collagen	
synthesis	and	degradation.	
	 As	mentioned	 above,	 collagen	 type	 I	 is	 also	 a	major	 component	of	 bone,	which	
may	 be	 a	 clue	 in	 the	 interpretation	 of	 the	 blood	 concentration	 of	 propeptides	 and	
telopeptides	of	collagen	type	I	when	assessing	myocardial	fibrosis.	Therefore,	to	minimize	
this	confounding	factor,	I	also	measured	markers	of	bone	synthesis	(B-AP)	and	resorption	
(type	5	tartrate-resistant	acid	phosphatase	[TRAP5b])	and	the	PICP	to	B-AP	and	the	CITP	
to	TRAP5b	ratios	were	assumed	as	markers	of	collagen	type	I	synthesis	and	degradation	
adjusted	for	bone	turnover,	respectively.	
	 I	 also	 anticipated	 that	 another	 confounding	 factor	 could	 be	 kidney	 function,	
because,	 as	 noted	 above,	 it	 is	 the	 main	 route	 for	 CITP	 clearance	 and	 patients	 with	
moderate	or	 severe	CKD	present	altered	bone	 turnover.	As	 renal	 involvement	 is	one	of	
the	predominant	 features	 of	 FD,	 adjustment	 for	GFR	was	 taken	 in	 consideration	 in	 the	
statistical	analysis.		
	 Given	that	there	are	no	validated	reference	values	for	the	tested	biomarkers,	the	
upper	limit	of	a	95%	confidence	interval	for	the	mean	of	the	control	group	was	assumed	
to	be	the	upper	limit	of	the	reference	value.	
	
5.1.1	Biological	samples	
Peripheral	 venous	 blood	 samples	were	 obtained	 less	 than	 6	months	 apart	 from	
the	echocardiogram	 (during	 the	 routine	blood	sampling	of	 the	patients	with	FD).	Blood	
samples	were	collected	in	ethylenediamine	tetra-acetic	acid	(EDTA)	and	serum	separator	
chemistry	(containing	a	separator	gel)	tubes,	spun	within	120	minutes	after	phlebotomy	
(2500rpm,	 during	 10	 minutes)	 and	 plasma	 and	 serum	 was	 separated	 and	 stored	
immediately	stored	at	-20°C,	in	Eppendorf	tubes.		
Frozen	stored	tubes	were	transported	to	the	laboratory	at	the	same	temperature	
conditions	 in	 dry	 ice	 and	 thawed	 and	 mixed	 thoroughly	 just	 prior	 to	 the	 assay.	 The	
serological	 assays	 were	 performed	 within	 less	 than	 12	 months	 after	 blood	 sample	
collection.		
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5.1.2	Serological	tests	
In	brief,	 TRAP5b	was	evaluated	by	 an	ELISA	method,	 according	 to	manufacturer	
instructions	and	measured	at	405	nm	(ids,	 Immunodiagnostic	Systems,	UK);	MMP-1	and	
MMP-2	were	evaluated	by	an	ELISA	method,	according	to	manufacturer	instructions	and	
measured	 at	 450	 nm	 (SunRed®,	 Shanghai,	 PRC);	 B-AP	 and	 PICP	 were	 evaluated	 by	 an	
ELISA	method,	according	to	manufacturer	instructions	and	measured	at	405	nm	(QUIDEL	
Corporation,	 San	 Diego,	 USA);	 CITP	 was	 evaluated	 by	 an	 electro-chemiluminescence	
immunoassay	(ECLIA)	 in	 a	 COBAS	 e411	 instrument	 (Roche®	 Diagnostics	 GmBH,	
Mannheim;	Germany).	Duplicate	determinations	were	made	for	each	 individual	and	the	
average	 result	 considered.	 Laboratory	determinations	were	blinded	 to	 clinical	 data	 and	
cardiac	assessments	(reference	tests).	
PICP	 was	 measured	 in	 serum,	 by	 an	 ELISA	 method	 (QUIDEL	 Corporation®,	
Hannover,	Germany),	according	to	manufacturer	instructions.	The	micro	ELISA	strip	plate	
is	 pre-coated	 with	 human	 PICP	 monoclonal	 antibody	 and	 the	 kit	 uses	 p-nitrophenyl	
phosphate	substrate	to	measure	the	immune	complex	obtained	during	the	reaction.	Final	
colorimetric	 reaction	 is	measured	 by	 photometry	 at	 405	 nm.	 In	 this	 assay	 system,	 the	
assay	sensitivity	of	PICP	was	over	0.2ng/mL;	coefficients	of	variations	of	 intra-assay	and	
inter-assay	were	5.5%	and	7.2%,	respectively.		
CITP	 was	measured	 in	 serum,	 by	 an	 ECLIA	method	 (Roche®	 Diagnostics	 GmBH,	
Mannheim;	 Germany)	 in	 an	 automated	 analyser	 COBAS	 e411	 instrument,	 according	 to	
manufacturer	 instructions.	 The	 detection	 of	 the	 marker	 in	 the	 samples	 is	 made	 using	
human	 CITP	 monoclonal	 antibody.	 In	 this	 assay	 system	 the	 minimum	 detectable	
concentration	of	CITP	was	over	0.01ng/mL.	 The	 intra-assay	and	 inter-assay	precision	of	
the	method	were	4.6%	and	4.7%,	respectively.	
MMP-1	 was	 also	 measured	 in	 serum,	 in	 an	 assay	 using	 a	 double-antibody	
sandwich	ELISA	 (SunRed®	Biotechnology	Company),	according	 to	 the	 instructions	of	 the	
manufacturer.	The	micro	ELISA	strip	plate	is	pre-coated	with	human	MMP-1	monoclonal	
antibody	 and	 the	 kit	 uses	 biotin-streptavidin-HRP	 technology	 to	 measure	 the	 immune	
complex	 obtained	 during	 the	 reaction.	 Final	 colorimetric	 reaction	 is	 measured	 by	
photometry	 at	 450	 nm.	 In	 this	 assay	 system,	 the	 assay	 sensitivity	 of	MMP-1	was	 over	
0.207ng/mL;	 coefficients	 of	 variations	 of	 intra-assay	 and	 inter-assay	 were	 <10%	 and	
<12%,	respectively.		
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MMP-2	was	measured	in	serum,	also	by	a	double-antibody	sandwich	ELISA	assay	
(SunRed®	 Biotechnology	 Company),	 according	 to	 the	 instructions	 of	 the	manufacturer.	
The	micro	ELISA	strip	plate	 is	pre-coated	with	human	MMP-2	monoclonal	antibody	and	
the	 kit	 uses	 biotin-streptavidin-HRP	 technology	 to	 measure	 the	 immune	 complex	
obtained	during	 the	 reaction.	 Final	 colorimetric	 reaction	 is	measured	by	photometry	at	
450	 nm.	 In	 this	 assay	 system,	 the	 assay	 sensitivity	 of	 MMP-2	 was	 over	 10.016ng/mL;	
coefficients	of	variations	of	intra-assay	and	inter-assay	were	<9%	and	<12%,	respectively.	
B-AP	 was	 measured	 in	 serum,	 by	 ELISA	 methodology	 (QUIDEL	 Corporation®,	
Hannover,	Germany)	according	to	the	instructions	of	the	manufacturer.	The	micro	ELISA	
strip	 plate	 is	 pre-coated	 with	 human	 B-AP	 monoclonal	 antibody	 and	 the	 kit	 uses	 p-
nitrophenyl	 phosphate	 substrate	 to	measure	 the	 immune	 complex	obtained	during	 the	
reaction.	Final	colorimetric	reaction	is	measured	by	photometry	at	405	nm.	In	this	assay	
system,	 the	minimum	detectable	concentration	of	B-AP	was	over	0.34ng/mL.	The	 intra-
assay	and	inter-assay	precision	of	the	method	were	6%	and	8%,	respectively.	
TRAP5b	 was	 measured	 in	 serum,	 by	 an	 ELISA	 assay	 (ids,	 Immunodiagnostic	
Systems®,	United	Kingdom),	according	to	the	manufacturer	instructions.	The	micro	ELISA	
strip	 plate	 is	 pre-coated	with	 human	 TRAP5b	monoclonal	 antibody	 and	 the	 kit	 uses	 p-
nitrophenyl	 phosphate	 substrate	 to	measure	 the	 immune	 complex	obtained	during	 the	
reaction.	Final	colorimetric	reaction	is	measured	by	photometry	at	405	nm.	In	this	assay	
system,	the	limit	of	TRAP5b	quantification	is	over	0.5U/L.	The	intra-assay	and	inter-assay	
precision	of	the	method	were	<9.6%	and	<9.2%,	respectively.	
	
5.2	Nephropathy	study		
	 As	mentioned	 in	 the	 research	design,	 I	measured	 two	biomarkers	of	 glomerular	
damage,	 one	 related	 to	 increased	permeability	 to	plasma	proteins	 (UTE)	 and	 the	other	
associated	 to	mesangial	 and	GBM	expansion	 (urinary	 ColIV	 excretion);	 I	 also	 evaluated	
three	 biomarkers	 of	 tubular	 injury,	 one	 low	 molecular	 weight	 protein	 (urinary	 A1MG	
excretion)	and	two	urinary	enzymes	(urinary	NAG	excretion	and	urinary	AAP	excretion).		
	 All	 biomarkers	 were	 measured	 in	 spot,	 random	 collected	 urine;	 this	 urine	 was	
taken	from	the	sample	used	to	determine	ACR.	All	biomarkers	urine	concentrations	were	
normalized	for	the	urinary	creatinine	concentration.	
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	 Given	that	there	are	no	validated	reference	values	for	the	tested	biomarkers,	the	
upper	limit	of	a	95%	confidence	interval	for	the	mean	of	the	control	group	was	assumed	
to	be	the	upper	limit	of	the	reference	value.	
	
5.2.1	Biological	samples	
	 Urine	was	collected	in	the	routine	follow-up	visits,	on	the	same	day	as	the	blood	
for	determination	of	serum	creatinine	or,	when	this	was	the	case,	on	the	same	day	as	the	
measurement	of	GFR	by	radioisotopic	method.	Urine	was	collected	in	a	tube	without	any	
conservative	treatment	and	immediately	stored	at	-20º,	without	any	processing.		
Frozen	stored	tubes	were	transported	to	the	laboratory	at	the	same	temperature	
conditions	 in	 dry	 ice	 and	 thawed	 and	 mixed	 thoroughly	 just	 prior	 to	 the	 assay.	 The	
serological	 assays	 were	 performed	 within	 less	 than	 12	 months	 after	 urine	 sample	
collection.		
	
5.2.2	Serological	tests	
In	 brief,	 transferrin,	 ColIV,	A1MG	and	AAP	were	evaluated	by	 an	 ELISA	method,	
according	 to	 manufacturer	 instructions	 and	 measured	 at	 450	 nm	 (SunRed®,	 Shanghai,	
PRC);	NAG	was	evaluated	by	a	colorimetric	assay	at	580	nm	(Roche®	Diagnostics	GmBH,	
Mannheim;	 Germany).	 Duplicate	 determinations	 were	 made	 for	 each	 individual	 and	
mean	results	are	presented.	Laboratory	determinations	were	blinded	to	clinical	data	and	
renal	function	assessment	(reference	tests).	
Transferrin	 was	measured	 in	 urine,	 by	 a	 double-antibody	 sandwich	 ELISA	 assay	
(SunRed®	Biotechnology	Company),	according	to	the	instruction	of	the	manufacturer.	The	
micro	ELISA	strip	plate	is	pre-coated	with	human	transferrin	monoclonal	antibody	and	the	
kit	 uses	 biotin-streptavidin-HRP	 technology	 to	measure	 the	 immune	 complex	 obtained	
during	the	reaction.	Final	colorimetric	reaction	is	measured	by	photometry	at	450	nm.	In	
this	assay	system,	the	assay	sensitivity	of	transferrin	was	over	0.014mg/L;	coefficients	of	
variations	of	intra-assay	and	inter-assay	were	<10%	and	<12%,	respectively.	
ColIV	 was	 measured	 in	 urine,	 by	 a	 double-antibody	 sandwich	 ELISA	 assay	
(SunRed®	 Biotechnology	 Company),	 according	 to	 the	 instructions	 of	 the	manufacturer.	
The	micro	ELISA	strip	plate	is	pre-coated	with	human	ColIV	monoclonal	antibody	to	the	7S	
domain	of	ColIV	molecule	and	the	kit	uses	biotin-streptavidin-HRP	technology	to	measure	
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the	 immune	 complex	 obtained	 during	 the	 reaction.	 Final	 colorimetric	 reaction	 is	
measured	by	photometry	at	450	nm.	 In	 this	assay	system,	 the	assay	sensitivity	of	ColIV	
was	over	0.108μg/mL;	coefficients	of	variations	of	intra-assay	and	inter-assay	were	<10%	
and	<12%,	respectively.	
A1MG	 was	 measured	 in	 urine,	 by	 a	 double-antibody	 sandwich	 ELISA	 assay	
(SunRed®	 Biotechnology	 Company),	 according	 to	 the	 instructions	 of	 the	manufacturer.	
The	micro	ELISA	strip	plate	is	pre-coated	with	human	A1MG	monoclonal	antibody	and	the	
kit	 uses	 biotin-streptavidin-HRP	 technology	 to	measure	 the	 immune	 complex	 obtained	
during	the	reaction.	Final	colorimetric	reaction	is	measured	by	photometry	at	450	nm.	In	
this	 assay	 system,	 the	 assay	 sensitivity	 of	 A1MG	was	 over	 4.118ng/mL;	 coefficients	 of	
variations	of	intra-assay	and	inter-assay	were	<10%	and	<12%,	respectively.	
NAG	was	measured	in	urine,	by	a	colorimetric	assay	(Roche®,	Diagnostics	GmBH).	3-
Cresolsulphonphthaleinyl-N-acetyl-β-D-glucosaminide,	sodium	salt,	is	hydrolyzed	by	NAG	(present	
in	the	sample),	releasing	3-resolsulfonphthalein,	sodium	salt	(3-cresol	purple),	which	is	measured	
by	photometry	at	580	nm.	In	this	assay	system,	the	limit	of	quantification	of	NAG	was	1.64	
U/L.	 The	 intra-assay	 and	 inter-assay	 precision	 of	 the	method	were	 <4.1%	 and	 <11.3%,	
respectively.	
AAP	was	measured	in	urine,	by	a	double-antibody	sandwich	ELISA	assay	(SunRed®	
Biotechnology	Company),	 according	 to	 the	 instructions	of	 the	manufacturer.	 The	micro	
ELISA	 strip	 plate	 is	 pre-coated	with	 human	 AAP	monoclonal	 antibody	 and	 the	 kit	 uses	
biotin-streptavidin-HRP	technology	to	measure	the	immune	complex	obtained	during	the	
reaction.	Final	colorimetric	reaction	is	measured	by	photometry	at	450	nm.	In	this	assay	
system,	 the	 assay	 sensitivity	 of	 AAP	was	 over	 0.204ng/mL;	 coefficients	 of	 variations	 of	
intra-assay	and	inter-assay	were	<10%	and	<12%,	respectively.	
	
6.	Statistical	analysis	
	 There	 was	 no	 formal	 sample	 size	 calculation	 in	 the	 cardiomyopathy	 and	
nephropathy	studies	due	to	various	reasons:	rarity	of	FD,	difficulty	to	match	the	patients	
with	a	rare	disease	with	the	predefined	subgroups	and	the	presence	of	several	exclusion	
criteria.	Therefore,	 I	estimated	sample	size	based	on	the	potentially	recruitable	number	
of	 patients.	 Nonetheless,	 for	 comparisons	 including	 all	 groups,	 with	 about	 20	 to	 25	
subjects	per	group,	 I	estimated	a	power	of	~90%	to	detect	differences	among	groups,	 if	
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the	within-group	 standard	deviation	 (SD)	was	 no	more	 than	 twice	 the	 SD	between	 the	
groups.	For	correlations,	using	all	 the	FD	patients	 (n	between	60	and	75),	 I	had	at	 least	
~90%	power	to	detect	even	small	correlations	(ρ2	~	0.2)	as	significant.	
	 Statistical	 analysis	 was	 performed	with	 SPSS®	 (Statistical	 Package	 for	 the	 Social	
Sciences,	 version	 24)	 software.	 Categorical	 variables	 were	 expressed	 as	 a	 number	 and	
percentage	 and	 continuous	 variables	 as	medians	 and	 interquartile	 range	 (IQR).	 Normal	
distribution	of	continuous	variables	was	tested	using	the	Shapiro-Wilk	test.	
	 For	 categorical	 variables,	 the	 Qui-square	 or	 Fisher	 exact	 tests	 were	 used	 to	
compare	the	variables’	distribution	between	the	groups.		
	 For	 continuous	 variables,	 comparison	 of	means	 /	medians	was	 performed	using	
Student	t-test	for	variables	that	followed	a	normal	distribution	and	Mann–Whitney	test	/	
related	 samples	Wilcoxon	 signed	 rank	 test	 for	 variables	 that	 did	 not.	 Related	 samples	
tests	were	only	used	for	comparison	between	age	and	sex-matched	controls	and	group	1	
and	longitudinal	measurements	for	each	patient	(these	respect	the	structure	of	the	data	
collection	and	also	have	more	power)	in	both	cardiomyopathy	and	nephropathy	studies.	
	 If	 the	qualitative	 variable	had	more	 than	2	 categories,	 an	ANOVA	 test	 (post-hoc	
analysis	with	Bonferroni	correction)	was	used	for	variables	with	normal	distribution,	and	
a	Kruskal–Wallis	test	was	used	for	those	without.	
	 Due	to	the	skewed	distribution	of	all	the	studied	biomarkers	(index	and	reference	
tests),	to	evaluate	the	correlation	between	the	biomarkers	and	the	quantitative	variables,	
Spearman’s	 correlation	 coefficient	was	 determined.	 In	 the	 case	 of	 correlation	 between	
normally	 distributed	 variables,	 Pearson’s	 correlation	 coefficient	 was	 determined.	 For	
easier	visualisation	of	correlation	in	skewed	distributions,	a	log	or	power	scale	was	used	
in	scatter	plot	graphs,	depending	on	the	direction	of	the	skewness.	
	 In	 order	 to	 construct	 a	 regression	 model	 to	 quantify	 an	 outcome	 variable	 (for	
example,	 LV	 mass),	 all	 potentially	 related	 variables	 were	 correlated,	 using	 Spearman’s	
rank	 correlation	 coefficient,	 with	 the	 outcome	 variable	 (in	 univariate	 analysis).	 The	
variables	showing	significant	correlation	(probability	value	<	0.05)	were	entered	into	the	
multivariate	 analysis.	 For	 multivariate	 analysis,	 stepwise	 regression	 combining	 both	
forward	 selection	 and	 backward	 elimination	was	 used.	 A	 cut-off	 limit	 to	 remain	 in	 the	
model	was	set	 to	an	F	statistic	probability	value	of	<	0.05.	Collinearity	diagnostics	were	
applied	to	detect	related	variables	in	the	model.		
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	 I	 also	 evaluated	 the	 diagnostic	 accuracy	 of	 the	 studied	 biomarkers	 to	 detect	
predefined	outcomes,	like	CKD	stage	≥2,	by	calculating	the	sensitivity	(S),	specificity	(Sp),	
positive	 predictive	 value	 (PPV),	 negative	 predictive	 value,	 likelihood	 ratio	 for	 a	 positive	
test	 result,	 likelihood	 ratio	 for	 a	 negative	 test	 result	 (LR-),	 diagnostic	 odds	 ratio	 (DOR),	
accuracy,	Youden’s	index	and	the	AUC	from	receiver	operating	characteristic	(ROC)	curves	
(I	 determined	 the	 confidence	 intervals	 of	 AUC	 [nonparametric	 method],	 with	 values	
between	1	[perfect	test]	and	0.5	[useless	test]).	
	 In	 the	 follow-up	 /	 prognostic	 analysis,	 I	 categorized	 the	 investigated	biomarkers	
into	 quartiles	 to	 evaluate	 relationships	 between	 levels	 of	 the	markers	 and	 the	 odds	 of	
progression,	using	contingency	tables.			
	 Given	 that	 this	 is	 a	 preliminary	 study,	 it	 is	 not	 powered	 for	 sub-group	
comparisons,	such	as	sub-analysis	by	sex	or	age	group.	Nonetheless,	I	performed	some	of	
these	 comparisons	 in	 an	 exploratory	 way,	 both	 by	 calculating	 the	 corresponding	
descriptive	 statistics	 and	 some	 inferential	 analysis	 (for	 example,	 2-way	 ANOVA	 with	
interactions).	 Analysis	 of	 covariance	 (ANCOVA)	 was	 used	 to	 explore	 the	 effect	 of	
treatment	 on	 the	 longitudinal	 variation	 of	 biomarkers,	 adjusting	 for	 clinical	meaningful	
variables	as	covariates.		
	 For	all	comparisons	and	correlations	a	probability	value	of	<	0.05	was	considered	
significant.		
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Results	
1.	Cardiomyopathy	study	
1.1	Pilot	study	
1.1.1	Population	characteristics	
As	mentioned	above,	for	the	pilot	study	10	patients	were	recruited	with	FD	and	LV	
hypertrophy	 (as	 previously	 defined)	 and	 10	 sex	 and	 age-matched	 healthy	 controls.	
Population	 characteristics	 are	 given	 in	 table	 4.	 The	median	 age	 at	 diagnosis	 of	 FD	was	
45.5	years	old,	30%	were	taking	renin-angiotensin-aldosterone	axis	inhibitors	(ACEi,	ARB	
and	aldosterone	antagonists)	and	70%	of	them	had	been	receiving	ERT	for	a	median	time	
of	8.2	years.	All	patients	in	the	FD	group	were	non-relatives	and	only	two	had	the	same	
pathogenic	mutation	(p.N215S).	
	
Table	 4:	 Cardiomyopathy	 pilot	 study:	 population	 characteristics.	 FD:	 Fabry	 disease;	 ERT:	 enzyme	
replacement	therapy;	RAAi:	renin-angiotensin-aldosterone	axis	inhibitors;	IQR:	interquartile	range.		
	 Control	group	(n=10)	
FD	group	
(n=10)	
Categorical	variables	(n	(%))	 	 	
Sex	(female)	 5	(50.0)	 5	(50.0)	
ERT	(yes)	 -	 7	(70.0)	
RAAi	(yes)	 -	 3	(30.0)	
Continuous	variable	(median	(IQR))		 	 	
Age	(years)	 57.0	(14.0)	 59.5	(14.0)	
Age	at	diagnosis	(years)	 -	 45.5	(19.0)	
Time	in	ERT	(years)	 -	 8.2	(7.9)	
	
	 As	per	inclusion	criteria,	all	patients	in	the	FD	group	presented	LV	hypertrophy,	as	
opposed	 to	 the	 control	 group.	 Therefore,	 FD	 group	 had	 a	 significantly	 higher	 LV	 wall	
thickness	and	LV	mass,	lower	systolic	and	early	diastolic	myocardial	velocities	and	higher	
estimated	left	ventricular	end-diastolic	pressure	(E/E’)	(table	5).	
	
1.1.2	Biomarkers	related	to	collagen	metabolism	
	 As	 compared	with	 PICP	 concentration	 in	 controls,	 PICP	 concentration	 in	 the	 FD	
group	was	 significantly	elevated	 (a	69%	 increase,	p=0.019);	 a	 significant	difference	 that	
remained	 even	 after	 adjustment	 for	 bone	 turnover	 (table	 6).	 The	 other	 biomarkers	 of	
collagen	type	I	and	type	III	synthesis	did	not	differ	significantly	between	healthy	controls	
and	FD	patients.	
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Table	5:	Cardiomyopathy	pilot	study:	echocardiographic	characteristics	of	the	study	population.	
Expressed	as	median	(IQR);	IVS:	diastolic	interventricular	septum	thickness;	PW:	diastolic	left	ventricular	posterior	wall	
thickness;	 LVMi:	 left	 ventricular	 mass	 index;	 S’:	 systolic	 mitral	 annular	 myocardial	 velocity;	 E’:	 early	 diastolic	 mitral	
annular	myocardial	velocity;	E/E’:	ratio	of	early	mitral	inflow	velocity	to	the	average	early	diastolic	myocardial	velocity.		
	 Control	group	 FD	group	 p	value	
dIVS	(mm)	 9.05	(1.47)	 13.95	(2.54)	 <0.001	
dLVPW	(mm)	 9.00	(1.85)	 11.96	(2.39)	 0.001	
LVMi	(g/m2.7)	 34.99	(11.30)	 66.46	(9.28)	 <0.001	
S’	septal	(cm/s)	 7.5	(3.0)	 5.0	(3.3)	 0.027	
S’	lateral	(cm/s)	 9.0	(5.5)	 6.5	(1.8)	 0.023	
E’	septal	(cm/s)	 10.1	(4.4)	 5.0	(1.8)	 <0.001	
E’	lateral	(cm/s)	 12.0	(4.6)	 7.5	(5.3)	 0.001	
E/E’	 6.21	(2.80)	 11.90	(10.97)	 0.029	
	
	 CITP,	 a	 product	 of	 collagen	 type	 I	 degradation,	 was	 non-significantly	 different	
between	both	groups,	even	after	adjustment	for	bone	turnover.	However,	a	trend	for	a	
decrease	in	enzymes	involved	in	collagen	degradation	in	the	FD	group	was	identified	(that	
was	statistically	significant	for	MMP-2).	
	
Table	 6:	 Cardiomyopathy	 pilot	 study:	 biomarkers	 related	 to	 collagen	metabolism.	 Expressed	as	
median	 (IQR);	 PICP:	 procollagen	 type	 I	 carboxy-terminal	 propeptide;	 B-AP:	 bone-specific	 alkaline	 phosphatase;	 PINP:	
procollagen	 type	 I	 amino-terminal	 propeptide;	 PIIINP:	 procollagen	 type	 III	 amino-terminal	 propeptide;	 CITP:	 collagen	
type	 I	 carboxy-terminal	 telopeptide;	 TRAP5b:	 type	 5b	 tartrate-resistant	 acid	 phosphatase;	 MMP:	 matrix	
metalloproteinase;	TIMP-1:	tissue	inhibitor	of	metalloproteinase	type	I.	
	 Control	group	 FD	group	 p	value	
Biomarkers	of	collagen	synthesis	 	 	 	
PICP	(ng/mL)	 141.8	(115.3)	 238.3	(207.9)	 0.019	
PICP:B-AP	 14.2	(5.4)	 25.2	(27.6)	 0.004	
PINP	(ng/mL)	 37.8	(42.8)	 44.5	(35.1)	 0.297	
PINP:B-AP	 3.7	(2.5)	 5.6	(3.6)	 0.016	
PIIINP	(ng/mL)	 3.3	(1.5)	 2.9	(0.9)	 0.297	
Biomarkers	of	collagen	degradation	 	 	 	
CITP	(ng/mL)	 0.18	(0.29)	 0.29	(0.36)	 0.387	
CITP:TRAP5b	 0.08	(0.09)	 0.14	(0.20)	 0.085	
MMP-1	(ng/mL)	 9.3	(2.1)	 8.5	(1.9)	 0.073	
MMP-2	(ng/mL)	 345.9	(58.1)	 277.4	(119.8)	 0.029	
MMP-3	(ng/mL)	 14.3	(1.7)	 12.8	(3.4)	 0.075	
TIMP-1	(ng/mL)	 76.3	(17.5)	 79.7	(32.0)	 0.710	
	
The	PICP	 to	CITP	 ratio	 (figure	5),	 reflecting	 the	balance	between	 collagen	 type	 I	
synthesis	and	degradation,	tended	to	be	higher	 in	the	FD	group	 in	comparison	with	the	
control	 group	 (a	 28%	 increase,	 p=0.730);	 this	 difference	 was	 of	 greater	 magnitude,	
although	non-significant,	after	adjustment	for	bone	turnover	(a	33%	increase,	p=0.254).	
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Figure	5:	Cardiomyopathy	pilot	study:	balance	between	collagen	synthesis	and	degradation	 in	
healthy	 controls	 and	 FD	 patients.	 Left	 image:	 non-adjusted	 for	 bone	 turnover;	 right	 image:	
adjusted	for	bone	turnover.	 PICP:	procollagen	type	I	carboxy-terminal	propeptide;	CITP:	collagen	type	I	carboxy-
terminal		telopeptide.	
	
Based	on	the	results	of	the	pilot	study,	I	selected	the	following	biomarkers	related	
to	collagen	metabolism	to	be	evaluated	 in	the	entire	cohort	of	recruited	patients:	PICP,	
CITP,	MMP-1	and	MMP-2.	
	
1.2	Population	characteristics		
	 From	 February	 2013	 to	 June	 2014,	 the	 planned	 60	 FD	 patients	 (20	 in	 each	
subgroup)	and	20	controls	(age	and	sex-matched	with	subgroup	1)	were	recruited	(study	
flow	diagram	in	figure	6).		
Population	characteristics	are	given	in	table	7.	In	the	60	FD	patients	group,	61.7%	
were	 female	 (significantly	 less	 females	 in	 subgroup	 3	 [patients	 with	 established	 LV	
hypertrophy]),	 with	 a	 median	 age	 of	 44.0	 years	 old,	 ranging	 from	 20	 to	 78	 years	 old	
(significantly	older,	comparing	the	most	severe	subgroup	3	with	the	less	severe	subgroup	
1	[patients	with	normal	echocardiogram]);	65.0%	of	the	patients	were	receiving	ERT	(no	
significance	 between	 subgroups;	 94.9%	 under	 agalsidase-α,	 5.1%	 under	 agalsidase-β),	
with	a	significantly	older	age	for	ERT	initiation	comparing	group	3	to	1.	The	use	of	ACEi	/	
ARB	 (48.3%	 of	 the	 entire	 cohort)	 and	 β-blockers	 was	 also	 not	 significantly	 different	
between	subgroups;	there	was	only	one	patient	within	the	entire	cohort	taking	AA.	There	
was	no	significant	difference	between	the	subgroups	 in	the	percentage	of	patients	with	
HBP,	as	well	as	in	the	NYHA	class	of	heart	failure.	As	expected,	the	severity	indexes	(MSSI	
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and	 FIPI)	were	 also	 significantly	 higher	 in	 the	most	 severe	 subgroup,	 as	well	 as	 plasma	
lyso-Gb3	 and	 NT-proBNP;	 in	 contrast,	 estimated	 GFR	 was	 significantly	 lower	 in	 the	
subgroup	3.	Plasma	α-galactosidase	A	activity	was	similar	between	FD	subgroups,	both	in	
male	and	in	female	patients.	
Figure	 6:	 Cardiomyopathy	 study:	 study	 flow	 diagram.	 PICP:	 procollagen	 type	 I	 carboxy-terminal	
propeptide;	 CITP:	 collagen	 type	 I	 carboxy-terminal	 telopeptide;	MMP:	matrix	metalloproteinase;	 TDI:	 tissue	 Doppler	
imaging;	LGE:	late	gadolinium	enhancement;	LV:	left	ventricular.	
	
	 Altogether	28	different	GLA	pathogenic	mutations	were	 identified	(table	8),	with	
p.N215S	and	p.F113L	(two	mutations	associated	with	attenuated	/	late-onset	phenotypes	
with	 predominant	 cardiac	 involvement)	 accounting	 for	 31.7%	 of	 the	 patients;	 the	
remainder	mutations	are	usually	associated	with	classical	phenotype.	
Poten&ally	eligible	par&cipants	(n=64)	
Excluded	(n=4):	
•  prosthe&c	valve	(n=1)	
•  hyperthyroidism	(n=1)	
•  bisphosphonates	(n=2)	
Eligible	par&cipants	(n=60)	
Index	tests	(n=60)	
PICP:	
•  nega&ve	(n=21)	
•  posi&ve	(n=39)	
•  inconclusive	(n=0)	
CITP:	
•  nega&ve	(n=49)	
•  posi&ve	(n=10)	
•  inconclusive	(n=1)	
MMP-1:	
•  nega&ve	(n=11)	
•  posi&ve	(n=47)	
•  inconclusive	(n=2)	
MMP-2:	
•  nega&ve	(n=18)	
•  posi&ve	(n=40)	
•  inconclusive	(n=2)	
Target	condi&on	(LV	hypertrophy):	
•  present	(n=26)	
•  absent	(n=33)	
•  inconclusive	(n=1)	
Target	condi&on	(TDI	abnormali&es):	
•  present	(n=38)	
•  absent	(n=20)	
•  inconclusive	(n=2)	
Target	condi&on	(LGE):	
•  present	(n=14)	
•  absent	(n=23)	
•  inconclusive	(n=23)	
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Table	 7:	 Cardiomyopathy	 study:	 clinical	 characteristics	 of	 the	 study	 population.	 HBP:	 arterial	
hypertension;	ERT:	enzyme	replacement	 therapy;	ACEi:	angiotensin	converting	enzyme	 inhibitors;	ARB:	angiotensin	 II	
receptor	blockers;	MSSI:	Mainz	Severity	Score	Index;	FIPI:	Fabry	International	Prognostic	Index;	α-gal:	α-galactosidase;	
NT-pro	BNP:	N-terminal	of	propeptide	of	brain	natriuretic	peptide;	eGFR:	estimated	glomerular	filtration	rate.	
	 FD	cohort	(n=60)	
FD	subgroups	
1	(n=20)	 2	(n=20)	 3	(n=20)	
Categorical	variables	(n	(%))	 	 	 	 	
Sex	(female)	Ŧ	 37	(61.7)	 14	(70.0)	 18	(90.0)	 5	(25.0)	
HBP	(yes)	 25	(41.7)	 8	(40.0)	 10	(50.0)	 7	(35.0)	
HF	class	(0	/	I	/	II)	 39	/	6	/	14	 15	/	3	/	2	 14	/	2	/	4	 10	/	2	/	8	
ERT	(yes)	 39	(65.0)	 14	(70.0)	 8	(40.0)	 17	(85.0)	
ACEi	/	ARB	(yes)	 29	(48.3)	 9	(45.0)	 10	(50.0)	 10	(50.0)	
β-blockers	(yes)	 11	(18.3)	 3	(15.0)	 3	(15.0)	 5	(25.0)	
Continuous	variables	(median	(IQR))		 	 	 	 	
Age	(years)	ζ	 44.0	(23.0)	 40.5	(21.0)	 48.5	(18.0)	 59.5	(13.0)	
Age	at	diagnosis	(years)	§	 41.5	(22.0)	 34.5	(24.0)	 44.0	(15.0)	 50.5	(35.0)	
Age	at	ERT	initiation	(years)	*	 49.0	(17.1)	 38.1	(25.4)	 52.4	(17.0)	 49.4	(19.9)	
Time	in	ERT	(years)	 6.3	(8.4)	 4.8	(8.0)	 5.9	(7.6)	 8.2	(9.1)	
MSSI	°	 18.5	(21.0)	 11.0	(11.0)	 12.5	(18.0)	 31.0	(16.0)	
FIPI	°	 2.0	(3.0)	 1.0	(2.0)	 1.0	(3.0)	 4.0	(2.0)	
Plasma	lyso-Gb3	(nmol/L)	**	 9.1	(16.6)	 3.6	(27.3)	 8.3	(9.9)	 18.8	(45.1)	
Plasma	α-gal	A	♀ (nmol/h/mL)		 4.3	(4.1)	 5.1	(2.8)	 3.5	(4.5)	 3.8	(.)	
Plasma	α-gal	A	♂	(nmol/h/mL)	 0.11	(0.3)	 0.14	(0.50)	 0.06	(.)	 0.20	(0.30)	
NT-proBNP	(ng/mL)	ζ	 142.0	(334.0)	 40.0	(122.0)	 129.5	(166.0)	 940.7	(1602)	
eGFR	(ml/min/1.73m2)	ζ	 93.0	(51.0)	 99.5	(53.0)	 101.0	(91.0)	 67.5	(51.0)	
Ŧ	p	<	0.01	for	difference	in	the	distribution	of	categorical	variable	between	subgroups.	
ζ	p	<	0.01	for	difference	between	group	1	and	3.		
§	p	<	0.05	for	difference	between	group	1	and	2.		
*	p	<	0.05	for	difference	between	group	1	and	3.		
°	p	<	0.01	for	difference	between	group	3	and	all	other	groups.	
**	p	<	0.05	for	difference	between	group	2	and	3.		
	
There	 were	 no	 significant	 echocardiographic	 differences	 between	 the	 control	
group	and	FD	subgroup	1	(table	9).	As	per	definition	of	FD	subgroups,	LV	wall	thickness	
and	mass	 were	 significantly	 higher	 in	 FD	 subgroup	 3,	 in	 contrast	 to	 TDI	 velocities	 and	
estimated	LV	end-diastolic	pressure	which	were	significantly	higher	in	FD	subgroup	1.	
	
Table	 8:	 Cardiomyopathy	 study:	mutation	 frequency.	 *	Mutations	presented	by	only	one	patient	 in	the	
study	
Mutation	 n	 %	
p.N215S	 10	 16.7	
p.F113L	 9	 15.0	
p.G35E	 7	 11.7	
c.700_702del	 2	 3.3	
p.R227X	 2	 3.3	
p.C52G	 2	 3.3	
p.L166P	 2	 3.3	
p.N42V	 2	 3.3	
p.R342Q	 2	 3.3	
unknown	 2	 3.3	
other*	 20	 33.3	
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A	 gadolinium-based	 contrast	 cardiac	MRI	 result	was	 available	 for	 37	 (61.7%)	 FD	
patients	(9,	13	and	15	patients	in	subgroups	1,	2	and	3,	respectively).	The	percentage	of	
patients	with	LGE	was	0%,	15.4%	and	80.0%	in	FD	subgroups	1,	2	and	3,	respectively.		
	
Table	 9:	 Cardiomyopathy	 study:	 echocardiographic	 characteristics	 of	 the	 study	 population.	
Expressed	as	median	(IQR);	dIVS:	diastolic	 interventricular	septal	 thickness;	dLVPW:	diastolic	 left	ventricular	posterior	
wall	thickness;	LVMi:	left	ventricular	mass	indexed	for	height;	LA:	left	atrium;	E/A:	left	ventricular	rapid	filling	(E	wave)	/	
atrial	contraction	(A	wave)	peak	velocities;	DT:	E	wave	decelerating	time;	S’:	systolic	myocardial	velocity	measured	at	
the	mitral	 annulus;	 E’:	 early	 diastolic	myocardial	 velocity	measured	 at	 the	mitral	 annulus;	 E/E’:	 left	 ventricular	 rapid	
filling	velocity	/	average	(septal	and	lateral)	early	diastolic	myocardial	velocity	measured	at	the	mitral	annulus.	
	 Controls	 FD	subgroups	1	 2	 3	
dIVS	(mm)	°	 9.0	(2.0)	 9.0	(2.0)	 9.0	(2.2)	 14.5	(4.0)	
dLVPW	(mm)	°	 9.0	(1.0)	 9.0	(3.0)	 8.9	(2.8)	 12.1	(4.5)	
LVMi	(g/m2.7)	°	 39.3	(10.9)	 35.2	(9.7)	 39.5	(19.6)	 63.3	(10.6)	
LA	area	(cm2)	°	 -	 17.0	(4.6)	 18.9	(5.6)	 23.3	(10.2)	
E/A	ratio	 -	 1.47	(0.85)	 1.25	(0.87)	 0.98	(0.95)	
DT	(ms)	*	 -	 184.0	(73.0)	 230.0	(62.0)	 249.5	(25.0)	
S’	septal	(cm/s)	Ŧ	 8.0	(2.0)	 8.0	(2.0)	 6.0	(2.0)	 6.0	(2.0)	
S’	lateral (cm/s)	Ŧ	 9.5	(5.0)	 11.0	(3.0)	 7.0	(3.0)	 6.5	(3.0)	
E’	septal	(cm/s)	ζ	 11.5	(5.0)	 11.5	(3.0)	 7.0	(4.0)	 5.0	(2.0)	
E’	lateral	(cm/s)	Ŧ	 15.5	(6.0)	 14.5	(4.0)	 9.0	(4.0)	 8.0	(4.0)	
E/E’	Ŧ	 6.3	(2.1)	 6.0	(2.3)	 9.4	(5.0)	 11.8	(6.5)	
°	p	<	0.01	for	difference	between	group	3	and	all	other	FD	groups.	
*	p	<	0.01	for	difference	between	group	1	and	3.		
Ŧ	p	<	0.01	for	difference	between	group	1	and	all	other	FD	groups.	
ζ	p	<	0.01	for	difference	between	all	FD	groups.		
	
1.3	Biomarkers	related	to	collagen	metabolism	at	baseline	
1.3.1	Concentration	in	healthy	controls	and	Fabry	disease	patients	
Collagen	type	I	synthesis	biomarker	(PICP)	was	increased	in	FD	patients	(table	10	
and	figure	7).	As	compared	with	PICP	levels	in	controls,	PICP	levels	in	FD	subgroup	1	were	
significantly	 elevated,	 a	 61%	 increase	 (p=0.006).	 Comparing	 FD	 subgroups,	 PICP	 levels	
were	significantly	higher	in	FD	subgroup	3	(p=0.001).	The	significant	results	comparing	FD	
subgroup	1	and	controls	and	FD	subgroups	remained	with	the	PICP	to	B-AP	ratio.		
Collagen	 type	 I	 degradation	 biomarker	 CITP	 and	 the	 enzymes	 involved	 in	 its	
degradation	(MMP-1	and	MMP-2)	levels	were	similar	between	the	control	group	and	FD	
subgroup	1.	The	difference	between	these	two	subgroups	attained	statistical	significance	
only	 after	 adjustment	 for	 bone	 degradation,	 with	 the	 CITP	 to	 TRAP5b	 ratio	 (p=0.011).	
Moreover,	 there	 was	 a	 significant	 trend	 of	 a	 decreased	 activity	 of	 MMP-1	 as	 severity	
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increased.	Comparison	of	CITP	between	controls	and	FD	subgroups	after	adjustment	for	
estimated	GFR	retrieved	similar	results.		
	
Table	 10:	 Biomarkers	 related	 to	 collagen	 metabolism	 in	 controls	 and	 FD	 subgroups.	 PICP:	
procollagen	 type	 I	 carboxy-terminal	 propeptide;	 B-AP:	 bone-specific	 alkaline	 phosphatase;	 CITP:	 collagen	 type	 I	
carboxy-terminal		telopeptide;	TRAP5b:	type	5b	tartrate-resistant	acid	phosphatase;	MMP:	matrix	metalloproteinase.	
	 Controls	 FD	subgroups	 p	value*	 p	valueŦ	1	 2	 3	
PICP	(ng/mL)	 107.3	(39.3)	 148.5	(129.0)	 115.7	(88.8)	 219.0	(98.4)	 0.006	 0.001	
PICP/B-AP	 10.1	(4.3)	 16.2	(10.3)	 12.7	(9.1)	 19.4	(24.1)	 0.003	 0.001	
CITP	(ng/mL)	 0.34	(0.20)	 0.25	(0.27)	 0.20	(0.19)	 0.29	(0.23)	 0.687	 0.236	
CITP/TRAP5b	 0.11	(0.07)	 0.16	(0.10)	 0.11	(0.07)	 0.13	(0.06)	 0.011	 0.186	
MMP-1	(ng/mL)	 16.8	(26.3)	 13.5	(19.3)	 14.1	(4.3)	 9.6	(4.6)	 0.159	 0.002	
MMP-2	(ng/mL)	 440.3	(541.0)	 341.8	(849.5)	 356.5	(187.0)	 318.7	(101.9)	 0.872	 0.108	
*	controls	versus	FD	disease	subgroup	1;	Ŧ	between	FD	subgroups.	
	
Figure	7:	Biomarkers	related	to	collagen	metabolism	with	significant	differences	in	controls	and	
FD	patient	 subgroups.	Upper	 left	 image:	PICP;	upper	 right	 image:	PICP	 to	B-AP	ratio;	 lower	 left	
image:	CITP	adjusted	 for	bone	 turnover;	 lower	 right	 image:	MMP-1.	 PICP:	procollagen	type	I	carboxy-
terminal	 propeptide;	 B-AP:	 bone-specific	 alkaline	 phosphatase;	 CITP:	 collagen	 type	 I	 carboxy-terminal	 telopeptide;	
TRAP5b:	type	5b	tartrate-resistant	acid	phosphatase;	MMP:	matrix	metalloproteinase.	
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	 The	 PICP	 to	 CITP	 ratio	 evaluation	 revealed	 a	 clear	 trend	 (only	 significant	 after	
adjustment	 for	 bone	 turnover	 [p=0.012])	 for	 prevalent	 collagen	 type	 I	 synthesis	 over	
degradation	within	the	subgroups	of	FD	patients	with	greater	severity	(figure	8).		
Figure	 8:	 Balance	 between	 collagen	 synthesis	 and	 degradation	 in	 healthy	 controls	 and	 FD	
patient	 subgroups.	 Left	 image:	non-adjusted	 for	bone	 turnover;	 right	 image:	 adjusted	 for	bone	
turnover.	PICP:	procollagen	type	I	carboxy-terminal	propeptide;	CITP:	collagen	type	I	carboxy-terminal	telopeptide.	
	
Correlation	between	PICP	to	CITP	ratio	and	MMP-1	reflects	the	influence	of	higher	
collagenase	activity	balancing	the	PICP	to	CITP	ratio	towards	collagen	type	I	degradation	
and	 lesser	 collagen	 type	 I	 deposition.	 Accordingly,	 we	 identified	 a	 significant	 inverse	
correlation	between	the	PICP	to	CITP	ratio	and	MMP-1	activity	before	(ρ=-0.348;	p=0.008)	
and	after	(ρ=-0.322;	p=0.015)	adjustment	for	bone	turnover	(figure	9).		
Figure	9:	Correlation	between	balance	collagen	synthesis	and	degradation	and	MMP-1	activity.	
Left	 image:	 non-adjusted	 for	 bone	 turnover;	 right	 image:	 adjusted	 for	 bone	 turnover.	 PICP:	
procollagen	type	I	carboxy-terminal	propeptide;	CITP:	collagen	type	I	carboxy-terminal	telopeptide.	
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1.3.2	Correlation	with	echocardiographic	variables	
For	the	entire	FD	cohort,	a	significant	direct	correlation	between	the	biomarker	of	
collagen	type	I	synthesis	(PICP)	and	both	LV	wall	thickness	and	mass	(table	11	and	figure	
10)	 was	 found	 (PICP	 with	 LV	 mass:	 ρ=0.378,	 p=0.003).	 This	 significant	 correlation	
remained	after	adjustment	for	bone	turnover	(PICP	to	B-AP	ratio	with	LV	mass:	ρ=0.313,	
p=0.016).	No	correlation	was	 found	between	the	biomarker	of	collagen	type	 I	 synthesis	
and	the	parameters	related	to	diastolic	function.	
	
Table	11:	Correlation	between	biomarkers	related	to	collagen	metabolism	and	cardiac	imaging	
parameters.	Mean	difference	for	categorical	variables;	ρ	for	continuous	variables;	PICP:	carboxy-terminal	propeptide	
of	procollagen	type	I;	B-AP:	bone-specific	alkaline	phosphatase;	CITP:	carboxy-terminal	telopeptide	of	type	I	collagen;	
TRAP:	 type	 5b	 tartrate-resistant	 acid	 phosphatase;	 MMP:	 matrix	 metalloproteinase;	 dIVS:	 diastolic	 interventricular	
septal	 thickness;	 dLVPW:	diastolic	 left	 ventricular	 posterior	wall	 thickness;	 LVMi:	 left	 ventricular	mass	 index;	 LA:	 left	
atrium;	DT:	E	wave	decelerating	time;	S’:	systolic	myocardial	velocity	measured	at	the	mitral	annulus;	E’:	early	diastolic	
myocardial	 velocity	measured	 at	 the	mitral	 annulus;	 E/E’:	 left	 ventricular	 rapid	 filling	 velocity	 /	 average	 (septal	 and	
lateral)	early	diastolic	myocardial	velocity	measured	at	the	mitral	annulus;	MRI:	magnetic	resonance	imaging;	LGE:	late	
gadolinium	enhancement.	
	 PICP	
(ng/mL)	 PICP:B-AP	
CITP		
(ng/mL)	 CITP:TRAP	
MMP-1	
(ng/mL)	
MMP-2	
(ng/mL)	
Echocardiogram	 	 	 	 	 	 	
dIVS	(mm)	 0.438*	 0.378*	 0.178	 -0.017	 -0.519*	 -0.300*	
dLVPW	(mm)	 0.322*	 0.234	 0.204	 0.043	 -0.438*	 -0.294*	
LVMi	(g/m2.7)	 0.378*	 0.313*	 0.197	 0.013	 -0.484*	 -0.235	
LA	area	(cm2)	 0.173	 0.066	 0.092	 0.080	 -0.129	 -0.239	
DT	(ms)	 0.103	 0.059	 -0.024	 -0.187	 -0.294*	 -0.145	
S’	septal	(cm/s)	 -0.023	 0.071	 0.020	 -0.046	 0.354*	 0.188	
S’	lateral (cm/s)	 -0.029	 -0,017	 -0.063	 0.083	 0.230	 0.127	
E’	septal	(cm/s)	 -0.125	 -0.113	 0.130	 0.139	 0.354*	 0.288	
E’	lateral	(cm/s)	 -0.037	 0.000	 0.127	 0.234	 0.280*	 0.200	
E/E’		 0.105	 0.005	 0.027	 -0.082	 -0.097	 0.087	
Cardiac	MRI	 	 	 	 	 	 	
LGE	(yes)	 88.8*	 12.5*	 0.066	 -0.024	 -5.27	 -239.3	
*	p	<	0.05		
	
For	 biomarkers	 of	 collagen	 type	 I	 degradation,	 there	 was	 a	 significant	 inverse	
correlation	 between	 the	 enzyme	MMP-1,	 involved	 in	 collagen	 type	 I	 cleavage,	 and	 LV	
thickness	and	mass	parameters	 (MMP-1	with	LV	mass:	ρ=-0.484,	p<0.001).	A	significant	
inverse	correlation	with	LV	wall	thickness,	but	not	with	LV	mass	was	found	for	MMP-2.	
Furthermore,	 a	 significant	 direct	 correlation	 was	 found	 for	 the	 MMP-1	 and	
echocardiographic	 parameters	 of	 diastolic	 dysfunction,	 namely	 early	 diastolic	 mitral	
velocities	 measured	 at	 the	 septal	 (ρ=0.354,	 p=0.016)	 and	 lateral	 (ρ=0.280,	 p=0.042)	
corners	of	the	mitral	annulus.	
	 147	
Figure	 10:	 Correlation	 various	 biomarkers	 related	 to	 collagen	 metabolism	 and	 LV	 mass.	 Left	
upper	image:	PICP;	right	upper	image:	PICP	adjusted	for	bone	turnover;	left	lower	image:	MMP-1;	
right	 lower	image:	PICP	to	CITP	ratio.	A	logarithmic	scale	was	used	for	better	visualization,	due	to	the	skewed	
distribution	of	 the	 variables;	 LVM:	 left	 ventricular	mass;	 PICP:	 procollagen	 type	 I	 carboxy-terminal	 propeptide;	B-AP:	
bone-specific	alkaline	phosphatase;	MMP:	matrix	metalloproteinase;	CITP:	collagen	type	I	carboxy-terminal	telopeptide.	
	
1.3.3	Correlation	with	late	gadolinium	enhancement		
There	was	a	clear	trend	of	higher	values	of	collagen	type	I	synthesis	and	decreased	
activity	of	the	enzymes	involved	in	collagen	type	I	cleavage	in	patients	with	LGE	in	cardiac	
MRI	 (table	 11),	 but	 the	 difference	 between	 patients	 with	 and	 without	 LGE	 was	 only	
significant	for	PICP,	even	after	adjustment	for	bone	turnover	(for	PICP	to	B-AP	ratio:	mean	
difference	12.5,	a	74%	increase	for	LGE	positive	group,	p=0.01)	(figure	11).	
After	 adjustment	 for	 bone	 turnover,	 there	was	 an	 almost	 significant	 correlation	
between	PICP	 to	CITP	 ratio	and	LV	mass	 (ρ=0.260,	p=0.051)	 (figure	10).	 Furthermore,	a	
significant	difference	between	LGE	negative	and	positive	patients	was	found	for	this	ratio	
(figure	11).		
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Figure	11	Significant	differences	in	collagen	biomarkers	between	patients	with	and	without	LGE	
in	 cardiac	MRI.	Left	 image:	PICP	to	B-AP	ratio;	right	 image:	PICP	to	CITP	ratio	adjusted	for	bone	
turnover.	 PICP:	 procollagen	 type	 I	 carboxy-terminal	 propeptide;	 B-AP:	 bone-specific	 alkaline	 phosphatase;	 CITP:	
collagen	type	I	carboxy-terminal	telopeptide;	LGE:	late	gadolinium	enhancement;	MRI:	magnetic	resonance	imaging.	
	
1.3.4	Correlation	with	other	variables	
For	 the	 rest	 of	 the	 variables	 not	 directly	 related	 to	 cardiac	 imaging	 (including	
demographic,	 diagnosis,	 severity	 and	 treatment	 related),	 a	 consistent	 and	 significant	
correlation	was	found	between	the	biomarker	of	collagen	type	I	synthesis	(PICP)	and	the	
disease	 severity	 indexes	 (MSSI	 and	 FIPI)	 as	well	 as	 plasma	 lyso-Gb3	 in	 female	 patients	
(table	12),	which	remained	after	adjustment	for	bone	turnover;	PICP	was	also	significantly	
higher	in	male	patients.	
I	 also	 identified	 a	 significant	 inverse	 correlation	 between	 MMP-1	 and	 severity	
indexes	 (MSSI	 and	 FIPI)	 or	 NT-proBNP;	 this	 biomarker	 related	 to	 collagen	 type	 I	
degradation,	also	presented	a	significant	inverse	correlation	with	age	or	age	at	diagnosis	
and	direct	correlation	with	estimated	GFR.	
In	order	to	understand	the	effect	of	each	variable	as	a	predictor	of	PICP	or	MMP-
1,	 I	 performed	 a	 multivariate	 regression	 analysis	 including	 the	 variables	 significantly	
correlated	with	each	of	these	biomarkers	(table	13).	After	adjustment	for	other	variables,	
LV	 mass	 remained	 the	 only	 variable	 significantly	 correlated	 with	 PICP.	 Multivariate	
regression	 analysis	 did	 not	 identify	 any	 variable	 significantly	 correlated	 with	 MMP-1;	
however,	LV	mass	was	the	predictor	variable	with	lowest	p	value	in	terms	of	correlation.				
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Table	12:	Influence	of	other	variables	in	biomarkers	of	collagen	type	I	turnover.	Mean	difference	for	
categorical	variables;	ρ	for	continuous	variables;	PICP:	carboxy-terminal	propeptide	of	procollagen	type	I;	B-AP:	bone-
specific	 alkaline	 phosphatase;	 CITP:	 carboxy-terminal	 telopeptide	 of	 type	 I	 collagen;	 TRAP:	 type	 5b	 tartrate-resistant	
acid	phosphatase;	MMP:	matrix	metalloproteinase;	α-gal:	α-galactosidase;	MSSI:	Mainz	Severity	Score	Index;	FIPI:	Fabry	
International	 Prognostic	 Index;	 NT-pro	 BNP:	 N-terminal	 of	 propeptide	 of	 brain	 natriuretic	 peptide;	 eGFR:	 estimated	
glomerular	 filtration	 rate;	 ERT:	 enzyme	 replacement	 therapy;	 ACEi:	 angiotensin	 converting	 enzyme	 inhibitors;	 ARB:	
angiotensin	II	receptor	blockers.	
	 PICP	(ng/mL)	 PICP:B-AP	
CITP	
(ng/mL)	 CITP:TRAP	
MMP-1	
(ng/mL)	
MMP-2	
(ng/mL)	
Demographic	 	 	 	 	 	 	
Sex	(female)	 -48.9*	 -7.5*	 -0.11*	 -0.02	 5.7	 -55.6	
Age	(years)	 0.077	 0.071	 -0.153	 -0.175	 -0.334*	 -0.277*	
Diagnosis	 	 	 	 	 	 	
Age	at	diagnosis	(years)	 -0.059	 0.009	 -0.142	 -0.100	 -0.308*	 -0.309*	
Plasma	α-gal	A	♀ (nmol/h/mL)	 -0.318	 -0.444*	 0.028	 0.029	 0.071	 -0.017	
Plasma	α-gal	A	♂	(nmol/h/mL)	 0.120	 0.145	 0.012	 0.035	 -0.121	 -0.055	
Disease	severity	 	 	 	 	 	 	
MSSI	 0.394*	 0.287*	 0.194	 0.189	 -0.392*	 -0.222	
FIPI	 0.258*	 0.141	 0.158	 0.043	 -0.374*	 -0.211	
Plasma	lyso-Gb3	♀	(nmol/L)	 0.402*	 0.463*	 0.225	 0.255	 -0.123	 0.094	
Plasma	lyso-Gb3	♂	(nmol/L)	 0.240	 0.095	 0.171	 0.308	 0.037	 0.266	
NT-pro	BNP	(ng/mL)	 0.289	 0.489*	 -0.163	 -0.084	 -0.533*	 -0.262	
eGFR	(ml/min/1.73m2)	 -0.122	 -0.081	 -0.060	 -0.059	 0.289*	 0.262*	
Treatment	 	 	 	 	 	 	
ERT	(yes)	 13.6	 3.8	 0.03	 -0.01	 -1.0	 -56.3	
Age	at	ERT	initiation	(years)	 -0.187	 -0.139	 -0.217	 -0.218	 -0.217	 -0.220	
Time	in	ERT	(years)	 0.204	 0.110	 -0.213	 -0.288	 -0.014	 0.146	
ACEi	/	ARB	(yes)	 -27.0	 -1.8	 -0.03	 -0.04	 -8.2	 -173.4	
β-blockers	(yes)	 6.3	 0.2	 -0.03	 -0.00	 4.7	 67.5	
*	p	<	0.05		
	
1.4	Association	between	predictive	variables	and	clinical	endpoints	
1.4.1	Predictors	of	left	ventricular	mass	
In	order	to	evaluate	clinical	and	laboratorial	variables	predicting	LV	mass,	variables	
with	 significant	 correlation	 with	 LV	 mass	 in	 univariate	 analysis	 were	 included	 in	 a	
multivariate	regression	model	(table	14).		
	
Table	13:	Multivariate	regression	analysis	of	predictive	variables	affecting	PICP	or	MMP-1.	PICP:	
carboxy-terminal	propeptide	of	procollagen	 type	 I;	MMP:	matrix	metalloproteinase;	 LV:	 left	 ventricular;	MSSI:	Mainz	
Severity	Score	Index;	FIPI:	Fabry	International	Prognostic	Index;	eGFR:	estimated	glomerular	filtration	rate.	
	 PICP	(multivariate)	 	 MMP-1	(multivariate)	β	 p	value	 	 β	 p	value	
LV	mass	(g/m2.7)	 0.366	 0.041	 	 -0.253	 0.209	
Sex	 -0.078	 0.576	 	 	 	
Age	(years)	 	 	 	 -0.303	 0.215	
Age	at	diagnosis	(years)	 	 	 	 0.055	 0.791	
MSSI	 0.358	 0.075	 	 -0.022	 0.983	
FIPI	 -0.214	 0.293	 	 0.119	 0.613	
eGFR	(ml/min/1.73m2)	 	 	 	 0.064	 0.720	
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In	this	model	only	two	variables	retained	statistical	significance:	PICP	to	B-AP	ratio	
and	 age,	 with	 the	 former	 expressing	 a	 better	 association	 with	 LV	 mass	 (β=0.919;	
p<0.001).	
	
Table	14:	Predictive	model	of	LV	mass	by	univariate	and	multivariate	regression	analysis.	LV:	left	
ventricular;	PICP:	 carboxy-terminal	 propeptide	 of	 procollagen	 type	 I;	 B-AP:	 bone-specific	 alkaline	 phosphatase;	CITP:	carboxy-terminal	telopeptide	of	type	I	collagen;	TRAP5b:	type	5b	tartrate	resistant	acid	phosphatase;	MMP:	matrix	 metalloproteinase;	 ERT:	 enzyme	 replacement	 therapy;	 α-gal:	 α-galactosidase;	MSSI:	Mainz	 Severity	 Score	
Index;	 FIPI:	 Fabry	 International	 Prognostic	 Index;	NT-pro	 BNP:	N-terminal	 of	 propeptide	 of	 brain	 natriuretic	 peptide;	
eGFR:	estimated	glomerular	filtration	rate.	
	 LV	mass	(univariate)	 	 LV	mass	(multivariate)	R	 p	value	 	 β	 p	value	
PICP		 0.413	 0.001	 	 0.081	 0.418	
PICP:B-AP	 0.510	 <0.001	 	 0.919	 <0.001	
CITP	 0.170	 0.202	 	 	 	
CITP:TRAP5b	 0.016	 0.906	 	 	 	
MMP-1		 -0.339	 0.010	 	 -0.066	 0.646	
MMP-2		 -0.285	 0.032	 	 0.016	 0.910	
PICP:CITP	 0.217	 0.102	 	 	 	
PICP:CITP	adjusted	 0.379	 0.004	 	 0.035	 0.751	
Age		 0.486	 <0.001	 	 0.392	 0.010	
Age	at	diagnosis		 0.274	 0.035	 	 0.066	 0.644	
Age	at	ERT	initiation		 0.310	 0.058	 	 	 	
Time	in	ERT		 0.320	 0.050	 	 -0.094	 0.288	
Plasma	α-gal	A	♀ 	 -0.027	 0.906	 	 	 	
Plasma	α-gal	A	♂		 -0.004	 0.987	 	 	 	
MSSI	 0.631	 <0.001	 	 0.041	 0.686	
FIPI	 0.658	 <0.001	 	 -0.149	 0.417	
Plasma	lyso-Gb3		 0.409	 0.009	 	 -0.012	 0.898	
NT-proBNP	 0.414	 0.040	 	 0.028	 0.759	
eGFR	 -0.388	 0.003	 	 -0.057	 0.645	
	
1.4.2	Diagnostic	accuracy	to	identify	Fabry	Disease	
I	 used	 the	 diagnostic	 accuracy	 of	 each	 biomarker	 to	 identify	 FD	 in	 order	 to	
compare	 the	 S	 of	 serum	 biomarkers	 with	 the	 one	 of	 the	 gold	 standards,	 TDI	
abnormalities,	to	identify	incipient	FD	cardiomyopathy	(table	15).	
Sp	and	positive	predictive	value	PPV	were	 influenced	by	 the	 inclusion	 criteria	 in	
the	control	group	(absence	of	TDI	abnormalities	in	echocardiogram)	and	the	definition	of	
the	 reference	 range	of	biomarkers	according	 to	 the	 control	 group,	overestimating	both	
measures	of	diagnostic	accuracy.	
Nonetheless,	the	S	and	global	diagnostic	accuracy	(measured	by	AUC	in	ROC)	were	
higher	 for	 PICP	 to	 B-AP	 ratio	 than	 for	 E’	 average	 imaging	 biomarker	 of	 incipient	 FD	
cardiomyopathy,	in	distinguishing	patients	with	FD	from	healthy	controls	(figure	12).	
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Table	 15:	 Diagnostic	 accuracy	 of	 serum	 and	 imaging	 biomarkers	 to	 identify	 Fabry	 Disease.	 S:	
sensitivity;	 Sp:	 specificity;	 PPV:	 positive	 predictive	 value;	 NPV:	 negative	 predictive	 value;	 LR+:	 likelihood	 ratio	 for	 a	
positive	test	result;	LR-:	likelihood	ratio	for	a	negative	test	result;	DOR:	diagnostic	odds	ratio;	A:	accuracy;	YI:	Youden’s	
index;	AUC:	area	under	the	curve;	CI:	confidence	interval;	LV:	left	ventricular;	S’:	systolic	myocardial	velocity	measured	
at	 the	mitral	annulus;	E’:	early	diastolic	myocardial	velocity	measured	at	 the	mitral	annulus;	PICP:	 carboxy-terminal	propeptide	of	procollagen	type	I;	B-AP:	bone-specific	alkaline	phosphatase;	CITP:	carboxy-terminal	telopeptide	of	type	I	collagen;	TRAP5b:	type	5b	tartrate-resistant	acid	phosphatase;	MMP:	matrix	metalloproteinase.	
	 S	 Sp	 PPV	 NPV	 LR+	 LR-	 DOR	 A	 YI	 AUC	(95%	CI)	
LV	mass	 0.44	 0.89	 0.93	 0.33	 4	 0.63	 6.30	 0.54	 0.33	 0.626	(0.500-0.753)	
S’	average	 0.30	 1	 1	 0.29	 NA	 0.70	 NA	 0.43	 0.30	 0.331	(0.194-0.468)	
E’	average	 0.65	 1	 1	 0.47	 NA	 0.35	 NA	 0.73	 0.65	 0.199	(0.097-0.302)	
PICP	 0.65	 0.75	 0.89	 0.42	 2.6	 0.47	 5.57	 0.68	 0.40	 0.765	(0.657-0.873)	
PICP:B-AP	 0.80	 0.75	 0.91	 0.56	 3.2	 0.27	 12	 0.79	 0.55	 0.845	(0.762-0.928)	
CITP	 0.17	 0.79	 0.71	 0.23	 0.81	 1.05	 0.77	 0.32	 -0.04	 0.407	(0.255-0.559)	
CITP:TRAP5b	 0.49	 0.79	 0.88	 0.34	 2.33	 0.65	 3.62	 0.57	 0.28	 0.652	(0.514-0.789)	
PICP:CITP	 0.58	 0.84	 0.92	 0.39	 3.63	 0.5	 7.25	 0.64	 0.42	 0.775	(0.644-0.907)	
PICP:CITP	adj	 0.38	 0.84	 0.88	 0.31	 2.38	 0.74	 3.26	 0.49	 0.22	 0.614	(0.479-0.750)	
MMP-1	 0.81	 0.5	 0.82	 0.48	 1.62	 0.38	 4.27	 0.73	 0.31	 0.298	(0.155-0.442)	
MMP-2	 0.69	 0.5	 0.80	 0.36	 1.38	 0.62	 2.22	 0.64	 0.19	 0.310	(0.186-0.434)	
	
Figure	12:	Global	diagnostic	 accuracy	 to	 identify	 Fabry	disease.	Left	 image:	PICP	to	B-AP	ratio;	
right	 image:	 E’	 average.	 PICP:	 procollagen	 type	 I	 carboxy-terminal	 propeptide;	 B-AP:	 bone-specific	 alkaline	
phosphatase;	E’:	early	diastolic	myocardial	velocity	measured	at	the	mitral	annulus.	
	
1.4.3	Diagnostic	accuracy	to	identify	tissue	Doppler	imaging	abnormalities	
Biomarkers	related	to	collagen	metabolism	did	not	present	diagnostic	accuracy	to	
identify	 S’	 abnormalities	 (as	 previously	 defined),	 a	 measure	 of	 systolic	 myocardial	
velocity,	being	useless	biomarkers,	as	expressed	by	the	AUC	of	ROC	(table	16).	However,	
decreased	MMP-1	had	a	good	S	(0.89)	and	a	DOR	of	2.1	to	detect	decreased	S’,	but	the	
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AUC	of	ROC	was	not	significantly	different	from	0.5	(useless	test).	Both	lyso-Gb3	in	female	
patients	 and	 NT-proBNP	 showed	 a	 significant	 global	 diagnostic	 accuracy	 to	 identify	 S’	
abnormalities.		
		
Table	 16:	 Diagnostic	 accuracy	 of	 blood	 and	 imaging	 biomarkers	 to	 identify	 decreased	 S’	 in	
patients	with	 FD.	 S:	sensitivity;	Sp:	specificity;	PPV:	positive	predictive	value;	NPV:	negative	predictive	value;	LR+:	
likelihood	ratio	for	a	positive	test	result;	LR-:	 likelihood	ratio	for	a	negative	test	result;	DOR:	diagnostic	odds	ratio;	A:	
accuracy;	 YI:	 Youden’s	 index;	 AUC:	 area	 under	 the	 curve;	 CI:	 confidence	 interval;	 LV:	 left	 ventricular;	 S’:	 systolic	
myocardial	 velocity	measured	 at	 the	mitral	 annulus;	 PICP:	 carboxy-terminal	 propeptide	 of	 procollagen	 type	 I;	 B-AP:	
bone-specific	 alkaline	 phosphatase;	 CITP:	 carboxy-terminal	 telopeptide	 of	 type	 I	 collagen;	 TRAP5b:	 type	 5b	 tartrate-
resistant	acid	phosphatase;	MMP:	matrix	metalloproteinase;	NT-pro	BNP:	N-terminal	of	propeptide	of	brain	natriuretic	
peptide;	eGFR:	estimated	glomerular	filtration	rate.	
	 S	 Sp	 PPV	 NPV	 LR+	 LR-	 DOR	 A	 YI	 AUC	(95%	CI)	
LV	mass	 0.82	 0.75	 0.58	 0.91	 3.28	 0.24	 14.0	 0.77	 0.57	 0.810	(0.697-0.924)	
PICP	 0.59	 0.35	 0.28	 0.67	 0.91	 1.17	 0.77	 0.42	 -0.06	 0.485	(0.322-0.648)	
PICP:B-AP	 0.82	 0.23	 0.31	 0.75	 1.06	 0.78	 1.35	 0.40	 0.05	 0.563	(0.401-0.726)	
CITP	 0.19	 0.85	 0.33	 0.72	 1.27	 0.95	 1.31	 0.66	 0.04	 0.472	(0.301-0.643)	
CITP:TRAP5b	 0.4	 0.51	 0.24	 0.69	 0.82	 1.18	 0.70	 0.48	 -0.09	 0.477	(0.299-0.654)	
PICP:CITP	 0.56	 0.4	 0.27	 0.70	 0.93	 1.1	 0.86	 0.45	 -0.04	 0.516	(0.317-0.714)	
PICP:CITP	adj	 0.4	 0.65	 0.3	 0.74	 1.14	 0.92	 1.24	 0.58	 0.05	 0.578	(0.390-0.767)	
MMP-1	 0.88	 0.23	 0.32	 0.82	 1.14	 0.52	 2.10	 0.42	 0.11	 0.346	(0.177-0.515)	
MMP-2	 0.69	 0.33	 0.30	 0.72	 1.03	 0.94	 1.1	 0.44	 0.02	 0.428	(0.257-0.599)	
Lyso-Gb3	
♀	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.770	(0.584-0.956)	
♂	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.600	(0.249-0.951)	
NT-proBNP	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.832	(0.658-1.000)	
eGFR	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.370	(0.220-0.520)	
	
Likewise,	 the	 global	 diagnostic	 accuracy	 to	 identify	 a	 decreased	 E’	 (a	 sensitive	
marker	of	diastolic	dysfunction),	was	non-significant	for	all	biomarkers	related	to	collagen	
metabolism	(table	17).	However,	both	the	marker	of	collagen	type	 I	 synthesis	 (adjusted	
for	bone	turnover)	and	MMP-1	showed	good	sensitivity	to	detect	the	decreased	E’,	but	as	
they	 seem	more	 sensitive	 to	 detect	 very	 early	 changes	 related	 to	 FD	 cardiomyopathy,	
they	exhibited	 low	 specificity.	Nonetheless,	 the	DOR	of	MMP-1	 to	detect	diminished	E’	
was	 4.67.	 In	 the	 same	 way,	 both	 lyso-Gb3	 in	 female	 patients	 and	 NT-proBNP	 showed	
significant	global	diagnostic	accuracy	to	identify	E’	abnormalities.	
	
1.4.4	Diagnostic	accuracy	to	identify	left	ventricular	hypertrophy	
Both	the	biomarker	of	collagen	type	I	synthesis	(PICP)	and	the	enzyme	MMP-1	had	
a	 significant	global	diagnostic	accuracy	 to	 identify	patients	with	LV	hypertrophy,	mainly	
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driven	 by	 a	 good	 S	 (0.85	 and	 0.92,	 respectively)	 and	 the	 applicability	 to	 rule	 out	 LV	
hypertrophy	(LR-	0.29	and	0.30,	respectively	(table	18).	
	
Table	 17:	 Diagnostic	 accuracy	 of	 blood	 and	 imaging	 biomarkers	 to	 identify	 decreased	 E’	 in	
patients	with	 FD.	 S:	sensitivity;	Sp:	specificity;	PPV:	positive	predictive	value;	NPV:	negative	predictive	value;	LR+:	
likelihood	ratio	for	a	positive	test	result;	LR-:	 likelihood	ratio	for	a	negative	test	result;	DOR:	diagnostic	odds	ratio;	A:	
accuracy;	YI:	Youden’s	index;	AUC:	area	under	the	curve;	CI:	confidence	interval;	LV:	left	ventricular;	E’:	early	diastolic	
myocardial	 velocity	measured	 at	 the	mitral	 annulus;	 PICP:	 carboxy-terminal	 propeptide	 of	 procollagen	 type	 I;	 B-AP:	
bone-specific	 alkaline	 phosphatase;	 CITP:	 carboxy-terminal	 telopeptide	 of	 type	 I	 collagen;	 TRAP5b:	 type	 5b	 tartrate-
resistant	acid	phosphatase;	MMP:	matrix	metalloproteinase;	NT-pro	BNP:	N-terminal	of	propeptide	of	brain	natriuretic	
peptide;	eGFR:	estimated	glomerular	filtration	rate.	
	 S	 Sp	 PPV	 NPV	 LR+	 LR-	 DOR	 A	 YI	 AUC	(95%	CI)	
LV	mass	 0.57	 0.89	 0.91	 0.52	 5.18	 0.48	 11.16	 0.68	 0.46	 0.772	(0.649-0.894)	
PICP	 0.65	 0.40	 0.67	 0.38	 1.08	 0.88	 1.23	 0.56	 0.05	 0.511	(0.353-0.669)	
PICP:B-AP	 0.78	 0.2	 0.64	 0.33	 0.98	 1.1	 0.91	 0.58	 -0.02	 0.504	(0.345-0.663)	
CITP	 0.14	 0.75	 0.5	 0.33	 0.56	 1.15	 0.48	 0.36	 -0.11	 0.415	(0.252-0.577)	
CITP:TRAP5b	 0.32	 0.3	 0.44	 0.21	 0.46	 2.27	 0.20	 0.31	 -0.38	 0.363	(0.204-0.522)	
PICP:CITP	 0.64	 0.5	 0.70	 0.43	 1.28	 0.72	 1.77	 0.59	 0.14	 0.606	(0.454-0-757)	
PICP:CITP	adj	 0.4	 0.7	 0.7	 0.4	 1.33	 1	 1.56	 0.51	 0.1	 0.633	(0.483-0.783)	
MMP-1	 0.89	 0.37	 0.73	 0.64	 1.41	 0.30	 4.67	 0.71	 0.26	 0.371	(0.216-0.527)	
MMP-2	 0.67	 0.32	 0.65	 0.33	 0.99	 1.03	 0.92	 0.55	 -0.01	 0.436	(0.270-0.601)	
Lyso-Gb3	
♀	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.824	(0.656-0.991)	
♂	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.300	(0.000-0.604)	
NT-proBNP	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.845	(0.679-1.000)	
eGFR	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.419	(0.257-0.581)	
	
	 Both	 lyso-Gb3	 in	 female	 patients,	 NT-proBNP	 and	 estimated	 GFR	 evinced	 a	
significant	 global	 diagnostic	 accuracy	 to	 identify	 LV	 hypertrophy.	 However,	 the	 global	
diagnostic	accuracy	of	PICP	and	MMP-1	to	identify	LV	hypertrophy	was	lower	than	that	of	
TDI	abnormalities	and	NT-proBNP	(figure	13).	
	
1.4.5	Diagnostic	accuracy	to	identify	late	gadolinium	enhancement	
The	AUC	for	LV	mass	to	identify	LGE	in	cardiac	MRI	was	larger	than	the	AUC	of	the	
biomarkers	 related	to	collagen	metabolism.	Nonetheless,	 the	global	diagnostic	accuracy	
of	 PICP	 and	 of	 the	 balance	 between	 collagen	 synthesis	 and	 degradation	 was	 also	
significant	(table	19	and	figure	14).		
The	most	 remarkable	 finding	was	 the	 100%	 S	 of	 biomarkers	 related	 to	 collagen	
type	 I	 synthesis	 (PICP	 and	 PICP	 to	 B-AP	 ratio)	 and	 MMP-1	 to	 detect	 LGE,	 with	 a	
corresponding	 LR-	 of	 0.	However,	 the	 specificity	 of	 both	biomarkers	 to	 detect	 LGE	was	
low.	
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Table	18:	Diagnostic	accuracy	of	biomarkers	to	identify	LV	hypertrophy	in	patients	with	FD.	LV:	
left	 ventricular;	 S:	 sensitivity;	 Sp:	 specificity;	 PPV:	 positive	 predictive	 value;	 NPV:	 negative	 predictive	 value;	 LR+:	
likelihood	ratio	for	a	positive	test	result;	LR-:	 likelihood	ratio	for	a	negative	test	result;	DOR:	diagnostic	odds	ratio;	A:	
accuracy;	 YI:	 Youden’s	 index;	 AUC:	 area	 under	 the	 curve;	 CI:	 confidence	 interval;	 S’:	 systolic	 myocardial	 velocity	
measured	at	the	mitral	annulus;	E’:	early	diastolic	myocardial	velocity	measured	at	the	mitral	annulus;	PICP:	carboxy-
terminal	propeptide	of	procollagen	type	I;	B-AP:	bone-specific	alkaline	phosphatase;	CITP:	carboxy-terminal	telopeptide	
of	type	I	collagen;	TRAP5b:	type	5b	tartrate-resistant	acid	phosphatase;	MMP:	matrix	metalloproteinase;	NT-pro	BNP:	
N-terminal	of	propeptide	of	brain	natriuretic	peptide;	eGFR:	estimated	glomerular	filtration	rate.	
	 S	 Sp	 PPV	 NPV	 LR+	 LR-	 DOR	 A	 YI	 AUC	(95%	CI)	
S’	average	 0.58	 0.91	 0.82	 0.75	 6.44	 0.46	 14	 0.77	 0.49	 0.157	(0.050-0.263)	
E’	average	 0.91	 0.52	 0.57	 0.89	 1.90	 0.17	 11.16	 0.68	 0.43	 0.155	(0.053-0.257)	
PICP	 0.85	 0.52	 0.58	 0.81	 1.77	 0.29	 5.84	 0.66	 0.37	 0.674	(0.537-0.810)	
PICP:B-AP	 0.88	 0.27	 0.49	 0.75	 1.21	 0.44	 2.87	 0.54	 0.15	 0.660	(0.518-0.801)	
CITP	 0.16	 0.85	 0.44	 0.57	 1.07	 0.99	 1.07	 0.55	 0.01	 0.565	(0.416-0.713)	
CITP:TRAP5b	 0.42	 0.47	 0.37	 0.52	 0.79	 1.23	 0.63	 0.45	 -0.11	 0.470	(0.317-0.623)	
PICP:CITP	 0.68	 0.48	 0.5	 0.67	 1.31	 0.67	 2	 0.57	 0.16	 0.587	(0.437-0.736)	
PICP:CITP	adj	 0.46	 0.67	 0.5	 0.63	 1.39	 0.81	 1.69	 0.58	 0.13	 0.658	(0.514-0.802)	
MMP-1	 0.92	 0.27	 0.48	 0.82	 1.26	 0.30	 4.12	 0.54	 0.19	 0.280	(0.139-0.421)	
MMP-2	 0.71	 0.33	 0.44	 0.61	 1.06	 0.88	 1.21	 0.49	 0.04	 0.436	(0.284-0.587)	
Lyso-Gb3	
♀	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.758	(0.546-0.970)	
♂	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.422	(0.116-0.729)	
NT-proBNP	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.827	(0.654-0.999)	
eGFR	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.342	(0.201-0.484)	
	
	
Figure	13:	Global	diagnostic	accuracy	 to	 identify	 LV	hypertrophy.	Left	upper	 image:	PICP;	right	
upper	 image:	 NT-proBNP;	 left	 lower	 image:	MMP-1;	 right	 lower	 image:	 E’.	 PICP:	 procollagen	 type	 I	
carboxy-terminal	 propeptide;	 NT-proBNP:	 N-terminal	 of	 propeptide	 of	 brain	 natriuretic	 peptide;	 MMP:	 matrix	
metalloproteinase;	E’:	early	diastolic	myocardial	velocity	measured	at	the	mitral	annulus.	
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Table	19:	Diagnostic	accuracy	of	blood	and	imaging	biomarkers	to	identify	LGE	in	patients	with	
FD.	 LGE:	 late	 gadolinium	 enhancement;	 S:	 sensitivity;	 Sp:	 specificity;	 PPV:	 positive	 predictive	 value;	 NPV:	 negative	
predictive	 value;	 LR+:	 likelihood	 ratio	 for	 a	 positive	 test	 result;	 LR-:	 likelihood	 ratio	 for	 a	 negative	 test	 result;	 DOR:	
diagnostic	 odds	 ratio;	 A:	 accuracy;	 YI:	 Youden’s	 index;	 AUC:	 area	 under	 the	 curve;	 CI:	 confidence	 interval;	 LV:	 left	
ventricular;	 S’:	 systolic	 myocardial	 velocity	 measured	 at	 the	 mitral	 annulus;	 E’:	 early	 diastolic	 myocardial	 velocity	
measured	at	the	mitral	annulus;	PICP:	carboxy-terminal	propeptide	of	procollagen	type	 I;	B-AP:	bone-specific	alkaline	
phosphatase;	 CITP:	 carboxy-terminal	 telopeptide	 of	 type	 I	 collagen;	 TRAP5b:	 type	 5b	 tartrate-resistant	 acid	
phosphatase;	 MMP:	 matrix	 metalloproteinase;	 NT-pro	 BNP:	 N-terminal	 of	 propeptide	 of	 brain	 natriuretic	 peptide;	
eGFR:	estimated	glomerular	filtration	rate.	
	 S	 Sp	 PPV	 NPV	 LR+	 LR-	 DOR	 A	 YI	 AUC	(95%	CI)	
LV	mass	 0.71	 0.65	 0.56	 0.79	 2.03	 0.45	 4.69	 0.68	 0.36	 0.835	(0.708-0.962)	
S’	average	 0.46	 0.74	 0.5	 0.71	 1.77	 0.73	 2.43	 0.64	 0.2	 0.268	(0.096-0.439)	
E’	average	 1	 0.39	 0.46	 1	 1.64	 0	 NA	 0.6	 0.39	 0.178	(0.039-0.317)	
PICP	 1	 0.43	 0.52	 1	 1.75	 0	 NA	 0.65	 0.43	 0.730	(0.569-0.890)	
PICP:B-AP	 1	 0.30	 0.47	 1	 1.43	 0	 NA	 0.57	 0.30	 0.752	(0.596-0.907)	
CITP	 0.23	 0.78	 0.38	 0.64	 1.05	 0.99	 1.08	 0.58	 0.01	 0.580	(0.383-0.778)	
CITP:TRAP5b	 0.38	 0.59	 0.36	 0.62	 0.93	 1.05	 0.90	 0.51	 -0.03	 0.472	(0.278-0.666)	
PICP:CITP	 0.69	 0.48	 0.43	 0.73	 1.33	 0.65	 2.06	 0.56	 0.17	 0.639	(0.454-0.824)	
PICP:CITP	adj	 0.62	 0.74	 0.57	 0.77	 2.38	 0.51	 4.53	 0.69	 0.36	 0.756	(0.594-0.918)	
MMP-1	 1	 0.18	 0.44	 1	 1.22	 0	 NA	 0.5	 0.18	 0.393	(0.205-0.580)	
MMP-2	 0.71	 0.36	 0.42	 0.67	 1.11	 0.81	 1.43	 0.5	 0.07	 0.451	(0.259-0.644)	
Lyso-Gb3	
♀	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.714	(0.288-1.000)	
♂	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.571	(0.223-0.920)	
NT-proBNP	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.742	(0.513-0.970)	
eGFR	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.266	(0.097-0.435)	
	
Figure	14:	Global	diagnostic	accuracy	to	identify	LGE.	Left	image:	PICP	to	CITP	ratio;	right	image:	
LV	 mass.	 PICP:	 procollagen	 type	 I	 carboxy-terminal	 propeptide;	 NT-proBNP:	 N-terminal	 of	 propeptide	 of	 brain	
natriuretic	 peptide;	 MMP:	 matrix	 metalloproteinase;	 E’:	 early	 diastolic	 myocardial	 velocity	 measured	 at	 the	 mitral	
annulus.		
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1.5	Biomarkers	related	to	collagen	metabolism	in	the	longitudinal	study:	
1.5.1	Compliance	and	population	characteristics	
During	the	longitudinal	follow-up	period	the	compliance	with	clinical	assessments	
was	 high	 (figure	 15),	 with	 all	 the	 recruited	 patients	 and	 55	 patients	 (91.7%)	 attending	
their	 appointments	 after	 12	 months	 and	 24	 months,	 respectively.	 In	 the	 last	 visit	 4	
patients	re-scheduled	their	visits	and	one	patient	changed	follow-up	to	another	hospital.	
Biomarkers	 were	measured	 in	 78.3%	 and	 68.3%	 of	 the	 patients,	 after	 12	 or	 24	
months,	respectively.	The	main	reason	for	no	sampling	for	biomarker	assessment	was	the	
re-scheduling	 of	 appointments;	 as	 the	 research	 team	 was	 unaware	 of	 the	 patient’s	
presence	the	samples	were	not	collected;	a	few	samples	were	also	inadvertently	wasted.				
Figure	15:	Cardiomyopathy	study:	flow	diagram	of	longitudinal	evaluation.	
	
Variables	 related	 to	 cardiomyopathy	 severity	 (heart	 failure	 functional	 class	 and	
NT-proBNP)	 remained	 essentially	 stable	 during	 the	 2	 year	 follow-up	 period	 (table	 20).	
Likewise,	severity	indexes	and	kidney	function	did	not	change	significantly	during	follow-
up,	 as	well	 as	 the	 percentage	 of	 patients	 treated	with	ACEi	 or	 ARB	 and	 β-blockers.	 Six	
patients	(10%)	started	ERT,	4	(6.7%)	patients	started	and	one	stopped	ACEi	or	ARB,	one	
patient	 started	 and	 2	 stopped	 β-blockers	 and	 one	 patients	 started	 aldosterone	
antagonists	during	the	study.		
	
baseline	
Clinical	(n=60)	
Biomarkers	(n=60)	
12	months	
Clinical	(n=60)	
Biomarkers	(n=47)	
24	months	
Clinical	(n=55)	
Biomarkers	(n=41)	
Non	evaluated	(n=5):	
•  non	aAending	(n=4)	
•  changed	hospital	(n=1)	
No	samples	(n=13):	
•  changed	appointment	(n=8)	
•  wasted	samples	(n=4)	
•  samples	condiGon		(n=1)	
No	samples	(n=19):	
•  changed	appointment	(n=9)	
•  wasted	samples	(n=5)	
•  non	aAending	(n=5)	
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Table	20:	Cardiomyopathy	study:	longitudinal	variation	of	disease	severity,	kidney	function	and	
treatment.	 MSSI:	 Mainz	 Severity	 Score	 Index;	 FIPI:	 Fabry	 International	 Prognostic	 Index;	 HF:	 heart	 failure;	 NT-
proBNP:	 amino-terminal	 fragment	 of	 the	 pro-hormone	 of	 brain	 natriuretic	 peptide;	 eGFR:	 estimated	 glomerular	
filtration	rate;	ERT:	enzyme	replacement	therapy;	ACEi:	angiotensin	converting	enzyme	 inhibitors;	ARB:	angiotensin	 II	
receptor	blockers.	
	 baseline	(n=60)	 12	months	(n=60)	 24	months	(n=55)	
p	value	
0	versus	
12	
12	versus	
24	
0	versus	
24	
Severity	(median/IQR)	 	 	 	 	 	 	
MSSI	 18.5	(21.0)	 20.5	(19.0)	 19.5	(21.0)	 0.445	 0.455	 0.622	
FIPI	 2.0	(3.0)	 2.0	(3.0)	 2.0	(2.0)	 0.871	 0.415	 0.560	
HF	class	 0.0	(1.0)	 0.0	(2.0)	 0.0	(1.0)	 0.048	 0.186	 1.000	
NT-proBNP	(ng/mL)	 142.0	(334.0)	 87.0	(222.0)	 97.0	(539)	 0.906	 0.246	 0.535	
eGFR	(ml/min/1.73m2)	 93.0	(51.0)	 92.0	(46.0)	 94.5	(53.0)	 0.005	 0.019	 0.788	
Treatment	(n/%)		 	 	 	 	 	 	
ERT	(yes)	 39	(65.0)	 43	(71.7)	 40	(72.7)	 0.125	 0.500	 0.031	
ACEi	/	ARB	(yes)	 29	(48.3)	 32	(53.3)	 30	(54.5)	 0.375	 1.000	 0.625	
β-blockers	(yes)	 11	(18.3)	 10	(16.7)	 8		(14.5)	 1.000	 1.000	 1.000	
	
Despite	a	significant	increase	in	diastolic	IVS	thickness	during	the	24	month	period	
(table	21),	diastolic	LVPW	thickness	and	LV	mass	remained	essentially	stable	during	this	
same	time.	The	remaining	variables	related	to	diastolic	function	also	remained	unchanged	
during	follow-up,	except	for	a	significant	reduction	in	the	E	wave	decelerating	time.	
Analysing	 indexed	LV	mass	and	the	E	to	E’	average	ratio	(an	estimate	of	LV	end-
diastolic	 pressure)	 by	 FD	 subgroups,	 for	 both	 variables	 there	was	no	 significant	 change	
between	baseline	and	24	months	follow-up	in	any	subgroup	of	FD	patients	(figure	16).	
	
Table	21:	Cardiomyopathy	study:	longitudinal	variation	of	echocardiographic	variables.	Expressed	
as	 median	 (IQR);	 dIVS:	 diastolic	 interventricular	 septal	 thickness;	 dLVPW:	 diastolic	 left	 ventricular	 posterior	 wall	
thickness;	 LVMi:	 left	 ventricular	mass	 indexed	 for	 height;	 LA:	 left	 atrium;	 E/A:	 left	 ventricular	 rapid	 filling	 (E	wave)	 /	
atrial	contraction	(A	wave)	peak	velocities;	DT:	E	wave	decelerating	time;	S’:	systolic	myocardial	velocity	measured	at	
the	mitral	 annulus;	 E’:	 early	 diastolic	myocardial	 velocity	measured	 at	 the	mitral	 annulus;	 E/E’:	 left	 ventricular	 rapid	
filling	velocity	/	average	(septal	and	lateral)	early	diastolic	myocardial	velocity	measured	at	the	mitral	annulus.	
	 baseline	(n=60)	 12	months	(n=51)	 24	months	(n=48)	
p	value	
0	versus	
12	
12	versus	
24	
0	versus	
24	
dIVS	(mm)		 10.1	(4.2)	 11.0	(5.3)	 12.0	(4.5)	 0.009	 0.206	 0.006	
dLVPW	(mm)		 10.0	(3.8)	 10.0	(5.0)	 10.2	(3.9)	 0.220	 0.581	 0.284	
LVMi	(g/m2.7)		 42.9	(25.5)	 52.6	(33.0)	 51.3	(28.5)	 0.110	 0.278	 0.056	
LA	area	(cm2)		 18.9	(7.3)	 20.1	(7.2)	 20.7	(6.8)	 0.861	 0.190	 0.185	
E/A	ratio	 1.29	(0.91)	 1.23	(0.85)	 1.16	(0.69)	 0.705	 0.150	 0.109	
DT	(ms)		 225.0	(68.0)	 215.5	(95.0)	 202.5	(70.0)	 0.557	 0.147	 0.001	
S’	septal	(cm/s)		 6.5	(2.0)	 7.0	(3.0)	 7.0	(2.0)	 0.383	 0.981	 0.189	
S’	lateral (cm/s)		 8.0	(4.0)	 8.0	(4.0)	 7.0	(4.0)	 0.434	 0.993	 0.583	
E’	septal	(cm/s)		 7.0	(6.0)	 8.0	(4.0)	 7.0	(5.0)	 0.897	 0.165	 0.457	
E’	lateral	(cm/s)		 10.0	(6.0)	 10.0	(5.0)	 9.0	(4.0)	 0.405	 0.720	 0.583	
E/E’		 8.80	(5.72)	 8.95	(5.24)	 9.71	(6.12)	 0.110	 0.789	 0.261	
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Figure	16:	Cardiomyopathy	study:	longitudinal	variation	of	indexed	LVM	and	E/E’	average	by	FD	
subgroups.	Left	 image:	LVM;	right	 image:	F/F’	average.	 Errors	bars:	±standard	error;	LVM:	left	ventricular	
mass;	 E/E’	 (a):	 left	 ventricular	 rapid	 filling	 velocity	 /	 average	 (septal	 and	 lateral)	 early	 diastolic	 myocardial	 velocity	
measured	at	the	mitral	annulus;	FD	Fabry	disease.	
	
According	to	the	definition	of	 indexed	LV	mass	(increase	≥10g/m2.7	in	 indexed	LV	
mass	between	baseline	and	24	months)	or	LVEDP	(increase	≥1.5	in	E	to	E’	average	ratio,	
associated	 with	 TDI	 abnormalities	 [pursuant	 to	 the	 definition	 in	 the	 methods	 section]	
upon	follow-up)	progressors,	mentioned	above	in	the	methods	section,	28.3%	and	31.1%	
of	 the	 FD	 patients	 presented	 LV	 mass	 and	 LVEDP	 progression,	 respectively	 (table	 22).	
There	was	 no	 significant	 difference	 in	 the	proportion	of	 LV	mass	 or	 LVEDP	progressors	
across	the	FD	subgroups.		
	
Table	22:	Patients	progressing	according	to	LVM	and	LVEDP	criteria	in	the	entire	FD	cohort	and	
by	 subgroups.	 LVM	 and	 LVEDP	 progressors	 were	 defined	 in	 the	 methods	 sections.	 LVM:	 left	
ventricular	mass;	LVEDP:	left	ventricular	end-diastolic	pressure;	FD:	Fabry	disease.	
	 LVM	 	 LVEDP	non	progressors	 progressors	 	 non	progressors	 progressors	
FD	cohort	 33	(71.7)	 13	(28.3)	 	 31	(68.9)	 14	(31.1)	
		Subgroup	1	 12	(80.0)	 3	(20.0)	 	 12	(85.7)	 2	(14.3)	
		Subgroup	2	 11	(68.8)	 5	(31.2)	 	 12	(70.6)	 5	(29.4)	
		Subgroup	3	 10	(66.7)	 5	(33.3)	 	 7	(50.0)	 7	(50.0)	
	
1.5.2	Variation	in	controls	and	Fabry	disease	patients	
There	was	no	 significant	 change	 in	any	biomarker	 in	 the	control	 group	between	
baseline	and	12	months,	 except	 for	 a	 significant	decrease	of	 the	biomarker	of	 collagen	
type	I	degradation,	even	after	adjustment	for	bone	turnover	(table	23).			
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Table	23:	Cardiomyopathy	study:	longitudinal	variation	of	biomarkers	in	control	group.	Expressed	
as	median	(IQR);	PICP:	procollagen	type	I	carboxy-terminal	propeptide;	B-AP:	bone-specific	alkaline	phosphatase;	CITP:	
collagen	type	I	carboxy-telopeptide;	TRAP5b:	tartrate-resistant	acid	phosphatase;	MMP:	matrix	metalloproteinase.	
	 baseline	(n=20)	 12	months	(n=20)	 p	value	
PICP	(ng/mL)	 107.3	(39.3)	 113.4	(39.1)	 0.053	
PICP/B-AP	 10.1	(4.3)	 10.5	(4.2)	 0.122	
CITP	(ng/mL)	 0.34	(0.20)	 0.14	(0.09)	 0.002	
CITP/TRAP5b	 0.11	(0.07)	 0.06	(0.02)	 0.009	
MMP-1	(ng/mL)	 16.8	(26.3)	 16.2	(38.3)	 0.744	
MMP-2	(ng/mL)	 440.3	(541.0)	 433.0	(676.3)	 0.647	
No	 significant	 change	 was	 identified	 in	 biomarkers	 concentration	 between	
baseline	and	24	months,	except	for	CITP	adjusted	for	bone	turnover,	which	significantly	
decreased	(table	24).	Also,	MMP-1	increased	significantly	at	first	follow-up,	but	returned	
to	close	to	baseline	values	after	24	months.		
Table	24:	Cardiomyopathy	study:	 longitudinal	variation	of	biomarkers	 in	the	entire	FD	cohort.	
Expressed	 as	 median	 (IQR);	 FD:	 Fabry	 disease;	 PICP:	 procollagen	 type	 I	 carboxy-terminal	 propeptide;	 B-AP:	 bone-
specific	 alkaline	phosphatase;	CITP:	 collagen	 type	 I	 carboxy-terminal	 	 telopeptide;	 TRAP5b:	 type	5b	 tartrate-resistant	
acid	phosphatase;	MMP:	matrix	metalloproteinase.	
	 baseline	(n=60)	 12	months	(n=47)	 24	months	(n=41)	
p	value	
0	versus	
12	
12	versus	
24	
0	versus	
24	
PICP	(ng/mL)	 158.1	(124.7)	 192.5	(112.2)	 182.1	(98.3)	 0.386	 0.623	 0.841	
PICP/B-AP	 17.2	(9.6)	 19.3	(14.2)	 18.6	(11.9)	 0.926	 0.369	 0.871	
CITP	(ng/mL)	 0.23	(0.20)	 0.21	(0.10)	 0.27	(0.23)	 0.332	 0.166	 0.640	
CITP/TRAP5b	 0.14	(0.10)	 0.13	(0.07)	 0.11	(0.10)	 0.502	 0.575	 0.007	
MMP-1	(ng/mL)	 12.7	(5.9)	 14.1	(0.32)	 11.4	(10.3)	 0.002	 0.175	 0.573	
MMP-2	(ng/mL)	 331.2	(149.7)	 349.8	(113.0)	 372.4	(105.1)	 0.743	 0.768	 0.627	
Even	when	analysing	all	biomarkers	by	FD	subgroups,	with	few	exceptions,	there	
was	no	significant	change	after	the	follow-up	period	 in	any	subgroup	of	patients	 (figure	
17).	 There	 was	 only	 a	 significant	 increase	 in	 PICP	 to	 B-AP	 ratio	 in	 the	 subgroup	 2	 of	
patients	with	FD	and	a	significant	decrease	in	CITP	adjusted	for	bone	turnover	in	the	less	
severe	 subgroup	 of	 FD	 patients.	 Per	 se,	 PICP	 to	 CITP	 ratio	 did	 not	 show	 a	 significant	
change	 during	 follow-up	 period	 (figure	 18);	 however,	 adjusted	 for	 bone	 turnover,	
variation	 during	 follow-up	 revealed	 a	 significant	 increase	 after	 24	 months	 due	 to	 a	
significant	increase	in	this	ratio	in	subgroups	1	and	2	of	FD	patients.			
	 160	
Figure	 17:	 Cardiomyopathy	 study:	 longitudinal	 variation	 of	 biomarkers	 by	 subgroups	 of	 FD	
patients.	 Errors	bars:	 ±standard	error;	 *	p<0.05	 for	 variation	between	baseline	and	24	months;	FD:	 Fabry	disease;	
PICP:	procollagen	type	 I	carboxy-terminal	propeptide;	B-AP:	 bone-specific	alkaline	phosphatase;	CITP:	collagen	type	 I	
carboxy-terminal		telopeptide;	TRAP5b:	type	5b	tartrate-resistant	acid	phosphatase;	MMP:	matrix	metalloproteinase.	
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Figure	 18:	 Cardiomyopathy	 study:	 longitudinal	 variation	 of	 balance	 between	 collagen	 type	 I	
synthesis	 and	 degradation	 by	 subgroups	 of	 FD	 patients.	 Left	 image:	 non-adjusted	 for	 bone	
turnover;	 right	 image:	 adjusted	 for	 bone	 turnover.	 Errors	 bars:	 ±standard	 error;	 *	 p<0.05	 for	 variation	
between	 baseline	 and	 24	 months;	 FD:	 Fabry	 disease;	 PICP:	 procollagen	 type	 I	 carboxy-terminal	 propeptide;	 CITP:	
collagen	type	I	carboxy-terminal		telopeptide.	
	
1.5.3	Baseline	biomarkers	concentration	and	risk	of	progression	
To	assess	the	effect	of	baseline	concentration	of	each	biomarker	in	the	indexed	LV	
mass	 and	 LVEDP	 progression	 status	 during	 follow-up,	 I	 divided	 the	 biomarkers	 into	
quartiles	and	compared	the	distribution	of	non-progressors	and	progressors	between	the	
quartiles.		
There	was	 no	 significant	 difference	 in	 the	 distribution	 of	 indexed	 LV	mass	 non-
progressors	 and	progressor	 between	 the	quartiles	 for	 all	 studied	biomarkers	 related	 to	
collagen	metabolism	(table	25);	however,	there	was	a	clear	trend	of	a	greater	proportion	
of	progressors	 in	the	higher	quartiles	of	PICP	(one	patient	 in	the	fourth	quartile	of	PICP	
concentration	 at	 baseline	 has	 an	 odds	 ratio	 (OR)	 of	 7.86	 [95%	 CI:	 0.75-82.13]	 to	 be	
progressor,	 in	comparison	with	a	patient	 in	the	first	quartile).	Contrariwise,	there	was	a	
clear	 trend	 of	 a	 smaller	 proportion	 of	 LV	 mass	 progressors	 in	 the	 higher	 quartiles	 of	
MMP-1	distribution	(OR	0.40	[95%	CI:	0.07-2.34]	to	be	a	progressor	comparing	the	fourth	
and	first	quartiles).	
Regarding	 LVEDP	 progression,	 I	 identified	 a	 significant	 difference	 in	 the	
distribution	 of	 non-progressors	 and	 progressors	 across	 the	 MMP-1	 quartiles,	 with	 a	
significant	protective	OR	ratio	of	0.58	(95%	CI:	0.36-0.94)	to	be	a	progressor,	comparing	
  
 
 
	 162	
patients	in	the	fourth	and	first	quartiles	of	MMP-1	distribution.	A	similar	protective	OR	of	
0.07	(95%	CI:	0.01-0.75)	was	found	for	MMP-2.				
	
Table	 25:	 Distribution	 of	 LVM	 or	 LVEDP	 progressors	 according	 to	 quartiles	 of	 the	 baseline	
concentration	of	the	biomarkers.	*	for	the	distribution	of	non-progressors	and	progressors	across	the	quartiles;	
**	of	being	a	progressor	comparing	fourth	to	first	quartile;	LVM:	indexed	left	ventricular	mass;	LVEDP:	left	ventricular	
end-diastolic	pressure;	OR:	odds	ratio;	NP:	non-progressor;	P:	progressor;	Q:	quartile;	PICP:	procollagen	type	I	carboxy-
terminal	 propeptide;	 B-AP:	 bone-specific	 alkaline	 phosphatase;	 CITP:	 collagen	 type	 I	 carboxy-terminal	 telopeptide;	
TRAP5b:	type	5b	tartrate-resistant	acid	phosphatase;	MMP:	matrix	metalloproteinase. 
	 LVM	 p	value*	 OR**	 	 LVEDP	 p	value*	 OR**	NP	(%)	 P	(%)	 	 NP	(%)	 P	(%)	
PICP	
Q1	 91.7	 8.3	
0.157	 7.86	(0.75-82.13)	
	 90.9	 9.1	
0.053	 4.29	(0.37-50.20)	
Q2	 81.8	 18.2	 	 36.4	 63.6	
Q3	 92.3	 7.7	 	 76.9	 23.1	
Q4	 58.3	 41.7	 	 70.0	 30.0	
PICP	/	
B-AP	
Q1	 90.9	 9.1	
0.657	 4.44	(0.42-47.50)	
	 77.8	 22.3	
0.494	 0.70	(0.08-6.22)	
Q2	 83.3	 16.7	 	 58.3	 41.7	
Q3	 83.3	 16.7	 	 58.3	 41.7	
Q4	 69.2	 30.8	 	 83.3	 16.7	
CITP	
Q1	 76.9	 23.1	
0.796	 1.25	(0.20-7.96)	
	 45.5	 54.5	
0.279	 0.21	(0.03-1.47)	
Q2	 83.3	 16.7	 	 66.7	 33.3	
Q3	 90.9	 9.1	 	 81.8	 18.2	
Q4	 72.7	 27.3	 	 80.0	 20.0	
CITP	/	
TRAP5b	
Q1	 84.6	 15.4	
0.175	 2.36	(0.31-17.85)	
	 53.8	 46.2	
0.518	 0.44	(0.08-2.44)	
Q2	 100.0	 0.0	 	 75.0	 25.0	
Q3	 72.7	 27.3	 	 85.7	 14.3	
Q4	 70.0	 30.0	 	 72.7	 27.3	
MMP-1	
Q1	 66.7	 33.3	
0.303	 0.40	(0.07-2.34)	
	 58.3	 41.7	
0.033	 0.58	(0.36-0.94)	
Q2	 72.7	 27.3	 	 45.5	 54.5	
Q3	 91.7	 8.3	 	 75.0	 25.0	
Q4	 92.3	 7.7	 	 100.0	 0	
MMP-2	
Q1	 75.0	 25.0	
0.795	 0.39	(0.07-2.13)	
	 41.7	 58.3	
0.095	 0.07	(0.01-0.75)	
Q2	 75.0	 25.0	 	 72.7	 27.3	
Q3	 90.0	 10.0	 	 72.7	 27.3	
Q4	 85.7	 14.3	 	 90.9	 9.1	
PICP	/	
CITP	
Q1	 90.0	 10.0	
0.886	 2.70	(0.24-30.85)	
	 81.8	 18.2	
0.574	 2.81	(0.42-18.74)	
Q2	 76.9	 23.1	 	 72.7	 27.3	
Q3	 81.8	 18.2	 	 55.6	 44.4	
Q4	 76.9	 23.1	 	 61.5	 38.5	
PICP	/	
CITP	adj	
Q1	 88.9	 11.1	
0.954	 1.78	(0.13-23.52)	
	 90.0	 10.0	
0.338	 3.86	(0.33-45.57)	
Q2	 76.9	 23.1	 	 70.0	 30.0	
Q3	 84.6	 15.4	 	 53.8	 46.2	
Q4	 81.8	 18.2	 	 70.0	 30.0	
	
Comparing	 the	 baseline	 concentration	 of	 biomarkers	 between	 indexed	 LV	mass	
progressors	and	non-progressor	(table	26),	there	was	no	significant	difference	for	any	of	
the	studied	biomarkers;	however,	there	was	a	clear	trend	of	a	higher	PICP	concentration	
(mean:	297.6	versus	188.6ng/mL)	and	a	lower	MMP-1	concentration	(mean:	15.0	versus	
20.2ng/mL).	
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Concerning	 the	 comparison	 of	 the	 baseline	 biomarker	 concentration	 between	
LVEDP	 progressors	 and	 non-progressors,	 it	 was	 significantly	 lower	 both	 for	 MMP-1	
(mean:	 10.0	 versus	 18.7ng/mL)	 and	 MMP-2	 (mean:	 302.3	 versus	 571.4ng/mL).	
Furthermore,	there	was	a	clear	trend	of	a	higher	PICP	to	CITP	ratio	in	patients	presenting	
LVEDP	progression	(mean:	1203.3	versus	802.4).	
	
Table	26:	Comparison	of	the	baseline	concentration	of	the	biomarkers	between	LVM	or	LVEDP	
non-progressors	 and	progressors.	 Expressed	as	median	(IQR);	LVM:	indexed	left	ventricular	mass;	LVEDP:	left	
ventricular	 end-diastolic	 pressure;	 NP:	 non-progressor;	 P:	 progressor;	 PICP:	 procollagen	 type	 I	 carboxy-terminal	
propeptide;	B-AP:	bone-specific	alkaline	phosphatase;	CITP:	collagen	type	I	carboxy-terminal	telopeptide;	TRAP5b:	type	
5b	tartrate-resistant	acid	phosphatase;	MMP:	matrix	metalloproteinase. 
	 LVM	 p	value	 	 LVEDP	 p	value	NP	 P	 	 NP	 P	
PICP	(ng/mL)	 151.2	(111.2)	 238.7	(217.8)	 0.077	 	 182.3	(114.3)	 149.3	(117.2)	 0.961	
PICP/B-AP	 17.0	(9.7)	 20.0	(28.7)	 0.114	 	 17.6	(10.7)	 16.2	(5.3)	 0.462	
CITP	(ng/mL)	 0.21	(0.20)	 0.21	(0.34)	 0.623	 	 0.24	(0.21)	 0.18	(0.18)	 0.094	
CITP/TRAP5b	 0.12	(0.10)	 0.16	(0.21)	 0.130	 	 0.14	(0.11)	 0.10	(0.15)	 0.167	
MMP-1	(ng/mL)	 13.5	(6.6)	 9.9	(4.0)	 0.134	 	 13.5	(6.6)	 10.6	(4.2)	 0.026	
MMP-2	(ng/mL)	 333.5	(214.4)	 325.8	(163.4)	 0.603	 	 345.0	(198.4)	 285.6	(109.9)	 0.023	
PICP/CITP	 743.0	(671.0)	 817.4	(965.2)	 0.464	 	 624.4	(744.3)	 894.0	(780.0)	 0.066	
PICP/CITP	adjusted	 132.6	(125.9)	 114.2	(231.5)	 0.943	 	 123.5	(141.7)	 144.0	(133.3)	 0.300	
	
1.5.4	Correlation	between	variations	of	biomarkers	and	left	ventricular	mass		
Indexed	 LV	mass	 variation	 significantly	 correlated	 with	 PICP	 variation	 (ρ=0.492;	
p=0.001),	 even	 after	 adjustment	 for	 bone	 turnover	 (table	 27).	 The	 variation	 of	 the	
remaining	biomarkers	did	not	correlate	significantly	with	LV	mass,	but	there	was	a	clear	
trend	of	an	inverse	correlation	between	CITP	variation	adjusted	for	bone	turnover	and	LV	
mass	 variation	 (ρ=-0.314;	 p=0.066)	 (figure	 19).	 There	 was	 no	 significant	 correlations	
between	the	variation	of	biomarkers	and	the	variation	of	LVEDP.	
	
Table	 27:	 Correlation	 between	 the	 variation	 of	 the	 biomarkers	 and	 LVM	 or	 LVEDP	 variation.	
LVM:	indexed	left	ventricular	mass;	LVEDP:	left	ventricular	end-diastolic	pressure;	Δ:	variation;	PICP:	procollagen	type	I	
carboxy-terminal	 propeptide;	 B-AP:	 bone-specific	 alkaline	 phosphatase;	 CITP:	 collagen	 type	 I	 carboxy-terminal	
telopeptide;	TRAP5b:	type	5b	tartrate-resistant	acid	phosphatase;	MMP:	matrix	metalloproteinase. 
	 LVM	variation	 	 LVEDP	variation	ρ	 p	value	 	 ρ	 p	value	
Δ	PICP	 0.492	 0.001	 	 0.163	 0.328	
Δ	PICP/B-AP	 0.341	 0.036	 	 0.171	 0.335	
Δ	CITP	 -0.081	 0.637	 	 0.216	 0.234	
Δ	CITP/TRAP5b	 -0.314	 0.066	 	 0.164	 0.378	
Δ	MMP-1	 0.266	 0.112	 	 -0.063	 0.728	
Δ	MMP-2	 -0.185	 0.273	 	 -0.068	 0.709	
Δ	PICP/CITP	 0.300	 0.076	 	 -0.115	 0.530	
Δ	PICP/CITP	adjusted	 0.178	 0.307	 	 -0.336	 0.065	
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Figure	 19:	 Correlation	 between	 LVM	 variation	 and	 PICP	 (left	 image)	 or	 CITP/TRAP5b	 (right	
image)	 variation.	 LVM:	 indexed	 left	ventricular	mass;	PICP:	procollagen	type	I	carboxy-terminal	propeptide;	CITP:	
collagen	type	I	carboxy-terminal	telopeptide;	TRAP5b:	type	5b	tartrate-resistant	acid	phosphatase.	
	
1.5.5	Longitudinal	variation	and	risk	of	progression		
Comparing	 LV	mass	 or	 LVEDP	 non-progressors	 and	 progressors,	 the	 variation	 of	
the	biomarkers	during	the	follow-up	was	only	significantly	higher	in	progressors	for	PICP	
concentration	 (even	 after	 adjustment	 for	 bone	 turnover),	 but	 only	 for	 LV	 mass	
progressors	 (table	 28).	Nonetheless,	 there	was	 also	 a	 clear	 trend	of	 significantly	 higher	
PICP	concentration	in	LVEDP	progressors	(mean	difference	between	progressors	and	non-
progressors:	34.08ng/mL;	p=0.071).		
	
Table	28:	Comparison	of	the	variation	in	the	concentration	of	the	biomarkers	between	LVM	or	
LVEDP	 non-progressors	 and	 progressors.	 Expressed	 as	 median	 (IQR);	 LVM:	 indexed	 left	 ventricular	 mass;	
LVEDP:	left	ventricular	end-diastolic	pressure;	NP:	non-progressor;	P:	progressor;	Δ:	variation;	PICP:	procollagen	type	I	
carboxy-terminal	 propeptide;	 B-AP:	 bone-specific	 alkaline	 phosphatase;	 CITP:	 collagen	 type	 I	 carboxy-terminal	
telopeptide;	TRAP5b:	type	5b	tartrate-resistant	acid	phosphatase;	MMP:	matrix	metalloproteinase. 
	 LVM	 p	value	 	 LVEDP	 p	value	NP	 P	 	 NP	 P	
Δ	PICP	(ng/mL)	 -7.6	(60.9)	 20.6	(95.6)	 0.001	 	 -11.2	(49.5)	 19.9	(95.4)	 0.071	
Δ	PICP/B-AP	 -1.76	(6.70)	 7.53	(14.14)	 0.018	 	 -1.49	(9.74)	 2.65	(8.08)	 0.204	
Δ	CITP	(ng/mL)	 -0.00	(0.17)	 -0.02	(0.17)	 0.727	 	 -0.04	(0.22)	 0.05	(0.08)	 0.106	
Δ	CITP/TRAP5b	 -0.00	(0.09)	 -0.07	(0.15)	 0.187	 	 -0.04	(0.17)	 0.01	(0.13)	 0.486	
Δ	MMP-1	(ng/mL)	 -1.28	(7.22)	 1.20	(2.64)	 0.104	 	 -0.08	(5.76)	 -0.66	(5.83)	 0.875	
Δ	MMP-2	(ng/mL)	 32.0	(215.0)	 -26.0	(138.8)	 0.194	 	 20.8	(219.4)	 34.8	(91.3)	 0.433	
Δ	PICP/CITP	 -144.6	(455.9)	 143.0	(339.0)	 0.403	 	 49.3	(487.5)	 -82.1	(509.5)	 0.912	
Δ	PICP/CITP	adjusted	 34.8	(92.3)	 50.7	(167.1)	 0.970	 	 68.5	(113.1)	 14.1	(79.8)	 0.056	
	
There	 was	 a	 significant	 difference	 in	 the	 distribution	 of	 indexed	 LV	 mass	 non-
progressors	 and	 progressors	 between	 the	 quartiles	 of	 PICP	 (even	 after	 adjustment	 for	
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bone	 turnover)	 (table	 29).	 Likewise,	 there	 was	 a	 significant	 higher	 proportion	 of	
progressors	in	the	higher	quartile	of	variation	of	PICP	concentration,	in	comparison	with	
the	first	quartile:	OR	25.00	(95%	CI:	1.80-346.69).	
The	distribution	of	 the	 variation	of	 all	 studied	biomarkers,	 between	 LVEDP	non-
progressors	and	progressors,	was	non-statistically	significant.		
	
Table	29:	Distribution	of	LVM	or	LVEDP	progressors	according	to	quartiles	of	the	variation	in	the	
concentration	of	the	biomarkers.	*	for	the	distribution	of	non-progressors	and	progressors	across	the	quartiles;	
**	of	being	a	progressor	comparing	fourth	to	first	quartile;	LVM:	indexed	left	ventricular	mass;	LVEDP:	left	ventricular	
end-diastolic	pressure;	OR:	odds	 ratio;	NP:	non-progressor;	 P:	 progressor;	Δ:	 variation;	Q:	quartile;	 PICP:	procollagen	
type	 I	 carboxy-terminal	propeptide;	B-AP:	 bone-specific	 alkaline	phosphatase;	CITP:	 collagen	 type	 I	 carboxy-terminal	
telopeptide;	TRAP5b:	type	5b	tartrate-resistant	acid	phosphatase;	MMP:	matrix	metalloproteinase. 
	 LVM	 p	value*	 OR**	 	 LVEDP	 p	value*	 OR**	NP	(%)	 P	(%)	 	 NP	(%)	 P	(%)	
Δ	PICP	
Q1	 90.9	 9.1	
0.008	 25.00	(1.80-346.69)	
	 77.8	 22.2	
0.147	 3.50	(0.43-28.45)	
Q2	 91.7	 8.3	 	 91.7	 8.3	
Q3	 58.3	 41.7	 	 55.6	 44.4	
Q4	 28.6	 71.4	 	 50.0	 50.0	
Δ	PICP	/	
B-AP	
Q1	 77.8	 22.2	
0.011	 8.17		(1.03-64.94)	
	 100.0	 0.0	
0.264	 1.60	(0.94-2.74)	
Q2	 91.7	 8.3	 	 66.7	 33.3	
Q3	 85.7	 14.3	 	 50.0	 50.0	
Q4	 30.0	 70.0	 	 62.5	 37.5	
Δ	CITP	
Q1	 66.7	 33.3	
1.000	 0.57		(0.07-4.64)	
	 100.0	 0.0	
0.037	 1.33		(0.89-1.99)	
Q2	 75.0	 25.0	 	 75.0	 25.0	
Q3	 70.0	 30.0	 	 33.3	 66.7	
Q4	 77.8	 22.2	 	 75.0	 25.0	
Δ	CITP	/	
TRAP5b	
Q1	 66.7	 33.3	
0.101	 0.57		(0.07-4.64)	
	 77.8	 22.2	
0.747	 1.17	(0.12-10.99)	
Q2	 50.0	 50.0	 	 80.0	 20.0	
Q3	 100.0	 0.0	 	 55.6	 44.4	
Q4	 77.8	 22.2	 	 75.0	 25.0	
Δ	MMP-1	
Q1	 88.9	 11.1	
0.362	 4.80	(0.39-59.90)	
	 85.7	 14.3	
0.591	 2.40		(0.17-34.93)	
Q2	 81.8	 18.2	 	 54.5	 45.5	
Q3	 55.6	 44.4	 	 75.0	 25.0	
Q4	 62.5	 37.5	 	 71.4	 28.6	
Δ	MMP-2	
Q1	 70.0	 30.0	
0.236	 0.39	(0.03-4.80)	
	 88.9	 11.1	
0.541	 3.20	(0.23-45.19)	
Q2	 50.0	 50.0	 	 57.1	 42.9	
Q3	 90.0	 10.0	 	 60.0	 40.0	
Q4	 85.7	 14.3	 	 71.4	 28.6	
Δ	PICP	/	
CITP	
Q1	 90.0	 10.0	
0.419	 3.00	(0.22-40.93)	
	 62.5	 37.5	
0.914	 0.48	(0.06-3.99)	
Q2	 66.7	 33.3	 	 62.5	 37.5	
Q3	 55.6	 44.4	 	 71.4	 28.6	
Q4	 75.0	 25.0	 	 77.8	 22.2	
Δ	PICP	/	
CITP	adj	
Q1	 66.7	 33.3	
0.740	 0.80	(0.09-6.85)	
	 71.4	 28.6	
0.072	 0.71	(0.45-1.14)	
Q2	 88.9	 11.1	 	 37.5	 62.5	
Q3	 70.0	 30.0	 	 77.8	 22.2	
Q4	 71.4	 28.6	 	 100.0	 0.0	
	
Comparing	 the	 indexed	 LV	 mass	 change	 according	 to	 variation	 quartiles,	 PICP	
showed	a	progressive	positive	variation	of	LV	mass	across	the	 increasing	quartiles	of	 its	
distribution	 (p=0.034	 for	 interquartile	 difference)	 (figure	 20).	Moreover,	 PICP	 variation	
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increased	 progressively	 between	 non-progressing	 patients,	 patients	 with	 only	 LVEDP	
progression,	patients	with	only	LV	mass	progression	and	patients	presenting	LVEDP	and	
LV	mass	progression	(p=0.01).	
Figure	20:	Longitudinal	variation	of	LVM	according	to	PICP	variation	quartiles	 (left	 image)	and	
comparison	 of	 PICP	 concentration	 variation	 (right	 image)	 between	 subgroups	 of	 progression.	
Right	 image	 -	 from	 left	 to	 right:	non-progressors,	only	 LVEDP	progressor	patients,	only	 LV	mass	
progressor	 patients	 and	 patients	 presenting	 LVEDP	 and	 LV	 mass	 progression.	 LVM:	 indexed	 left	
ventricular	mass;	LVEDP:	left	ventricular	end-diastolic	pressure;	PICP:	procollagen	type	I	carboxy-terminal	propeptide.	
	
Only	 the	 higher	 quartile	 of	 variation	 of	 PICP	was	 associated	with	 a	 significantly	
higher	 risk	of	an	 individual	patient	being	a	progressor	of	LV	mass	and/or	LVEDP:	 fourth	
quartile	of	PICP	variation	(adjusted	for	bone	turnover)	gives	an	OR	of	14.00	(95%	CI:	1.54-
127.23)	to	be	a	progressor,	in	comparison	with	the	first	quartile	(table	30).		
	
Table	30:	Distribution	of	progressors	 (LV	mass	and/or	LVEDP)	and	non-progressors	 in	 the	 first	
and	 fourth	 quartiles	 of	 biomarkers	 variation.	 *	 for	 the	 distribution	 of	 non-progressors	 and	 progressors	
between	 quartiles	 1	 and	 4;	 **	 of	 being	 a	 progressor	 comparing	 fourth	 to	 first	 quartile;	 OR:	 odds	 ratio;	 NP:	 non-
progressor;	P:	progressor;	Q:	quartile;	Δ:	variation;	PICP:	procollagen	type	I	carboxy-terminal	propeptide;	B-AP:	 bone-
specific	 alkaline	 phosphatase;	 CITP:	 collagen	 type	 I	 carboxy-terminal	 telopeptide;	 TRAP5b:	 type	 5b	 tartrate-resistant	
acid	phosphatase;	MMP:	matrix	metalloproteinase. 
	 Q1	 	 Q4	 p	value*	 OR**	NP	(%)	 P	(%)	 	 NP	(%)	 P	(%)	
Δ	PICP	 72.7	 27.3	 	 22.2	 77.8	 0.070	 9.33	(1.19-72.99)	
Δ	PICP/B-AP	 77.8	 22.2	 	 20.0	 80.0	 0.023	 14.00	(1.54-127.23)	
Δ	CITP	 66.7	 33.3	 	 66.7	 33.3	 1.000	 1.00	(0.14-7.10)	
Δ	CITP/TRAP5b	 55.6	 44.4	 	 55.6	 44.4	 1.000	 1.00	(0.16-16.42)	
Δ	MMP-1	 77.8	 22.2	 	 50.0	 50.0	 0.335	 3.50	(0.43-28.45)	
Δ	MMP-2	 60.0	 40.0	 	 62.5	 37.5	 1.000	 0.90	(0.13-6.08)	
Δ	PICP/CITP	 60.0	 40.0	 	 55.6	 44.4	 1.000	 1.20	(0.19-7.44)	
Δ	PICP/CITP	adjusted	 44.4	 55.6	 	 71.4	 28.6	 0.358	 0.32	(0.04-2.62)	
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1.5.6	Longitudinal	variation:	influence	of	gender	and	treatment		
Gender	 was	 not	 a	 significant	 risk	 factor	 to	 be	 an	 indexed	 LV	 mass	 or	 a	 LVEDP	
progressor	(table	31).	
	
Table	 31:	 Progressing	 and	 non-progressing	 Fabry	 disease	 patients:	 analysis	 by	 gender.	 LVM:	
indexed	 left	ventricular	mass;	LVEDP:	 left	ventricular	end-diastolic	pressure;	NP:	non-progressors;	P:	progressors;	OR:	
odds	ratio.	
	 LVM	 	 LVEDP	NP	(%)	 P	(%)	 OR	 	 NP	(%)	 P	(%)	 OR	
Females	 67.9	 32.1	 0.60	
(0.15-2.36)	
	 63.0	 37.0	 0.49	
(0.13-1.89)	Males	 77.8	 22.2	 	 77.8	 22.2	
	
However,	this	exploratory	analysis	by	gender	was	hampered	by	the	small	sample	
of	 patients	 classified	 as	 progressors.	 However,	 in	 males	 the	 difference	 in	 baseline	
concentration	 of	 PICP	 to	 B-AP	 ratio	 and	 PICP	 to	 CITP	 ratio	 adjusted	 for	 bone	 turnover,	
between	indexed	LV	mass	non-progressors	and	progressors	has	became	significant	(table	
32).	 I	also	noticed	a	significant	difference	 in	PICP	concentration	at	baseline	between	LV	
mass	 non-progressors	 and	 progressors	 in	 females.	 The	 significant	 difference	 baseline	
MMP-1	 and	 MMP-2	 concentrations	 at	 baseline	 between	 LVEDP	 non-progressors	 and	
progressors	only	remained	significant	for	female	patients	and	solely	for	MMP-1.	
	
Table	32:	Comparison	of	the	baseline	concentration	of	the	biomarkers	between	LVM	or	LVEDP	
non-progressors	and	progressors:	stratification	by	gender.	Expressed	as	median	(IQR);	LVM:	indexed	left	
ventricular	mass;	 LVEDP:	 left	 ventricular	 end-diastolic	 pressure;	NP:	 non-progressor;	 P:	 progressor;	 PICP:	 procollagen	
type	 I	 carboxy-terminal	propeptide;	B-AP:	 bone-specific	 alkaline	phosphatase;	CITP:	 collagen	 type	 I	 carboxy-terminal	
telopeptide;	TRAP5b:	type	5b	tartrate-resistant	acid	phosphatase;	MMP:	matrix	metalloproteinase.	
	 LVM	 	 LVEDP	NP	 P	 p	value	 	 NP	 P	 p	value	
PICP	(ng/mL)	 ♀	 124.6	(94.2)	 238.7	(340.0)	 0.033	 	 111.5	(102.7)	 146.0	(133.2)	 0.315	
♂	 210.5	(107.5)	 225.0	(.)	 0.673	 	 211.0	(104.9)	 193.0	(123.4)	 0.671	
PICP/B-AP	 ♀	 13.7	(10.1)	 18.5	(28.5)	 0.148	 	 15.8	(9.6)	 16.3	(13.3)	 0.725	
♂	 18.4	(10.1)	 47.0	(.)	 0.049	 	 22.3	(10.7)	 15.9	(3.5)	 0.111	
CITP	(ng/mL)	 ♀	
0.18	(0.17)	 0.21	(0.44)	 0.211	 	 0.21	(0.15)	 0.12	(0.14)	 0.126	
♂	 0.29	(0.24)	 0.26	(.)	 0.412	 	 0.29	(0.23)	 0.25	(0.35)	 0.903	
CITP/TRAP5b	 ♀	 0.10	(0.10)	 0.23	(0.21)	
0.018	 	 0.13	(0.11)	 0.08	(0.19)	 0.225	
♂	 0.14	(0.14)	 0.11	(.)	 0.456	 	 0.14	(0.14)	 0.12	(0.12)	 0.428	
MMP-1	(ng/mL)	 ♀	 13.6	(9.6)	 10.3	(4.4)	 0.178	 	 14.1	(6.9)	 10.0	(4.4)	 0.010	
♂	 12.4	(7.0)	 9.0	(.)	 0.399	 	 11.8	(9.2)	 11.7	(4.2)	 0.750	
MMP-2	(ng/mL)	 ♀ 348.6	(198.4)	 329.0	(214.3)	 0.864	 	 356.5	(190.1)	 316.6	(115.9)	 0.108	
♂ 328.1	(357.4)	 275.7	(.)	 0.399	 	 333.2	(480.5)	 256.4	(146.3)	 0.111	
PICP/CITP	 ♀ 820.4	(681.3)	 817.4	(1071.8)	 0.980	 	 599.2	(726.1)	 1187.5	(958.9)	 0.018	
♂ 636.3	(292.2)	 1063.5	(.)	 0.371	 	 636.3	(852.7)	 701.8	(381.3)	 0.821	
PICP/CITP	adj	
♀	 133.2	(157.4)	 90.2	(58.5)	 0.162	 	 119.5	(78.4)	 178.0	(223.0)	 0.071	
♂	 132.1	(131.1)	 445.1	(.)	 0.037	 	 150.6	(184.5)	 138.1	(60.4)	 0.571	
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The	significant	difference	in	longitudinal	variation	of	PICP	concentration	between	
LVM	non-progressors	and	progressors	remained	significant	in	the	sub-analysis	by	gender	
in	both	females	and	males	(table	33).	The	variation	of	all	other	biomarkers,	in	sub-analysis	
by	gender,	was	no	different	between	non-progressors	and	progressors.	
		
Table	33:	Comparison	of	the	variation	in	the	concentration	of	the	biomarkers	between	LVM	or	
LVEDP	 non-progressors	 and	 progressors:	 stratification	 by	 gender.	 Expressed	 as	median	 (IQR);	 LVM:	
indexed	 left	 ventricular	 mass;	 LVEDP:	 left	 ventricular	 end-diastolic	 pressure;	 NP:	 non-progressor;	 P:	 progressor;	 Δ:	
variation;	 PICP:	 procollagen	 type	 I	 carboxy-terminal	 propeptide;	 B-AP:	 bone-specific	 alkaline	 phosphatase;	 CITP:	
collagen	 type	 I	 carboxy-terminal	 telopeptide;	 TRAP5b:	 type	 5b	 tartrate-resistant	 acid	 phosphatase;	 MMP:	 matrix	
metalloproteinase.	
	 LVM	 	 LVEDP	NP	 P	 p	value	 	 NP	 P	 p	value	
Δ	PICP	(ng/mL)	 ♀	 -14.5	(87.2)	 24.3	(78.0)	 0.031	 	 -9.7	(58.6)	 20.6	(106.6)	 0.115	
♂	 -11.4	(68.8)	 35.5	(72.2)	 0.007	 	 -11.2	(80.31)	 -3.2	(.)	 0.734	
Δ	PICP/B-AP	 ♀	 -1.8	(4.2)	 6.7	(12.6)	 0.048	 	 -0.8	(9.8)	 -0.4	(8.0)	 0.614	
♂	 -2.1	(11.3)	 9.5	(.)	 0.310	 	 -2.8	(12.0)	 5.1	(.)	 0.157	
Δ	CITP	(ng/mL)	 ♀	 0.00	(0.18)	 0.04	(0.17)	
0.682	 	 -0.03	(0.22)	 0.03	(0.17)	 0.586	
♂	 -0.01	(0.26)	 -0.08	(.)	 0.918	 	 -0.09	(0.25)	 0.06	(.)	 0.117	
Δ	CITP/TRAP5b	 ♀	 -0.03	(0.11)	 -0.09	(0.12)	
0.263	 	 -0.04	(0.18)	 0.00	(0.15)	 0.823	
♂	 0.02	(0.12)	 -0.06	(.)	 0.224	 	 -0.03	(0.16)	 0.08	(.)	 0.037	
Δ	MMP-1	(ng/mL)	♀	 -2.03	(8.03)	 1.58	(6.00)	 0.061	 	 0.89	(7.58)	 -0.76	(4.76)	 0.633	
♂	 -0.62	(6.71)	 1.20	(.)	 0.612	 	 -1.16	(5.96)	 0.77	(.)	 0.814	
Δ	MMP-2	(ng/mL)	♀ 22.2	(177.8)	 -26.3	(123.2)	 0.172	 	 18.4	(178.8)	 25.9	(96.0)	 0.838	
♂ 54.9	(476.6)	 19.9	(.)	 0.735	 	 20.8	(898.3)	 72.9	(.)	 0.346	
Δ	PICP/CITP	 ♀ -192.0	(543.9)	 139.8	(301.1)	 0.092	 	 -109.9	(487.5)	 -82.1	(821.8)	 0.849	
♂ -37.8	(388.0)	 231.8	(.)	 0.495	 	 151.1	(613.7)	 -100.4	(.)	 0.296	
Δ	PICP/CITP	adj	
♀	 48.7	(59.1)	 58.4	(107.6)	 0.944	 	 78.5	(86.2)	 34.1	(177.7)	 0.052	
♂	 0.2	(105.3)	 -48.3	(.)	 0.644	 	 39.2	(179.1)	 -5.4	(.)	 0.602	
	
This	study	was	not	designed	to	access	the	effect	of	ERT	or	anti-proteinuric	agents	
(ACEi	or	ARB)	on	the	biomarkers.	However,	this	issue	was	approached	as	an	exploratory	
endpoint.	 All	 comparative	 analysis	 has	 been	 adjusted	 for	 indexed	 LV	 mass	 variation	
during	follow-up.		
After	 adjustment,	 all	 biomarkers	 related	 to	 collagen	 type	 I	 synthesis	 showed	 a	
trend	for	a	decrease	in	patients	under	ERT,	a	difference	that	was	significant	for	PICP	after	
adjustment	 for	 bone	 turnover,	which	 increased	 in	 untreated	patients	 and	decreased	 in	
those	treated	(table	34).	The	biomarkers	related	to	collagen	type	 I	degradation	and	the	
enzymes	 involved	 in	 its	degradation	presented	a	non-significant	 trend	of	 increase	/	 less	
evident	decrease	in	treated	patients.	The	effect	of	ACEi	/	ARB	treatment	on	the	variation	
of	 the	 biomarkers	 concentration	 was	 less	 evident,	 without	 any	 consistent	 variation	 in	
treated	patients.		
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Table	 34:	 Cardiomyopathy	 study:	 comparison	 of	 the	 variation	 in	 the	 concentration	 of	 the	
biomarkers	 between	patients	 under	 or	 not	 under	 ERT	or	ACEi	 /	ARB.	 Expressed	as	mean	(standard	
error);	ERT:	enzyme	replacement	 therapy;	ACEi:	angiotensin	converting	enzyme	 inhibitors;	ARB:	angiotensin	 receptor	
blockers;	Δ:	variation;	PICP:	procollagen	type	I	carboxy-terminal	propeptide;	B-AP:	 bone-specific	alkaline	phosphatase;	
CITP:	collagen	type	I	carboxy-terminal	telopeptide;	TRAP5b:	type	5b	tartrate-resistant	acid	phosphatase;	MMP:	matrix	
metalloproteinase. 
	 ERT	 p	value	 	 ACEi	/	ARB	 p	value	No	 Yes	 	 No	 Yes	
Δ	PICP	(ng/mL)	 -1.8	(22.7)	 -32.2	(18.7)	 0.308	 	 -18.2	(20.4)	 -21.8	(21.4)	 0.904	
Δ	PICP/B-AP	 3.43	(2.53)	 -3.82	(2.15)	 0.036	 	 -0.03	(2.42)	 -1.60	(2.56)	 0.663	
Δ	CITP	(ng/mL)	 -0.01	(0.04)	 -0.00	(0.03)	 0.950	 	 -0.00	(0.03)	 -0.00	(0.04)	 0.986	
Δ	CITP/TRAP5b	 -0.07	(0.02)	 -0.03	(0.02)	 0.295	 	 -0.07	(0.02)	 -0.02	(0.02)	 0.131	
Δ	MMP-1	(ng/mL)	 -1.8	(13.4)	 16.4	(12.0)	 0.318	 	 16.5	(12.1)	 -1.9	(13.5)	 0.323	
Δ	MMP-2	(ng/mL)	 -156.0	(128.2)	 -54.1	(114.6)	 0.557	 	 -142.4	(115.5)	 -45.6	(129.3)	 0.583	
Δ	PICP/CITP	 -50.1	(113.9)	 32.9	(98.6)	 0.586	 	 71.3	(100.0)	 -90.5	(109.0)	 0.284	
Δ	PICP/CITP	adjusted	 66.0	(28.1)	 14.3	(24.9)	 0.179	 	 58.0	(25.1)	 10.7	(28.2)	 0.221	
	
Due	 to	 the	 reduced	 number	 of	 patients	 starting	 ERT	 or	 ACEi	 /	 ARB	 during	 the	
study,	 the	 comparison	 between	 patients	 starting	 these	 treatments,	 or	 not,	 was	 clearly	
underpowered.	However,	patients	starting	ERT	presented	a	significant	decrease	in	PICP	to	
B-AP	ratio,	in	comparison	with	patients	non-starting	ERT	(table	35).	
	
Table	 35:	 Cardiomyopathy	 study:	 comparison	 of	 the	 variation	 in	 the	 concentration	 of	 the	
biomarkers	between	patients	 starting	ERT	or	ACEi	 /	ARB,	or	not,	during	 the	 study.	Expressed	as	
mean	 (standard	 error);	 ERT:	 enzyme	 replacement	 therapy;	 ACEi:	 angiotensin	 converting	 enzyme	 inhibitors;	 ARB:	
angiotensin	receptor	blockers;	Δ:	variation;	PICP:	procollagen	type	I	carboxy-terminal	propeptide;	B-AP:	 bone-specific	
alkaline	 phosphatase;	 CITP:	 collagen	 type	 I	 carboxy-terminal	 telopeptide;	 TRAP5b:	 type	 5b	 tartrate-resistant	 acid	
phosphatase;	MMP:	matrix	metalloproteinase. 
	 Starting	ERT	 p	value	 	 Starting	ACEi	/	ARB	 p	value	No	 Yes	 	 No	 Yes	
Δ	PICP	(ng/mL)	 -27.0	(25.7)	 -38.7	(34.8)	 0.792	 	 -46.4	(23.2)	 -36.0	(61.2)	 0.877	
Δ	PICP/B-AP	 3.09	(2.35)	 -6.40	(3.04)	 0.028	 	 -3.12	(1.85)	 -7.07	(4.62)	 0.446	
Δ	CITP	(ng/mL)	 -0.02	(0.05)	 0.03	(0.07)	 0.587	 	 0.01	(0.04)	 -0.12	(0.10)	 0.261	
Δ	CITP/TRAP5b	 -0.06	(0.04)	 -0.08	(0.05)	 0.835	 	 -0.05	(0.03)	 -0.18	(0.07)	 0.114	
Δ	MMP-1	(ng/mL)	 -0.09	(2.02)	 1.67	(2.61)	 0.604	 	 19.97	(18.07)	 3.79	(45.19)	 0.748	
Δ	MMP-2	(ng/mL)	 -180.4	(166.6)	 -115.7	(215.1)	 0.816	 	 -125.6	(114.2)	 -234.3	(285.5)	 0.733	
Δ	PICP/CITP	 -14.4	(181.6)	 -285.4	(292.8)	 0.443	 	 -103.2	(146.6)	 453.8	(427.5)	 0.236	
Δ	PICP/CITP	adjusted	 77.1	(23.6)	 49.7	(34.1)	 0.534	 	 48.6	(24.0)	 118.3	(69.9)	 0.359	
	
1.6	Discussion	
1.6.1	Increased	collagen	type	I	synthesis	
PICP	 levels	 suggest	 an	 increased	 myocardial	 collagen	 type	 I	 synthesis	 in	 FD	
patients	 with	 established	 LV	 hypertrophy	 and,	 to	 a	 lesser	 extent,	 in	 FD	 patients	 with	
normal	echocardiogram	or	with	isolated	TDI	abnormalities	(figure	21).	Biomarkers	related	
	 170	
to	collagen	type	I	synthesis	also	had	the	highest	S	and	global	diagnostic	accuracy	to	detect	
FD,	 confirming	 the	 added	 value	 of	 these	 biomarkers	 in	 detection	 of	 incipient	 FD	
cardiomyopathy.		
Figure	 21:	Main	 findings	 of	 cardiomyopathy	 study.	A	significant	 increase	 in	PICP	 (biomarker	of	
collagen	type	I	synthesis)	and	a	significant	decrease	in	MMP-1	(biomarker	related	to	collagen	type	
I	 degradation)	 was	 found;	 when	 collagen	 type	 I	 build	 up,	 in	 patients	 with	 left	 ventricular	
hypertrophy,	a	significant	increase	in	PICP	to	CITP	ratio	was	identified.	PINP:	procollagen	type	I	amino-
terminal	propeptide;	PICP:	procollagen	type	I	carboxy-terminal	propeptide;	BMP:	bone	morphogenic	protein;	PCOLCE:	
procollagen	 carboxy-proteinase	 enhancer;	 ADAMST:	 a	 disintegrin-like	 and	 metalloproteinase	 domain	 with	
thrombospodin	type	motif;	LOX:	lysil	oxidase;	AGE:	advanced	glycation	end	product;	SPARC:	secreted	protein	acidic	and	
rich	 in	 cysteine;	 TP:	 thrombospondin;	 MMP:	 matrix	 metalloproteinase;	 TIMP:	 tissue	 inhibitor	 of	 matrix	
metalloproteinases;	CITP:	collagen	type	I	carboxy-terminal	telopeptide;	GHL:	tripeptide	glycyl-histidyl-lysine.	
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These	results	remained	after	adjustment	 for	bone	synthesis	 (with	the	ratio	to	B-
AP)	 confirming	 the	myocardial	 origin	 of	 the	 excessive	 collagen	 type	 I	 synthesis	 (rather	
than	higher	bone	metabolic	activity).	This	correction	for	bone	activity	is	important	mainly	
in	 post-menopausal	 women,	 because	 the	 concentration	 of	 collagen	 type	 I	 synthesis	
biomarkers,	 including	 PICP,	 is	 higher	 by	 about	 20%	 in	 this	 population	 (even	 in	women	
without	evidence	of	osteoporosis).394,	395	 This	 correction	 in	 female	patients	may	explain	
the	 increase	 in	 the	 magnitude	 of	 the	 difference	 between	 genders	 in	 PICP	 levels	 after	
adjustment	for	bone	turnover	(expectable	given	the	gender	unbalance	in	the	most	severe	
subgroup	of	FD	patients,	with	only	25%	female).	Furthermore,	given	that,	unexpectedly,	a	
greater	proportion	of	female	patients	progressed	either	in	 indexed	LV	mass	or	 in	LVEDP	
during	 the	 follow-up	 period,	 the	 adjustment	 for	 bone	 turnover	 was	 paramount	 for	 an	
accurate	interpretation	of	the	results	regarding	the	prognostic	value	of	the	biomarkers.				
Elevation	of	PICP	levels	in	FD	patients	with	normal	echocardiograms	suggests	that	
it	may	be	a	serologic	marker	of	risk	detectable	before	the	earlier	echocardiographic	signs	
of	cardiac	dysfunction.	Moreover,	 it	hints	 that	 the	stimulus	 for	myocardial	 fibrosis	 is	an	
early	 event	 in	 FD	 cardiomyopathy	 (probably	 directly	 related	 to	 the	 disease	
pathophysiology),	instead	of	a	secondary	event	due	to	mechanical	stress	or	ischemia	at	a	
microcirculatory	level.		
In	 HCM,	 as	 mentioned	 above,	 a	 pathological	 model	 with	 similarities	 with	 FD	
cardiomyopathy,	 a	 few	 studies	 reported	 an	 increase	 in	 serum	 PICP	 concentration	 in	
patients	with	overt	 cardiomyopathy	 (defined	by	 the	presence	of	 LV	hypertrophy).422,	423	
Furthermore,	 one	 study	 of	 genotyped	 patients	 investigated	 the	 role	 of	 the	 biomarkers	
related	 to	 collagen	 metabolism	 to	 detect	 early	 cardiac	 involvement.	 The	 authors	
compared	 biomarkers	 of	 collagen	 metabolism	 between	 mutation	 carriers	 with	 and	
without	 LV	 hypertrophy	 and	mutation-negative	 normal	 controls	 and	 reported	 elevated	
serum	 levels	 of	 PICP	 even	 in	mutation	 carriers	without	 LV	 hypertrophy	 (that	 remained	
after	adjustment	 for	bone	 turnover),	 further	 supporting	 this	profibrotic	 state	preceding	
overt	 cardiomyopathy	 development.397	Moreover,	 a	 histological	 study	 in	 cats	with	 pre-
clinical	 HCM	 has	 shown	 an	 increase	 in	myocardial	 collagen	 deposition,	 compared	with	
healthy	 controls.694	 Comparable	 results	were	 found	 in	 hypertensive	 heart	 disease,	with	
hypertensive	 patients	 evidencing	 increased	 PICP	 concentration,	 even	 lacking	 overt	
cardiomyopathy.326,	446	
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GLA	 knockout	 mice	 (“Fabry	 mice”)	 display	 mild	 accumulation	 of	
glycosphingolipids,	but	do	not	develop	significant	cardiomyopathy,	so	this	animal	model	
does	 not	 help	 in	 understanding	 the	 pathophysiological	 mechanism	 of	 early	
cardiomyopathy.695	 However,	 studies	 in	 murine	 models	 of	 HCM	 have	 shown	 an	 up-
regulation	 of	 several	 extracellular	matrix	 proteins	 (connective	 tissue	 growth	 factor	 and	
POSTN)	 in	 the	 very	 early	 stage	 of	 the	 disease	 (pre-hypertrophic	 stage,	 with	 normal	
histologic	findings).696-699	Both	proteins	are	regulated	by	TGF-β1	pathway,700,	701	which	is	
activated	in	several	HCM	murine	models,	with	increased	values	in	the	pre-fibrotic	stages	
and	required	for	fibrosis	development	(its	inhibition	reduces	fibrosis).696,	698	
In	FD,	there	are	no	experiments	evaluating	the	direct	toxic	effects	of	Gb3	and	lyso-
Gb3	in	cardiomyocytes	or	cardiac	fibroblasts,	but	increasing	evidence	in	various	cell	lines	
suggests	 that	 these	metabolites	may	 exert	 a	 direct	 pro-fibrotic	 stimulus.	 Actually,	 lyso-
Gb3	 promotes:	 proliferation	 of	 smooth	 muscle	 cells	 in	 culture;17	 production	 of	
extracellular	matrix	proteins	(ColIV	and	fibronectin)	 in	human	glomerular	podocytes,	via	
the	 activation	of	 TGF-β1	 and	Notch	 1	 pathways;18,	70	 activation	of	 TGF-β1	pathway	 and	
expression	 of	 epithelial-mesenchymal	 transition	 markers	 both	 in	 proximal	 tubular	
epithelial	or	mesangial	cell	lines;702	inhibition	of	the	growth	of	fibroblasts,	as	well	as	their	
differentiation	into	myofibroblasts.703	All	these	findings	support	our	observations	that	up-
regulation	 of	 cardiac	 fibrogenesis	 is	 an	 early	 event	 and	 directly	 related	 to	 the	 disease	
pathophysiology,	 serving	 as	 rational	 for	 the	 results	 found	 in	 this	 study	 and	 for	 the	
usefulness	 of	 biomarkers	 related	 to	 collagen	 type	 I	 synthesis	 in	 incipient	 FD	
cardiomyopathy.		
The	 correlations	 between	 serum	 PICP	 concentration	 and	 variables	 related	 to	
demographics,	 diagnosis,	 severity	 and	 treatment	 were	 often	 non-significant,	 which	
suggests	that	this	biomarker	 is	related	to	FD	cardiomyopathy	and	not	to	overall	disease	
burden.	 However,	 there	 are	 a	 few	 exceptions:	 PICP	 presented	 a	 significant	 correlation	
with	severity	indexes	(MSSI	and	FIPI),	but	both	indexes	present	variables	directly	related	
to	cardiac	involvement229,	693	and	cardiomyopathy	is	a	well-known	determinant	of	overall	
disease	 prognosis	 and	 burden.10,	 86,	 87	 Furthermore,	 PICP	 concentration	 significantly	
correlated	 with	 plasma	 lyso-Gb3	 in	 female	 patients,	 an	 expectable	 result	 given	 the	
significant	 direct	 correlation	 identified	 between	 plasma	 lyso-Gb3	 and	 LV	 mass	 in	
heterozygotes.17,	 235	 Therefore,	 the	 significant	 correlations	 between	 PICP	 and	 these	
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variables	seems	related	to	FD	cardiomyopathy	severity,	as	confirmed	by	the	multivariate	
regression	analysis	showing	that	the	sole	significant	predictor	of	PICP	was	LV	mass.	
	
1.6.2	Collagen	type	I	degradation:	matrix	metalloproteinases	down-regulation		
In	 contrast	 to	 the	evidence	of	 increased	 collagen	 type	 I	 synthesis,	 there	was	no	
increase	 in	 the	 biomarker	 related	 to	 collagen	 type	 I	 degradation	 (CITP),	 even	 after	
adjustment	for	bone	turnover	or	estimated	GFR	(the	main	route	of	CITP	elimination	is	the	
kidney	and	 impairment	of	glomerular	 function	may	 increase	serum	CITP	concentration).	
Nonetheless,	 I	 found	 a	 significant	 decrease	 in	 the	 activity	 of	MMP-1	 (as	well	 as	 a	 non-
significant	 clear	 trend	 of	 a	 decrease	 in	 MMP-2)	 across	 the	 subgroups	 of	 increasing	
severity	of	FD	cardiomyopathy	(figure	21).		
Serum	MMPs	concentrations	did	not	differ	significantly	between	healthy	controls	
and	 FD	 patients	 in	 the	 less	 severe	 subgroup.	 However,	 decreased	 MMP-1	 or	 MMP-2	
concentrations	had	better	sensitivity	to	diagnose	FD	than	the	standard	echocardiographic	
measurements	 used	 in	 the	 identification	 of	 early	 cardiomyopathy	 (TDI	 abnormalities).	
Thus,	 a	 decrease	 in	 serum	 MMPs	 seems	 to	 occur	 early	 in	 the	 development	 of	 FD	
cardiomyopathy	and	they	may	be	good	biomarkers	of	incipient	cardiomyopathy.		
As	 an	 index	 of	 degree	 of	 coupling	 between	 the	 collagen	 type	 I	 synthesis	 and	
degradation,	 the	 PICP	 to	 CITP	 ratio	 (only	 after	 adjustment	 for	 bone	 turnover)	 was	
significantly	 higher	 in	 the	 subgroup	 of	 patients	 with	 established	 LV	 hypertrophy	
(compared	 with	 the	 two	 less	 severe	 subgroups)	 and	 inversely	 correlated	 with	 MMP-1	
activity	 (figure	21).	The	previous	 findings	support	 the	hypothesis	of	coupling	between	a	
decrease	 in	MMP-1	activity	and	a	higher	balance	between	collagen	type	 I	synthesis	and	
degradation;	in	other	words,	collagen	type	I	seems	to	build	up	when	there	is	suppression	
of	MMPs	activity.		
Similar	 results	 were	 reported	 in	 HCM,	 with	 two	 studies	 showing	 a	 significant	
decrease	 in	MMP-1	 in	 patients	 with	 overt	 HCM	 and	 one	 study	 displaying	 a	 significant	
increase	in	PICP	to	CITP	ratio,	even	in	the	early	phases	of	HCM	(patients	with	sarcomere	
mutation,	 without	 LV	 hypertrophy).397,	 422,	 423	 The	 suppression	 of	 MMPs	 as	 a	
physiopathological	mechanism	for	cardiac	fibrosis	has	been	previously	described	in	HCM.	
Münch	et	al.	 found	an	 inverse	 correlation	between	MMP-1	or	MMP-2,	 in	patients	with	
established	HCM,	and	the	amount	of	cardiac	fibrosis	(measured	by	the	quantity	of	LGE	in	
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cardiac	MRI),	but	 this	correlation	was	only	significant	 for	MMP-2	 in	 females	patients.428	
Lombardi	et	al.	 also	established	a	 significant	direct	 correlation	between	difference	of	A	
dur	 and	 Ar	 dur	 and	 free	MMP-1	 or	 active	MMP-2,	 suggesting	 that	 diastolic	 function	 is	
impaired	when	collagen	type	I	catabolic	enzyme	activity	decreases.426		
Moreover,	a	study	in	a	mice	model,	supports	MMP-2	as	a	mediator	of	metabolic	
cardioprotection,	 because	 the	 MMP-2	 knockout	 mice	 developed	 a	 greater	 extent	 of	
cardiac	 hypertrophy	 and	 presented	 up-regulation	 of	 fibrosis	 markers	 after	 infusion	 of	
angiotensin	 II,	when	compared	with	wild-type	mice.704	Two	other	examples	corroborate	
the	 deleterious	 effect	 of	MMP-2	 suppression:	 functional	 genetic	 polymorphisms,	which	
increase	MMP-2	gene	expression,	 reportedly	protect	 against	 cardiac	 remodelling	 in	 the	
hypertensive	subject,	preventing	an	increase	in	LV	end-diastolic	diameter	and	indexed	LV	
mass;705	a	rare	pan-ethnic	genetic	disease	of	deficiency	in	human	MMP-2	enzyme	activity	
affects	 some	 Saudi	 Arabian,	 Indian	 and	 Turkish	 families	 with	 congenital	 heart	 disease,	
including	atrial	and	ventricular	septal	defects.706	
The	multiple	 pathways	 involved	 in	MMPs	 suppression	 are	 not	well	 understood,	
but	 recent	 studies	 imply	aldosterone-induced	TIMP-1	expression,	acting	mainly	 through	
MMP-1	inhibition	increases	net	cardiac	collagen	content.707	Furthermore,	microRNA-214	
(an	anti-fibrotic	microRNA)	may	play	an	important	role	in	MMP-1	regulation,	as	shown	by	
Dong	et	al.	demonstrating	that	suppression	of	MMP-1	 in	cardiac	fibroblasts,	 induced	by	
angiotensin	II,	could	be	reversed	after	administration	of	pre-miR-214	(this	also	decreased	
TIMP-1	and	TGF-β).708	
Therefore,	 based	 on	 these	 data,	 I	 can	 hypothesize	 that:	 in	 incipient	 FD	
cardiomyopathy,	 increased	 collagen	 synthesis	 is	 balanced	 by	 degradation	 (limiting	
fibrogenesis),	 but	 when	 collagen	 type	 I	 synthesis	 exceeds	 the	 degradation,	 there	 is	
deposition	of	collagen	in	the	myocardium	and	LV	hypertrophy;	the	suppression	of	MMPs	
may	be	another	mechanism	of	myocardial	collagen	type	I	build-up.	
As	 expected,	 MMP-1	 also	 presented	 a	 significant	 inverse	 correlation	 with	 both	
severity	 indexes	 (MSSI	 and	 FIPI),	 probably	 due	 to	 the	 aforesaid	 explanation	 (cardiac	
variables	in	both	indexes).229,	693	A	significant	inverse	correlation	with	NT-proBNP	was	also	
found,	 presumed	 in	 the	 setting	 of	 the	 correlation	 between	 NT-proBNP	 and	 FD	
cardiomyopathy	severity.251,	252		Furthermore,	serum	MMP-1	also	presented	a	significant	
inverse	 correlation	 with	 age,	 which	 I	 assumed	 as	 a	 confounding	 factor,	 because	 age	
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correlates	 directly	 with	 LV	 mass	 in	 FD	 patients;85,	 88,	 91,	 92	 this	 hypothesis	 is	 further	
supported	by	previous	reports	showing	a	significant	increase	in	MMP-1	with	ageing.709,	710	
Therefore,	the	significant	inverse	correlations	between	MMP-1	and	these	variables	seem	
related	to	FD	cardiomyopathy	severity,	with	multivariate	regression	analysis	showing	that	
indexed	LV	mass	presented	the	strongest	correlation	with	MMP-1,	although	it	was	non-
significant.		
	
1.6.3	Prognostic	value	of	biomarkers:	correlation	with	cardiac	imaging	
The	identification	of	prognostic	biomarkers	is	paramount,	as	shown	in	this	study:	
indexed	LV	mass	and	LVEDP	remained	essentially	stable	during	the	follow-up	period,	but	
about	 30%	 of	 the	 patients	 progressed	 in	 LV	 mass	 and/or	 LVEDP,	 according	 to	 the	
definitions	 in	 the	 study.	 Thus,	 biomarkers	 identifying	 this	 subgroup	 of	 patients	 are	
essential	for	a	personalized	follow-up.		
In	 this	 study,	 I	 selected	 intermediate	 /	 surrogate	 imaging	 markers	 to	 define	
prognosis,	because	the	relatively	small	cohort	and	short	follow-up	time	hindered	the	use	
of	 “hard”	 outcomes,	 such	 as	 arrhythmias	 and	 cardiac	 death,	 to	 define	 prognosis.	
However,	 there	 is	 evidence	 showing	 that	 patients	 with	 LV	 hypertrophy	 have	 higher	
prevalence	of	heart	failure	and	arrhythmias,	so	LV	mass	may	be	an	acceptable	surrogate	
marker	of	clinical	meaningful	progression.85,	88	
This	 study	demonstrated	 the	prognostic	 value	of	 biomarkers	 related	 to	 collagen	
type	 I	 synthesis.	 I	 was	 not	 only	 able	 to	 show	 a	 significant	 difference	 in	 serum	 PICP	
concentration	 between	 the	 subgroups	 of	 FD	 patients	 (with	 higher	 values	 in	 the	 most	
severe	subgroup),	but	also	a	direct	correlation	with	LV	mass	(PICP	to	B-AP	ratio	remained	
as	the	most	significant	predictor	of	LV	mass	in	multivariate	regression	analysis)	and	a	high	
S	 to	 detect	 LV	 hypertrophy.	 Furthermore,	 although	 PICP	 did	 not	 significantly	 change	
during	 the	 follow-up	period	 (in	 accordance	with	 the	 relative	 stability	 in	 heart	 structure	
and	 function	 in	 this	 cohort	 of	 FD	 patients),	 there	 was	 a	 non-significant	 clear	 trend	 of	
higher	serum	PICP	(even	after	adjustment	for	bone	turnover)	concentration	at	baseline	in	
patients	presenting	subsequent	indexed	LV	mass	progression,	as	well	as	a	non-significant	
higher	proportion	of	LV	mass	progressing	patients	in	the	fourth	quartile	of	baseline	PICP	
distribution.		
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Nonetheless,	 the	 longitudinal	 variation	 of	 PICP	 emerged	 as	 the	most	 important	
prognostic	marker:	 its	variation	not	only	presented	a	significant	 inverse	correlation	with	
indexed	LV	mass	variation	(that	remained	after	adjustment	for	bone	turnover),	but	PICP	
variation	was	significantly	higher	in	LV	mass	progressors,	with	a	significant	OR	of	25.0	to	
be	 a	 progressor	 in	 patients	 in	 the	 fourth	 quartile	 of	 PICP	 variation	 distribution,	 in	
comparison	with	patients	 in	the	first	quartile.	Furthermore,	PICP	presented	a	clear	non-
significant	trend	of	higher	variation	in	LVEDP	progressors	and	a	significant	difference	in	LV	
mass	 variation,	 with	 progressively	 higher	 increases	 in	 LV	 mass	 across	 the	 increasing	
quartiles	 of	 PICP	 variation.	 These	 findings	 of	 longitudinal	 evolution	 strongly	 suggest	 a	
pathophysiological	link	between	myocardial	collagen	type	I	deposition	and	increase	in	LV	
mass.		
Previous	 studies	 in	 hypertensive	 heart	 disease	 also	 identified	 a	 significant	
correlation	 between	 serum	PICP	 concentration	 and	 indexed	 LV	mass.404,	443	 In	 contrast,	
studies	in	HCM	provided	conflicting	results	regarding	correlation	with	echocardiographic	
imaging,	 with	 two	 studies	 reporting	 no	 correlation	 between	 PICP	 and	 severity	 of	 LV	
hypertrophy397,	426	and	one	study	evidencing	significant	correlation	between	PICP	and	IVS	
thickness.422	Morphological	studies	in	HCM	elucidating	relative	contribution	of	fibrosis	to	
the	magnitude	of	hypertrophy	and	heart	weight	found	clear,	but	weak	correlations.711,	712	
In	FD,	the	main	determinant	of	LV	mass	seems	to	be	cardiomyocytes	hypertrophy,	
as	 the	magnitude	of	 the	 increase	of	 fibrotic	 tissue	 in	endomyocardial	 tissue	was	not	as	
high	 as	 the	 cardiomyocyte	 area	 and	 glycosphingolipids	 vacuoles.29	 However,	 in	 view	of	
the	present	results	I	can	hypothesize	that	cardiomyocyte	hypertrophy	and	collagen	type	I	
deposition	are	parallel	pathophysiological	pathways,	activated	by	a	common	mechanism:	
α-galactosidase	A	per	se	and	accumulating	substrates	(Gb3	and	lyso-Gb3).	This	hypothesis	
is	 supported	 by	 the	 aforementioned	 experiments	 showing	 that	 lyso-Gb3	 is	 not	 only	
certainly	 involved	 in	 cardiomyocyte	 hypertrophy,	 but	 also	 promotes	 activation	 of	
profibrotic	pathways	and	justifies	the	evident	predictive	value	of	collagen	type	I	synthesis	
biomarker	to	LV	mass.18,	70,	702				
In	 contrast	 to	 a	 study	 in	 HCM	 showing	 a	 significant	 correlation	 between	 serum	
PICP	concentration	and	diastolic	 function,	 I	 find	no	significant	correlation	between	PICP	
and	any	of	the	measurements	related	to	diastolic	function	in	FD.426		
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I	was	also	able	to	show	the	prognostic	added	value	of	serum	MMP-1	and	MMP-2	
concentrations.	 MMP-1	 was	 not	 only	 inversely	 correlated	 with	 LV	 mass	 and	 wall	
thickness,	but	had	a	high	sensitivity	to	detect	LV	hypertrophy,	as	well	as	to	rule	out	this	
condition,	given	the	low	negative	LR.	MMP-1	also	exhibited	a	direct	correlation	with	TDI	
abnormalities	 (either	systolic	or	diastolic).	MMP-2	only	 inversely	correlates	with	LV	wall	
thickness.		
These	findings	and	those	previously	described	for	serum	PICP	concentration	might	
indicate	that	increased	collagen	synthesis	and	inhibition	of	collagenolysis	are	syntropic	in	
the	process	of	LV	hypertrophy	and	further	support	the	role	of	MMPs	inhibition	in	diastolic	
function	impairment,	as	previously	described	for	HCM.426	
The	prognostic	value	of	MMP-1	and	MMP-2	 suppression	 in	diastolic	dysfunction	
progression	 was	 clearly	 indicated	 by	 the	 findings	 of	 significantly	 lower	 baseline	MMPs	
concentrations	in	patients	subsequently	progressing	in	LVEDP,	with	patients	in	the	fourth	
quartile	 of	MMPs	 baseline	 distribution	 being	 significantly	 “protected”	 from	progressive	
diastolic	dysfunction.	Longitudinal	evolution	of	MMPs	did	not	correlate	with	the	variation	
in	 diastolic	 dysfunction.	 Progressive	 suppression	 of	 collagenolysis	 in	 patients	 with	
increasing	LV	hypertrophy	was	also	supported	by	the	clear	trend	of	an	inverse	correlation	
between	variation	of	CITP	(adjusted	for	bone	turnover)	and	variation	of	LV	mass.	 In	the	
same	way,	the	balance	between	collagen	type	I	synthesis	and	degradation	(PICP	to	CITP	
ratio)	presented	an	almost	significant	correlation	with	LV	mass	and	a	clear	trend	of	higher	
value	in	LVEDP	progressors.		
As	expected,	PICP	was	the	only	biomarker	with	significant	difference	between	LGE	
positive	and	negative	FD	patients,	as	 it	 is	a	 surrogate	biomarker	of	myocardial	 collagen	
type	 I	 synthesis.	 Furthermore,	 PICP	 was	 already	 elevated	 in	 FD	 patients	 with	 normal	
echocardiograms	and	without	LGE.	Accordingly,	the	PICP	to	CITP	ratio	(adjusted	for	bone	
turnover)	was	also	significantly	higher	in	patients	presenting	LGE	in	cardiac	MRI,	further	
supporting	that	myocardial	collagen	type	I	bulking	occurs	when	the	synthesis	exceeds	the	
degradation	capacity.			
Both	 increased	 serum	 PICP	 concentration	 or	 decreased	 serum	 MMP-1	
concentration	presented	an	S	of	100%	to	detect	LGE	in	cardiac	MRI	and,	consequently,	a	
negative	LR	of	0.	This	finding	is	of	paramount	clinical	 importance,	because,	according	to	
these	results,	in	patients	with	normal	serum	PICP	and	MMP-1	concentrations	LGE	may	be	
	 178	
ruled	 out,	 precluding	 the	 need	 for	 a	 cardiac	MRI;	moreover	 it	may	 have	 an	 important	
prognostic	value	that	must	be	further	 investigated,	as	the	presence	of	LGE	is	associated	
with	 worse	 prognosis	 in	 terms	 of	 exercise	 capacity	 and	 risk	 for	 malignant	 ventricular	
arrhythmias.106,	116	
Previous	results	in	HCM	showed	no	significant	correlation	between	collagen	type	I	
metabolism	biomarkers	and	the	amount	of	LGE	in	cardiac	MRI.397,	423,	425	These	results	are	
certainly	related	to	the	 limited	resolution	of	LGE	to	detect	 focal	 replacement	fibrosis272,	
273	 and	 inability	 to	 detect	 early	 diffuse	 interstitial	 fibrosis.274	 However,	 sensitive	 ELISA	
assays	may	detect	 very	 small	 amounts	of	 circulating	PICP	and	 certainly	provide	a	more	
sensitive	 index	 of	 fibrosis	 and	 reflect	 subtle	 changes	 in	 myocardial	 composition,	 non-
detectable	by	cardiac	MRI.	
	 A	novel	cardiac	MRI	 technique,	T1	mapping	 (assessing	T1	 relaxation	 times),	may	
overcome	 the	 inability	 of	 LGE	 to	 detect	 diffuse	 interstitial	 fibrosis.	 High	 T1	 relaxation	
times	are	observed	 in	diffuse	 fibrosis,	protein	deposition	and	water	 in	oedema.	Low	T1	
values	 are	 seen	 in	 iron	 or	 lipid	 deposition.713	 However,	 in	 FD	 cardiomyopathy,	 cardiac	
lipid	storage	is	a	hallmark	and	T1	mapping	has	been	studied	as	an	imaging	biomarker	for	
early	detection	of	cardiac	involvement	(with	low	native	T1).278-280	Thus,	the	capacity	of	T1	
mapping	 to	detect	early	diffuse	 fibrosis	may	be	 impaired	due	 to	 low	native	T1	 (fibrosis	
may	only	be	detected	in	the	“pseudo	normalization”	stage,	when	the	amount	of	fibrotic	
tissue	 is	 enough	 to	 overcome	 the	 low	 native	 characterizing	 FD	 cardiomyopathy.)	 and	
needs	further	evaluation.		
	
1.6.4	Biomarkers	related	to	collagen	metabolism:	influence	of	therapeutics	
This	 study	was	not	designed	 to	 access	 the	effect	 of	 ERT	on	 the	biomarkers,	 but	
given	the	trend	of	a	higher	proportion	of	patients	on	ERT	in	the	more	severe	subgroups,	it	
is	 reasonable	 to	assume	that	 this	 is	 the	 reason	why	the	concentration	of	biomarkers	at	
baseline	was	similar	between	treated	and	untreated	patients.		
However,	 in	an	exploratory	analysis,	adjusted	 for	variation	 in	 indexed	LV	mass,	 I	
evaluated	the	effect	of	patients	under	/	starting	ERT	on	the	variation	of	the	biomarkers	
related	 to	 collagen	 metabolism.	 Regarding	 the	 biomarkers	 related	 to	 collagen	 type	 I	
synthesis,	patients	under	ERT	presented	a	clear	trend	of	a	greater	decrease	in	PICP	than	
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the	 untreated	 patients,	 a	 difference	 that	 became	 significant	 after	 adjustment	 for	 bone	
turnover	(with	treated	patients	presenting	a	progressive	decrease	and	the	untreated	ones	
an	 increase).	 Moreover,	 patients	 starting	 treatment	 during	 the	 follow-up	 period	
presented	a	decrease	in	PICP	to	B-AP	ratio,	whereas	the	patients	that	remained	untreated	
showed	an	increase	in	the	same	ratio.				
Patients	 under	 ERT	 also	 presented	 a	 trend	 in	 the	 variation	 of	 the	 biomarkers	
related	 to	 collagen	 type	 I	 degradation	 that	 was	 in	 agreement	 with	 an	 increase	 in	
collagenolysis,	namely:	a	smaller	decrease	in	serum	CITP	(adjusted	for	bone	turnover)	and	
MMP-2	 concentrations	 and	 an	 increase	 in	MMP-1	 concentration	 in	 treated	 patients,	 in	
comparison	 with	 untreated	 patients.	 All	 these	 findings	 suggest	 that	 ERT	 may	 affect	
myocardial	 collagen	 type	 I	 metabolism,	 preventing	 its	 synthesis	 and	 increasing	 its	
degradation,	 probably	 limiting	 myocardial	 collagen	 type	 I	 build-up-	 This	 hypothesis	
deserves	detailed	study	and	may	be	of	paramount	interest	in	clinical	practice.		
There	 is	 no	 evidence	 about	 the	 effect	 of	 ERT	 on	 myocardial	 collagen	 content,	
because	the	pathological	studies	evaluating	the	effects	of	ERT	on	cardiac	morphology	and	
Gb3	 inclusions	did	not	 report	 the	effect	on	myocardial	 fibrosis.	Nevertheless,	 ERT	does	
not	 appear	 to	 have	 an	 effect	 on	 LGE,	 with	 two	 studies	 reporting	 an	 increase	 in	 the	
amount	or	de	novo	development	of	LGE	in	treated	patients.116,	190	However,	as	mentioned	
above,	 LGE	 only	 detects	 focal	 replacement	 (irreversible)	 and	 not	 interstitial	 diffuse	
(reversible)	 myocardial	 fibrosis;274	 thus,	 a	 response	 of	 focal	 fibrosis	 to	 ERT	 is	 not	
expected,	as	it	is	composed	of	relatively	large	areas	of	organized	collagen	fibres.	
Instead,	 interstitial	 diffuse	 fibrosis	 may	 be	 reversible	 and	 susceptible	 to	 the	
influence	of	ERT,	through	the	effects	of	enzyme	deficiency	correction	and	Gb3	clearance	
in	 the	 suppression	 of	 the	 activated	 profibrotic	 pathways	 that	 are	 involved	 in	 FD	
pathophysiology.	Little	evidence	supports	this	hypothesis,	but	in	a	human	kidney	tubular	
cell	 line	 treated	 with	 Gb3,	 where	 there	 was	 an	 up-regulation	 of	 TGF-β1	 pathway	 and	
activation	 of	 an	 epithelial-mesenchymal	 transition	 phenotype	 (characterized	 by	 a	
decrease	in	E-cadherin	and	an	increase	in	N-cadherin	and	α-smooth	muscle	actin);	when	
this	cell	line	was	treated	with	recombinant	α-galactosidase	A,	it	prevented	the	activation	
both	of	TGF-β1	pathway	and	epithelial-mesenchymal	transition	phenotype.702	Thus,	in	the	
setting	of	 the	present	 results,	 the	effect	of	ERT	on	 the	 transcription	profile	and	protein	
synthesis	in	cardiomyocytes	should	be	further	evaluated.			
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The	effect	of	ACEi	 /	ARB	on	 the	biomarkers	 related	 to	 collagen	metabolism	was	
less	evident.	Nonetheless,	there	was	a	trend,	of	smaller	magnitude,	of	a	decrease	in	PICP	
and	PICP	to	B-AP	ratio	 in	patients	 treated	with	these	agents.	The	effect	 in	 the	enzymes	
related	to	collagen	type	I	degradation	was	less	consistent.		
However,	 in	 hypertensive	 heart	 disease,	 there	 is	 evidence	 that	 serum	 PICP	
concentration	 decreases	 with	 treatment	 with	 anti-hypertensive	 drugs	 (ARB	 and	 loop	
diuretics)	and	that	this	decrease	was	accompanied	by	a	histological	validation	of	parallel	
changes	in	the	amount	of	myocardial	fibrosis.377,	380		
	 In	HCM,	there	is	only	one	study	showing	a	decrease	in	serum	PICP	concentration	
in	the	group	of	patients	treated	with	an	ARB,	whereas	in	the	group	of	patients	not	treated	
with	 an	 renin-angiotensin-aldosterone	 axis	 antagonist	 serum	 PICP	 concentration	
remained	 unchanged;	 however,	 a	 histological	 validation	 of	 a	 parallel	 response	 in	 the	
myocardial	collagen	content	was	not	performed.405	
	 In	 FD	 cardiomyopathy,	 the	 lack	 of	 expressive	 results	 may	 be	 related	 to	 the	
activation	 of	 distinct	 pathophysiological	 pathways,	 but	 the	 possibility	 that	 studies	 in	
larger	cohorts	and	for	a	longer	follow-up	period	may	reveal	an	effect	in	these	biomarkers	
of	myocardial	fibrosis	must	be	kept	in	mind.		
	
1.6.5	Collagen	type	I	biomarkers:	previous	findings	in	FD	cardiomyopathy		
To	my	 knowledge,	 only	 two	 studies	 have	 evaluated	 cardiac	 extracellular	matrix	
turnover	in	FD.	As	previously	mentioned,	Shah	et	al.	reported	increased	levels	of	MMP-9,	
with	 significant	 correlation	 with	 MSSI	 and	 inverse	 correlation	 with	 midwall	 fractional	
shortening	of	the	LV.413	In	contrast	to	the	identified	decrease	in	MMP-1	and	MMP-2	with	
increasing	cardiomyopathy	severity,	MMP-9	has	been	 identified	 in	HCM	as	a	profibrotic	
marker.428,	714	
Krämer	 et	 al.	 reported	 an	 increase	 in	 three	 biomarkers	 of	 collagen	metabolism	
(PICP,	ICTP	and	PIIINP),	compared	with	healthy	historical	controls.	However,	no	difference	
in	 these	 markers,	 between	 patients	 with	 and	 without	 fibrosis	 in	 the	 cardiac	 MRI	 was	
observed,	 additionally	 no	 significant	 change	 between	 baseline	 and	 follow-up	
measurements	was	 found,	 regardless	 of	 ERT	 status.	 The	 authors	 explained	 this	 finding	
assuming	a	systemic	fibrotic	state	in	FD,	involving	the	heart,	the	kidney	and	other	organs.	
Nevertheless,	 a	 sub-analysis	 by	 gender	 and	 adjustment	 for	 bone	 turnover	 was	 not	
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performed,	which	would	 had	 been	 crucial,	 since	 usually	 female	 patients	 have	 a	milder	
phenotype,	but	the	rise	of	collagen	markers	due	to	bone	turnover	can	misleadingly	over-
estimate	 myocardial	 fibrosis.	 Moreover,	 the	 previously	 described	 limitations	 of	 LGE	
techniques	to	detect	cardiac	fibrosis	certainly	influenced	the	results.116		
	
1.6.4	Difficulties	and	limitations	
A	few	difficulties	emerged	during	the	study	design,	related	to	the	epidemiology	of	
FD,	because	as	a	rare	disease,	it	is	difficult	to	recruit	a	cohort	large	enough	to	allow	sub-
analysis	and	to	detect	small	differences,	which	may	be	of	clinical	importance.	During	the	
study	I	recruited	a	cohort	of	the	initially	planned	size,	but	the	recruitment	period	had	to	
be	longer	than	planned	(not	affecting	the	longitudinal	follow-up	period).	Ideally,	a	longer	
follow-up	period	would	be	desirable	for	a	more	accurate	analysis	of	the	prognostic	value	
of	 the	 biomarkers,	 but	 due	 to	 constrains	 of	 the	 timeline	 in	 the	 research	 and	 doctoral	
program	 and	 in	 the	 setting	 of	 a	 long	 recruitment	 period,	 a	 24	 months	 longitudinal	
evaluation	was	the	possible	timeline.		
The	 multicenter	 design	 of	 the	 study	 generated	 some	 difficulties,	 due	 to	 the	
organization	 of	 patients	 collecting	 samples	 at	 various	 centres	 at	 the	 same	 time,	which	
caused	 some	 loss	 of	 data	 during	 follow-up,	 but	 did	 not	 hamper	 accurate	 statistical	
analysis.	I	did	not	experience	difficulties	in	the	laboratorial	tasks	and	interpretation	of	the	
results.					
	 This	 study	 has,	 per	 se,	 several	 limitations,	 namely:	 i)	 theabsence	 of	 histological	
correlation,	which	could	be	useful	to	biomarker	validation,	but	endomiocardial	biopsy	is	
an	invasive	and	potentially	harmful	technique;	ii)	the	available	cohort	size	and	short	time	
of	 follow-up,	 hindering	 an	 accurate	 definition	 of	 the	 prognostic	 value	 of	 the	 studied	
biomarkers;	 iii)	 the	 study	 was	 not	 designed	 to	 access	 the	 effect	 of	 treatments	 in	 the	
biomarkers,	so	this	was	just	an	exploratory	analysis;	iv)	the	laboratory	standardization	of	
these	 biomarkers’	 assays	 is	 an	 urgent	 need	 to	 improve	 their	 clinical	 application;	 v)	 no	
correlation	with	speckle-tracking	analysis	of	echocardiograms,	since	this	was	not	available	
in	 the	 majority	 of	 the	 cohort	 and	 no	 quantification	 of	 the	 LGE	 area,	 although	 no	
correlation	was	identified	in	previous	studies;	vi)	no	correlation	with	T1	mapping	cardiac	
MRI	techniques.	
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2.	Nephropathy	study	
2.1	Pilot	study	
2.1.1	Population	characteristics	
As	noted	above,	for	the	pilot	study	I	recruited	10	patients	with	FD	and	CKD	stage	
≥3	 (as	 previously	 defined)	 and	 10	 sex	 and	 age-matched	 healthy	 controls.	 Population	
characteristics	 are	 given	 in	 table	 36.	 The	median	 age	of	 diagnosis	 of	 FD	was	54.0,	 70%	
were	taking	ACEi	or	ARB,	20%	were	on	β-blockers	and	90%	of	 them	were	on	ERT,	 for	a	
median	time	of	8.7	years.		
All	patients	in	the	FD	group	were	non-relatives	with	seven	distinctive	pathogenic	
mutations	 (three	 have	 p.N215S,	 two	 have	 p.R227X	 and	 the	 others	 have	 unique	
mutations).	
	
Table	 36:	 Nephropathy	 pilot	 study:	 population	 characteristics.	 FD:	 Fabry	 disease;	 ERT:	 enzyme	
replacement	therapy;	RAAi:	renin-angiotensin-aldosterone	axis	inhibitors;	IQR:	interquartile	range.		
	 Control	group	(n=10)	
FD	group	
(n=10)	
Categorical	variables	(n	/	%)	 	 	
Sex	(female)	 4	(40.0)	 4	(40.0)	
ERT	(yes)	 -	 9	(90.0)	
RAAi	(yes)	 -	 7	(70.0)	
β-blocker	(yes)	 -	 2	(20.0)	
Continuous	variable	(median	/	IQR)		 	 	
Age	(years)	 61.5	(25.0)	 61.5	(25.0)	
Age	at	diagnosis	(years)	 -	 54.0	(31.0)	
Time	in	ERT	(years)	 -	 8.7	(3.3)	
	
	 As	 per	 definition	 of	 the	 groups,	 FD	 group	 had	 a	 significantly	 higher	 serum	
creatinine	and	 lower	estimated	GFR	 than	 the	control	 group	 (table	37).	A	wide	 range	of	
ACR	 values	 were	 observed	 in	 the	 FD	 patients,	 with	 one	 patient	 with	 ACR	 within	 the	
normal	 range,	 3	 with	 ACR	 30	 -	 300mg/g	 and	 6	 patients	 with	 ACR	 >300mg/g;	 ACR	was	
significantly	higher	in	the	FD	group.	
	
2.1.2	Novel	biomarkers	of	glomerular	or	tubular	damage	
	 The	 studied	 glomerular	 damage	 biomarkers	 (UTE	 and	 urinary	 ColIV	 excretion)	
were	 both	 increased	 in	 FD	 group	 (table	 38).	 As	 compared	 with	 UTE	 in	 controls,	
transferrinuria	in	the	FD	group	had	a	231%	increase,	p=0.001.	Likewise,	the	urinary	ColIV	
excretion	was	significantly	higher	in	patients	with	FD	(a	230%	increase,	p=0.001).	
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Table	37:	Nephropathy	pilot	study:	kidney	function	 in	study	population.	Expressed	as	median	(IQR);	
ACR:	urinary	albumin	to	creatinine	ratio;	eGFR:	estimated	glomerular	filtration	rate.		
	 Control	group	 FD	group	 p	value	
ACR	(mg/g)	 4.1	(6.3)	 342.6	(404.9)	 <0.001	
Creatinine	(mg/dL)	 0.72	(0.41)	 1.48	(0.65)	 0.001	
eGFR	(ml/min/1.73m2)	 84.0	(18.0)	 40.5	(19.0)	 <0.001	
	
Urinary	RBP	and	FLC	κ	and	λ	concentrations	were	bellow	the	limit	of	detection	of	
the	 assay	 in	 controls	 and	 in	 some	 of	 the	 FD	 patients,	 so	 they	were	 excluded	 from	 the	
statistical	 analysis.	 The	 other	 tubular	 injury	 biomarkers	 (urinary	 A1MG,	 NAG	 and	 APP	
excretion)	 were	 all	 significantly	 increased	 in	 FD	 group,	 in	 comparison	 with	 the	 control	
group	(table	38).	
For	the	freely	filtered	protein	A1MG,	as	compared	with	urinary	A1MG	excretion	in	
controls,	 it	was	significantly	 increased	 in	FD	patients	 (a	86%	 increase,	p=0.006).	For	 the	
urinary	enzymes	secreted	by	the	tubules,	I	also	found	a	significant	difference	between	FD	
and	control	groups:	for	NAG	a	119%	increase,	p=0.001;	for	AAP	a	105%	increase,	p=0.005.	
	
Table	38:	Nephropathy	pilot	study:	novel	biomarkers	of	glomerular	or	tubular	damage.	Expressed	
as	median	(IQR);	UTE:	urinary	transferrin	excretion;	ColIV:	collagen	type	IV;	A1MG:	α1-microglobulin;	NAG:	N-acetyl-β-
D-glucosaminidase;	AAP:	alanine	aminopeptidase.	
	 Control	group	 FD	group	 p	value	
Biomarkers	of	glomerular	damage	 	 	 	
UTE	(mg/g)	 0.42	(0.29)	 1.21	(0.65)	 <0.001	
Urinary	ColIV	excretion	(μg/g)	 3.55	(1.46)	 11.06	(12.47)	 <0.001	
Biomarkers	of	tubular	damage	 	 	 	
Urinary	A1MG	excretion	(μg/g)	 203.1	(112.6)	 441.6	(192.9)	 0.006	
Urinary	NAG	excretion	(U/g)	 11.8	(17.4)	 30.3	(14.0)	 0.001	
Urinary	AAP	excretion	(μg/g)	 6.49	(5.84)	 14.36	(5.03)	 0.004	
	
Based	 on	 the	 results	 of	 the	 pilot	 study,	 I	 selected	 the	 urinary	 excretion	 of	 the	
following	 biomarkers	 to	 be	 evaluated	 in	 the	 entire	 cohort	 of	 recruited	 patients:	 UTE,	
ColIV,	A1MG,	NAG	and	AAP.	
	
2.2	Population	characteristics		
	 From	February	2013	to	June	2014,	78	FD	patients	(subgroups:	1	-	25	patients;	2	-	
22	patients;	3	-	10	patients;	4	-	21	patients)	and	25	controls	(age	and	sex-matched	with	
subgroup	1)	were	recruited	(study	flow	diagram	in	figure	22).		
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Figure	22:	Nephropathy	study:	study	flow	diagram.	ColIV:	collagen	type	IV;	A1MG:	α1-microglobulin;	NAG:	
N-acetyl-β-D-glucosaminidase;	AAP:	alanine	aminopeptidase;	CKD:	chronic	kidney	disease.	
	
Population	characteristics	are	given	in	table	39.	In	the	78	FD	patient	group,	56.4%	
were	 females	 (distribution	non-significantly	different	between	subgroups),	with	a	mean	
age	of	50.0	years	old,	ranging	from	19	to	80	years	old	(significantly	older,	comparing	the	
most	severe	subgroup	4	[patients	with	CKD	stage	≥3]	with	the	two	less	severe	subgroups);	
69.2%	 of	 the	 patients	 were	 on	 ERT	 (significantly	 more	 in	 subgroup	 4;	 94.4%	 under	
agalsidase-α,	 5.6%	 under	 agalsidase-β),	 with	 a	 significantly	 older	 age	 for	 ERT	 initiation	
comparing	group	4	to	1;	the	use	of	renin-angiotensin-aldosterone	axis	blockers	(48.7%	of	
the	 entire	 cohort)	 was	 also	 significantly	 higher	 in	 the	most	 severe	 subgroup.	 HBP	was	
Poten&ally	eligible	par&cipants	(n=82)	
Excluded	(n=4):	
•  diabetes	(n=3)	
•  systemic	lupus	(n=1)	
Eligible	par&cipants	(n=78)	
Index	tests	(n=78)	
Transferrin:	
•  nega&ve	(n=32)	
•  posi&ve	(n=46)	
•  inconclusive	(n=0)	
ColIV:	
•  nega&ve	(n=28)	
•  posi&ve	(n=50)	
•  inconclusive	(n=0)	
A1MG:	
•  nega&ve	(n=27)	
•  posi&ve	(n=51)	
•  inconclusive	(n=0)	
NAG:	
•  nega&ve	(n=24)	
•  posi&ve	(n=54)	
•  inconclusive	(n=0)	
AAP:	
•  nega&ve	(n=29)	
•  posi&ve	(n=49)	
•  inconclusive	(n=0)	
Target	condi&on	(CKD	stage	≥	2):	
•  present	(n=37)	
•  absent	(n=41)	
•  inconclusive	(n=0)	
Reference	standard	(albumin):	
•  nega&ve	(n=29)	
•  posi&ve	(n=49)	
•  inconclusive	(n=0)	
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identified	 in	 42.3%	 of	 the	 patients,	 significantly	more	 in	 the	most	 severe	 subgroup.	 As	
expected,	the	severity	 indexes	(MSSI	and	FIPI)	were	also	significantly	higher	 in	the	most	
severe	subgroup.	Plasma	lyso-Gb3	and	α-galactosidase	A	activity	were	similar	between	FD	
subgroups,	both	in	male	and	female	patients.		
Table	39:	Nephropathy	study:	clinical	characteristics	of	the	study	population.	FD:	Fabry	disease;	HBP:	
arterial	 hypertension;	 ERT:	 enzyme	 replacement	 therapy;	 ACEi:	 angiotensin	 converting	 enzyme	 inhibitors;	 ARB:	
angiotensin	II	receptor	blockers;	MSSI:	Mainz	Severity	Score	Index;	FIPI:	Fabry	International	Prognostic	Index;	α-gal:	α-
galactosidase.	
	 FD	cohort	(n=78)	
FD	subgroups	
1	(n=25)	 2	(n=22)	 3	(n=10)	 4	(n=21)	
Categorical	variables	(n	(%))	 	 	 	 	 	
Sex	(female)	 44	(56.4)	 18	(72.0)	 14	(63.6)	 4	(40.0)	 8	(38.1)	
HBP	(yes)Ŧ	 33	(42.3)	 4	(16.0)	 9	(40.9)	 3	(30.0)	 17	(81.0)	
ERT	(yes)*	 54	(69.2)	 15	(60.0)	 13	(59.0)	 6	(60.0)	 20	(95.2)	
ACEi	/	ARB	(yes)Ŧ	 38	(48.7)	 8	(32.0)	 8	(36.4)	 4	(40.0)	 18	(85.7)	
β-blockers	(yes)	 16	(20.5)	 2	(8.0)	 3	(13.6)	 3	(30.0)	 8	(38.1)	
Continuous	variables				
(median	(IQR))		 	 	 	 	 	
Age	(years)ζ	 50.0	(20.0)	 43.0	(21.0)	 48.5	(13.0)	 59.0	(16.0)	 62.0	(24.0)	
Age	at	diagnosis	(years)	 42.0	(24.0)	 35.0	(27.0)	 42.5	(17.0)	 53.5	(32.0)	 49.0	(44.0)	
Age	at	ERT	initiation	(years)	§	 48.1	(17.3)	 42.9	(25.2)	 44.0	(16.2)	 50.7	(17.1)	 53.5	(25.0)	
Time	in	ERT	(years)	 4.9	(7.6)	 3.9	(8.4)	 4.8	(5.4)	 4.2	(6.7)	 8.5	(8.9)	
MSSI°	 21.0	(20.0)	 10.0	(12.0)	 20.5	(18.0)	 31.0	(11.0)	 32.0	(10.0)	
FIPI**	 2.0	(3.0)	 1.0	(1.0)	 2.0	(2.0)	 4.0	(1.5)	 5.0	(2.0)	
Plasma	lyso-Gb3	(nmol/L)	 9.58	(15.33)	 6.03	(12.88)	 9.22	(14.36)	 11.79	(71.50)	 17.79	(36.60)	
Plasma	α-gal	A	♀ (nmol/h/mL)	 4.3	(4.0)	 6.6	(5.0)	 3.8	(7.2)	 4.2	(.)	 4.5	(4.7)	
Plasma	α-gal	A	♂	(nmol/h/mL)	 0.11	(0.30)	 0.15	(0.50)	 0.16	(0.80)	 0.10	(0.20)	 0.20	(0.30)	
Ŧ	p	<	0.01	for	difference	in	the	distribution	of	categorical	variable	between	subgroups.	
*	p	<	0.05	for	difference	in	the	distribution	of	categorical	variable	between	subgroups.	
ζ	p	<	0.01	for	difference	between	group	1	and	4;	p	<	0.05	for	difference	between	group	2	and	4.	
§	p	<	0.05	for	difference	between	group	1	and	4.	
°	p	<	0.01	for	difference	between	group	1	and	all	other	groups	and	also	between	group	2	and	4.	
**	p	<	0.01	 for	difference	between	group	1	and	all	other	groups	and	also	between	group	2	and	4;	p	<	0.05	 for	difference	between	
group	2	and	3.	
	
	 Altogether,	35	different	GLA	pathogenic	mutations	were	identified	(table	40),	with	
p.N215S	and	p.F113L,	two	mutations	associated	with	attenuated	/	late-onset	phenotypes	
with	 predominant	 cardiac	 involvement,	 accounting	 for	 34.6%	 of	 the	 patients;	 the	
remaining	mutations	are	usually	associated	with	classical	phenotype.	
	
Table	40:	Nephropathy	study:	mutation	frequency.	*	Mutations	presented	by	one	patient	within	the	study	
Mutation	 n	 %	 	 Mutation	 n	 %	 	 Mutation	 n	 %	
p.N215S	 18	 23.1	 	 c.802-3_802-2delCA	 2	 2.6	 	 p.N42V	 2	 2.6	
p.F113L	 9	 11.5	 	 p.C52G	 2	 2.6	 	 p.R342Q	 2	 2.6	
p.G35E	 5	 6.4	 	 p.I317T	 2	 2.6	 	 p.T410I	 2	 2.6	
p.R227X	 3	 3.8	 	 p.L166P	 2	 2.6	 	 unknown	 2	 2.6	
c.700_702del	 2	 2.6	 	 p.L372P	 2	 2.6	 	 other*	 23	 29.5	
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There	was	a	slight,	but	significant	difference	in	kidney	function	tests	between	the	
control	 group	 and	 FD	 subgroup	 1	 (table	 41),	 with	 higher	 albuminuria	 and	 serum	
creatinine	 and	 lower	 GFR	 in	 FD	 patients.	 However,	 all	 these	 results	 were	 within	 the	
reference	 interval	 in	patients	of	 the	 FD	 subgroup	1.	 As	per	definition	of	 FD	 subgroups,	
estimated	GFR	was	significantly	lower	in	FD	subgroup	3,	in	contrast	to	albuminuria,	that	
was	significantly	higher	in	subgroups	3	and	4.	
	
Table	41:	Nephropathy	study:	kidney	function	in	the	population	of	the	study.	Expressed	as	median	
(IQR);	ACR:	urinary	albumin	to	creatinine	ratio;	eGFR:	estimated	glomerular	filtration	rate.	
	 Controls	 FD	subgroups	1	 2	 3	 4	
ACR	(mg/g)	*	 3.9	(4.4)	 9.6	(14.2)	 88.2	(108.2)	 614.8	(454.7)	 206.2	(515.4)	
Creatinine	(mg/dL)	Ŧ	 0.62	(0.25)	 0.76	(0.23)	 0.76	(0.27)	 0.87	(0.21)	 1.53	(0.63)	
eGFR	(ml/min/1.73m2)	Ŧ	 119.0	(20.0)	 105.0	(30.0)	 102.0	(22.0)	 87.5	(28.0)	 39.0	(25.0)	
*	p	<	0.01	 for	difference	between	controls	and	group	1,	between	group	1	and	3	or	4	and	also	between	group	2	and	3;	p	<	0.05	 for	
difference	between	group	2	and	4.	
Ŧ	p	<	0.05	for	difference	between	controls	and	group	1;	p	<	0.01	for	difference	between	group	4	and	all	other	groups.	
	
2.3	Glomerular	and	tubular	damage	biomarkers	at	baseline	
2.3.1	Concentration	in	healthy	controls	and	Fabry	disease	patients	
Glomerular	and	tubular	damage	biomarkers	were	all	 increased	 in	FD	patients,	 in	
comparison	with	healthy	controls	(table	42	and	figure	23).	A	significant	 increase	in	both	
glomerular	 damage	biomarkers	was	 evidenced,	 even	 in	 the	 less	 severe	 subgroup	of	 FD	
patients	 (normoalbuminuric	patients,	without	evidence	of	kidney	 involvement),	with	an	
increase	 of	 132%	 (p=0.018)	 for	UTE	 and	of	 120%	 (p=0.040)	 for	 urinary	 ColIV	 excretion,	
comparing	this	subgroup	and	the	controls.	
	
Table	42:	Studied	biomarkers	of	kidney	 injury	 in	 controls	and	FD	subgroups.	Expressed	as	median	
(IQR);	 UTE:	 urinary	 transferrin	 excretion;	 ColIV:	 urinary	 collagen	 type	 IV	 excretion;	 A1MG:	 urinary	 α1-microglobulin	
excretion;	NAG:	urinary	N-acetyl-β-D-glucosaminidase	excretion;	AAP:	urinary	alanine	aminopeptidase	excretion.	
	 Controls	 FD	subgroups	 p	value*	 p	valueŦ	1	 2	 3	 4	
UTE	(μg/g)	 0.81	(0.62)	 0.99	(2.10)	 1.09	(0.94)	 0.95	(0.94)	 1.26	(1.16)	 0.018	 0.45	
ColIV	(mg/g)	 5.09	(5.54)	 7.92	(14.28)	 10.88	(8.31)	 7.53	(9.76)	 9.75	(11.86)	 0.040	 0.53	
A1MG	(mg/g)	 298.3	(260.9)	 489.2	(1121.9)	 570.5	(549.7)	 580.7	(767.9)	 522.9	(360.1)	 0.009	 0.91	
NAG	(U/g)	 8.72	(5.66)	 10.79	(17.91)	 13.44	(8.37)	 25.04	(23.04)	 22.02	(19.22)	 0.037	 0.023	
AAP	(U/g)	 4.98	(7.13)	 13.07	(20.46)	 13.02	(15.98)	 16.68	(12.73)	 13.37	(9.25)	 0.009	 0.97	
*	controls	versus	FD	disease	subgroup	1;	Ŧ	between	FD	subgroups.	
	
Likewise,	there	was	a	significant	 increase	 in	all	 tubular	 injury	biomarkers	even	 in	
the	subgroup	1	of	FD	patients,	with	increases	of	206%	(p=0.009),	87%	(p=0.037)	and	162%	
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(p=0.009)	for	urinary	A1MG,	NAG	and	AAP,	respectively,	comparing	this	subgroup	and	the	
controls.	However,	a	significant	progressive	increase	between	FD	subgroups	of	increasing	
severity	was	only	found	for	urinary	NAG	excretion. 
Figure	 23:	Glomerular	 and	 tubular	 damage	 biomarkers	 in	 controls	 and	 FD	patient	 subgroups.	
ACR:	urinary	albumin	 to	creatinine	 ratio;	UTE:	urinary	 transferrin	excretion;	ColIV:	urinary	collagen	 type	 IV	excretion;	
A1MG:	urinary	α1-microglobulin	excretion;	NAG:	urinary	N-acetyl-β-D-glucosaminidase	excretion;	AAP:	urinary	alanine	
aminopeptidase	excretion.	
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2.3.2	Correlation	with	urinary	albumin	excretion	
For	the	entire	FD	cohort,	the	correlation	between	ACR	and	the	novel	biomarkers	
(table	43)	was	stronger	for	urinary	NAG	excretion	(ρ=0.447,	p<0.001)	(figure	23),	although	
also	significant	for	UTE	and	urinary	ColIV	excretion.		
Table	43:	Correlation	between	novel	biomarkers	of	kidney	injury	and	ACR	for	all	FD	cohort	and	
subgroup	1.	ACR:	urinary	albumin	to	creatinine	ratio;	UTE:	urinary	transferrin	excretion;	ColIV:	urinary	collagen	type	
IV	 excretion;	 A1MG:	 urinary	 α1-microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-glucosaminidase	 excretion;	 AAP:	
urinary	alanine	aminopeptidase	excretion. 
	 all	FD	cohort	 	 Subgroup	1	ρ	 p	value	 	 ρ	 p	value	
UTE	 0.240	 0.034	 	 0.487	 0.013	
ColIV		 0.302	 0.007	 	 0.464	 0.019	
A1MG	 0.184	 0.107	 	 0.457	 0.022	
NAG		 0.447	 <	0.001	 	 0.586	 0.002	
AAP		 0.173	 0.141	 	 0.238	 0.252	
	
If	 only	 the	 FD	 patients	 of	 subgroup	 1	 were	 considered	 (patients	 without	 any	
evidence	of	 renal	 involvement)	 the	 correlations	with	ACR	would	be	even	 stronger,	 also	
with	 a	 higher	 correlation	 coefficient	 for	 urinary	 NAG	 excretion	 (ρ=0.586,	 p=0.002),	 but	
also	 significant	 for	 UTE,	 urinary	 ColIV	 excretion	 and	 urinary	 A1MG	 excretion.	 Several	
normoalbuminuric	patients	had	biomarkers	concentrations	above	the	assumed	reference	
value	 (upper	 limit	of	 a	95%	confidence	 interval	 for	 the	mean	of	 the	 control	 group);	 for	
example	 for	NAG,	48%	of	 the	normoalbuminuric	patients	had	NAG	excretion	above	 the	
reference	range	(figure	24	and	figure	25).	
Figure	 24:	 Correlation	 between	 NAG	 and	 ACR.	 Left	 image:	 entire	 FD	 cohort;	 right	 image:	
subgroup	 1	 of	 FD	 patients.	 Vertical	 line	 in	 right	 image	 represents	 the	upper	 limit	of	 the	 reference	value;	 ACR:	
urinary	albumin	to	creatinine	ratio;	NAG:	urinary	N-acetyl-β-D-glucosaminidase	excretion;	FD:	Fabry	disease.		
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Figure	25:	Subgroup	1:	correlation	between	ACR	and	novel	biomarkers.	Left	upper	image:	UTE;	
right	upper	image:	ColIV;	left	lower	image:	A1MG;	right	lower	image:	AAP.	Vertical	line	in	right	image	
represents	 the	 upper	 limit	 of	 the	 reference	 value;	 ACR:	 urinary	 albumin	 to	 creatinine	 ratio;	 UTE:	 urinary	 transferrin	
excretion;	 ColIV:	 urinary	 collagen	 type	 IV	 excretion;	 A1MG:	 urinary	 α1-microglobulin	 excretion;	 AAP:	 urinary	 alanine	
aminopeptidase	excretion.		
	
2.3.3	Correlation	with	estimated	glomerular	filtration	rate	
For	 the	 entire	 FD	 cohort,	 I	 found	 significant	 negative	 correlations	 between	
estimated	GFR	and	ACR,	UTE,	urinary	Col	IV	or	urinary	NAG	(table	44).	Furthermore,	the	
correlation	 between	 urinary	NAG	 and	 estimated	GFR	 (ρ=-0.420;	 p<0.001)	was	 stronger	
than	the	correlation	between	ACR	and	estimated	GFR	(ρ=-0.374;	p=0.001)	(figure	26).	
In	FD	subgroup	1	 (patients	without	evidence	of	FD	nephropathy),	all	biomarkers	
but	urinary	AAP	had	better	correlation	with	estimated	GFR	than	ACR,	with	the	strongest	
correlation	for	urinary	NAG	excretion	(ρ=-0.668;	p<0.001),	in	comparison	with	a	ρ=-0.416,	
p=0.039	for	ACR	(table	44	and	figure	26).		
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Table	44:	Correlation	between	novel	biomarkers	of	kidney	injury	and	estimated	GFR	for	all	FD	
cohort	 and	 subgroup	 1.	 GFR:	 glomerular	 filtration	 rate;	 FD:	 Fabry	 disease;	 ACR:	 urinary	 albumin	 to	 creatinine	
ratio;	 UTE:	 urinary	 transferrin	 excretion;	 ColIV:	 urinary	 collagen	 type	 IV	 excretion;	 A1MG:	 urinary	 α1-microglobulin	
excretion;	NAG:	urinary	N-acetyl-β-D-glucosaminidase	excretion;	AAP:	urinary	alanine	aminopeptidase	excretion. 
	 all	FD	cohort	 	 Subgroup	1	ρ	 p	value	 	 ρ	 p	value	
ACR	 -0.374	 0.001	 	 -0.416	 0.039	
UTE		 -0.305	 0.007	 	 -0.537	 0.006	
ColIV		 -0.351	 <0.001	 	 -0.493	 0.012	
A1MG		 -0.215	 0.058	 	 -0.544	 0.005	
NAG		 -0.420	 <0.001	 	 -0.668	 <0.001	
AAP		 -0.019	 0.872	 	 -0.167	 0.424			
Figure	26:	Correlation	between	eGFR	and	ACR	or	urinary	NAG	excretion.	Left	upper	image:	ACR	
(entire	FD	cohort);	right	upper	image:	NAG	(entire	FD	cohort);	left	lower	image:	ACR	(subgroup	1	
of	 FD	 patients);	 right	 lower	 image:	 NAG	 (subgroup	 1	 of	 FD	 patients).	 eGFR:	 estimated	 glomerular	
filtration	rate;	ACR:	urinary	albumin	to	creatinine	ratio;	NAG:	urinary	N-acetyl-β-D-glucosaminidase	excretion;	FD:	Fabry	
disease.		
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A	significant	 increase	of	the	biomarkers,	according	to	CKD	stage,	was	only	found	
for	NAG	 (p=0.014).	Notably,	a	 similar	 increase	was	not	 found	 for	albuminuria	 (p=0.068)	
(table	45	and	figure	27).			
	
Table	45:	Biomarkers	in	patients	with	FD	according	to	CKD	stage.	CKD:	chronic	kidney	disease;	FD:	Fabry	
disease;	 ACR:	 urinary	 albumin	 to	 creatinine	 ratio;	 UTE:	 urinary	 transferrin	 excretion;	 ColIV:	 urinary	 collagen	 type	 IV	
excretion;	 A1MG:	 urinary	 α1-microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-glucosaminidase	 excretion;	 AAP:	
urinary	alanine	aminopeptidase	excretion. 
	 CKD	stage	 p	value	1	 2	 ≥3	
ACR	(mg/g)	 34.2	(121.2)	 53.0	(372.3)	 170.6	(390.9)	 0.068	
UTE	(μg/g)	 0.92	(0.97)	 1.08	(1.85)	 1.26	(1.16)	 0.067	
ColIV	(mg/g)	 8.4	(10.1)	 11.0	(13.4)	 9.8	(11.9)	 0.561	
A1MG	(mg/g)	 468.2	(647.5)	 715.2	(867.9)	 522.9	(360.1)	 0.080	
NAG	(U/g)	 12.6	(11.1)	 22.3	(16.0)	 22.0	(19.2)	 0.014	
AAP	(U/g)	 13.2	(14.6)	 14.5	(17.9)	 13.4	(9.2)	 0.955		
Figure	27:	Boxplot	comparing	ACR	and	urinary	NAG	excretion	between	CKD	stages.	CKD:	chronic	
kidney	disease;	ACR:	urinary	albumin	to	creatinine	ratio;	NAG:	urinary	N-acetyl-β-D-glucosaminidase	excretion.		
	
2.3.4	Correlation	with	other	variables	
For	 other	 variables	 (including	 demographic,	 diagnosis,	 severity	 and	 treatment	
related),	 not	 directly	 related	 to	 kidney	 function,	 a	 significant	 correlation	 was	 found	
between	ACR	or	urinary	NAG	excretion	and	disease	severity	(both	MSSI	and	FIPI	scores)	
(table	46).	
Moreover,	 there	 was	 a	 significant	 correlation	 between	 NAG	 and	 age	 (ρ=0.365;	
p=0.001).	However,	 the	significant	 inverse	correlation	between	estimated	GFR	and	NAG	
(ρ=-0.355;	 p=0.002)	 remained	 significant	 after	 adjustment	 for	 age.	 Other	 correlations	
were	less	consistent	and	reliable.		
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Table	46:	Influence	of	other	variables	in	biomarkers	of	kidney	injury.	Mean	difference	for	categorical	
variables;	ρ	for	continuous	variables;	ACR:	urinary	albumin	to	creatinine	ratio;	UTE:	urinary	transferrin	excretion;	ColIV:	
urinary	 collagen	 type	 IV	 excretion;	 A1MG:	 urinary	 α1-microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-
glucosaminidase	excretion;	AAP:	urinary	alanine	aminopeptidase	excretion;	α-gal:	α-galactosidase;	MSSI:	Mainz	Severity	
Score	Index;	FIPI:	Fabry	International	Prognostic	Index;	ERT:	enzyme	replacement	therapy;	ACEi:	angiotensin	converting	
enzyme	inhibitors;	ARB:	angiotensin	II	receptor	blockers.	
	 ACR	(mg/g)	
UTE	
(μg/g)	
ColIV	
(mg/g)	
A1MG	
(mg/g)	
NAG	
(U/g)	
AAP	
(U/g)	
Demographic	 	 	 	 	 	 	
Sex	(female)	 -11.1*	 0.14	 0.36	 340.3	 1.65	 3.28	
Age	(years)	 0.197	 0.192	 0.120	 0.181	 0.305*	 -0.033	
Diagnosis	 	 	 	 	 	 	
Age	at	diagnosis	(years)	 0.113	 0.000	 0.055	 0.078	 0.125	 -0.094	
Plasma	α-gal	A	♀ (nmol/h/mL)	 -0.042	 -0.094	 -0.023	 -0.085	 -0.165	 0.027	
Plasma	α-gal	A	♂	(nmol/h/mL)	 -0.046	 0.330	 0.387*	 0.438*	 0.205	 0.309	
Disease	severity	 	 	 	 	 	 	
MSSI	 0.579*	 0.145	 0.097	 0.046	 0.329*	 -0.048	
FIPI	 0.514*	 0.153	 0.148	 0.059	 0.309*	 0.013	
Plasma	lyso-Gb3	♀	(nmol/L)	 0.390*	 0.027	 -0.016	 -0.043	 0.065	 -0.091	
Plasma	lyso-Gb3	♂	(nmol/L)	 0.074	 -0.420	 -0.415	 -0.556*	 -0.112	 -0.478	
Treatment	 	 	 	 	 	 	
ERT	(yes)	 149.8	 0.41	 3.14	 -90.6	 1.97	 -0.24	
Age	at	ERT	initiation	(years)	 0.021	 0.082	 0.123	 0.142	 0.141	 -0.070	
Time	in	ERT	(years)	 -0.057	 0.240	 0.066	 0.197	 0.287*	 0.051	
ACEi	/	ARB	(yes)	 173.9	 0.20	 3.06	 -71.9	 1.65	 0.20	
β-blockers	(yes)	 -83.0	 -0.05	 -1.54	 -185.7	 -1.98	 -5.35	
*	p	<	0.05		
	
	 Remarkably,	a	significant	difference	between	male	and	female	patients	was	only	
observed	 for	 ACR.	 In	 female	 patients,	 there	was	 only	 a	 significant	 correlation	 between	
estimated	GFR	and	urinary	ColIV	or	NAG		(table	47).	
	
Table	47:	Correlation	of	biomarkers	with	ACR	and	eGFR	stratified	by	gender.	ACR:	urinary	albumin	to	
creatinine	ratio;	eGFR:	estimated	glomerular	 filtration	rate;	UTE:	urinary	 transferrin	excretion;	ColIV:	urinary	collagen	
type	 IV	 excretion;	 A1MG:	 urinary	 α1-microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-glucosaminidase	 excretion;	
AAP:	urinary	alanine	aminopeptidase	excretion.	
	 ACR	 	 eGFR	ρ	 p	value	 	 ρ	 p	value	
ACR	 ♀	 -	 -	 	 -0.219	 0.153	
♂	 -	 -	 	 -0.468	 0.005	
UTE		 ♀	 0.221	 0.150	 	 -0.245	 0.109	
♂	 0.264	 0.131	 	 -0.384	 0.025	
ColIV		
♀	 0.340	 0.024	 	 -0.340	 0.007	
♂	 0.328	 0.059	 	 -0.385	 0.013	
A1MG		 ♀	 0.191	 0.214	
	 -0.176	 0.252	
♂	 0.327	 0.059	 	 -0.307	 0.077	
NAG		 ♀	 0.410	 0.006	 	 -0.412	 0.005	
♂	 0.628	 <0.001	 	 -0.421	 0.013	
AAP		
♀	 0.150	 0.330	 	 0.099	 0.521	
♂	 0.350	 0.058	 	 -0.220	 0.244	
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2.4	Association	between	predictive	variables	and	clinical	endpoints	
2.4.1	Predictors	of	estimated	glomerular	filtration	rate	
Multivariate	regression	analysis	was	performed	to	evaluate	the	urine	biomarkers	
as	predictors	of	estimated	GFR	(table	48).	No	significant	difference	between	genders	was	
identified	 for	estimated	GFR	 (mean	difference	8.39ml/min/1.73m2	between	 female	and	
male	patients,	p=0.311).		
As	expected,	age	was	identified	as	the	most	significant	predictor	of	eGFR,	so	the	
multivariate	regression	was	weighted	for	age	and	identified	urinary	NAG	excretion	as	the	
only	significant	predictor	of	estimated	GFR	(β-0.296,	p=0.009).	
	
Table	 48:	 Predictive	 model	 of	 eGFR	 by	 univariate	 and	 multivariate	 regression	 analysis.	 An	
algorithmic	 transformation	 of	 variables	 with	 non-normal	 distribution	 was	 performed	 for	 correlation	 analysis;	 eGFR:	
estimated	glomerular	filtration	rate;	ACR:	urinary	albumin	to	creatinine	ratio;	UTE:	urinary	transferrin	excretion;	ColIV:	
urinary	 collagen	 type	 IV	 excretion;	 A1MG:	 urinary	 α1-microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-
glucosaminidase	excretion;	AAP:	urinary	alanine	aminopeptidase	excretion.	
	 eGFR	(univariate)	 	 eGFR	(multivariate)	R	 p	value	 	 β	 p	value	
Log	ACR	 -0.353	 0.002	 	 -0.178	 0.815	
Log	UTE	 -0.231	 0.042	 	 0.055	 0.608	
Log	ColIV	 -0.226	 0.021	 	 0.214	 0.530	
Log	A1MG	 -0.149	 0.193	 	 	 	
Log	NAG		 -0.391	 <0.001	 	 -0.296	 0.009	
Log	AAP	 -0.049	 0.670	 	 	 	
Age		 -0.629	 <0.001	 	 	 	
	
2.4.2	Diagnostic	accuracy	to	identify	Fabry	Disease	
I	 used	 the	 diagnostic	 accuracy	 of	 each	 biomarker	 to	 identify	 FD	 in	 order	 to	
compare	 the	S	of	 serum	biomarkers	with	 the	gold	standard	ACR	 in	 the	 identification	of	
incipient	FD	nephropathy	(table	49).	
Specificity	 (Sp)	 and	 positive	 predictive	 value	 (PPV)	 were	 influenced	 by	 the	
inclusion	criteria	in	the	control	group	(albuminuria	A1)	and	the	definition	of	the	reference	
range	 of	 biomarkers	 according	 to	 the	 control	 group,	 overestimating	 both	measures	 of	
diagnostic	accuracy	(mainly	for	ACR).	
Nonetheless,	the	sensitivity	to	identify	FD	was	highest	for	urinary	NAG	excretion;	
moreover,	except	for	the	AUC	for	albuminuria	(influenced	by	the	definition	of	the	control	
group),	 which	 was	 higher	 than	 0.9,	 the	 AUC	 for	 tubular	 injury	 biomarkers	 was	 slightly	
larger	 than	 those	 of	 the	 novel	 glomerular	 biomarkers	 (figure	 28).	 Furthermore,	 plasma	
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lyso-Gb3	did	not	significantly	correlate	with	estimated	GFR	in	female	(ρ=-0.373;	p=0.051)	
and	male	(ρ=0.240;	p=0.370)	patients.		
	
Table	49:	Diagnostic	accuracy	of	eGFR	and	urinary	biomarkers	to	identify	Fabry	Disease.	For	this	
purpose,	abnormal	eGFR	was	defined	as	CKD	stage	≥2;	S:	sensitivity;	Sp:	specificity;	PPV:	positive	predictive	value;	NPV:	
negative	predictive	value;	LR+:	 likelihood	ratio	for	a	positive	test	result;	LR-:	 likelihood	ratio	for	a	negative	test	result;	
DOR:	diagnostic	odds	ratio;	A:	accuracy;	YI:	Youden’s	index;	AUC:	area	under	the	curve;	CI:	confidence	interval;	eGFR:	
estimated	glomerular	filtration	rate;	ACR:	urinary	albumin	to	creatinine	ratio;	UTE:	urinary	transferrin	excretion;	ColIV:	
urinary	 collagen	 type	 IV	 excretion;	 A1MG:	 urinary	 α1-microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-
glucosaminidase	excretion;	AAP:	urinary	alanine	aminopeptidase	excretion.	
	 S	 Sp	 PPV	 NPV	 LR+	 LR-	 DOR	 A	 YI	 AUC	(95%	CI)	
eGFR	 0.53	 0.88	 0.93	 0.37	 4.42	 0.53	 8.12	 0.61	 0.41	 0.196	(0.102-0.291)	
ACR	 0.63	 1	 1	 0.46	 NA	 0.37	 NA	 0.72	 0.63	 0.945	(0.903-0.987)	
UTE	 0.59	 0.72	 0.87	 0.36	 2.11	 0.57	 3.70	 0.62	 0.31	 0.694	(0.584-0.803)	
ColIV	 0.64	 0.68	 0.86	 0.38	 2	 0.53	 3.79	 0.65	 0.32	 0.706	(0.603-0.810)	
A1MG	 0.65	 0.68	 0.86	 0.39	 2.03	 0.51	 4.01	 0.66	 0.33	 0.743	(0.645-0.842)	
NAG	 0.69	 0.72	 0.89	 0.43	 2.46	 0.43	 5.79	 0.70	 0.41	 0.757	(0.663-0.851)	
AAP	 0.66	 0.76	 0.89	 0.43	 2.75	 0.45	 6.21	 0.66	 0.42	 0.763	(0.655-0.871)	
	
Figure	 28:	 Global	 diagnostic	 accuracy	 to	 identify	 Fabry	 disease.	 Left	 image:	 ACR;	 right	 image:	
NAG.	ACR:	urinary	albumin	to	creatinine	ratio;	NAG:	urinary	N-acetyl-β-D-glucosaminidase	excretion.	
	
2.4.3	Diagnostic	accuracy	to	identify	chronic	kidney	disease	stage	≥2	
Urinary	 NAG	 excretion	 presented	 the	 highest	 S	 (0.83)	 and	 global	 diagnostic	
accuracy	(AUC=0.708)	to	identify	CKD	stage	≥2	(table	50	and	figure	29);	nevertheless,	its	
DOR	was	not	higher	than	the	relatively	lower	Sp	(related	to	its	high	S	to	detect	incipient	
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FD	 nephropathy	 in	 stage	 1	 of	 CKD).	 Lyso-Gb3	 did	 not	 demonstrate	 a	 significant	 global	
diagnostic	accuracy	to	identify	CKD	stage	≥2	neither	in	female,	nor	in	male	patients.		
	
Table	50:	Diagnostic	accuracy	of	biomarkers	to	identify	CKD	stage	≥2.	CKD:	chronic	kidney	disease;	S:	
sensitivity;	 Sp:	 specificity;	 PPV:	 positive	 predictive	 value;	 NPV:	 negative	 predictive	 value;	 LR+:	 likelihood	 ratio	 for	 a	
positive	test	result;	LR-:	likelihood	ratio	for	a	negative	test	result;	DOR:	diagnostic	odds	ratio;	A:	accuracy;	YI:	Youden’s	
index;	 AUC:	 area	 under	 the	 curve;	 CI:	 confidence	 interval;	 ACR:	 urinary	 albumin	 to	 creatinine	 ratio;	 UTE:	 urinary	
transferrin	excretion;	ColIV:	urinary	collagen	type	IV	excretion;	A1MG:	urinary	α1-microglobulin	excretion;	NAG:	urinary	
N-acetyl-β-D-glucosaminidase	excretion;	AAP:	urinary	alanine	aminopeptidase	excretion.	
	 S	 Sp	 PPV	 NPV	 LR+	 LR-	 DOR	 A	 YI	 AUC	(95%	CI)	
ACR	 0.71	 0.46	 0.59	 0.59	 1.31	 0.63	 2.05	 0.59	 0.17	 0.653	(0.531-0.774)	
UTE	 0.70	 0.53	 0.61	 0.63	 1.49	 0.57	 2.59	 0.62	 0.23	 0.653	(0.529-0.776)	
ColIV	 0.71	 0.43	 0.58	 0.57	 1.25	 0.67	 1.84	 0.58	 0.14	 0.570	(0.441-0.700)	
A1MG	 0.77	 0.46	 0.59	 0.67	 1.43	 0.50	 2.86	 0.62	 0.23	 0.625	(0.498-0.751)	
NAG	 0.83	 0.45	 0.61	 0.71	 1.51	 0.38	 3.82	 0.64	 0.28	 0.708	(0.590-0.825)	
AAP	 0.68	 0.35	 0.55	 0.48	 1.05	 0.91	 1.13	 0.50	 0.03	 0.482	(0.347-0.617)	
Lyso-Gb3	
♀	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.644	(0.398-0.891)	
♂	 -	 -	 -	 -	 -	 -	 -	 -	 -	 0.330	(0.040-0.627)	
	
Figure	 29:	 Global	 diagnostic	 accuracy	 to	 identify	 CKD	 stage	 ≥2.	 Left	 image:	 ACR;	 right	 image:	
NAG.	ACR:	urinary	albumin	to	creatinine	ratio;	NAG:	urinary	N-acetyl-β-D-glucosaminidase	excretion.	
	
2.5	Glomerular	and	tubular	damage	biomarkers	in	the	longitudinal	study	
2.5.1	Compliance	and	population	characteristics	
There	 was	 high	 compliance	 with	 longitudinal	 evaluation	 (figure	 30),	 with	 all	
recruited	 patients	 attending	 their	 appointments	 after	 12	months.	 After	 24	months,	 70	
(89.7%)	 patients	 attended	 the	 appointment;	 6	 patients	 re-scheduled	 their	 visits,	 one	
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patient	died	during	the	study	(due	to	haemorrhagic	stroke)	and	another	patient	changed	
follow-up	to	another	hospital.	
During	follow-up,	biomarkers	were	measured	in	76.9%	of	the	patients,	either	after	
12	or	24	months.	The	main	reason	for	no	sampling	to	biomarkers	assessment	was	the	re-
scheduling	of	 appointments,	 so	 the	 research	 team	was	not	 aware	 that	 the	patient	was	
present	 and	 the	 samples	 were	 not	 collected;	 a	 few	 samples	 were	 also	 inadvertently	
wasted.				
	
Figure	30:	Nephropathy	study:	flow	diagram	of	longitudinal	evaluation.			
Glomerular	 function	 remained	 essentially	 stable	 during	 the	 2	 years	 follow-up	
period	 (table	 51),	 with	 no	 significant	 changes	 in	 serum	 creatinine	 or	 estimated	 GFR;	
although	 serum	 creatinine	 and	 estimated	 GFR	 significantly	 increased	 and	 decreased,	
respectively	 after	 12	 months,	 there	 was	 a	 recovery	 to	 near	 baseline	 values	 for	 both	
variables	after	24	months.	Furthermore,	the	two	severity	indexes	(MSSI	and	FIPI)	did	not	
change	 significantly	 during	 follow-up,	 and	 likewise	 the	 percentage	 of	 patients	 treated	
with	ACEi	or	ARB	and	β-blockers.	Six	patients	(7.7%)	started	ERT	during	the	study.		
Analysing	glomerular	 function	by	FD	subgroups	or	CKD	stage,	estimated	GFR	did	
not	change	significantly	between	baseline	and	24	months	follow-up	in	any	subgroup	of	FD	
patients	(figure	31);	similar	results	were	also	found	for	the	control	group,	with	no	change	
in	estimated	GFR	after	12	months.	
baseline	
Clinical	(n=78)	
Biomarkers	(n=78)	
12	months	
Clinical	(n=78)	
Biomarkers	(n=60)	
24	months	
Clinical	(n=70)	
Biomarkers	(n=60)	
Non	evaluated	(n=8):	
•  non	aAending	(n=6)	
•  death	(n=1)	
•  changed	hospital	(n=1)	
No	samples	(n=18):	
•  changed	appointment	(n=10)	
•  wasted	samples	(n=4)	
•  samples	condiEon		(n=4)	
No	samples	(n=18):	
•  changed	appointment	(n=14)	
•  wasted	samples	(n=3)	
•  samples	condiEon		(n=1)	
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Table	51:	Nephropathy	study:	longitudinal	variation	of	kidney	function,	severity	and	treatment.	
ACR:	urinary	albumin	to	creatinine	ratio;	eGFR:	estimated	glomerular	filtration	rate;	MSSI:	Mainz	Severity	Score	Index;	
FIPI:	 Fabry	 International	 Prognostic	 Index;	 ERT:	 enzyme	 replacement	 therapy;	 ACEi:	 angiotensin	 converting	 enzyme	
inhibitors;	ARB:	angiotensin	II	receptor	blockers.	
	 baseline	(n=78)	 12	months	(n=78)	 24	months	(n=70)	
p	value	
0	versus	
12	
12	versus	
24	
0	versus	
24	
Kidney	function	(median/IQR)	 	 	 	 	 	 	
Creatinine	(mg/dL)	 0.85	(0.60)	 0.86	(0.64)	 0.83	(0.59)	 0.005	 <0.001	 0.488	
eGFR	(ml/min/1.73m2)	 92.5	(49.0)	 86.0	(52.0)	 91.0	(51.0)	 0.002	 0.004	 0.675	
Severity	(median/IQR)	 	 	 	 	 	 	
MSSI	 21.0	(20.0)	 21.0	(20.0)	 20.0	(20.0)	 0.277	 0.089	 0.075	
FIPI	 2.0	(3.0)	 2.0	(3.0)	 2.0	(3.0)	 0.903	 0.003	 0.078	
Treatment	(n/%)		 	 	 	 	 	 	
ERT	(yes)	 54	(69.2)	 58	(74.4)	 54	(77.1)	 0.125	 0.500	 0.031	
ACEi	/	ARB	(yes)	 38	(48.7)	 42	(53.8)	 39	(55.7)	 0.219	 1.000	 0.375	
β-blockers	(yes)	 16	(20.5)	 16	(20.5)	 13	(18.6)	 1.000	 1.000	 1.000	
	
Figure	31:	Nephropathy	study:	longitudinal	variation	of	kidney	function	by	subgroups	and	CKD	
stage	 in	 FD	patients.	Left	 image:	FD	subgroups;	right	 image:	CKD	stage.	 Errors	bars:	±standard	error;	
eGFR:	estimated	glomerular	filtration	rate;	CKD:	chronic	kidney	disease;	FD	Fabry	disease.	
	
According	 to	 the	 definition	 of	 ACR	 progressors	 (increase	 ≥1.5	 times	 of	 ACR	
between	 baseline	 and	 24	 months,	 for	 at	 least	 ≥30mg/g	 or	 as	 a	 change	 between	
albuminuria	A1	and	A2	or	A2	and	A3)	or	GFR	progessors	 (decrease	≥5ml/min/1.73m2	 in	
GFR	between	baseline	and	24	months,	for	at	least	a	GFR	<90ml/min/1.73m2),	mentioned	
above	 in	 the	methods	 section,	20.8%	and	28.2%	of	 the	FD	patients	presented	ACR	and	
GFR	 progression,	 respectively	 (table	 52).	 There	 was	 no	 significant	 difference	 in	 the	
proportion	of	ACR	progressors	across	the	FD	subgroups;	however,	there	were	significantly	
more	GFR	progressors	in	the	FD	subgroups	in	the	most	severe	subgroups.		
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Table	52:	Patients	progressing	according	to	ACR	and	GFR	criteria	in	the	entire	FD	cohort	and	by	
subgroups.	ACR	and	GFR	progressors	were	defined	in	the	methods	sections.	ACR:	urinary	albumin	to	
creatinine	ratio;	GFR:	estimated	glomerular	filtration	rate;	FD:	Fabry	disease.	
	 ACR	 	 GFR	non-progressors	 progressors	 	 non-progressors	 progressors	
FD	cohort	 61	(79.2)	 16	(20.8)	 	 56	(71.8)	 22	(28.2)	
		Subgroup	1	 22	(88.0)	 3	(12.0)	 	 23	(92.0)	 2	(8.0)	
		Subgroup	2	 18	(81.8)	 4	(18.2)	 	 17	(77.3)	 5	(22.7)	
		Subgroup	3	 8	(80.0)	 2	(20.0)	 	 4	(40.0)	 6	(60.0)	
		Subgroup	4	 13	(61.9)	 7	(33.3)	 	 12	(57.1)	 9	(42.9)	
	
2.5.2	Variation	in	controls	and	Fabry	disease	patients	
There	was	no	 significant	 change	 in	 any	biomarker,	 including	ACR,	 in	 the	 control	
group	between	baseline	and	12	months	(table	53).			
	
Table	53:	Nephropathy	study:	longitudinal	variation	of	biomarkers	in	control	group.	Expressed	as	
median	(IQR);	ACR:	urinary	albumin	to	creatinine	ratio;	UTE:	urinary	transferrin	excretion;	ColIV:	urinary	collagen	type	
IV	 excretion;	 A1MG:	 urinary	 α1-microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-glucosaminidase	 excretion;	 AAP:	
urinary	alanine	aminopeptidase	excretion.	
	 baseline	(n=25)	 12	months	(n=25)	 p	value	
ACR	(mg/g)	 3.9	(4.4)	 3.3	(4.8)	 0.626	
UTE	(μg/g)	 0.81	(0.62)	 0.60	(0.30)	 0.317	
ColIV	(mg/g)	 5.09	(5.54)	 5.30	(2.51)	 0.909	
A1MG	(mg/g)	 298.3	(260.9)	 250.7	(206.4)	 0.689	
NAG	(U/g)	 8.72	(5.66)	 10.10	(8.06)	 0.167	
AAP	(U/g)	 4.98	(7.13)	 6.79	(5.07)	 0.693	
	
I	did	not	identify	a	significant	change	in	biomarker	urinary	concentration	between	
baseline	 and	 24	 months	 (including	 ACR),	 except	 for	 urinary	 NAG	 excretion,	 which	
increased	significantly	during	that	period	(table	54).	Furthermore,	there	was	a	significant	
increase	 in	 urinary	 ColIV	 excretion	 after	 12	 months,	 which	 returned	 to	 near	 baseline	
values	after	24	months.		
	
Table	 54:	 Nephropathy	 study:	 longitudinal	 variation	 of	 biomarkers	 in	 the	 entire	 FD	 cohort.	
Expressed	 as	 median	 (IQR);	 FD:	 Fabry	 disease;	 ACR:	 urinary	 albumin	 to	 creatinine	 ratio;	 UTE:	 urinary	 transferrin	
excretion;	ColIV:	urinary	collagen	type	IV	excretion;	A1MG:	urinary	α1-microglobulin	excretion;	NAG:	urinary	N-acetyl-β-
D-glucosaminidase	excretion;	AAP:	urinary	alanine	aminopeptidase	excretion.	
	 baseline	(n=78)	 12	months	(n=60)	 24	months	(n=60)	
p	value	
0	versus	
12	
12	versus	
24	
0	versus	
24	
ACR	(mg/g)	 59.2	(269.2)	 94.5	(257.4)	 30.4	(210.0)	 0.074	 0.055	 0.474	
UTE	(μg/g)	 1.08	(1.38)	 1.19	(1.44)	 1.14	(1.39)	 0.480	 0.158	 0.834	
ColIV	(mg/g)	 8.61	(11.53)	 13.08	(17.36)	 10.12	(12.71)	 <0.001	 0.007	 0.519	
A1MG	(mg/g)	 530.3	(638.3)	 563.0	(799.9)	 574.3	(633.2)	 0.216	 0.095	 0.900	
NAG	(U/g)	 14.68	(18.83)	 26.23	(49.06)	 22.41	(33.17)	 <0.001	 0.492	 0.001	
AAP	(U/g)	 13.21	(13.30)	 13.74	(16.62)	 12.63	(15.88)	 0.126	 0.037	 0.206	
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Accordingly,	even	when	analysing	all	biomarkers	by	FD	subgroups,	 there	was	no	
significant	 change	 after	 the	 follow-up	 period	 in	 any	 subgroup	 of	 patients,	 except	 for	 a	
significant	 increase	 in	 UTE	 in	 subgroup	 3,	 after	 24	 months	 of	 follow-up	 (figure	 32).	
Furthermore,	as	previously	mentioned,	at	baseline	only	ACR	and	urinary	NAG	excretion	
differed	significantly	across	the	FD	subgroups	of	increasing	severity.	This	finding	remained	
during	 follow-up,	 with	 an	 enlargement	 in	 the	 difference	 of	 urinary	 NAG	 excretion	
between	subgroups,	driven	by	an	almost	significant	increase	in	subgroups	3	(p=0.091)	and	
4	(p=0.056).	
Analysing	biomarker	variations	according	to	baseline	CKD	stage,	I	identified	similar	
findings,	with	a	 significant	 increase	only	 in	urinary	NAG	excretion,	 in	patients	with	CKD	
stage	1	at	baseline	(figure	33).	Furthermore,	as	noted	above	only	NAG	excretion	differed	
significantly	 between	 CKD	 stages	 at	 baseline	 and	 this	 difference	 widened	 during	 the	
follow-up	period.		
	
2.5.3	Baseline	concentration	and	risk	of	progression	
To	assess	the	effect	of	baseline	concentration	of	each	biomarker	on	the	ACR	and	
GFR	variation	during	follow-up,	I	divided	the	biomarkers	into	quartiles	and	compared	the	
patients	in	quartiles	1	and	4.		
According	 to	 baseline	 concentration,	 none	 of	 the	 biomarkers,	 including	 ACR,	
significantly	predicted	the	ACR	change	during	follow-up,	without	a	significant	difference	
between	quartiles	1	and	4	for	any	of	them	(table	55).	
Contrariwise,	GFR	variation	during	 the	 follow-up	period	was	significantly	distinct	
between	quartiles	1	and	4	of	urinary	NAG	excretion	(table	56),	with	a	mean	difference	of	
6.8ml/min/1.73m2	 (95%	 CI:	 0.7-12.9ml/min/1.73m2;	 p=0.028).	 For	 the	 remaining	
biomarkers,	including	ACR,	there	was	no	significant	difference	between	quartiles	1	and	4;	
for	 example,	 for	 ACR	 the	 mean	 difference	 was	 2.0ml/min/1.73m2	 (95%	 CI:	 -4.6-
8.6ml/min/1.73m2;	p=0.540).	
Furthermore,	 comparing	 the	 GFR	 change	 according	 to	 baseline	 quartiles,	 NAG	
evidenced	a	progressive	negative	variation	of	GFR	across	the	increasing	quartiles	(figure	
34);	for	ACR,	quartiles	1,	2	and	3	showed	similar	declines	in	GFR,	only	somewhat	different	
in	quartile	4.			
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Figure	32:	Nephropathy	study:	longitudinal	variation	of	biomarkers	by	subgroups	of	FD	patients.	
Errors	 bars:	 ±standard	 error;	 *	 p<0.05	 for	 variation	 between	 baseline	 and	 24	 months;	 ACR:	 urinary	 albumin	 to	
creatinine	 ratio;	 UTE:	 urinary	 transferrin	 excretion;	 ColIV:	 urinary	 collagen	 type	 IV	 excretion;	 A1MG:	 urinary	 α1-
microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-glucosaminidase	 excretion;	 AAP:	 urinary	 alanine	 aminopeptidase	
excretion.	
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Figure	33:	Nephropathy	 study:	 longitudinal	 variation	of	biomarkers	according	 to	CKD	stage	at	
baseline.	Errors	bars:	±standard	error;	*	p<0.05	for	variation	between	baseline	and	24	months;	ACR:	urinary	albumin	
to	 creatinine	 ratio;	 UTE:	 urinary	 transferrin	 excretion;	 ColIV:	 urinary	 collagen	 type	 IV	 excretion;	 A1MG:	 urinary	 α1-
microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-glucosaminidase	 excretion;	 AAP:	 urinary	 alanine	 aminopeptidase	
excretion;	CKD:	chronic	kidney	disease.	
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Table	55:	ACR	variation	according	to	quartiles	of	the	baseline	concentration	of	the	biomarkers.	
Expressed	as	median	(IQR);	*	represents	the	comparison	between	Q4	and	Q1;	ACR:	urinary	albumin	to	creatinine	ratio;	
Q:	 quartile;	 UTE:	 urinary	 transferrin	 excretion;	 ColIV:	 urinary	 collagen	 type	 IV	 excretion;	 A1MG:	 urinary	 α1-
microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-glucosaminidase	 excretion;	 AAP:	 urinary	 alanine	 aminopeptidase	
excretion. 
	 ACR	change	(mg/g)	 p	value*	Q1	 Q2	 Q3	 Q4	
ACR	 3.4	(12.9)	 -6.1	(24.6)	 -31.4	(118.5)	 64.8	(1037.2)	 0.233	
UTE		 -0.1	(45.8)	 -1.7	(132.0)	 -8.9	(155.5)	 2.0	(82.1)	 0.624	
ColIV		 0.9	(37.8)	 -3.3	(61.6)	 -2.0	(220.4)	 2.0	(501.6)	 0.518	
A1MG		 -1.0	(99.2)	 -0.1	(49.1)	 -2.1	(334.7)	 0.1	(52.6)	 0.599	
NAG		 1.9	(34.6)	 -13.2	(407.5)	 -4.7	(126.6)	 6.0	(421.8)	 0.433	
AAP		 -3.5	(112.5)	 4.8	(69.2)	 -5.4	(85.1)	 2.0	(154.3)	 0.308	
	
	 I	also	assessed	the	risk	of	each	patient	being	an	ACR	or	GFR	progressor	according	
to	baseline	quartiles	of	the	biomarkers.	
	
Table	56:	GFR	variation	according	to	quartiles	of	the	baseline	concentration	of	the	biomarkers.	
Expressed	 as	 median	 (IQR);	 *	 represents	 the	 comparison	 between	 Q4	 and	 Q1;	 GFR:	 glomerular	 filtration	 rate;	 Q:	
quartile;	 ACR:	 urinary	 albumin	 to	 creatinine	 ratio;	 UTE:	 urinary	 transferrin	 excretion;	 ColIV:	 urinary	 collagen	 type	 IV	
excretion;	 A1MG:	 urinary	 α1-microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-glucosaminidase	 excretion;	 AAP:	
urinary	alanine	aminopeptidase	excretion. 
	 GFR	change	(ml/min/1.73m
2)	
p	value*	
Q1	 Q2	 Q3	 Q4	
ACR		 0.0	(14.0)	 1.0	(12.0)	 0.0	(8.0)	 -5.0	(15.0)	 0.540	
UTE		 1.0	(14.0)	 -5.0	(18.0)	 -5.0	(9.0)	 -2.0	(13.0)	 0.534	
ColIV		 0.0	(14.0)	 -6.0	(12.0)	 -3.5	(11.0)	 1.0	(10.0)	 0.718	
A1MG		 2.0	(14.0)	 -5.0	(12.0)	 -5.0	(11.0)	 -2.0	(13.0)	 0.471	
NAG		 3.0	(12.0)	 -2.0	(11.0)	 -5.0	(15.0)	 -5.0	(12.0)	 0.028	
AAP		 2.0	(15.0)	 -2.0	(7.0)	 -5.0	(16.0)	 -1.5	(2.0)	 0.706	
	
Figure	 34:	 Longitudinal	 variation	 of	 GFR	 according	 to	 ACR	 (left	 image)	 or	 NAG	 (right	 image)	
quartiles	 at	 baseline.	 Errors	 bars:	 ±standard	 error;	 GFR:	 glomerular	 filtration	 rate;	 ACR:	 urinary	 albumin	 to	
creatinine	ratio;	NAG:	urinary	N-acetyl-β-D-glucosaminidase	excretion.	
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There	 was	 no	 significant	 difference	 in	 the	 distribution	 of	 ACR	 or	 GFR	 non-
progressors	and	progressor	between	 the	quartiles	 for	all	 studied	biomarkers	 (table	57);	
however,	there	was	a	trend	of	a	great	proportion	of	progressor	in	the	higher	quartiles.	
For	ACR	progression,	 one	patient	 in	 the	 fourth	quartile	 of	ACR	 concentration	 at	
baseline	 has	 OR	 of	 10.5	 (95%	 CI:	 1.14-96.58)	 to	 be	 progressor,	 in	 comparison	 with	 a	
patient	 in	 the	 first	 quartile;	 none	 of	 the	 other	 biomarkers	 exhibited	 a	 significant	 OR	
comparing	quartile	1	and	4.	
ACR	and	urinary	NAG	excretion	both	presented	a	significant	OR	to	identify	a	GFR	
progressor,	 comparing	quartile	1	and	4.	A	patient	 in	 the	 fourth	quartile	of	ACR	or	NAG	
distribution	presented	an	OR	of	4.17	 (95%	CI:	 1.00-17-31)	or	4.80	 (95%	CI:	 1.04-22.10),	
respectively	to	be	a	progressor,	in	comparison	with	a	patient	in	the	first	quartile.	For	the	
other	biomarkers	the	OR	was	non-significant.		
	
Table	 57:	 Distribution	 of	 ACR	 or	 GFR	 progressors	 according	 to	 quartiles	 of	 the	 baseline	
concentration	of	the	biomarkers.	*	for	the	distribution	of	non-progressors	and	progressors	across	the	quartiles;	
**	of	being	a	progressor	comparing	fourth	to	 first	quartile;	ACR:	urinary	albumin	to	creatinine	ratio;	GFR:	glomerular	
filtration	rate;	OR:	odds	ratio;	NP:	non-progressor;	P:	progressor;	Q:	quartile;	UTE:	urinary	transferrin	excretion;	ColIV:	
urinary	 collagen	 type	 IV	 excretion;	 A1MG:	 urinary	 α1-microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-
glucosaminidase	excretion;	AAP:	urinary	alanine	aminopeptidase	excretion. 
	 ACR	 p	value*	 OR**	 	 GFR	 p	value*	 OR**	NP	(%)	 P	(%)	 	 NP	(%)	 P	(%)	
ACR	
Q1	 94.7	 5.3	
0.122	 10.50	(1.14-96.58)	
	 78.9	 21.1	
0.065	 4.17	(1.00-17.31)	
Q2	 80	 20	 	 75.0	 25.0	
Q3	 78.9	 21.1	 	 85.0	 15.0	
Q4	 63.2	 36.8	 	 47.4	 52.6	
UTE	
Q1	 90.0	 10.0	
0.303	 4.15	(0.72-23.95)	
	 80.0	 20.0	
0.433	 1.85	(0.43-7.96)	
Q2	 72.2	 27.8	 	 68.4	 31.6	
Q3	 85.0	 15.0	 	 55.0	 45.0	
Q4	 68.4	 31.6	 	 68.4	 31.6	
ColIV	
Q1	 89.5	 10.5	
0.153	 4.96		(0.87-28.15)	
	 78.9	 21.1	
0.635	 1.00	(0.21-4.76)	
Q2	 89.5	 10.5	 	 65.0	 25.0	
Q3	 75.0	 25.0	 	 65.0	 25.0	
Q4	 63.2	 36.8	 	 78.9	 21.1	
A1MG	
Q1	 89.5	 10.5	
0.665	 3.04	(0.51-18.11)	
	 84.2	 15.8	
0.084	 1.42		(0.27-7.44)	
Q2	 78.9	 21.1	 	 60.0	 40.0	
Q3	 75.0	 25.0	 	 50.0	 50.0	
Q4	 73.7	 26.3	 	 78.9	 21.1	
NAG	
Q1	 83.3	 16.7	
0.238	 2.92	(0.62-13.76)	
	 83.3	 16.7	
0.149	 4.80	(1.04-22.10)	
Q2	 90.0	 10.0	 	 75.0	 25.0	
Q3	 80.0	 20.0	 	 60.0	 40.0	
Q4	 63.2	 36.8	 	 52.6	 47.4	
AAP	
Q1	 83.3	 16.7	
0.825	 1.92		(0.38-9.65)	
	 72.2	 27.8	
0.197	 0.52	(0.10-2.61)	
Q2	 77.8	 22.2	 	 78.9	 21.1	
Q3	 84.2	 15.8	 	 52.6	 47.4	
Q4	 72.2	 27.8	 	 83.3	 16.7	
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Comparing	 the	 baseline	 concentration	 of	 biomarkers	 between	 ACR	 progressors	
and	non-progressors,	it	was	significantly	higher	for	ACR	(mean:	320.8	versus	250.3mg/g),	
urinary	 ColIV	 excretion	 (mean:	 22.21	 versus	 11.81mg/g)	 and	 urinary	 NAG	 excretion	
(mean:	24.90	versus	18.22U/g)	(table	58).		
Concerning	the	comparison	of	the	baseline	biomarker	concentration	between	GFR	
progressors	 and	 non-progressors,	 it	 was	 only	 significantly	 higher	 for	 ACR	 (mean:	 562.0	
versus	144.7mg/g)	and	urinary	NAG	excretion	(mean:	23.44	versus	17.59U/g).		
	
Table	 58:	 Comparison	 of	 the	 baseline	 concentration	 of	 the	 biomarkers	 between	 ACR	 or	 GFR	
non-progressors	 and	 progressors.	 Expressed	as	median	 (IQR);	ACR:	urinary	albumin	 to	 creatinine	 ratio;	GFR:	
glomerular	filtration	rate;	NP:	non-progressor;	P:	progressor;	UTE:	urinary	transferrin	excretion;	ColIV:	urinary	collagen	
type	 IV	 excretion;	 A1MG:	 urinary	 α1-microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-glucosaminidase	 excretion;	
AAP:	urinary	alanine	aminopeptidase	excretion. 
	 ACR	 p	value	 	 GFR	 p	value	NP	 P	 	 NP	 P	
ACR	(mg/g)	 42.6	(239.8)	 131.0	(1077.6)	 0.032	 	 37.6	(122.0)	 252.1	(678.5)	 0.019	
UTE	(μg/g)	 1.07	(1.42)	 1.20	(2.06)	 0.312	 	 1.02	(1.49)	 1.18	(0.86)	 0.366	
ColIV	(mg/g)	 8.06	(10.26)	 13.00	(14.11)	 0.037	 	 8.76	(13.43)	 8.61	(6.49)	 0.890	
A1MG	(mg/g)	 522.9	(623.6)	 710.6	(983.7)	 0.292	 	 510.5	(870.5)	 587.3	(289.5)	 0.338	
NAG	(U/g)	 13.99	(15.39)	 22.20	(23.0)	 0.049	 	 13.80	(14.60)	 22.02	(19.18)	 0.029	
AAP	(U/g)	 13.21	(13.50)	 16.68	(17.25)	 0.571	 	 12.86	(17.44)	 13.78	(9.31)	 0.843	
	
Moreover,	there	was	a	progressive	increase	in	the	ACR	and	urinary	NAG	excretion	
between	non-progressing	patients,	patients	with	only	ACR	progression,	patients	with	only	
GFR	progression	and	patients	presenting	ACR	and	GFR	progression	(figure	35).		
Figure	35:	Comparison	of	ACR	(left	image)	or	NAG	(right	image)	baseline	concentration	between	
subgroups	of	progression.	From	left	to	right:	non-progressors,	only	ACR	progressor	patients,	only	
GFR	progressor	patients	 and	patients	presenting	ACR	and	GFR	progression.	 ACR:	urinary	albumin	to	
creatinine	ratio;	GFR:	glomerular	filtration	rate;	NAG:	urinary	N-acetyl-β-D-glucosaminidase	excretion.	
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2.5.4	Correlation	between	variations	of	biomarkers	and	glomerular	filtration	rate		
To	 evaluate	 the	 correlation	 between	 the	 variation	 of	 the	 biomarkers	 and	 the	
variation	 of	 ACR	 or	 estimated	 GFR,	 I	 evaluated	 the	 variation	 of	 the	 different	 variables	
between	baseline	and	12	months	and	between	12	and	24	months	and	considered	each	
variation	in	correlation	analysis.	
ACR	variation	only	significantly	correlated	with	urinary	A1MG	excretion	(ρ=0.226;	
p=0.019)	 (table	 59).	 The	 unique	 biomarker	 whose	 variation	 has	 significant	 inverse	
correlation	 with	 GFR	 variation	 was	 NAG	 (ρ=-0.361;	 p<0.001);	 remarkably,	 this	 inverse	
correlation	 was	 non-significant	 between	 ACR	 and	 GFR	 variations	 (ρ=-0.127;	 p=0.131)	
(figure	36).	
	
Table	59:	Correlation	between	the	variation	of	 the	biomarkers	and	ACR	or	GFR	variation.	 ACR:	
urinary	 albumin	 to	 creatinine	 ratio;	 GFR:	 glomerular	 filtration	 rate;	 Δ:	 variation;	 UTE:	 urinary	 transferrin	 excretion;	
ColIV:	 urinary	 collagen	 type	 IV	 excretion;	 A1MG:	 urinary	 α1-microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-
glucosaminidase	excretion;	AAP:	urinary	alanine	aminopeptidase	excretion. 
	 ACR	variation	 	 GFR	variation	ρ	 p	value	 	 ρ	 p	value	
Δ	ACR	 -	 -	 	 -0.127	 0.131	
Δ	UTE		 0.133	 0.175	 	 0.118	 0.227	
Δ	ColIV		 0.148	 0.125	 	 0.020	 0.837	
Δ	A1MG	 0.226	 0.019	 	 0.094	 0.332	
Δ	NAG	 0.135	 0.161	 	 -0.361	 <0.001	
Δ	AAP		 0.148	 0.131	 	 0.228	 0.019	
	
Figure	 36:	 Correlation	 between	 GFR	 variation	 and	 ACR	 (left	 image)	 or	 NAG	 (right	 image)	
variation.	 GFR:	 glomerular	 filtration	 rate;	 ACR:	 urinary	 albumin	 to	 creatinine	 ratio;	 NAG:	 urinary	 N-acetyl-β-D-
glucosaminidase	excretion.	
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2.5.5	Longitudinal	variation	and	risk	of	progression		
Comparing	the	ACR	or	GFR	non-progressors	and	progressors,	the	variation	of	the	
biomarkers	during	follow-up	was	only	significantly	higher	in	progressors	for	urinary	NAG	
excretion,	both	for	ACR	and	GFR	progressors	(table	60).	For	example,	there	was	a	mean	
difference	of	31.74U/g	(p<0.001)	for	urinary	NAG	excretion,	comparing	GFR	progressors	
and	non-progressors;	whereas	for	ACR	the	mean	difference	was	34.1mg/g	(p=0.792).		
	
Table	60:	Comparison	of	the	variation	in	the	concentration	of	the	biomarkers	between	ACR	or	
GFR	 non-progressors	 and	 progressors.	 Expressed	as	median	(IQR);	ACR:	urinary	albumin	to	creatinine	ratio;	
GFR:	 glomerular	 filtration	 rate;	 NP:	 non-progressor;	 P:	 progressor;	 Δ:	 	 variation;	 UTE:	 urinary	 transferrin	 excretion;	
ColIV:	 urinary	 collagen	 type	 IV	 excretion;	 A1MG:	 urinary	 α1-microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-
glucosaminidase	excretion;	AAP:	urinary	alanine	aminopeptidase	excretion. 
	 ACR	 p	value	 	 GFR	 p	value	NP	 P	 	 NP	 P	
Δ	ACR	(mg/g)	 -	 -	 -	 	 -0.05	(42.7)	 -0.1	(261.2)	 0.792	
Δ	UTE		(μg/g)	 0.09	(1.30)	 0.17	(1.57)	 0.792	 	 0.09	(1.89)	 0.13	(0.78)	 0.919	
Δ	ColIV		(mg/g)	 2.39	(10.59)	 -3.21	(16.74)	 0.060	 	 1.33	(16.27)	 2.43	(8.60)	 0.780	
Δ	A1MG		(mg/g)	 -17.06	(525.33)	 78.62	(632.49)	 0.983	 	 69.79	(648.69)	 -39.03	(406.16)	 0.591	
Δ	NAG	(U/g)	 4.92	(27.84)	 23.22	(22.76)	 0.027	 	 1.49	(19.77)	 27.55	(48.95)	 <0.001	
Δ	AAP	(U/g)	 -2.56	(13.63)	 2.37	(33.25)	 0.396	 	 -2.71	(15.88)	 -1.51	(12.05)	 0.554	
	
There	was	no	significant	difference	in	the	distribution	of	ACR	non-progressors	and	
progressors	between	 the	quartiles	 for	 all	 studied	biomarkers	 (table	61),	 although	 there	
was	 a	 trend	 of	 a	 great	 proportion	 of	 progressors	 in	 the	 higher	 quartile	 of	 variation	 of	
urinary	NAG	excretion.	However,	the	OR	of	a	patient	in	the	fourth	quartile	to	be	an	ACR	
progressor,	in	comparison	with	a	patient	in	the	first	quartile	was	non-significant:	OR	3.08	
(95%	CI:	0.51-18.54).	
Furthermore,	 the	 distribution	 of	 urinary	 NAG	 excretion	 variation	 between	 GFR	
non-progressors	and	progressors	was	also	significantly	different	(p<0.001),	with	an	OR	of	
13.00	(95%	CI:	2.59-65.20)	to	be	a	progressor	comparing	quartiles	4	and	1;	72.2%	of	the	
patients	 in	 the	 fourth	quartile	were	GFR	progressors,	 in	 comparison	with	only	16.7%	 in	
the	first	quartile.		
Contrariwise,	 ACR	 variation	 during	 follow-up	 did	 not	 significantly	 predict	 the	
probability	of	an	individual	patient	being	a	progressor,	with	an	OR	of	1.25	(95%	CI:	0.34-
4.59)	 between	 quartiles	 4	 and	 1.	 The	 distribution	 of	 the	 variation	 of	 the	 remaining	
biomarkers	was	also	non-statistically	significant.		
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Table	61:	Distribution	of	ACR	or	GFR	progressors	according	to	quartiles	of	the	variation	 in	the	
concentration	of	the	biomarkers.	*	for	the	distribution	of	non-progressors	and	progressors	across	the	quartiles;	
**	of	being	a	progressor	comparing	fourth	to	 first	quartile;	ACR:	urinary	albumin	to	creatinine	ratio;	GFR:	glomerular	
filtration	 rate;	 OR:	 odds	 ratio;	 NP:	 non-progressor;	 P:	 progressor;	 Δ:	 variation;	 Q:	 quartile;	 UTE:	 urinary	 transferrin	
excretion;	ColIV:	urinary	collagen	type	IV	excretion;	A1MG:	urinary	α1-microglobulin	excretion;	NAG:	urinary	N-acetyl-β-
D-glucosaminidase	excretion;	AAP:	urinary	alanine	aminopeptidase	excretion. 
	 ACR	 p	value*	 OR**	 	 GFR	 p	value*	 OR**	NP	(%)	 P	(%)	 	 NP	(%)	 P	(%)	
Δ	ACR	
Q1	 -	 -	
-	 -	
	 63.2	 36.8	
0.266	 1.25	(0.34-4.59)	
Q2	 -	 -	 	 82.4	 17.6	
Q3	 -	 -	 	 80.9	 19.1	
Q4	 -	 -	 	 57.9	 42.1	
Δ	UTE	
Q1	 77.8	 22.2	
0.480	 0.44	(0.07-2.76)	
	 77.8	 22.2	
0.067	 0.70	(0.13-3.70)	
Q2	 83.3	 16.7	 	 61.1	 38.9	
Q3	 66.7	 33.3	 	 44.4	 55.6	
Q4	 88.9	 11.1	 	 83.3	 16.7	
Δ	ColIV	
Q1	 61.1	 38.9	
0.138	 0.20	(0.03-1.13)	
	 77.8	 22.2	
0.447	 1.00	(0.21-4.81)	
Q2	 77.8	 22.2	 	 72.2	 27.8	
Q3	 88.9	 11.1	 	 55.6	 44.4	
Q4	 88.9	 11.1	 	 77.8	 22.2	
Δ	A1MG	
Q1	 77.8	 22.2	
0.919	 0.70	(0.13-3.70)	
	 77.8	 22.2	
0.067	 0.70	(0.13-3.70)	
Q2	 83.3	 16.7	 	 44.4	 55.6	
Q3	 72.2	 27.8	 	 61.1	 38.9	
Q4	 83.3	 16.7	 	 83.3	 16.7	
Δ	NAG	
Q1	 88.9	 11.1	
0.291	 3.08	(0.51-18.54)	
	 83.3	 16.7	
<0.001	 13.00	(2.59-65.20)	
Q2	 88.9	 11.1	 	 100	 0	
Q3	 66.7	 33.3	 	 55.6	 44.4	
Q4	 72.2	 27.8	 	 27.8	 72.2	
Δ	AAP	
Q1	 82.4	 17.6	
0.750	 1.44	(0.27-7.68)	
	 76.5	 23.5	
0.344	 1.35	(0.29-6.26)	
Q2	 88.2	 11.8	 	 82.4	 17.6	
Q3	 70.6	 29.4	 	 52.9	 47.1	
Q4	 76.5	 23.5	 	 70.6	 29.4		
Only	 the	 higher	 quartile	 of	 variation	 of	 two	 biomarkers,	 ACR	 and	 urinary	 NAG	
excretion,	was	associated	with	a	significantly	higher	risk	of	an	 individual	patient	being	a	
progressor	 (ACR	and/or	GFR)	 (table	62).	However,	 for	ACR	 it	was	 a	predictor	 (OR:	 9.14	
[95%	CI:	1.95-42.90])	due	to	the	definition	of	an	ACR	progressor	(patients	certainly	in	the	
higher	 quartiles	 for	 ACR	 variation),	 given	 that	 there	 was	 no	 difference	 between	 non-
progressors	and	GFR	progressors	 (figure	37),	only	between	ACR	progressors	or	GFR	and	
AACR	progressors	and	the	remaining	subgroups.	
On	the	other	hand,	the	higher	quartile	of	urinary	NAG	excretion	variation	not	only	
gives	an	OR	of	28.00	(95%	CI:	4.44-176.78)	to	be	a	progressor	(in	comparison	with	the	first	
quartile),	 but	 urinary	 NAG	 variation	 increased	 progressively	 between	 non-progressing	
patients,	 patients	 with	 only	 ACR	 progression,	 patients	 with	 only	 GFR	 progression	 and	
patients	presenting	both	ACR	and	GFR	progression	(p<0.001).	
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Table	 62:	 Distribution	 of	 progressors	 (ACR	 and/or	 GFR)	 and	 non-progressors	 in	 the	 first	 and	
fourth	 quartile	 of	 the	 biomarkers’	 variation.	 *	 for	 the	 distribution	 of	 non-progressors	 and	 progressors	
between	 quartiles	 1	 and	 4;	 **	 of	 being	 a	 progressor	 comparing	 fourth	 to	 first	 quartile;	 OR:	 odds	 ratio;	 NP:	 non-
progressor;	 P:	 progressor;	Q:	 quartile;	Δ:	 variation;	ACR:	 urinary	 albumin	 to	 creatinine	 ratio;	UTE:	 urinary	 transferrin	
excretion;	ColIV:	urinary	collagen	type	IV	excretion;	A1MG:	urinary	α1-microglobulin	excretion;	NAG:	urinary	N-acetyl-β-
D-glucosaminidase	excretion;	AAP:	urinary	alanine	aminopeptidase	excretion. 
	 Q1	 	 Q4	 p	value*	 OR**	NP	(%)	 P	(%)	 	 NP	(%)	 P	(%)	
Δ	ACR	 63.2	 36.8	 	 15.8	 84.2	 0.007	 9.14	(1.95-42.90)	
Δ	UTE	 61.1	 38.9	 	 77.8	 22.2	 0.471	 0.45	(0.10-1.93)	
Δ	ColIV	 55.6	 44.4	 	 72.2	 27.8	 0.489	 0.48	(0.12-1.93)	
Δ	A1MG	 61.1	 38.9	 	 72.2	 27.8	 0.725	 0.60	(0.15-2.45)	
Δ	NAG	 77.8	 22.2	 	 11.1	 88.9	 <0.001	 28.00	(4.44-176.78)	
Δ	AAP	 64.7	 35.3	 	 58.5	 41.5	 1.000	 1.28	(0.32-5.13)	
	
Figure	 37:	 Comparison	 of	 ACR	 (left	 image)	 or	 NAG	 (right	 image)	 variation	 in	 concentration	
between	 subgroups	 of	 progression.	 From	 left	 to	 right:	 non-progressors,	 only	 ACR	 progressor	
patients,	 only	 GFR	 progressor	 patients	 and	 patients	 presenting	 ACR	 and	 GFR	 progression.	 ACR:	
urinary	 albumin	 to	 creatinine	 ratio;	 GFR:	 glomerular	 filtration	 rate;	 NAG:	 urinary	 N-acetyl-β-D-glucosaminidase	
excretion.	
	
2.5.6	Longitudinal	variation:	influence	of	gender	and	treatment		
Male	gender	was	a	significant	risk	factor	to	be	an	ACR	progressor	(OR	5.71	[95%	
CI:	1.64-19.92),	but	not	a	GFR	progressor	(OR:	1.54	[95%	CI:	0.53-3.87])	(table	63).	
	
Table	63:	Progressing	and	non-progressing	Fabry	disease	patients:	analysis	by	gender.	ACR:	urinary	
albumin	 to	 creatinine	 ratio;	GFR:	 estimated	glomerular	 filtration	 rate;	NP:	non-progressors;	 P:	 progressors;	OR:	odds	
ratio.	
	 ACR	 	 GFR	NP	(%)	 P	(%)	 OR	 	 NP	(%)	 P	(%)	 OR	
Females	 90.9	 9.1	 5.71	
(1.64-19.92)	
	 75.0	 25.0	 1.44		
(0.53-3.87)	Males	 63.6	 36.4	 	 67.6	 32.4	
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However,	this	exploratory	analysis	by	gender	was	hampered	by	the	small	sample	
of	 patients	 classified	 as	 progressors,	 mainly	 in	 the	 female	 gender.	 Therefore,	 the	
significant	 difference	 in	 baseline	 concentration	 of	 ACR	 and	 urinary	 NAG	 excretion,	
between	ACR	or	GFR	non-progressors	 and	progressors,	was	no	 longer	 significant	 in	 the	
female	 patient	 subgroup	 (table	 64).	 Furthermore,	 the	 same	 was	 also	 true	 for	 the	
difference	 of	 ACR	 concentration	 between	ACR	 non-progressors	 and	 progressor	 in	male	
patients.	Nonetheless,	 the	difference	 in	baseline	urinary	A1MG	concentration,	between	
ACR	or	GFR	non-progressors	and	progressors,	emerged	as	significant	in	the	male	patient	
subgroup.		
	
Table	 64:	 Comparison	 of	 the	 baseline	 concentration	 of	 the	 biomarkers	 between	 ACR	 or	 GFR	
non-progressors	 and	 progressors:	 stratification	 by	 gender.	 Expressed	 as	 median	 (IQR);	 ACR:	 urinary	
albumin	to	creatinine	ratio;	GFR:	glomerular	filtration	rate;	NP:	non-progressor;	P:	progressor;	UTE:	urinary	transferrin	
excretion;	ColIV:	urinary	collagen	type	IV	excretion;	A1MG:	urinary	α1-microglobulin	excretion;	NAG:	urinary	N-acetyl-β-
D-glucosaminidase	excretion;	AAP:	urinary	alanine	aminopeptidase	excretion.	
	 ACR	 	 GFR	NP	 P	 p	value	 	 NP	 P	 p	value	
ACR	(mg/g)	 ♀	 28.7	(116.1)	 106.8	(522.4)	 0.351	 	 26.1	(111.1)	 43.4	(1506.2)	 0.650	
♂	 206.2	(320.6)	 242.8	(513.2)	 0.258	 	 74.2	(311.5)	 350.5	(433.5)	 0.013	
UTE		(μg/g)	 ♀	 1.09	(1.33)	 1.36	(3.17)	 0.953	 	 1.18	(1.73)	 1.00	(0.74)	 0.612	
♂	 1.01	(1.26)	 1.20	(1.95)	 0.200	 	 0.70	(1.20)	 1.31	(1.13)	 0.060	
ColIV	(mg/g)	
♀	 8.93	(13.38)	 11.42	(26.81)	 0.768	 	 11.18	(15.37)	 8.60	(5.51)	 0.321	
♂	 6.58	(7.23)	 14.79	(14.11)	 0.006	 	 7.71	(11.25)	 8.62	(10.12)	 0.403	
A1MG		(mg/g)	 ♀	 600.61	(818.1)	 569.35	(1116.3)	
0.738	 	 683.5	(912.1)	 537.6	(343.1)	 0.594	
♂	 464.1	(365.7)	 710.6	(977.7)	 0.030	 	 342.7	(365.7)	 628.8	(301.6)	 0.022	
NAG	(U/g)	 ♀	 14.64	(17.40)	 18.88	(24.07)	 0.798	 	 15.34	(16.04)	 17.94	(20.93)	 0.928	
♂	 13.45	(9.80)	 25.95	(25.99)	 0.016	 	 9.67	(8.02)	 22.02	(20.57)	 0.001	
AAP	(U/g)	
♀	 16.02	(16.19)	 7.82	(23.63)	 0.293	 	 17.56	(20.78)	 11.78	(12.89)	 0.238	
♂	 11.70	(8.34)	 16.95	(31.12)	 0.035	 	 11.70	(13.69)	 14.47	(4.29)	 0.145	
	
The	 significant	 difference	 in	 longitudinal	 variation	 of	 urinary	NAG	 concentration	
between	 ACR	 non-progressors	 and	 progressors	 was	 no	 longer	 significant	 in	 the	 sub-
analysis	by	gender	(table	65).	However,	the	significant	difference	in	longitudinal	variation	
between	GFR	non-progressors	and	progressors	 remained	significant	 in	both	 female	and	
male	 patients.	 The	 variation	 of	 all	 other	 biomarkers	 was	 no	 different	 between	 non-
progressors	and	progressors.		
This	study	was	not	designed	to	access	the	effect	of	ERT	or	anti-proteinuric	agents	
(ACEi	 or	 ARB)	 on	 the	 biomarkers.	 However,	 I	 approached	 this	 issue	 as	 an	 exploratory	
endpoint.	 All	 comparative	 analysis	 has	 been	 adjusted	 for	 age,	 ACR,	 estimated	GFR	 and	
MSSI,	as	treated	patients	usually	have	a	more	severe	disease.		
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Table	65:	Comparison	of	the	variation	in	the	concentration	of	the	biomarkers	between	ACR	or	
GFR	non-progressors	and	progressors:	stratification	by	gender.	Expressed	as	median	(IQR);	ACR:	urinary	
albumin	to	creatinine	ratio;	GFR:	glomerular	filtration	rate;	NP:	non-progressor;	P:	progressor;	Δ:	variation;	UTE:	urinary	
transferrin	excretion;	ColIV:	urinary	collagen	type	IV	excretion;	A1MG:	urinary	α1-microglobulin	excretion;	NAG:	urinary	
N-acetyl-β-D-glucosaminidase	excretion;	AAP:	urinary	alanine	aminopeptidase	excretion.	
	 ACR	 	 GFR	NP	 P	 p	value	 	 NP	 P	 p	value	
Δ	ACR	(mg/g)	 ♀	 -	 -	 -	 	 -3.0	(54.1)	 -0.1	(103.7)	 0.612	
♂	 -	 -	 -	 	 3.4	(79.2)	 -0.1	(821.3)	 0.925	
Δ	UTE		(μg/g)	 ♀	 0.13	(1.73)	 0.25	(.)	 0.723	 	 0.07	(2.30)	 0.18	(0.37)	 0.591	
♂	 -0.01	(1.30)	 0.13	(1.40)	 0.675	 	 0.10	(1.71)	 -0.15	(1.09)	 0.441	
Δ	ColIV	(mg/g)	
♀	 2.44	(14.38)	 -1.47	(.)	 0.345	 	 1.41	(22.27)	 3.73	(7.08)	 0.393	
♂	 1.06	(7.03)	 -3.55	(16.00)	 0.164	 	 1.20	(7.42)	 -3.10	(9.14)	 0.502	
Δ	A1MG		(mg/g)	 ♀	 4.98	(744.68)	 78.62	(.)	
0.869	 	 15.78	(1073.24)	 45.90	(290.08)	 0.896	
♂	 -17.06	(416.72)	 2.50	(597.17)	 0.965	 	 72.94	(454.13)	 -146.26	(372.01)	 0.401	
Δ	NAG	(U/g)	 ♀	 1.47	(24.61)	 0.17	(.)	 0.759	 	 -1.18	(15.67)	 27.54	(66.63)	 0.007	
♂	 11.99	(37.05)	 24.26	(8.60)	 0.269	 	 9.62	(23.30)	 34.92	(41.29)	 0.007	
Δ	AAP	(U/g)	
♀	 -2.43	(13.88)	 7.00	(8.41)	 0.122	 	 -2.27	(18.15)	 2.18	(11.55)	 0.466	
♂	 -2.68	(13.62)	 -2.39	(16.44)	 0.857	 	 -3.41	(16.07)	 -1.98	(11.30)	 0.859	
	
After	adjustment	for	disease	severity	all	biomarkers,	except	urinary	AAP	excretion,	
evidenced	a	trend	of	a	decreased	variation	in	patients	under	ERT,	but	this	difference	was	
not	 significant	 for	 any	biomarker	 (table	 66).	 The	 effect	 of	 anti-proteinuric	 treatment	 in	
the	 variation	of	 the	biomarkers	 concentration	was	 less	 evident,	without	 any	 consistent	
decreased	variation	in	treated	patients.		
	
Table	 66:	 Nephropathy	 study:	 comparison	 of	 the	 variation	 in	 the	 concentration	 of	 the	
biomarkers	 between	patients	 under	 or	 not	 under	 ERT	or	ACEi	 /	ARB.	 Expressed	as	mean	(standard	
error);	ERT:	enzyme	replacement	 therapy;	ACEi:	angiotensin	converting	enzyme	 inhibitors;	ARB:	angiotensin	 receptor	
blockers;	 Δ:	 variation;	 ACR:	 urinary	 albumin	 to	 creatinine	 ratio;	 UTE:	 urinary	 transferrin	 excretion;	 ColIV:	 urinary	
collagen	 type	 IV	 excretion;	 A1MG:	 urinary	 α1-microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-glucosaminidase	
excretion;	AAP:	urinary	alanine	aminopeptidase	excretion. 
	 ERT	 p	value	 	 ACEi	/	ARB	 p	value	No	 Yes	 	 No	 Yes	
Δ	ACR	(mg/g)	 30.4	(90.4)	 17.3	(55.1)	 0.910	 	 -33.5	(63.2)	 79.0	(65.1)	 0.245	
Δ	UTE		(μg/g)	 -0.09	(0.45)	 -0.19	(0.29)	 0.865	 	 -0.29	(0.34)	 -0.02	(0.33)	 0.590	
Δ	ColIV		(mg/g)	 1.91	(4.21)	 -0.18	(2.68)	 0.700	 	 1.02	(3.14)	 -0.04	(3.14)	 0.823	
Δ	A1MG		(mg/g)	 -181.2	(201.2)	 -40.6	(129.0)	 0.586	 	 -261.0	(152.9)	 80.5	(148.1)	 0.139	
Δ	NAG	(U/g)	 17.53	(7.38)	 12.60	(4.99)	 0.609	 	 13.84	(6.60)	 14.60	(5.70)	 0.938	
Δ	AAP	(U/g)	 -4.11	(4.17)	 -0.18	(2.65)	 0.471	 	 -1.36	(2.98)	 -1.54	(3.08)	 0.968	
	
Due	to	the	reduced	number	of	patients	starting	ERT	or	anti-proteinuric	during	the	
study,	 the	 comparison	 between	 patients	 starting	 these	 treatment,	 or	 not,	 was	 clearly	
underpowered.	However,	there	was	a	non-significant	trend	of	a	decreased	variation	in	all	
biomarkers	in	patients	staring	ERT	or	ACEi	/	ARB	(table	67).	
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Table	 67:	 Nephropathy	 study:	 comparison	 of	 the	 variation	 in	 the	 concentration	 of	 the	
biomarkers	between	patients	 starting	ERT	or	ACEi	 /	ARB,	or	not,	during	 the	 study.	Expressed	as	
mean	 (standard	 error);	 ERT:	 enzyme	 replacement	 therapy;	 ACEi:	 angiotensin	 converting	 enzyme	 inhibitors;	 ARB:	
angiotensin	receptor	blockers;	Δ:	variation;	ACR:	urinary	albumin	to	creatinine	ratio;	UTE:	urinary	transferrin	excretion;	
ColIV:	 urinary	 collagen	 type	 IV	 excretion;	 A1MG:	 urinary	 α1-microglobulin	 excretion;	 NAG:	 urinary	 N-acetyl-β-D-
glucosaminidase	excretion;	AAP:	urinary	alanine	aminopeptidase	excretion. 
	 Starting	ERT	 p	value	 	 Starting	ACEi	/	ARB	 p	value	No	 Yes	 	 No	 Yes	
Δ	ACR	(mg/g)	 36.0	(44.4)	 -150.3	(153.0)	 0.247	 	 29.5	(44.4)	 -95.8	(172.6)	 0.486	
Δ	UTE		(μg/g)	 -0.10	(0.23)	 -0.67	(0.77)	 0.483	 	 -0.16	(0.23)	 -0.21	(0.88)	 0.949	
Δ	ColIV		(mg/g)	 0.96	(2.15)	 -4.64	(7.19)	 0.459	 	 0.71	(2.14)	 -2.42	(8.10)	 0.711	
Δ	A1MG		(mg/g)	 -46.9	(103.1)	 -510.4	(345.2)	 0.204	 	 -81.8	(105.3)	 -135.4	(396.5)	 0.897	
Δ	NAG	(U/g)	 16.61	(3.35)	 9.87	(11.21)	 0.567	 	 16.74	(3.37)	 5.69	(12.69)	 0.406	
Δ	AAP	(U/g)	 -1.31	(2.06)	 -3.73	(8.43)	 0.782	 	 -1.41	(2.06)	 -2.07	(8.43)	 0.940	
	
2.6	Discussion	
	 In	 this	 study	my	main	objective	was	 the	 identification	of	biomarkers	of	 incipient	
and	 progressive	 nephropathy	 in	 FD	 and	 not	 biomarkers	 of	 FD	 or	 FD	 nephropathy	 (not	
elevated	 in	 other	 forms	 of	 nephropathy).	 I	 also	 defined	 the	 effect	 of	 therapeutic	
interventions	on	biomarkers	as	an	exploratory	endpoint.		
	 The	 results	 suggest	 that	 the	 studied	 biomarkers	 are	more	 sensitive	 than	ACR	 in	
detecting	incipient	FD	nephropathy,	with	a	significant	increase	for	all	of	them	in	the	early	
stages	of	FD	nephropathy	(subgroup	of	patients	with	albuminuria	A1	and	estimated	GFR	≥	
60ml/min/1.73m2).	Around	50%	of	the	patients	with	albuminuria	A1	presented	increased	
urinary	excretion	of	every	novel	biomarker.	These	findings	were	further	supported	by	the	
highest	sensitivity	of	urinary	NAG	excretion	in	the	diagnosis	of	patients	with	FD	disease,	
showing	that	it	identifies	more	patients	with	nephropathy	than	ACR.	
Moreover,	urinary	NAG	excretion	outperformed	albuminuria	in	the	sensitivity	and	
diagnostic	 accuracy	 for	 CKD	 stage	 ≥	 2.	 The	 relatively	 modest	 DOR	 of	 the	 various	
biomarkers	 was	 mainly	 related	 to	 their	 ability	 to	 identify	 patients	 with	 GFR	 ≥	
90ml/min/1.73m2,	 but	 certainly	 with	 kidney	 involvement	 from	 FD,	 thereby	 diminishing	
their	 specificity	 for	 CKD	 stage	 ≥	 2.	 Nonetheless,	 the	 different	 biomarkers	 are	
complementary,	given	that	for	a	few	patients	only	some	of	them	are	increased	(including	
some	patients	with	ACR	elevation	only)	and	may	be	used	as	a	whole	 in	the	diagnosis	of	
incipient	 FD	 nephropathy,	 reflecting	 the	 aforementioned	 several	 pathophysiological	
pathways	contributing	to	the	development	of	FD	nephropathy	(figure	2).				
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	 Concerning	 the	 prognostic	 value	 of	 the	 biomarkers,	 although	 a	 significant	
progressive	 increase	of	the	biomarkers	along	the	FD	subgroups	of	 increasing	severity	or	
CKD	stages	was	only	found	for	urinary	NAG	excretion,	the	correlation	with	estimated	GFR	
was	 strongest	 for	 urinary	 NAG	 excretion,	 but	 also	 significant	 for	 ACR,	 UTE	 and	 urinary	
ColIV	 excretion.	Moreover,	 in	 the	 earlier	 stage	 of	 FD	 nephropathy,	 all	 but	 one	 (urinary	
AAP	excretion)	of	the	biomarkers	showed	better	correlations	with	GFR	than	albuminuria	
and	 in	multivariate	regression	analysis	urinary	NAG	excretion	was	the	only	remaining	 in	
the	model	of	estimated	GFR	prediction,	after	adjustment	for	age.	
	 The	 prognostic	 value	 of	 urinary	 NAG	 excretion	 was	 further	 confirmed	 in	
longitudinal	 evaluation,	 showing	 that	 urinary	 NAG	 was	 not	 only	 the	 sole	 biomarker	
significantly	 increasing	 its	 urinary	 concentration	 during	 follow-up,	 but	 also	 that	 the	
difference	 in	 urinary	 NAG	 excretion	 between	 CKD	 stages	widened	 in	 the	 same	 period.	
Moreover,	urinary	NAG	concentration	at	baseline	was	the	only	one,	compared	with	the	
other	 biomarkers	 (including	 ACR),	 accurately	 predicting	 the	 subsequent	 slope	 in	 GFR	
variation.	 Urinary	 NAG	 variation	 was	 also	 the	 only	 one	 that	 had	 a	 significant	 inverse	
correlation	 with	 GFR	 variation	 in	 the	 same	 period,	 suggesting	 a	 possible	
pathophysiological	link.				
	 The	 importance	of	the	prognostic	value	of	a	biomarker	 is	clearly	depicted	 in	this	
study,	since,	considering	the	FD	cohort	as	a	whole,	kidney	function	remained	essentially	
stable,	even	in	patients	within	CKD	stages	≥3	or	in	the	most	severe	subgroups;	however,	
according	to	the	definition	in	the	study,	one	fifth	or	more	than	a	quarter	of	the	patients	
were	ACR	or	GFR	progressors,	respectively.			
	 This	 is	 in	accordance	with	several	 studies	 in	 treated	patients	and	natural	history	
studies,	 showing	 that	 the	 progression	 of	 FD	 nephropathy	 is	 heterogeneous	 and	 that	 a	
proportion	 of	 patients	 progress,	 even	 under	 ERT.149,	 194,	 206,	 207	 Several	 risk	 factors	 for	
progression	 in	 treated	 and	 untreated	 patients	 were	 identified,	 namely	 male	 gender,	
proteinuria,	 CKD	 stage	 at	 baseline,	 higher	 degree	 of	 glomerulosclerosis,	 longer	 time	
between	symptom	onset	and	ERT	beginning	and	residual	enzymatic	activity.82,	141,	149,	152,	
194,	206,	207,	212	Actually,	as	noted	above,	proteinuria	seems	to	have	an	important	role	in	FD	
nephropathy	progression,	but	the	magnitude	of	this	influence	is	not	well	established.15,	83,	
141	 These	 findings	 were	 confirmed	 by	 the	 present	 study,	 showing	 that	 the	 prognostic	
value	 of	 ACR	 to	 predict	 subsequent	 GFR	 decline,	 though	 significant,	 is	 limited.	
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Nonetheless,	both	ACR	and	urinary	NAG	excretion	were	significantly	higher	in	ACR	or	GFR	
progressors,	 in	comparison	with	non-progressors	and	the	proportion	of	progressors	was	
also	higher	 in	 the	highest	quartiles	of	both	ACR	and	urinary	NAG	distributions.	Though,	
the	variation	of	urinary	NAG	concentration	during	 follow-up	was	clearly	superior	 to	 the	
variation	of	ACR	in	the	identification	of	progressing	patients,	with	a	very	high	OR	to	be	a	
progressor	in	patients	within	the	fourth	quartile	of	urinary	NAG	variation.		
Thus,	not	only	do	the	studied	biomarkers	seem	to	have	an	important	added	value	
in	the	identification	of	incipient	FD	nephropathy,	but	also	urinary	NAG	excretion	appears	
to	outperform	ACR	as	a	prognostic	biomarker,	clearly	identifying	patients	at	increased	risk	
of	progressive	nephropathy.		
The	 correlations	with	 variables	 related	 to	 demographics,	 diagnosis,	 severity	 and	
treatment	were	not	 significant,	which	argues	 for	 these	biomarkers	 to	be	markers	of	FD	
nephropathy	 and	 not	 of	 overall	 disease	 burden.	 One	 exception	 was	 the	 correlation	
between	ACR	and	urinary	NAG	excretion	with	severity	indexes	(MSSI	and	FIPI),	but	both	
indexes	 comprise	 a	 renal	 component	 /	 involvement229,	 693	 and	 nephropathy	 is	 a	 well-
known	 determinant	 of	 overall	 disease	 prognosis	 and	 burden.10,	 86,	 87	 The	 correlation	
between	urinary	NAG	excretion	and	age	seems	related	to	the	decrease	in	kidney	function	
associated	 with	 ageing,	 as	 evidenced	 by	 the	 maintenance	 of	 the	 significant	 inverse	
correlation	between	NAG	and	estimated	GFR	after	adjustment	for	age.			
The	 absence	 of	 difference	 in	 the	 various	 biomarkers	 according	 to	 gender	 is	
understandable,	 given	 the	 balanced	 gender	 distribution	 within	 the	 subgroups	 of	
increasing	FD	nephropathy.	However,	when	cross-sectional	and	longitudinal	correlations	
and	 comparisons	 were	 stratified	 by	 gender,	 the	 correlations	 were	 weaker	 and	
comparisons	of	smaller	magnitude	in	female	patients.	This	finding	may	be	related	to	the	
small	sample	for	subgroup	analysis;	however,	as	in	female	patients	disease	onset	occurs	
latter	and	the	phenotype	tends	to	be	milder	and	nephropathy	progression	slower,10,	11,	82,	
141	 accurate	 prognostic	 biomarkers	 are	 crucial	 and	 an	 appropriate	 study	 design	 to	
establish	the	prognostic	value	of	biomarkers	in	both	genders	is	mandatory.				
The	study	was	also	not	designed	to	access	the	effect	of	ERT	on	the	biomarkers,	but	
given	 the	 greater	 proportion	 of	 patients	 on	 ERT	 in	 the	 more	 severe	 subgroups,	 it	 is	
probably	 due	 to	 this	 reason	 that	 the	 concentration	of	 biomarkers	was	 similar	 between	
treated	and	untreated	patients.	Actually,	in	an	exploratory	analysis,	adjusted	for	age	and	
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nephropathy	and	overall	disease	severity,	 I	was	able	to	 identify	that	 in	patients	under	/	
starting	ERT,	the	biomarkers	increased	less	or	even	decreased	during	follow-up,	although	
the	difference	to	the	remaining	patients	was	non-significant.		
The	effects	of	ERT	on	nonspecific	chronic	histological	 lesions	of	FD	nephropathy,	
like	glomerulosclerosis,	vascular	hyalinosis	and	tubulointerstitial	fibrosis	in	not	known.	A	
few	studies	confirmed	that	ERT	clears	glycosphingolipid	inclusions	from	several	renal	cell	
types,	including	endothelial,	tubular,	interstitial	and	mesangial	cells	(with	an	inconsistent	
and	only	 partial	 clearance	of	 inclusions	 in	 glomerular	 podocytes),79,	166,	178	 but	 only	 one	
study	showed	 that	ERT	decreased	mesangial	widening.165	Thus,	 the	 influence	of	ERT	on	
these	 biomarkers	 that	 seems	 to	 be	 related	 to	 histological	 findings,	 like	 mesangial	
widening	 (urinary	 ColIV	 excretion)	 and	 tubular	 atrophy	 and	 dysfunction	 (urinary	 NAG	
excretion),	deserves	detailed	study	and	may	be	of	paramount	interest	in	clinical	practice.			
	
2.6.1	Glomerular	damage	biomarkers		
As	 previously	 mentioned,	 transferrin	 is	 a	 molecule	 slightly	 larger	 than	 albumin	
(molecular	radius	4.0nm	versus	3.6nm),	but	less	anionic,	thus	expected	to	be	more	readily	
filtered	through	the	glomeruli	and	useful	as	a	surrogate	marker	of	glomerular	damage.480,	
481	Moreover,	UTE	 is	also	a	marker	of	proximal	 tubular	dysfunction,	because	transferrin	
resorption	 depends	 on	 the	 integrity	 of	 late	 endosomal	 /	 lysosomal	 trafficking	 for	
intracellular	processing	in	the	tubular	proximal	cells.485			
	 Therefore,	 as	 both	 GBM	 and	 lysosomal	 system	 in	 proximal	 tubular	 cells	 are	
damaged	 in	FD,	 there	 is	a	good	 rational	 for	 the	use	of	 transferrin	as	a	biomarker	 in	FD	
nephropathy.	Actually,	an	increase	in	UTE	was	found	in	a	small	cohort	of	females	with	FD,	
which	 tended	 to	 decrease	 in	 patients	 treated	with	 ERT;307	 I	 was	 able	 to	 confirm	 these	
results,	showing	an	increase	in	UTE	in	FD	patients	in	comparison	with	healthy	controls.	
	 Moreover,	as	reported	in	diabetic	nephropathy	(in	up	to	61%	of	the	patients	with	
albuminuria	A1),488,	498	UTE	may	be	a	more	sensitive	marker	of	glomerular	damage	being	
raised	 in	the	subgroup	of	FD	patients	and	albuminuria	A1.	However,	distinct	to	diabetic	
nephropathy,	I	did	not	find	a	progressive	increase	in	UTE	with	increasing	albuminuria	and	
an	almost	universal	increase	in	UTE	in	patients	presenting	albuminuria	A2	and	A3	(I	found	
some	 patients	 in	 subgroups	 2	 and	 3	with	 UTE	 in	 the	 range	 of	 the	 control	 group).	 This	
difference	 may	 be	 explained	 by	 methodological	 aspects	 (studies	 evaluating	 UTE	 in	 24	
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hour	urine	and	 the	 laboratorial	methods	used)	and	 the	heterogeneity	of	 FD	phenotype	
and	 physiopathological	 pathways	 involved.488,	 498	 Nonetheless,	 as	 in	 diabetic	
nephropathy,	I	was	able	to	show	a	significant	correlation	with	ACR,	documenting	a	similar	
glomerular	leak	and	tubule	handling	for	these	two	proteins,	as	well	as	a	significant	inverse	
correlation	with	estimated	GFR.488,	490						
	 UTE	was	identified	as	a	good	prognostic	marker	in	diabetes,	because	it	identified	
patients	at	higher	risk	of	developing	albuminuria	A2	in	two	studies	with	follow-up	periods	
of	24	and	60	months	and	may	contribute	 to	 tubular	damage	due	 to	 release	of	 reactive	
iron	 and	 oxidative	 stress	 in	 the	 tubular	 epithelium;480,	 490,	 509	 in	 diabetic	 nephropathy	
model	there	are	no	reports	evaluating	the	prognostic	significance	of	UTE	in	terms	of	GFR	
decline.	 In	 this	 study,	 the	prognostic	 value	of	UTE	was,	 at	 least,	 limited,	 since	UTE	 just	
increased	in	the	subgroup	of	patients	with	albuminuria	A3	and	neither	its	baseline	values,	
nor	its	variation	during	follow-up	predicted	the	progression	in	terms	of	an	increase	in	ACR	
or	a	decline	in	GFR.	However,	this	study	is	limited	by	the	sample	dimension	(in	the	setting	
of	 a	 rare	 disorder),	 with	 only	 25	 normoalbuminuric	 patients	 recruited	 (a	 very	 small	
proportion	 progressing	 to	 albuminuria	 A2)	 and	 by	 the	 short	 follow-up	 period	 of	 24	
months.	 In	 a	 slowly	 progressive	 disorder	 in	 the	 early	 phases	 of	 nephropathy	 and	with	
heterogeneous	phenotypes,	kidney	function	remained	stable	during	the	follow-up	period	
(considering	the	whole	cohort),	thus	I	think	that	a	prognostic	value	of	UTE	should	not	be	
ruled	out	without	further	research.					
	 The	effect	of	ERT	on	UTE	was	approached	as	an	exploratory	endpoint	and	there	
was	a	trend	of	a	greater	decrease	in	UTE	in	treated	patients	during	the	follow-up	period,	
in	 comparison	 with	 untreated	 patients.	 A	 similar	 effect	 was	 identified	 in	 diabetic	
nephropathy	after	correction	of	the	metabolic	defect	with	hypoglycaemic	agents,	with	a	
significant	decrease	in	the	percentage	of	patients	with	increased	UTE.508		
	 As	 previously	 mentioned,	 in	 males	 ERT	 does	 not	 seem	 to	 decrease	 total	
proteinuria	and	ACR	in	FD	patients.	As	UTE	depends,	as	ACR,	on	increased	permeability	of	
glomerular	membrane	to	plasma	proteins,	the	response	to	ERT	may	be	limited.	However,	
UTE	 is	 also	 a	 biomarker	 of	 proximal	 tubular	 dysfunction	 and,	 although	 Gb3	 storage	 in	
proximal	 tubules	 seems	 of	 lesser	 magnitude	 than	 in	 distal	 tubules,57,	 77,	 79	 UTE	 may	
decrease	 in	 response	 to	 ERT	 if	 tubular	 proximal	 function	 ameliorates.	 Gb3	 storage	 in	
proximal	 tubular	 cells	 may	 decrease	 in	 patients	 under	 ERT,79,	 178	 but	 the	 evidence	
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supporting	 the	 response	 of	 tubulointerstitial	 fibrosis	 to	 ERT	 is	 scant,	 with	 two	 studies	
showing	 no	 increase	 in	 tubulointerstitial	 fibrosis	 in	 treated	 patients.79,	165	Nevertheless,	
experiments	 in	 animal	 models	 and	 cell	 lines,	 not	 only	 showed	 that	 recombinant	 α-
galactosidase	A	reaches	the	proximal	tubular	cells	mainly	via	the	glomerular	filtrate	(and	
to	 a	 lesser	 extent	 by	 uptake	 by	 mannose-6	 phosphate	 receptors	 in	 the	 basolateral	
membrane)	 and	 is	 uptake	 via	 the	 megalin	 receptor,	 but	 also	 that	 ERT	 inhibits	 the	
epithelial-mesenchymal	transition	induced	by	Gb3	and	lyso-Gb3	in	tubular	proximal	cells,	
which	is	one	of	the	pathways	involved	in	tubulointerstitial	fibrosis.702,	715,	716		
	 Concluding,	transferrin	and	albumin	seems	to	be	handled	by	the	glomerulus	and	
proximal	tubule	in	a	similar	manner,	but	UTE	appears	to	have	higher	sensitivity	than	ACR	
to	 detect	 incipient	 FD	 nephropathy,	 although	 its	 prognostic	 value	 seems	 limited	 in	
comparison	with	ACR.		
Due	to	its	high	molecular	weight,	ColIV	is	not	filtered	through	the	glomerulus	and	
its	urinary	excretion	seems	only	marginally	affected	by	the	serum	levels;	thus,	since	the	
source	 of	 urinary	 ColIV	 seems	 to	 be	 GBM	 and	 mesangial	 matrix,	 it	 appears	 to	 be	 a	
surrogate	 marker	 of	 glomerular	 basement	 membrane	 synthesis	 and	 mesangial	 matrix	
remodelling.537	Histological	 studies	 corroborated	urinary	ColIV	excretion	as	a	biomarker	
of	mesangial	expansion	and	GBM	thickening.545,	546			
	 In	 FD,	 podocytes	 are	 among	 the	 earliest	 cells	 to	 be	 (heavily)	 loaded	 with	
glycosphingolipids	deposits,	which	may	activate	pathophysiological	cascades	culminating	
in	 podocyte	 detachment,	 GBM	 thickening	 and	 mesangial	 expansion.58,	 77	 Lyso-Gb3	
activates	 various	 deleterious	 pathways	 in	 podocytes:	 expression	 of	 CD80,	 activation	 of	
Notch1	pathways	and	expression	of	the	cytokine	receptor	CD74,	increased	expression	of	
the	 fibrogenic	 cytokine	 TGF-β1	 and	 subsequent	 increasing	 in	 extracellular	 matrix	
synthesis	(fibronectin	and	ColIV).18,	70,	71		
Urinary	ColIV	excretion	has	never	been	studied	in	FD	nephropathy,	but,	due	to	the	
aforementioned	 reasons,	 its	 concentration	 would	 be	 increased	 in	 FD	 patients.	 In	 this	
study,	 I	 was	 able	 to	 confirm	 this	 hypothesis	 and	 also	 showed	 an	 increase	 of	 ColIV	
excretion	 in	 early	 stages	 of	 FD	 nephropathy	 (in	 FD	 patients	 with	 albuminuria	 A1),	
consistent	 with	 the	 pathological	 findings	 of	 thickening	 or	 duplication	 of	 glomerular	
basement	 membrane	 and	 increased	 mesangial	 extracellular	 in	 incipient	 FD	
nephropathy.57,	 77	 The	 better	 sensitivity	 than	 albuminuria	 to	 detect	 initial	 glomerular	
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damage	 has	 also	 been	 documented	 in	 diabetic	 nephropathy,	with	 up	 to	 49%	 of	 T2DM	
patients	 with	 albuminuria	 A1	 presenting	 increased	 urinary	 ColIV	 excretion.536,	 547,	 552	
However,	 as	 also	 reported	 in	 diabetic	 nephropathy,	 some	 patients	 with	 increased	
albuminuria	 did	 not	 show	 an	 increase	 in	 urinary	 ColIV	 excretion	 and	 there	 was	 no	
progressive	 increase	 in	 urinary	 ColIV	 excretion	 across	 CKD	 stages	 or	 subgroups	 of	
increasing	severity.469,	536,	555	As	in	diabetic	nephropathy,	I	found	a	significant	correlation	
between	 urinary	 ColIV	 excretion	 and	ACR;536,	555	 furthermore,	 ACR	 progressing	 patients	
presented	significantly	higher	excretion	of	ColIV	at	baseline.	Thus,	ACR	and	urinary	ColIV	
excretion	 does	 not	 seem	 to	 reflect	 the	 same	 pathophysiological	 pathway,	 but	 rather	
complementary	 processes,	 certainly	 linked	 and	 contributing	 to	 each	 other,	 given	 that	
mesangial	 and	 GBM	 pathology	 is	 associated	 with	 altered	 permeability	 of	 glomerular	
filtration	barrier	to	plasma	proteins.		
The	 significant	 inverse	 correlation,	 in	 both	 genders,	 between	 urinary	 ColIV	
excretion	and	estimated	GFR	would	suggest	that	ColIV	excretion	is	a	prognostic	factor	in	
FD	 nephropathy.	 This	 is	 in	 accordance	 with	 several	 findings	 in	 diabetic	 nephropathy:	
patients	 with	 greater	 thickening	 of	 glomerular	 basement	 membrane	 and	 mesangial	
fractional	 volumes	 were	 at	 greater	 risk	 of	 decline	 in	 GFR;471	 a	 significant	 inverse	
correlation	 between	 ColIV	 and	 the	 reciprocal	 of	 serum	 creatinine;558	 greater	 risk	 of	
progression	 from	normoalbuminuria	 to	albuminuria	A2	 in	patients	with	 increased	ColIV	
excretion;536,	556	baseline	values	of	urinary	ColIV	were	strong	predictors	of	GFR	changes	in	
follow-up	 studies	 in	 patients	with	 T1DM	and	 T2DM.557,	559,	560	 Even	 in	 FD,	 degenerative	
glomerular	 /	 tubulointerstitial	 lesions	 or	 arterial	 sclerosis	 scores	 are	 the	 histological	
alterations	with	best	correlation	with	age	or	GFR	and,	under	light	microscopy,	segmental	
and/or	 global	 glomerulosclerosis	 were	 found	 to	 be	 the	 only	 pathologic	 correlates	 of	
proteinuria	at	early	stages	of	Fabry	nephropathy.83,	84,	717	
However,	in	the	longitudinal	analysis,	baseline	urinary	ColIV	excretion	was	related,	
as	 noted	 above,	 to	 ACR	 progression,	 but	 not	 to	 GFR	 progression.	 Moreover,	 although	
urinary	ColIV	significantly	increased	in	the	first	twelve	months	and	decreased	thereafter,	
in	a	pattern	similar	to	the	changes	observed	in	estimated	GFR,	there	was	no	correlation	
between	 the	 two	 variables	 and	 variation	 of	 urinary	 ColIV	 excretion	 did	 not	 predict	 the	
GFR	progression	status.	These	findings	may	be	related	to	the	small	sample	and	short	time	
of	follow-up,	as	explained	above	for	UTE.	
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I	 also	 found	 a	 non-significant	 trend	 of	 decreased	 urinary	 ColIV	 excretion	 in	
patients	 treated	with	ERT	or	ACEi	 /	ARB,	whereas	 an	 increasing	 trend	was	 identified	 in	
untreated	patients.	Actually,	 ColIV	may	be	a	 good	biomarker	of	 response	 to	ERT,	 given	
that	the	mesangial	widening	was	showed	to	decrease	in	patients	under	ERT.165	Similarly,	
in	T2DM,	glycaemic	control	with	agonist	of	glucagon-like	peptide-1	and	thiazolidinediones	
significantly	 decreased	 urinary	 ColIV	 excretion.562-564	 The	 effect	 of	 anti-proteinuric	
treatment	 in	 ColIV	 excretion,	 in	 patients	 with	 T2DM	 is	 less	 consistent,	 with	 studies	
showing	conflicting	results.565-567		
Concluding,	 in	 strict	 correlation	 with	 histological	 findings,	 showing	 mesangial	
expansion	 as	 an	 early	 event	 in	 FD	 nephropathy,	 urinary	 ColIV	 excretion	 appears	 to	
increase	 in	 incipient	 FD	 nephropathy	 and	 seems	 a	 good	 predictor	 in	 terms	 of	 ACR	
progression.	However,	its	prognostic	significance	in	terms	of	GFR	progression	and	value	in	
assessing	 response	 to	 ERT	 deserves	 further	 research,	 due	 to	 the	 strong	 rational	
supporting	its	role	as	a	biomarker	in	these	two	settings.		
	
2.6.2	Tubular	damage	biomarkers		
As	stated	previously,	 in	FD	glycosphingolipids	storage	occurs	also	in	tubular	cells,	
where	they	may	have	a	direct	toxic	effect,	even	in	the	early	phases	of	the	disease,	which	
are	clinically	silent	in	terms	of	the	standard	renal	tests.57,	77	Moreover,	the	main	source	of	
urinary	Gb3	seems	to	be	the	tubular	cells	and	the	urinary	collecting	system,	with	an	80%	
reduction	in	urinary	Gb3	after	nephrectomy	or	transplantation.162,	718	Other	contributors	
to	tubular	injury	in	FD	may	be	the	hemodynamic	damage	(as	result	of	Gb3	accumulation	
in	the	renal	microvasculature)	and	persistent	proteinuria.74,	75,	494	
Tubular	injury	preceding	glomerular	involvement	was	also	observed	in	other	renal	
diseases,	such	as	diabetic	nephropathy,	where	an	increase	in	several	tubular	proteins	and	
enzymes	 become	 apparent	 before	 albuminuria	 A2.642,	 649	 In	 diabetic	 nephropathy,	 the	
concentration	 of	 tubular	 injury	 biomarkers	 has	 been	 correlated	 with	 the	 severity	 of	
nephropathy,	 so	 it	 has	 been	 hypothesized	 that	 the	 long-term	 outcome	 in	 diabetic	
nephropathy	was	more	related	to	the	degree	of	the	tubulointerstitial	impairment	than	to	
the	severity	of	glomerular	lesions.719	In	this	study	I	also	demonstrated	that	tubular	injury	
biomarkers	increase	in	FD	nephropathy	before	albumin	excretion	and	one	of	them	(NAG)	
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seems	to	have	better	prognostic	value	in	terms	of	GFR	decline.	Previous	smaller	studies	in	
FD	have	shown	an	increase	in	tubular	injury	biomarkers.307,	308	
A1MG	is	a	small	protein	that	is	freely	filtered	through	the	glomerular	membrane	
and	 reabsorbed	by	 the	proximal	 tubules.	Hence,	a	decrease	of	 creatinine	clearance	will	
increase	 its	plasma	 levels	and	any	proximal	 tubular	cell	dysfunction	 results	 in	 increased	
quantities	of	A1MG	in	the	urine.594,	720	
As	in	diabetic	nephropathy	(where	up	to	33.6%	of	the	normoalbuminuric	patients	
presents	 increased	 A1MG	 excretion),	 I	 was	 able	 to	 demonstrate	 that	 urinary	 A1MG	
excretion	 increases	 in	 patients	 with	 albuminuria	 A1	 and	 was	 more	 sensitive	 than	
albuminuria	 to	 detect	 FD	 and	 CKD	 stage	 ≥2.579,	 607	 Thus,	 it	 seems	 a	 good	 marker	 of	
incipient	 FD	 nephropathy,	 which	 is	 in	 accordance	 with	 the	 findings	 of	 severe	 tubular	
inclusions	 (mainly	 in	 the	 distal	 tubules)	 and	 tubule-interstitial	 fibrosis	 in	 patients	 with	
clinically	 silent	 FD	 nephropathy.57,	 77	 However,	 urinary	 A1MG	 excretion	 is	 a	 biomarker	
mainly	related	to	proximal	tubular	dysfunction,	demonstrating	that	despite	the	relatively	
smaller	amounts	of	inclusions	in	the	proximal	nephron,	significant	dysfunction	may	occur	
without	clinical	signs	of	glomerular	damage.	This	is	supported	by	the	finding	of	highest	α-
galactosidase	A	 in	 proximal	 tubular	 cells	 of	 normal	 human	 kidneys,	 in	 comparison	with	
other	renal	cells,	so	these	cells,	with	high	turnover	rate,	may	be	particularly	susceptible	in	
the	 setting	 of	 α-galactosidase	 A	 deficiency.	 Furthermore,	 in	 the	 early	 stages	 of	 FD	
nephropathy,	increased	filtration	of	albumin	and	other	proteins,	that	will	be	reabsorbed	
by	proximal	tubular	cells	(resulting	in	no	increase	in	net	excretion	of	these	proteins),	will	
compete	 for	 megalin	 receptors,	 also	 responsible	 for	 A1MG	 resorption	 in	 the	 proximal	
tubules	and	may	result	in	an	increased	excretion	of	this	protein.715		
Nonetheless,	as	in	diabetic	nephropathy,	some	patients	with	albuminuria	A2	and	
A3	may	 present	 A1MG	within	 in	 the	 normal	 range,	 resulting	 in	 no	 increase	 of	 urinary	
A1MG	excretion	across	the	subgroup	of	patients	with	increasing	severity	and	absence	of	a	
significant	 correlation	 with	 ACR.469,	 607	 This	 finding	 may	 indicate	 that	 increased	 A1MG	
excretion	and	ACR	represent	different	pathophysiological	pathway	involvement	and	that	
A1MG	excretion	may	complement	ACR	rather	than	outperform	it.	
	 I	 found	 no	 significant	 inverse	 correlation	 between	 urinary	 A1MG	 excretion	 and	
GFR,	 as	 well	 a	 significant	 increase	 of	 A1MG	 excretion	 across	 CKD	 stages.	 Conflicting	
results	 regarding	 the	 correlation	 between	 A1MG	 and	 GFR	 were	 also	 found	 in	 diabetic	
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nephropathy.579,	 614	 A	 possible	 explanation	 is	 that	 if	 plasma	 concentration	 of	 A1MG	 is	
influenced	 by	 the	 GFR,	 in	 the	 setting	 of	 proximal	 tubular	 dysfunction,	 urinary	 A1MG	
excretion	 may	 be	 influenced	 by	 its	 filtration,	 justifying	 decreased	 A1MG	 excretion	 in	
patients	 with	 lower	 GFR.594	 This	 hypothesis	 is	 further	 supported	 by	 the	 absence	 of	
prognostic	value	of	A1MG	variation	in	terms	of	prediction	of	ACR	or	GFR	progression.	
	 The	 prognostic	 value	 of	 urinary	 A1MG	 excretion	 has	 never	 been	 studied	 in	
diabetic	 nephropathy,	 but	 in	 FD,	 despite	 no	 significant	 OR	 to	 predict	 ACR	 and	 GFR	
progression	 in	 patients	 with	 higher	 urinary	 A1MG	 concentration	 at	 baseline,	 in	 sub-
analysis	 by	 gender,	 male	 patients	 showed	 a	 significantly	 higher	 A1MG	 excretion	 at	
baseline	in	both	ACR	and	GFR	progressors,	in	comparison	with	non-progressors.	The	lack	
of	predictive	value	in	female	patients	may	be	related	to	the	small	cohort	and	short	follow-
up	period	(with	minimal	number	of	progressing	female	patients),	but	also	to	the	X-linked	
nature	of	FD.	
		 As	 in	diabetic	nephropathy,	where	metabolic	 control	with	hypoglycaemic	agents	
significantly	decreased	A1MG	excretion,501,	618,	622	 in	this	study	I	 found	a	clear	trend	of	a	
decrease	 in	urinary	A1MG	excretion	 in	 the	 small	 subgroup	of	patients	 that	 started	ERT	
during	the	study.	This	finding	is	also	in	accordance	with	a	previous	small	previous	study	in	
FD	 (with	 13	 women)	 reporting	 a	 significant	 decrease	 in	 urinary	 A1MG	 excretion	 with	
ERT,307	and	could	mean	a	surrogate	of	an	amelioration	of	proximal	tubular	dysfunction	or	
an	improvement	in	glomerular	filtration	barrier,	leading	to	decreased	competition	of	the	
proteins	in	the	glomerular	filtrate	for	megalin	receptors.		
	 Concluding,	 urinary	 A1MG	 excretion	 increases	 in	 incipient	 FD	 nephropathy,	
supporting	 proximal	 tubular	 injury	 as	 an	 early	 event	 in	 FD,	 but	 it	 does	 not	 appears	 to	
correlate	with	GFR;	nonetheless,	A1MG	excretion	seems	to	be	of	prognostic	value	in	male	
patients	and	needs	to	be	further	studied	as	predictor	in	females.	 	
	 NAG	 is	an	urinary	enzyme	that	 is	distributed	along	the	whole	nephron,	but	with	
highest	activity	in	the	straight	portion	of	the	proximal	tubule.637	Due	to	its	high	molecular	
weight,	 it	cannot	be	 filtered	through	the	glomeruli	and	 its	presence	 in	 the	urine	results	
exclusively	from	tubular	secretion.633	Moreover,	increased	urinary	NAG	excretion	may	not	
only	occur	in	tubular	damage,	but	also	in	increased	tubular	lysosomal	turnover.640	
	 I	was	able	to	confirm	previous	data	showing	an	increase	in	urinary	NAG	excretion	
in	 FD,641	 but	 I	 also	 showed	 that	 this	 biomarker	 rises	 before	 and	 significantly	 correlates	
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with	 albuminuria.	 Moreover,	 among	 the	 studied	 biomarkers,	 confirming	 their	 added	
value	 in	 detecting	 incipient	 FD	 nephropathy,	 urinary	 NAG	 excretion	 had	 the	 highest	
sensitivity	to	detect	FD	patients	and	CKD	stage	≥2.	These	results	are	 in	accordance	with	
histological	 findings	 previously	 described	 for	 A1MG	 excretion.57,	 77	 	 Comparable	 results	
were	 found	 in	 diabetic	 nephropathy,	 reporting	 urinary	 NAG	 excretion	 as	 the	 most	
sensitive	marker	 for	early	detection	of	 tubular	damage	or	 for	prediction	of	albuminuria	
A2.642,	 649,	 721	 Moreover,	 this	 greater	 sensitivity	 than	 albuminuria	 to	 detect	 early	 renal	
malfunction	may	 be	 related	 to	 an	 increase	 in	 urinary	 NAG	 excretion	 at	 a	 stage	where	
tubular	 reabsorption	 capacity	 may	 still	 be	 sufficient	 to	 balance	 increased	 glomerular	
filtration	of	albumin.481,	651	
	 As	 reported	 in	 diabetic	 nephropathy,	 the	 prognostic	 value	 of	 urinary	 NAG	
excretion	has	been	clearly	depicted	in	this	study,	overcoming	albuminuria	as	a	predictor	
of	estimated	GFR	(urinary	NAG	excretion	was	the	only	significant	predictor	in	multivariate	
regression	 analysis)	 and	 progressively	 increasing	 across	 CKD	 stages.642,	643	 Furthermore,	
urinary	NAG	excretion	at	baseline	and	its	variation	during	follow-up	had	the	best	value	to	
predict	GFR	progression:	not	only	did	patients	in	the	higher	quartiles	at	baseline	present	
more	 pronounced	 decrease	 of	 GFR,	 but	 also	 patients	 for	whom	urinary	NAG	 excretion	
increased	more	during	follow-up	had	a	worse	prognosis	in	terms	of	GFR	decline.	Urinary	
NAG	excretion	has	also	established	prognostic	value	in	diabetic	nephropathy.658,	666,	667	As	
noted	 above,	 degenerative	 glomerular,	 tubular,	 interstitial	 and	 arterial	 lesions	 are	 the	
histological	 alterations	 best	 correlated	 with	 age	 or	 GFR;83,	 84,	 717	 however,	 longitudinal	
studies	are	required	to	establish	the	predictive	value	of	 these	degenerative	changes	 for	
the	ultimate	progression	of	Fabry	renal	disease.	Nonetheless,	in	the	present	study,	for	the	
first	 time,	 I	 present	 evidence	 supporting	 that	 a	 biomarker	 related	 to	 degenerative	
changes	 in	 the	 tubulointerstitial	 compartment	 has	 better	 prognostic	 value	 than	 the	
biomarkers	related	to	glomerular	barrier	(ACR).	Notwithstanding,	this	evidence	needs	to	
be	further	confirmed	and	correlated	with	histological	findings.	
	 As	 for	 the	 other	 biomarkers,	 there	was	 a	 trend	 of	 a	 smaller	 increase	 in	 urinary	
NAG	 excretion	 in	 patients	 treated	with	 ERT	 or	 starting	 ERT	 during	 the	 study.	 This	 is	 in	
accordance	with	 finding	 in	 diabetic	 nephropathy	 showing	 a	 decrease	 in	 NAG	 excretion	
after	 amelioration	of	 the	metabolic	 defect	 by	 glycaemic	 control.646,	647,	668	As	previously	
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mentioned,	 these	 results	 may	 be	 an	 evidence	 supporting	 improvement	 of	 tubular	
dysfunction	during	ERT.	
	 The	 better	 diagnostic	 and	 prognostic	 performance	 of	 NAG	 in	 comparison	 with	
other	tubular	injury	biomarker	may	be	related	to	various	aspects:	biomarker	proper	value	
(in	 terms	 of	measuring	 tubular	 damage);	more	 accurate	 laboratorial	 technique,	 with	 a	
colorimetric	 assay,	 in	 comparison	 with	 ELISA	 methodology	 applied	 for	 the	 other	
biomarkers’	 measurement;	 widespread	 distribution	 of	 NAG	 along	 the	 nephron	 (not	 a	
specific	marker	of	proximal	or	distal	tubular	dysfunction);	NAG	is	not	only	a	biomarker	of	
tubular	injury,	but	also	of	increased	lysosomal	turnover	in	tubular	cells.	
	 Concluding,	 performance	 of	 urinary	 NAG	 excretion	 as	 a	 biomarker	 may	
substantiate	 several	 concepts:	 tubular	 injury	 in	FD	nephropathy	occurs	early;	 long-term	
outcome	of	FD	nephropathy	may	be	more	related	to	the	extent	of	the	tubulointerstitial	
impairment	 than	 to	 the	 severity	 of	 glomerular	 lesions;	 proteinuria	 is	 a	 contributor	 to	
tubular	injury.			
	 AAP	is	another	tubular	enzyme	present	in	the	brush	border	membrane	(mainly	in	
the	proximal	 tubules).	 I	was	able	 to	show	that,	as	 in	diabetic	nephropathy,	urinary	AAP	
excretion	 increases	 early	 in	 the	 course	 of	 FD	 nephropathy,	 even	 in	 patients	 with	
albuminuria	A1.645,	684,	685	However,	as	also	shown	in	diabetic	nephropathy,	the	prognostic	
value	of	urinary	AAP	excretion	and	its	response	to	ERT	appears	limited.646,	689		
	 The	 restricted	 clinical	 utility	 of	 urinary	 AAP	 excretion	 as	 a	 biomarker	 in	 FD	
nephropathy	may	 be	 related	 to	 its:	 infradian	 rhythm,677	 inverse	 correlation	with	 age678	
and	reduced	stability	after	urine	collection.682	
	
2.6.3	Difficulties	and	limitations	
I	 faced	 several	minor	 difficulties	 during	 the	 study,	most	 of	 them	 related	 to	 the	
epidemiology	 of	 FD	 and	 longitudinal	 and	 multicenter	 design	 of	 the	 study.	 As	 a	 rare	
disease,	it	is	difficult	to	recruit	a	cohort	large	enough	to	allow	sub-analysis	and	to	detect	
small	differences,	which	may	have	clinical	 importance.	While	it	was	possible	to	recruit	a	
cohort	with	the	initially	planned	size,	the	recruitment	period	was	larger	than	planned	(not	
affecting	 the	 longitudinal	 follow-up	period).	 Ideally,	a	 longer	 follow-up	period	would	be	
desirable	for	a	more	accurate	analysis	of	the	prognostic	value	of	the	biomarkers,	but	due	
to	constrains	of	the	timeline	in	the	research	and	doctoral	program	and	in	the	setting	of	a	
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long	recruitment	period,	a	24	months	 longitudinal	evaluation	was	the	possible	timeline.	
The	multicenter	design	of	the	study	generated	some	difficulties,	due	to	the	organization	
of	patients	 collecting	 samples	 at	 various	 centres	 at	 the	 same	 time,	which	 caused	 some	
loss	of	data	during	 follow-up,	but	did	not	hamper	accurate	statistical	analysis.	 I	did	not	
experience	difficulties	in	the	laboratorial	tasks	and	interpretation	of	the	results.					
	 This	 study	 has,	 per	 se,	 a	 few	 limitations,	 namely:	 absence	 of	 histological	
correlation,	which	would	be	very	useful	in	biomarker	validation,	for	example,	of	ColIV	as	a	
marker	of	mesangial	expansion	and	NAG	as	a	marker	of	tubular	injury;	cohort	dimension	
and	 follow-up	period,	 hindering	 the	 prognostic	 value	 of	 these	 biomarkers	 and	 allowing	
only	an	exploratory	analysis	of	the	influence	of	ERT	and	ACEi	/	ARB.	It	would	be	important	
to	standardize	the	assay	of	biomarkers	to	allow	more	widespread	use	in	clinical	practice.	
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Final	discussion	and	future	perspectives	
Only	 in	 1967,	 almost	 70	 years	 after	 the	 first	 description,	 in	 1898,	 of	 FD	 by	
Johannes	Fabry	and	William	Anderson,	was	 the	genetic	defect	 causing	 this	multisystem	
disorder	identified.1,	2	However,	the	last	20	years	have	provided	an	impressive	increase	in	
the	understanding	of	the	disease	and	knowledge	about	the	pathophysiological	pathways	
involved.	Notwithstanding,	this	emerging	comprehension	about	FD	has	raised	many	more	
unanswered	questions,	than	those	that	we	can,	actually,	undoubtedly	answer.	Moreover,	
when	 research	 in	 FD	 is	 considered,	 various	 challenges	 arise,	 including:	 advantages	 and	
limitations	 of	 cell	 and	 animal	 models,	 disease	 epidemiology,	 diagnostic	 difficulties,	
therapeutic	objectives,	new	treatment	approaches,	biomarkers	and	many	others.	
The	 introduction,	 in	 2001,	 of	 a	 disease-specific	 ERT,	 with	 two	 commercially	
available	 preparations,165,	 166	 both	 based	 on	 the	 infusion	 of	 recombinant	 enzymes	 fully	
changed	the	scenario	of	FD	in	the	scientific	community:	from	an	orphan	disease	causing	
significant	 morbidity	 and	 premature	 death3,	 4	 to	 a	 treatable	 disease	 with	 multiple	 and	
intriguing	genetic	issues,	pathological	pathways	and	organ	systems	involved.		
This	increasing	knowledge	in	FD	completely	changed	its	epidemiology	and	clinical	
picture	 from	 the	 classical	 concept	 of	 a	 rare	 disorder	 with	 reported	 incidences	 ranging	
from	1:117.000	to	1:833.000,19-21	to	a	much	higher	prevalence	revealed	by	the	screening	
of	 high-risk	 populations	 and	 newborns.22,	 23	 However,	 up	 to	 90%	 of	 the	 mutations	 /	
genetic	variants	identified	in	these	screenings	are	associated	with	attenuated	phenotypes	
or	late-onset	forms	and	some	of	them	are	genetic	variants	of	unknown	significance.	The	
genetic	 variants	 of	 unknown	 significance	 have	 posed	 new	 diagnostic	 challenges	 and	
dilemmas	in	FD.222			
Therefore,	 the	 full-blown	 classical	 phenotype	described	 in	male	 patients,	with	 a	
relatively	 well-described	 natural	 history	 constitutes	 no	 longer	 the	 largest	 cohort	 of	
patients	that	are	currently	under	follow-up	across	the	FD	outpatient	clinics	and	reference	
centres	 across	 the	 entire	 world.82,	 83	 Instead,	 the	 FD	 cohorts	 comprise	mainly	 patients	
with	 late-onset	 forms,	 with	 an	 unpredictable	 and	 fully	 heterogeneous	 course	 of	 the	
disease,	 for	 whom	 the	 scientific	 evidence	 supporting	 the	 utilization	 of	 disease-specific	
treatment	 is,	 at	 least,	 scarce.	 The	 disease	 clinical	 heterogeneity	 is	 expanded	 by	 its	 X-
linked	 inheritance	 pattern,	 with	 females	 usually	 presenting	 a	 milder	 and	 time-delayed	
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phenotype.10,	 15,	 82	 Skewed	 X-chromosome	 inactivation	 may	 explain	 part	 of	 the	 clinical	
heterogeneity	 in	 female	 patients,	 but	 many	 other	 unknown	 factors	 are	 certainly	
involved.14	
However,	 in	 the	new	ERT	and	chaperones	 therapy	era,	diagnostic	dilemmas	and	
clinical	heterogeneity	are	not	the	only	unsolved	questions.	Currently,	after	more	than	15	
years	of	 treatment	 there	 is	 increasing	evidence	 supporting	 its	 efficacy,	but	 there	 is	 still	
little	 evidence	 supporting	 that	 ERT	 can	 actually	 prevent	 major	 clinical	 events	 and	 a	
proportion	 of	 patients,	 namely	 those	 with	 severe	 LV	 hypertrophy	 or	 cardiac	 fibrosis,	
advanced	 CKD	 and	 heavy	 proteinuria,	 are	 still	 progressing	 despite	 standard	 treatment	
with	ERT.187,	190,	194,	199,	202	Moreover,	a	bulk	of	 increasing	evidence	suggest	 that	an	early	
treatment	 strategy	 	 may	 be	 more	 effective	 to	 prevent	 disease	 progression	 and	 major	
clinical	events,	given	that	patients	experiencing	irreversible	organ	changes	may	not	fully	
respond	to	ERT.	Nevertheless,	the	ideal	moment	for	disease-specific	treatment	initiation,	
as	well	as	the	treatment’s	ability	to	reverse	the	earliest	pathophysiological	pathways	and	
pathological	 findings	 involved	 in	 FD	 are	 still	 motives	 of	 debate	 in	 the	 scientific	
community.		
Therefore,	 the	 greatest	 challenges	 and	 most	 urgent	 needs	 in	 FD	 are	 the	
identification	 of	 very	 early	 signs	 of	 cardiac	 and	 kidney	 involvement	 enabling	 a	 timely	
institution	 of	 disease-specific	 treatment	 (permitting	 each	 patient	 to	 get	 the	 maximal	
benefit	 from	 it)	 and	 the	 accurate	 definition	 of	 each	 patient	 prognosis,	 understanding	
which	untreated	and	treated	patients	are	at	higher	risk	for	disease	progression.	Reliable	
and	 validated	biomarkers,	 ideally	measured	by	 a	 non-invasive	 technique	may	 aid	 filling	
these	gaps	of	unanswered	questions	of	routine	clinical	practice.	
	Actually,	 biomarkers	 may	 be	 useful	 in	 various	 clinical	 settings:	 diagnosis	
(distinguishing	 pathogenic	 from	 non-pathogenic	 mutations),	 identification	 of	 incipient	
organ,	 risk	 prediction	 (patients	 at	 greater	 risk	 of	 disease	 progression),	 response	 to	
treatment	and	design	of	clinical	trials	(surrogate	biomarkers	of	the	long	term-response	to	
a	 treatment).	Currently,	even	with	 the	gold-standard	biomarkers	 in	 the	 identification	of	
early	 heart	 (advanced	 echocardiographic	 techniques)	 or	 kidney	 (albuminuria)	
involvement,	 there	 is	 a	 long	 clinically	 silent	 period,	 characterized	 by	 histological	 (often	
irreversible)	and	transcriptional	profile	changes,	before	overt	evidence	of	cardiac	or	renal	
involvement.57,	77,	104,	195	
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Due	 to	 the	 all	 the	 aforesaid	 reasons,	 I	 decided	 to	 proceed	 with	 the	 search	 for	
biomarkers	 to	detect	 incipient	 cardiac	 and	 renal	 involvement	and	 to	predict	 the	 risk	of	
disease	 progression	 in	 these	 two	 organs.	 Searching	 for	 new	 biomarkers	 is	 a	 very	
challenging	 and	 laborious	 task,	 for	which	 I	 can	 use	 a	 one	 by	 one	 approach	 or	 “omics”	
medicine	 tools.	 In	 these	 research	projects	 I	 tried	 to	 identify	biomarkers,	using	a	one	by	
one	approach,	with	the	aforementioned	goals	in	mind,	but	also	strictly	related	to	possible	
pathophysiological	pathways	 involved	 in	 FD	 cardiomyopathy	and	nephropathy,	 in	order	
to	deepen	our	understanding	about	FD	and	its	mechanisms.		
As	 noted	 above,	 myocardial	 fibrosis	 is	 one	 of	 the	 histological	 hallmarks	 of	 FD	
cardiomyopathy,	appearing	to	be	predominantly	interstitial	diffuse	(with	only	focal	areas	
of	replacement	fibrosis).28,	29,	53,	54	Moreover,	some	serum	biomarkers	related	to	collagen	
metabolism	seem	to	be	closely	related	to	the	histological	evidence	of	myocardial	fibrosis	
in	 patients	 with	 hypertensive	 heart	 disease	 and	 there	 is	 evidence	 that	 their	 serum	
concentration	may	 increase	 in	 very	 early	 phases	 of	 cardiac	 diseases	 (prior	 to	 an	 overt	
clinical	or	imaging	phenotype).378,	397	
	 Thus,	in	a	longitudinal	study,	recruiting	a	relatively	large	cohort	of	60	FD	patients,	I	
measured	 the	 serum	 concentration	 of	 various	 biomarkers	 related	 to	 collagen	 type	 I,	 in	
order	to	assess	not	only	their	value	as	biomarkers	of	incipient	cardiomyopathy	and	assess	
their	predictive	value	of	progressive	cardiac	 involvement,	but	also	the	natural	history	of	
fibrogenesis	in	FD	cardiomyopathy.		
In	this	study,	I	was	able	to	demonstrate	that	collagen	type	I	synthesis	is	increased	
even	before	any	echocardiographic	evidence	of	FD	cardiomyopathy	and	seems	to	directly	
contribute	 or	 is	 correlated	 to	 the	 development	 of	 LV	 hypertrophy	 in	 patients	with	 FD.	
Moreover,	I	showed	that	an	inhibition	of	collagen	type	I	degradation,	with	suppression	of	
MMPs	activity	is	also	involved	in	the	progression	of	FD	cardiomyopathy,	not	only	in	terms	
of	LV	hypertrophy,	but	also	of	diastolic	dysfunction.	These	findings	are	supported	by	an	
accumulating	bulk	of	 rationale	 and	evidence:	 accumulating	 substrates	 in	 FD	 can	 induce	
activation	of	pathophysiological	pathways	directly	 involved	in	fibrogenesis.18,	70,	702,	716	As	
these	substrates	accumulate	since	the	antenatal	period,	an	increase	in	collagen	synthesis	
certainly	occurs	early	in	the	disease	course,	as	suggested	by	the	study	results.722	
I	was	also	able	to	show	that	biomarkers	related	to	collagen	metabolism	are	more	
sensitive	than	LGE	in	the	detection	of	myocardial	fibrosis,	and	appear	to	have	an	excellent	
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performance	 in	 ruling	 out	 focal	 replacement	 fibrosis.	 These	 findings	 are	 also	 in	 clear	
agreement	with	the	limited	resolution	of	LGE	and	its	inability	to	detect	diffuse	interstitial	
fibrosis.272-274	
The	 prognostic	 value	 of	 the	 biomarker	 of	 collagen	 type	 I	 synthesis	 was	 also	
evidenced	in	this	study.	Not	only	is	the	serum	PICP	concentration	in	a	defined	time	point	
a	good	predictor	of	LV	mass,	but	with	greater	significance,	its	longitudinal	variation	clearly	
correlates	 with	 the	 probability	 of	 a	 progressive	 disease	 and	 may	 identify	 patients	 at	
higher	risk	for	a	worse	prognosis.	Serum	MMPs	measurement	also	appears	to	be	valuable	
in	terms	of	prognosis,	because	it	may	identify	patients	at	high	risk	of	progression	in	terms	
of	diastolic	dysfunction	in	subsequent	years.			
In	an	exploratory	way,	I	raised	the	possibility	that	ERT	may	mitigate	fibrogenesis	in	
FD	cardiomyopathy,	decreasing	collagen	type	 I	 synthesis	and	 increasing	 its	degradation.	
These	 findings	 are	 supported	 by	 the	 experimental	 evidence	 showing	 that	 ERT	 may	
suppress	TGF-β1	activation	 induced	by	Gb3	 in	a	cell	 line.702	The	prognostic	value	of	 the	
biomarkers	 related	 to	 collagen	 metabolism	 and	 their	 possible	 response	 to	 ERT	 clearly	
suggest	that	activation	of	profibrotic	pathways	 is	 linked	to	disease	progression	and	that	
measurements	 of	 the	 studied	biomarkers	may	be	 clinically	meaningful	 in	 the	 follow-up	
and	risk	stratification	of	FD	patients.				
Concluding,	 this	 study	 of	 biomarkers	 related	 to	 collagen	 type	 I	 provided	 new	
relevant	data	to	understand	the	natural	history	of	fibrogenesis	in	FD	cardiomyopathy	and	
showed,	for	the	first	time,	that	serum	biomarkers	of	collagen	type	I	metabolism	identify	
ongoing	fibrosis	in	the	early	pre-clinical	stages	of	FD	cardiomyopathy	and	possibly	predict	
the	development	of	LV	hypertrophy,	heralding	the	importance	of	developing	therapies	to	
mitigate	 fibrosis	 and	 change	 the	natural	 history	of	 FD	 cardiomyopathy.	Moreover,	 they	
may	be	useful	biomarkers	in	the	evaluation	of	the	short-term	response	to	the	treatments	
that	are	under	development	and	evaluation	in	clinical	trials,	namely	substrate	reduction	
therapy	and	the	modified	forms	of	plant	derived	ERT.	
FD	 nephropathy	 is	 also	 characterized	 by	 involvement	 of	 both	 glomerular	 and	
tubule-interstitial	 compartments,	with	patients	without	 alteration	 in	 the	 standard	 renal	
tests	already	presenting	heavy	glycosphingolipids	storage,	as	well	as	glomerular	sclerosis,	
tubular	 atrophy	 and	 interstitial	 fibrosis.57,	 77,	 80	 Thus,	 I	 designed	 a	 longitudinal	 study	 to	
identify	 the	 early	 diagnostic	 and	 prognosis	 value	 of	 various	 biomarkers	 of	 mesangial	
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expansion	 and	 tubular	 dysfunction,	 which	 have	 previously	 demonstrated	 their	 added	
value	in	diabetic	nephropathy.723,	724			
		 I	was	able	to	demonstrate	that	biomarkers	either	related	to	mesangial	expansion	/	
altered	 permeability	 of	 glomerular	 barrier	 or	 to	 tubular	 dysfunction	 /	 injury	 identified	
patients	with	incipient	FD	nephropathy	with	better	S	than	ACR.	This	is	in	accordance	with	
previous	findings	showing	that	accumulating	glycosphingolipids	may	induce	activation	of	
pro-fibrotic	 and	 pro-inflammatory	 pathways	 in	 podocytes	 and	 mesangial	 or	 proximal	
tubular	 cells;	 they	 may	 also	 promote	 epithelial-mesenchymal	 transition	 in	 proximal	
tubular	cells	(a	known	critical	step	in	the	development	of	interstitial	fibrosis).18,	62,	70,	71,	702	
Thus,	 in	 contrast	 to	albuminuria,	 that	 increases	as	 consequence	of	 glomerular	damage,	
the	 identified	 biomarkers	 seems	 to	 be	 directly	 related	 to	 and	 support	 the	 current	
knowledge	about	FD	nephropathy.	
	 Moreover,	 one	of	 the	 studied	biomarkers	 related	 to	 tubular	 injury,	 urinary	NAG	
excretion,	evidenced	a	clearly	better	prognosis	value	than	ACR:	not	only	did	its	excretion	
at	a	specific	time	point	predict	the	subsequent	variation	of	GFR,	but,	with	an	expressive	
significance,	 its	 longitudinal	 clearly	 correlated	with	 the	 changes	 in	 GFR.	 These	 findings	
support	the	concept	that	tubular	injury	is,	at	least,	as	important	as	glomerular	pathology	
in	FD	nephropathy	and	may	be	critical	for	subsequent	progressive	decline	of	GFR.	This	is	
further	 reinforced	 by	 the	 reports	 showing	 that	 chronic	 kidney	 lesions	 have	 better	
prognostic	significance,	than	the	severity	of	kidney	cell	inclusions.717	
Furthermore,	 ERT	 seems	 to	 have	 a	 beneficial	 effect	 on	 urinary	 excretion	
biomarkers,	which	 is	 supported	by	 the	 fact	 that	ERT	may	actually	ameliorate	mesangial	
widening	and	allowing	my	hypothesis	that	it	may	also	probably	improve	tubule-interstitial	
pathology.165	 However,	 this	 hypothesis	 needs	 to	 be	 further	 studied	 and	 accurately	
correlated	with	histological	findings.	
Concluding,	 in	 this	 study	 of	 kidney	 biomarkers	 I	 showed	 that	 albuminuria	
limitations	as	a	sensitive	marker	of	early	renal	dysfunction	in	FD	and	as	a	marker	for	risk	
of	progression	of	CKD,	may	be	overcome	with	the	identification	of	these	newly	identified	
biomarkers,	 all	 increased	 in	 normoalbuminuric	 patients	 and	 one	 of	 them	 (NAG)	 with	
better	prognostic	value	than	albuminuria.	Apart	 from	improving	the	management	of	FD	
nephropathy	 (with	 potential	 implications	 for	 ERT	 initiation	 criteria),	 these	 biomarkers	
may	 also	 define	 novel	 early	 stages	 of	 FD	 nephropathy	 characterized	 by	 mesangial	
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expansion	 (ColIV)	 and/or	 tubular	 damage	 (NAG).	 They	 may	 also	 be	 useful	 in	 the	
evaluation	of	new	treatment	strategies	under	development,	assessing	treatment	ability	to	
reverse	these	initial	changes	related	to	FD	nephropathy.	
Although	assuming	 that	all	 these	 results	needs	 to	be	 further	 confirmed	 in	other	
cohorts	 of	 patients,	 in	 this	 final	 chapter	 of	 my	 thesis,	 I	 think	 that	 it	 is	 appropriate	 to	
reflect	on	 the	work	 I	 have	done	 so	 far,	 highlight	 the	questions	 it	 raised	and	 considerer	
how	they	are	being	or	may	be	pursued	in	the	future.		
With	 this	 research	 project	 I	 not	 only	 constructed	 a	 relatively	 large	 database,	
including	more	than	80	patients	with	FD	diagnosis,	with	clinical	and	research	meaningful	
information,	 but	 also	 started	 and	 pursued	 important	 investigational	 collaborations,	 of	
paramount	significance	in	the	development	of	new	research	projects	not	only	in	the	field	
of	biomarkers	in	FD,	but	also	in	other	research	topics	in	FD.	
This	research	project	answered	some	of	the	questions	that	I	had	in	my	mind	when	
I	 started	 this	 work.	 However,	 I	 now	 clearly	 realise	 that	 these	 first	 results	 are	 only	 the	
beginning	of	a	path	in	the	demanding	search	for	new	biomarkers,	because	my	work	has	
generated	many	more	questions	than	answers.		
I	clearly	showed	that	cardiac	fibrosis,	mesangial	expansion	and	tubular	injury	are	
early	events	in	FD	and	that	biomarkers	translating	these	processes	may	be	of	good	value	
in	 the	 identification	 of	 incipient	 FD	 cardiomyopathy	 and	 nephropathy.	 However,	 this	
value	in	the	identification	of	incipient	organ	involvement	needs	to	be	confirmed	in	other	
cohorts	of	patients	together	with	histological	evaluation.		
Histological	validation	of	the	serum	biomarkers	related	to	collagen	metabolism	is	
hampered	 by	 the	 potential	 harm	 caused	 by	 endomiocardial	 biopsies.	 However,	 this	
correlation	 between	 peripheral	 blood	 PICP	 concentration	 and	 the	 myocardial	 collagen	
type	I	content	has	already	been	established	in	hypertensive	heart	disease	and	there	is	no	
rational	to	suppose	a	different	and	specific	behaviour	in	FD.326,	378	
Nonetheless,	 advanced	 cardiac	 imaging	 techniques,	 like	 strain	 and	 strain	 rate	
echocardiography	and	T1	mapping	in	cardiac	MRI	may	present	better	sensitivity	to	detect	
incipient	 FD	 cardiomyopathy	 than	 the	 TDI	 abnormalities	 that	 I	 used	 in	 this	 study.	
Moreover,	 T1	mapping	may	 detect	 lipid	 deposition	 in	 the	myocardium,	 so	 it	 is	 directly	
related	with	the	disease	pathophysiology,	characterized	by	glycosphingolipids	storage.278-
280	In	this	setting,	I	have	already	started	a	research	project	in	order	to	validate	the	results	
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of	 the	 biomarkers	 related	 to	 collagen	metabolism	 in	 incipient	 FD	 cardiomyopathy	 in	 a	
large	cohort	of	120	FD	patients	and	also	 to	correlate	 the	 results	with	 strain,	 strain	 rate	
and	 advanced	 cardiac	MRI	 techniques	 (T1	mapping,	 T2	mapping	 and	 feature	 tracking).	
This	 study	 will	 certainly	 provide	 new	 insights	 in	 FD	 pathophysiology,	 evaluating	 the	
correlation	between	glycosphingolipids	deposits	and	stimulus	for	collagen	type	I	synthesis	
/	suppression	of	collagen	type	I	degradation.		
Furthermore,	 this	 study	 of	 correlation	 with	 cardiac	 imaging	 has	 a	 longitudinal	
design,	with	a	 follow-up	period	of	60	months	 (evaluations	at	baseline,	after	24	months	
and	 after	 60	 months).	 Therefore,	 I	 hope	 to	 confirm	 the	 prognostic	 value	 of	 the	
biomarkers	related	to	collagen	metabolism	in	a	 larger	cohort	and	for	a	 longer	follow-up	
period.	 I	will	also	evaluate	 the	exploratory	 trend	of	a	beneficial	effect	of	ERT	 in	cardiac	
fibrogenesis	and	further	explore	the	effect	of	renin-angiotensin-aldosterone	antagonists.	
Histological	 correlation	 of	 the	 urinary	 biomarkers	 is	 paramount	 for	 their	
validation.	Both	urinary	ColIV	and	NAG	excretion	has	been	correlated,	 respectively	with	
mesangial	 widening	 and	 scores	 of	 tubule-interstitial	 fibrosis	 in	 patients	 with	 diabetic	
nephropathy	 or	 primary	 glomerulopathies.545,	 546,	 671,	 672	 I	 am	 currently	 developing	 a	
protocol	 and	 establishing	 the	 research	 collaboration	 for	 evaluation	 of	 histological	
correlations	of	urinary	ColIV	and	NAG	excretion,	in	a	small	cohort	of	up	to	20	FD	patients.	
If	the	results	of	the	abovementioned	studies	of	correlation	with	cardiac	imaging	or	
kidney	biopsy	findings	confirm	the	results	of	the	present	research,	I	will	design	studies	to	
confirm	 the	 prognostic	 value	 of	 these	 biomarkers	 and	 specifically	 to	 evaluate	 their	
behaviour	in	patients	starting	ERT.	
So	far,	my	results	clearly	support	the	importance	of	fibrosis	in	FD	cardiomyopathy	
and	nephropathy,	but	these	biomarkers	do	not	explain	the	heterogeneity	of	FD	and	the	
reasons	behind	the	prognosis	in	each	individual	patient,	because	they	are	the	“effectors”	
at	the	end	of	the	pathophysiological	cascades.	
In	an	attempt	to	identify	accurate	biomarkers	implied	in	the	regulation	of	fibrotic	
and	 other	 pathophysiological	 pathways,	 I	 have	 already	 started	 a	 research	 project	 for	
evaluation	of	microRNAs	 in	FD.	MicroRNAs	are	 short	non-coding	RNAs,	able	to	regulate	
gene	 expression	 at	 the	 post-transcriptional	 level.	 The	 available	 evidence	 shows	 that	
microRNAs	are	key	players	in	heart	development	and	myocardial	conditions,	as	well	as	in	
organ	fibrosis	with	different	origins.338,	725	They	have	also	been	implicated	in	the	up	and	
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down-regulation	of	 the	TGF-β/Smad	signalling	pathway	and	 the	epithelial-mesenchymal	
transition	(mediated	by	E-cadherin	expression),	both	involved	in	mesangial	expansion	and	
tubulointerstitial	fibrosis.726,	727	Given	the	promising	results	of	the	entire	microRNAnome	
evaluation	 in	a	 small	 cohort	of	12	FD	patients	with	a	 severe	phenotype,	 I	 am	presently	
finishing	the	evaluation	of	the	31	differentially	expressed	microRNAs	in	a	large	cohort	of	
100	 FD	 patients;	 depending	 on	 these	 results,	 research	 of	 microRNAs	 biomarkers	 may	
proceed	with	a	longitudinal	study.	
Finally,	 as	 an	 inflammatory	 background	 also	 characterizes	 FD	 and	 infusion	 of	
recombinant	proteins	(ERT)	may	cause	an	immunological	response,	not	only	humoral,	but	
also	cellular	or	innate,	I	am	currently	starting	a	research	project	aimed	at	evaluating	ERT	
immunogenicity,	where	I	will	also	try	to	evaluate,	as	an	exploratory	endpoint,	the	effects	
of	immunological	response	in	these	studied	biomarkers.	
To	 conclude,	 my	 overall	 research	 goal	 would	 be	 to	 establish	 a	 reliable	 and	
accurate	 panel	 of	 biomarkers	 to	 define	 early	 cardiac	 and	 renal	 involvement	 and	 to	
delineate	 a	 prognosis	model	 in	 untreated	 and	 treated	patients.	 If	 achieved,	 both	 these	
tools	will	certainly	help	in	clinical	decisions,	timely	initiation	of	disease-specific	treatment	
and	an	individualized	approach	to	the	patient	treatment,	according	to	the	risk	profile	of	
each	patient.				
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Scientific	output	
The	 overall	 work	 developed	 during	 this	 PhD	 thesis	 originated	 the	 following	
publications,	as	well	as	participation	in	several	scientific	meetings.		
	
1.	Publications	
Currently,	 I	 already	 published	 the	 results	 of	 the	 baseline	 evaluation	 of	 the	
nephropathy	and	cardiomyopathy	studies:	
-	 Aguiar	 P,	 Azevedo	 O,	 Pinto	 R,	Marino	 J,	 Baker	 R,	 Cardoso	 C,	 Ducla	 Soares	 JL,	
Hughes	 D.	 New	 biomarkers	 defining	 a	 novel	 early	 stage	 of	 Fabry	 nephropathy:	 A	
diagnostic	test	study.	Mol	Genet	Metab.	2017;	121	(2):	162-169.	(appendix	A.1)	
-	Aguiar	P,	Azevedo	O,	Pinto	R,	Marina	J,	Cardoso	C,	Sousa	N,	Cunha	D,	Hughes	D,	
Ducla	 Soares	 JL.	 Biomarkers	 of	 myocardial	 fibrosis:	 revealing	 the	 natural	 history	 of	
fibrogenesis	in	Fabry	disease	cardiomyopathy.	J	Am	Heart	Assoc.	2018;	7	(6):	pii:	e007124.		
(appendix	A.2)	
Two	 more	 publications	 are	 now	 under	 preparation,	 with	 the	 results	 of	 the	
longitudinal	evaluation	of	cardiomyopathy	and	nephropathy	studies.	
The	interim	results	of	these	research	projects	have	been	published	as	abstracts	in	
scientific	proceedings	or	special	issues	of	scientific	journals:	
-	 Aguiar	 P,	 Azevedo	 O,	 Pinto	 R,	 Marino	 J,	 Ducla	 Soares	 JL,	 Hughes	 D.	 Collagen	
turnover	 biomarkers	 in	 Fabry	 disease	 cardiomyopathy.	 J	 Inherit	 Metab	 Dis.	 2014;	 37	
(Suppl	1):	S142	(appendix	B.1);	
-	Aguiar	P,	Azevedo	O,	Pinto	R,	Marino	J,	Hughes	D,	Ducla	Soares	 JL.	Glomerular	
and	tubular	damage	biomarkers	in	Fabry	disease.	J	Inherit	Metab	Dis.	2014;	37	(Suppl	1):	
S142	(appendix	B.2);	
-	 Aguiar	 P,	 Pinto	 R,	 Azevedo	 O,	Marino	 J,	 Baker	 R,	 Cardoso	 C,	 Ducla	 Soares	 JL,	
Hughes	D.	Urinary	 type	 IV	 collagen:	 Better	 than	 albuminuria	 to	 identify	 incipient	 Fabry	
nephropathy.	Mol	Genet	Metab.	2016;	117	(2):	S16	(appendix	B.3);	
-	Aguiar	P,	Azevedo	O,	Pinto	R,	Marino	 J,	Cardoso	C,	Ducla	Soares	 JL,	Hughes	D.	
Increased	 synthesis	 of	 collagen	 type	 I:	 an	 early	 event	 in	 Fabry	 cardiomyopathy.	 New	
biomarkers?.	Mol	Genet	Metab.	2017;	120	(1-2):	S17-S18	(appendix	B.4);	
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-	Aguiar	P,	Azevedo	O,	Pinto	R,	Marino	J,	Cardoso	C,	Sousa	N,	Cunha	D,	Hughes	D,	
Ducla	 Soares	 JL.	 	 Collagen	 type	 I	 synthesis	 biomarkers	 predict	 the	progression	of	 Fabry	
disease	cardiomyopathy.	Mol	Genet	Metab.	2018;	123	(2):	S16	(appendix	B.5);	
-	Aguiar	P,	Azevedo	O,	Pinto	R,	Marino	 J,	Cardoso	C,	Ducla	Soares	 JL,	Hughes	D.	
Tubular	 dysfunction	 biomarkers	 in	 Fabry	 disease:	 better	 than	 albuminuria	 to	 identify	
patients	 at	 risk	 of	 nephropathy	 progression.	Mol	 Genet	Metab.	 2018;	 123	 (2):	 S16-S17	
(appendix	B.6).	
	
2.	Communications	in	scientific	meetings	
Presented	as	oral	communications:		
-	 “Urinary	 type	 IV	 collagen:	 Better	 than	 albuminuria	 to	 identify	 incipient	 Fabry	
nephropathy”:	 presented	 as	 oral	 communication	 (as	well	 as	 poster)	 at	 the	 12th	 Annual	
WORLD	Symposium	(2016)	–	San	Diego,	United	States	of	America;		
-	“New	biomarkers	defining	a	novel	early	stage	of	Fabry	nephropathy”:	presented	
as	oral	communication	(as	well	as	poster)	at	the	Fabry	Master	Class	 IX	(2017)	–	Madrid,	
Spain.		
Presented	as	panel	communication	(posters):		
-	“Collagen	turnover	biomarkers	 in	Fabry	disease	cardiomyopathy”:	presented	as	
poster	 at	 the	 Annual	 Symposium	 of	 the	 Society	 for	 the	 Study	 of	 Inborn	 Errors	 of	
Metabolism	(2014)	–	Innsbruck,	Austria;	
-	 “Glomerular	 and	 tubular	 damage	 biomarkers	 in	 Fabry	 disease”:	 presented	 as	
poster	 at	 the	 Annual	 Symposium	 of	 the	 Society	 for	 the	 Study	 of	 Inborn	 Errors	 of	
Metabolism	(2014)	–	Innsbruck,	Austria;	
-	“Increased	synthesis	of	collagen	type	I:	an	early	event	in	Fabry	cardiomyopathy.	
New	biomarkers?”:	presented	as	poster	at	the	13th	Annual	WORLD	Symposium	(2017)	–	
San	Diego,	United	States	of	America.		
-	 “Collagen	 type	 I	 synthesis	biomarkers	predict	 the	progression	of	 Fabry	disease	
cardiomyopathy”:	 presented	 as	 poster	 at	 the	 14th	 Annual	WORLD	 Symposium	 (2018)	 –	
San	Diego,	United	States	of	America.			
-	 “Tubular	 dysfunction	 biomarkers	 in	 Fabry	 disease:	 better	 than	 albuminuria	 to	
identify	 patients	 at	 risk	 of	 nephropathy	 progression”:	 presented	 as	 poster	 at	 the	 14th	
Annual	WORLD	Symposium	(2018)	–	San	Diego,	United	States	of	America.			
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Background: Renal involvement in Fabry disease is amajor determinant of overall disease prognosis and early en-
zyme replacement therapy seems effective in preventing progression of kidney injury. Gb3 storage, glomerular
sclerosis and tubulo-interstitial ﬁbrosis may occur with minimal or no changes on standard renal tests, hence al-
ternative markers of renal dysfunction are crucial. In this study we compared several biomarkers with albumin-
uria in the identiﬁcation of incipient Fabry nephropathy and their diagnostic accuracy to identify chronic kidney
disease (CKD) stage ≥ 2.
Methods: In this multicentre, prospective, cross-sectional and diagnostic test study, a cohort of 78 Fabry patients
and 25 healthy controls was consecutively recruited. Patients were grouped by severity of nephropathy: 1) albu-
minuria b 30mg/g; 2) albuminuria 30–299mg/g; 3) albuminuria N 300mg/g; 4) glomerular ﬁltration rate (GFR)
b 60 mL/min/1.73 m2. Several index tests, namely biomarkers of glomerular (transferrin and type IV collagen)
and tubular (α1-microglobulin, N-acetyl-β-glucosaminidase and alanine aminopeptidase) dysfunction were
compared with the reference standard (albuminuria).
Results: Signiﬁcant increase of all tested biomarkers in Fabry patients, even in the subgroup of patients without
evidence of nephropathy. We also found inverse signiﬁcant correlations between estimated GFR and collagen
type IV (ρ=−0.289; p= 0.003) orN-acetyl-β-glucosaminidase (ρ=−0.448; p b 0.001), whichwere stronger
than with albumin (ρ = −0.274; p = 0.019). There was also better diagnostic accuracy of N-acetyl-β-
glucosaminidase to predict CKD stage ≥ 2.
Conclusions: These results suggest that studied biomarkers may overcome the limitations of albuminuria as sen-
sitive marker of early renal dysfunction and as marker for CKD progression risk. These biomarkers may also de-
ﬁne novel early stages of nephropathy characterized by mesangial expansion and/or tubular damage.
© 2017 Elsevier Inc. All rights reserved.
Keywords:
Fabry disease nephropathy
Biomarkers
Collagen type IV
N-acetyl-β-glucosaminidase
Albuminuria
1. Introduction
Anderson-Fabry disease (FD) is an X-linked lysosomal storage
disorder caused by mutations in the GLA gene that encodes the enzyme
α-galactosidase A. The deﬁciency of this enzyme leads to the lysosomal
accumulation of neutral glycosphingolipids (mainly
globotriaosylceramide [Gb3]) and organ failure. Involvement of the
heart, kidney and brain causes signiﬁcant morbidity and premature
death [1,2].
In the past, before renal dialysis and transplant becamewidely avail-
able, kidney failure was the main cause of death in male patients with
FD [3,4]. More recent studies reported cardiovascular disease as the
main cause of death. However, the majority of patients dying from car-
diovascular events had previously received renal replacement therapy
[4,5].
In FD nephropathy Gb3 storage occurs in all renal cells and the dis-
ease progression results in the development of glomerulosclerosis, tu-
bular atrophy and interstitial ﬁbrosis [6]. There is limited knowledge
about the renal histology of young patients with incipient nephropathy.
However, heavy storage in podocytes and distal tubules, as
well as segmental foot process effacement have been shown in
children and patients with minimal or no alterations in standard renal
tests [7–12]. Moreover, mesangial and endothelial cells inclusions,
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glomerulosclerosis, tubule-interstitial ﬁbrosis and arteriopathy have
also been described in this group of patients [7,10]. There is massive
storage in the podocytes and early podocytopathy, with increased
podocyturia and reduced expression of nephrin in the slit diaphragm
in patients without increased albuminuria [13–15].
Albuminuria is usually considered to be the gold standard and a sen-
sitive marker of early renal dysfunction in FD [16–18]. In fact, protein-
uria is one of the most important indicators of renal disease
progression in adult FD patients [19,20] and there is a signiﬁcant corre-
lation between urinary protein excretion rates and foot process width
and fractional volume of Gb3 inclusions in the podocytes [8]. Neverthe-
less, signiﬁcant histological changes may occur without pathological al-
buminuria and/or proteinuria [7–12], thus the sensitivity of albuminuria
and/or proteinuria to identify incipient FD nephropathy is questionable.
Nowadays, enzyme replacement therapy (ERT) is the gold standard
for the treatment of FD. ERT has shown to slow or halt the deterioration
of renal function in patients with mild to moderate renal impairment
[21–26]. These beneﬁts may be limited patients with advanced renal
disease [23,24,26–28]. Moreover, early ERT has a good safety proﬁle
(even in Paediatric population) [29] and is effective preventing kidney
injury progression and reversing early pathological changes previously
described [9,10].
Based on the two assumptions that early kidney involvement is
clinically silent and early treatment is more likely to prevent pro-
gressive kidney injury, alternative markers of kidney dysfunction
are mandated. So, the identiﬁcation of biomarkers correlated to the
earliest pathological ﬁndings is paramount, as these biomarkers may
become a non-invasive, diagnostic method of pre-clinical renal involve-
ment by FD.
In this study, we investigated several markers of glomerular and tu-
bular damage in a large cohort of FD patients (within the entire spec-
trum of FD nephropathy severity), with an emphasis on the usefulness
of these markers in incipient FD nephropathy.
2. Material and methods (Appendix 1 for extended methods)
2.1. Study design and population
In this multicentre, cross-sectional, prospective and diagnostic test
study, a cohort of 78 FD patients and 25 healthy controls was consecu-
tively recruited, between February 2013 and June 2014.
For FD patients the sole inclusion criteria were diagnosis of FD and
age ≥ 18 years old. The control group included individuals with none
of the exclusion criteria hereinafter listed and a normal kidney function
(estimated GFR ≥ 60 mL/min/1.73 m2 and albuminuria b30 mg/g).
The exclusion criteria deﬁned for the control group included dis-
eases with possible kidney involvement: systemic hypertension, diabe-
tes, nephritic or nephrotic syndrome, immunoglobulin A nephropathy,
systemic vasculitis, systemic lupus erythematosus, hepatitis C, amyloid-
osis and multiple myeloma. The exclusion criteria for FD patients were
the same, except systemic hypertension, because it may be manifesta-
tion of FD nephropathy.
To ensure the entire spectrum of severity of FD nephropathy, the re-
cruitment was made in accordance to subgroups of increasing severity:
1) albuminuria b30 mg/g and GFR ≥ 60 mL/min/1.73 m2 (objective: 25
patients); 2) albuminuria 30–299 mg/g and GFR ≥ 60 mL/min/1.73 m2
(objective: 20 patients); 3) albuminuria ≥300 mg/g and GFR ≥ 60 mL/
min/1.73m2 (objective: 10 patients); 4) GFR b 60mL/min/1.73m2 (ob-
jective: 20 patients). The control group was age- and sex-matchedwith
the less severe FD subgroup.
The study protocol was approved by the local or national Ethical
Committees of each participating centre and studywas conducted in ac-
cordancewith this protocol and the ethical principles of the Declaration
of Helsinki. Written informed consent was obtained from all partici-
pants before enrolment.
2.2. Clinical work-up, renal function assessment and outcomes
For each recruited patient, clinical data were collected and renal
function was evaluated by the determination of serum creatinine, albu-
minuria and measurement or estimation of GFR.
Albuminuria (albumin-to-creatinine ratio) was used as the refer-
ence test to compare the index tests, as it is considered to be the gold
standard and a sensitive marker of early renal dysfunction in FD
[16–18]. It was quantiﬁed from spot urine, in random urine samples. In-
creased albuminuria was deﬁned as ≥30 mg/g [30].
In FD patients, serum creatinine was assessed at routine follow-up
(collected in the same day of the urine used to determine the albumin-
uria and the index tests). GFR was estimated by the 2009 CKD-
EPIcreatinine formula [30]. In a single centre GFR is often measured
using Cr-51 EDTA clearance in FD patients. CKD staging by GFR catego-
ries [30] was based in estimated GFR, except in patients in which radio-
isotopic measurement of GFR was available.
Laboratories assessing the renal function were unaware of the mea-
surements of the investigated glomerular and tubular damage bio-
markers and clinical data.
The prespeciﬁed outcomes were to compare the index tests with al-
buminuria in the identiﬁcation of incipient Fabry nephropathy (com-
paring subgroup 1 patients with controls) and their diagnostic
accuracy to identify chronic kidney disease (CKD) stage ≥ 2.
2.3. Novel biomarkers of kidney injury analysis/index tests
Twomarkers of glomerular damage (transferrin and type IV collagen
[ColIV]) and threemarkers of tubular injury (α1-microglobulin [A1MG],
N-acetyl-β-D-glicosaminidase [NAG] and alanine aminopeptidase
[AAP]) were quantiﬁed from spot urine. Each spot urine has been
splitted from the sample used to determine albuminuria and immedi-
ately stored at−20 °C, transported to the laboratory at the same tem-
perature conditions in dry ice and thawed just prior to the assay.
Transferrin, col IV, A1MG andAAPwere evaluated by an ELISAmeth-
od, according to manufacturer instructions and measured at 450 nm
(SunRed®, Shanghai, PRC); NAG was evaluated by a colorimetric assay
at 580 nm (Roche®Diagnostics GmBH,Mannheim;Germany) (detailed
description in Supplementary methods). Duplicate determinations
were made for each individual and mean results are presented. All bio-
markers levels were normalized for the urinary creatinine concentra-
tion. Laboratory researchers were blinded to clinical data and renal
function assessment (reference test).
Given that there are no validated reference values for the tested bio-
markers, the upper limit of 95% conﬁdence interval for mean of the con-
trol group was assumed to be the upper limit of the reference value.
2.4. Statistical analysis
Statistical analysis was performed with SPSS® (Statistical Package
for the Social Sciences, version 21) software. Continuous variables
were expressed as medians and interquartile range (IQR) and as num-
ber and percentage for categorical variables. Normal distribution of con-
tinuous variables was tested using Shapiro-Wilk test.
For continuous variables, comparison of means/medians was per-
formed using Student t-test for variables that followed a normal distri-
bution and Mann–Whitney test/related samples Wilcoxon signed rank
test for variables who did not.
If the qualitative variable had N2 categories, an ANOVA test (post-
hoc analysis with Bonferroni correction) was used for variables with
normal distribution, and a Kruskal–Wallis test was used for those with-
out. For categorical variables, the comparison of the variables distribu-
tion between groups was done using the Qui-square or Fisher exact
tests.
To evaluate the correlation between the several biomarkers and the
quantitative variables, Pearson's correlation coefﬁcient was determined
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and presented in dispersion diagrams. Due to the skewed distribution of
all the studied biomarkers (index and reference tests), a logarithmic
transformation of these variables has been performed for correlation
analysis. Normal distribution of log-transformed variables was tested
using Shapiro-Wilk test. For easier visualization, a log scale was also
used in scatterplots.
We evaluated the diagnostic accuracy of the several biomarkers to
diagnose CKD stage ≥ 2 (deﬁned byGFR b 90mL/min/1.73m2) by calcu-
lating the diagnostic odds ratio (DOR) and the area under the curve
(AUC) from receiver operating characteristic (ROC) curves (we deter-
mined the conﬁdence intervals of area under the curve [nonparametric
method], whereas values between 1 [perfect test] and 0.5 [useless
test]).
For all comparisons and correlations a probability value of b0.05was
considered statistically signiﬁcant. For comparisons including all
groups, with about 25 subjects per group, we expect a power of ~90%
to detect differences among groups, if the within group SD is no more
than twice the SD between the groups. For correlations, using all the
FD patients (n≈ 75), we will have at least ~90% power to detect even
small correlations (ρ2 ~ 0.2) as signiﬁcant.
3. Results
3.1. Population characteristics
78 FD patients (subgroups: 1–25 patients; 2–22 patients; 3–10 pa-
tients; 4–21 patients) and 25 controls (age- and sex-matchedwith sub-
group 1) were recruited (Fig. 1). Population characteristics are given in
Table 1 (detailed information in Supplemental Table 1). Altogether 35
different GLA pathogenic mutations were identiﬁed (Supplemental
Table 2), with p.N215S and p.F113L, mutations associated with late-
onset phenotypes with predominant cardiac involvement, accounting
for 34.6% of the patients; the remainder mutations were usually associ-
ated with classical phenotype.
3.2. Novel biomarkers of kidney injury (index tests): correlation with albu-
minuria (reference standard)
The index testswere all increased in FDpatients comparedwith con-
trols (Table 2), even in the less severe subgroup of FD patients.
Fig. 1. Study ﬂow diagram. ColIV: collagen type IV; A1MG: α1-microglobulin; NAG: N-acetyl-β-D-glicosaminidase; AAP: alanine aminopeptidase; CKD: chronic kidney disease.
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However, a signiﬁcant progressive increase between FD subgroups of
increasing severity was only found for NAG (Supplemental Fig. 1).
For the entire FD cohort, the correlation between albuminuria and
the novel biomarkers (Table 3) was stronger for NAG (Fig. 2), although
signiﬁcant for all but one (A1MG) of the studied biomarkers. Several
normoalbuminuric patients had biomarkers concentrations above the
assumed upper limit of the reference value (Fig. 2; Supplemental Fig. 2).
3.3. Biomarkers of kidney injury: correlation with GFR and CKD stage (tar-
get condition)
For the whole FD cohort, the signiﬁcant negative correlations be-
tween Col IV and estimated GFR (ρ=−0.289; p= 0.003) and between
NAG and estimated GFR (ρ=−0.448; p b 0.001) were stronger than
the correlation between albumin and estimated GFR (ρ =−0.274; p
= 0.019) (Table 4). In subgroup 1, all biomarkers but AAP had better
correlation with estimated GFR than albuminuria (Table 4; Fig. 3).
A signiﬁcant increase of the biomarkers, according to CKD stage, was
only found for NAG (p= 0.016). Notably, it was not signiﬁcant even for
albuminuria (p = 0.062) (Supplemental Fig. 3).
The global diagnostic accuracy of the biomarkers (including albu-
minuria) for CKD stage ≥ 2 (GFR b 90 mL/min/1.73 m2) was better for
NAG excretion (Fig. 4), with a diagnostic accuracy of 74.6%, compared
with the diagnostic accuracy of 65.9% for albuminuria. Moreover, the
DOR was also higher for NAG, compared with all the other biomarkers.
3.4. Novel biomarkers of kidney injury: correlation with other variables
For other variables not directly related to kidney function (including
demographic, diagnosis, severity and treatment), a signiﬁcant correla-
tion was sole found between albuminuria or NAG and disease severity
(MSSI and FIPI) (Supplemental Table 3). Remarkably, a signiﬁcant dif-
ference between male and female patients was only observed for albu-
minuria; nonetheless, although slightly weaker in female patients, the
correlation between estimated GFR and ColIV or NAG was signiﬁcant
for both genders (Supplemental Table 4).
Moreover, there was a signiﬁcant correlation between NAG and age
(ρ=0.365; p=0.001). However, the signiﬁcant inverse correlation be-
tween estimated GFR and NAG (ρ=−0.355; p= 0.002) remained sig-
niﬁcant after adjustment for age.
Table 1
Clinical characteristics of study population.
FD cohort (n = 78)
FD subgroups
1 (n = 25) 2 (n = 22) 3 (n = 10) 4 (n = 21)
Categorical variables (n/%)
Sex (female) 44 (56.4) 18 (72.0) 14 (63.6) 4 (40.0) 8 (38.1)
ERT (yes)⁎ 54 (69.2) 15 (60.0) 13 (59.0) 6 (60.0) 20 (95.2)
ACEi/ARB (yes)Ŧ 38 (48.7) 8 (32.0) 8 (36.4) 4 (40.0) 18 (85.7)
β-Blockers (yes) 16 (20.5) 2 (8.0) 3 (13.6) 3 (30.0) 8 (38.1)
Continuous variables (median/IQR)
Age (yrs)ζ 50.0 (20.0) 43.0 (21.0) 48.5 (13.0) 59.0 (16.0) 62.0 (24.0)
Age at diagnosis (yrs) 42.0 (24.0) 35.0 (27.0) 42.5 (17.0) 53.5 (32.0) 49.0 (44.0)
Age at ERT initiation (yrs)§ 48.1 (17.3) 42.9 (25.2) 44.0 (16.2) 50.7 (17.1) 53.5 (25.0)
Time in ERT (yrs) 4.9 (7.6) 3.9 (8.4) 4.8 (5.4) 4.2 (6.7) 8.5 (8.9)
MSSI° 21.0 (20.0) 10.0 (12.0) 20.5 (18.0) 31.0 (11.0) 32.0 (10.0)
FIPI⁎⁎ 2.0 (3.0) 1.0 (1.0) 2.0 (2.0) 4.0 (1.5) 5.0 (2.0)
Plasma lyso-Gb3 (nmol/L) 9.58 (15.33) 6.03 (12.88) 9.22 (14.36) 11.79 (71.50) 17.79 (36.60)
Plasma α-gal A ♀ (nmol/h/mL) 4.3 (4.0) 6.6 (5.0) 3.8 (7.2) 4.2 (.) 4.5 (4.7)
Plasma α-gal A♂ (nmol/h/mL) 0.11 (0.30) 0.15 (0.50) 0.16 (0.80) 0.10 (0.20) 0.20 (0.30)
Albuminuria (mg/g)ŦŦ 59.2 (269.2) 9.6 (14.2) 88.2 (108.2) 614.8 (454.7) 206.2 (515.4)
Creatinine (mg/dL)ζζ 0.85 (0.60) 0.76 (0.23) 0.76 (0.27) 0.87 (0.21) 1.53 (0.63)
eGFR (mL/min/1.73 m2)ζζ 92.5 (49.0) 105.0 (30.0) 102.0 (22.0) 87.5 (28.0) 39.0 (25.0)
ERT: enzyme replacement therapy; ACEi: angiotensin converting enzyme inhibitors; ARB: angiotensin II receptor blockers; MSSI: Mainz Severity Score Index; FIPI: Fabry International
Prognostic Index; eGFR: estimated glomerular ﬁltration rate.
Note: conversion factors for units: creatinine in mg/dL to μmol/L: ×88.4; albuminuria in mg/g to mg/mmol: ×0.113.
⁎ p b 0.05 for difference in the distribution of categorical variable between subgroups.
Ŧ p b 0.01 for difference in the distribution of categorical variable between subgroups.
ζ p b 0.01 for difference between groups 1 and 4; p b 0.05 for difference between groups 2 and 4.
§ p b 0.05 for difference between groups 1 and 4.
° p b 0.01 for difference between group 1 and all other groups and also between groups 2 and 4.
⁎⁎ p b 0.01 for difference between group 1 and all other groups and also between groups 2 and 4; p b 0.05 for difference between groups 2 and 3.
ŦŦ p b 0.01 for difference between groups 1 and 3 or 4 and also between groups 2 and 3; p b 0.05 for difference between groups 2 and 4.
ζζ p b 0.01 for difference between group 4 and all other groups.
Table 2
Novel biomarkers of kidney injury in controls and FD subgroups (median (IQR)).
Controls
FD subgroups
p valuea p valueŦ
(n = 25) 1 (n = 25) 2 (n = 22) 3 (n = 10) 4 (n = 21)
Transferrin (μg/g) 0.81 (0.62) 0.99 (2.10) 1.09 (0.94) 0.95 (0.94) 1.26 (1.16) 0.018 0.45
ColIV (mg/g) 5.09 (5.54) 7.92 (14.28) 10.88 (8.31) 7.53 (9.76) 9.75 (11.86) 0.040 0.53
A1MG (mg/g) 298.3 (260.9) 489.2 (1121.9) 570.5 (549.7) 580.7 (767.9) 522.9 (360.1) 0.009 0.91
NAG (U/g) 8.72 (5.66) 10.79 (17.91) 13.44 (8.37) 25.04 (23.04) 22.02 (19.22) 0.037 0.023
AAP (U/g) 4.98 (7.13) 13.07 (20.46) 13.02 (15.98) 16.68 (12.73) 13.37 (9.25) 0.009 0.97
All biomarkers presented a non-normal distribution, so non parametric tests were used.
ColIV: collagen type IV; A1MG: α1-microglobulin; NAG: N-acetyl-β-D-glicosaminidase; AAP: alanine aminopeptidase.
a Controls vs FD disease subgroup 1.
Ŧ Between FD subgroups.
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4. Discussion
In this study, with the objective to identify biomarkers of incipient
nephropathy in FD and not biomarkers of FD or FD nephropathy (not el-
evated in other forms of nephropathy), our results suggest that several
of the studied biomarkers are more sensitive than albuminuria in de-
tecting incipient FD nephropathy, with a signiﬁcant increase for all of
them in patients without any evidence of nephropathy.
Furthermore, although a signiﬁcant progressive increase of the bio-
markers across the prespeciﬁed FD subgroups and the CKD stage (nota-
bly non-signiﬁcant for albuminuria) was sole found for NAG, the
correlation with estimated GFR was stronger for ColIV and NAG, than
for albuminuria. Thus, the studied biomarkers (NAG and ColIV) seems,
at least, as good as albuminuria in the identiﬁcation of the FD nephrop-
athy severity spectrum (increasing correspondingly).
Additionally, NAG outperformed albuminuria in the diagnostic accu-
racy for CKD stage ≥ 2. The relatively modest DOR of the several bio-
markers were mainly related to their ability to identify patients with
GFR ≥ 90 mL/min/1.73 m2, but certainly with kidney involvement
from FD, thereby diminishing their speciﬁcity for CKD stage ≥ 2. Thus,
NAG seems to have an important added value, not only in the identiﬁca-
tion of incipient FD nephropathy, but also as a prognostic marker, with
signiﬁcant correlation with estimated GFR and diagnostic accuracy to
identify CKD stage ≥ 2.
The correlation with other variables was not signiﬁcant, which ar-
gues for these biomarkers to be markers of FD nephropathy and not of
overall disease burden. One exception is the correlations between albu-
minuria or NAG with severity indexes: both comprise a renal compo-
nent/involvement [31,32] and nephropathy is a well-known
determinant of overall disease prognosis [3–5]. The correlation between
NAG and age seems to be related to the decrease in kidney function as-
sociated with ageing. The absence of difference in the several bio-
markers according to gender and ERT is understandable, given the
balanced gender distribution within the subgroups of increasing FD ne-
phropathy and a greater proportion of patients on ERT in the more se-
vere subgroups (may have, by this reason, biomarkers' levels similar
to the patients not in ERT). Furthermore, the stratiﬁed analysis of corre-
lations with estimated GFR by gender showed that signiﬁcant correla-
tions remained in male and female patients. Nevertheless, an ongoing
longitudinal evaluation of these biomarkers will help to clarify the inﬂu-
ence of ERT on them.
4.1. Glomerular damage biomarkers
Transferrin is amolecule slightly larger than albumin, but less anion-
ic, thus expected to bemore readily ﬁltered through the glomeruli [33].
To our knowledge, it has never been studied in FD, but as reported in di-
abetic nephropathy, transferrinuria may be a more sensitive marker of
glomerular damage, raised in normoalbuminuric patients [34].
ColIV excretion appears to be a surrogatemarker of glomerular base-
ment membrane synthesis and mesangial matrix remodelling [35] and
podocytes are among the earliest cells to be loaded with
glycosphingolipid deposits [7,8]. The progressive accumulation of lyso-
Gb3 in these cells leads to increased expression of the ﬁbrogenic cyto-
kine TGF-β1 and, subsequent, increasing in extracellularmatrix synthe-
sis (ﬁbronectin and ColIV) [36]. This study results shows, as in diabetic
nephropathy [37], an increase of ColIV excretion in early stages of FD ne-
phropathy, consistent with the pathological ﬁndings of thickening or
duplication of glomerular basement membrane and increased
mesangial extracellular in incipient FD nephropathy [7,11]. The
Table 3
Correlation of novel biomarkers of kidney injurywith albuminuria for all FD cohort (a log-
arithmic transformation of the variables has been performed).
ρ p value
Transferrin 0.251 0.027
ColIV 0.306 0.007
A1MG 0.179 0.12
NAG 0.468 b0.001
AAP 0.249 0.033
ColIV: collagen type IV; A1MG: α1-microglobulin; NAG: N-acetyl-β-D-glicosaminidase;
AAP: alanine aminopeptidase.
Fig. 2. Concentration of urinary NAG and albuminuria: entire FD cohort (top image) and
subgroup 1 (bottom image). Vertical line in right image represents the upper limit of
95% conﬁdence interval for mean of the control group (assumed to be the upper limit of
the reference value). For easier visualization, a log scale has been used for the studied
biomarkers.
Table 4
Correlation of biomarkers of kidney damagewith estimatedGFR for all FD cohort and sub-
group 1 (a logarithmic transformation of the biomarkers has been performed).
All FD cohort Subgroup 1
ρ p value ρ p value
Albumin −0.274 0.019 −0.381 0.060
Transferrin −0.230 0.043 −0.551 0.004
ColIV −0.289 0.003 −0.487 0.014
A1MG −0.149 0.19 −0.542 0.005
NAG −0.448 b0.001 −0.623 0.001
AAP −0.049 0.68 −0.007 0.97
ColIV: collagen type IV; A1MG: α1-microglobulin; NAG: N-acetyl-β-D-glicosaminidase;
AAP: alanine aminopeptidase.
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signiﬁcant inverse correlation between ColIV and estimated GFR sug-
gests that ColIV excretion is a prognostic factor in FD nephropathy, as
previously demonstrated in diabetic nephropathy [38,39]. Furthermore,
ColIV may be a good biomarker of response to ERT, given that the
mesangial wideningwas showed to decrease in patients under ERT [22].
In FD nephropathy, other biomarkers of glomerular dysfunction
have been studied, mainly related to podocytopathy. However, in previ-
ous studies evaluating podocyturia in FD, it was increased in patients
without albuminuria and overt nephropathy, but a signiﬁcant inverse
correlation with estimated GFR was only found in one study (and only
in male patients) and the added value against albuminuria, in terms of
diagnostic accuracy and nephropathy prognosis, has not been
established [13,14,40].
4.2. Tubular injury biomarkers
Sphingolipid storage occurs also in tubular cells [6] andmay be pres-
ent in early phases of the disease, in patients with minimal albuminuria
[7]. Other contributors to tubular injury in FDmay be the hemodynamic
damage and persistent proteinuria [41].
The tubular injury preceding glomerular involvement was also ob-
served in diabetic nephropathy, where, as in our study, an increase in
several tubular proteins and enzymes became apparent before
albuminuria A2 and has been correlated with the severity of nephropa-
thy [42]. Thus, it has been hypothesized that the long-term outcome in
diabetic nephropathy was more related to the degree of the
tubulointersticial impairment than to the severity of glomerular lesions
[43]. Previous smaller studies in FD have shown an increase in tubular
injury biomarkers [44,45].
A1MG is a small protein, whose urinary excretion increases with
proximal tubular cell dysfunction [46]. A small previous study in FD
(with 13 women) reported a signiﬁcant decrease in A1MG with ERT
[45]. In type 2 diabetes, A1MG has been also correlated with albumin-
uria [47].
NAG is an urinary enzyme and, due to its high molecular weight, it
cannot be ﬁltered through the glomeruli and its presence in the urine
results exclusively from tubular secretion [33].Wewere able to conﬁrm
previous data showing an increase in urinary NAG in FD [48], but also
that this biomarker rises before and signiﬁcantly correlates with albu-
minuria and outperformed albuminuria as predictor of estimated GFR
and CKD stage ≥ 2, like previously reported in type 2 diabetes [44,49].
These ﬁndings substantiate several concepts: tubular injury in FD ne-
phropathy occurs early; long-term outcome of FD nephropathy may
be more related to the extent of the tubulointersticial impairment
than to the severity of glomerular lesions; proteinuria is a contributor
to tubular injury. This greater sensitivity than albuminuria to detect
Fig. 3. Correlation of estimated GFRwith albuminuria or NAG: entire FD cohort (upper images) and subgroup 1 (bottom images). For easier visualization, a log scale has been used for the
studied biomarkers.
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early renal malfunction,may be related to an increase in urinary NAG at
a stage where tubular reabsorption capacity may still be sufﬁcient to
balance increased glomerular ﬁltration of albumin [33].
AAP is another tubular enzyme, to our knowledge, never studied be-
fore in FD nephropathy. However, as for diabetic nephropathy, although
useful to detect tubular dysfunction at an early stage, it has lower sensi-
tivity and prognostic value than NAG excretion [50].
4.3. Limitations
This study has several limitations, namely: absence of histological
correlation, which would be very useful in biomarkers validation; the
cross-sectional design (an ongoing longitudinal evaluation is in prog-
ress), hindering the prognostic value of these biomarkers and the inﬂu-
ence of ERT and ACEi/ARB on them. It would be important to
standardize the assay of biomarkers to allow more widespread use in
clinical practice.
4.4. Conclusion
In this study, we have demonstrated that limitations of albuminuria
as a sensitive marker of early renal dysfunction in FD and as a marker of
risk of progression of CKD, may be overcome by the newly identiﬁed
biomarkers, all increased in normoalbuminuric patients and some of
them (ColIIV and NAG) with better correlations with estimated GFR
than albuminuria. These biomarkers may improve the management of
FD nephropathy, inform criteria for starting ERT and may also deﬁne
novel early stages of FD nephropathy characterized by mesangial ex-
pansion (ColIV) and/or tubular damage (NAG).
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1DivMetab Dis, Ege Univ Med Faculty, İzmir, Turkey, 2Div Genetic Dis,
Ege Univ Med Faculty, İzmir, Turkey, 3Div Molacular Gen, Ege Univ
Med Faculty, İzmir, Turkey
Niemann-Pick disease type B (NPD-B) is an inborn error of
metabolism where reduced acid sphingomyelinase activity leads
to multisystem disease with survival into adulthood. The natural
history of NPD-B is progressive hepatosplenomegaly and gradual
deterioration of pulmonary function. Familial Mediterranean fever
(FMF) is a rare inherited autosomal recessive autoinflammatory
disorder characterized by recurrent and self-limited episodes of
fever and painful serositis. We describe a case who has NPD-B
and FMF, concomitantly. An 11 months old boy was referred due
to hepatosplenomegaly and prolonged fever. In laboratory analy-
ses thrombocytopenia, hypertriglyceridemia and elevated transam-
inases were found. Bone marrow biopsy showed foam cells.
Sphingomyelinase enzyme level was 0.003 nmol/17 hour/mg pro-
tein. We found homozygote c.409 T>C mutation in SMPD1 gene
and diagnosis of NPD-B was established. During follow-up peri-
od, he developed recurrent prolonged fever attacks. We suspected
FMF and detected homozygote M694V mutation on MEFV gene.
Our patient benefitted from colchicine treatment. Coexistence of
NPD-B and FMF is a rare situation. Although recurrent fever
could be thought to be a manifestation of NPD-B due to pulmo-
nary infections; in the case of positive inflammatory markers
without proof of infection, FMF should be kept in mind.
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Collagen turnover biomarkers in Fabry disease cardiomyopathy
Aguiar P1, Azevedo O2, Pinto R3, Marino J4, Ducla Soares J L1,
Hughes D4
1Med Dep, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, 2Card Dep,
Centro Hospitalar do Alto Ave, Guimarães, Portugal, 3Laboratório Dr.
Joaquim Chaves, Lisbon, Portugal, 4LSD Unit, Royal Free Hospital,
London, United Kingdom
Background and objectives: Cardiomyopathy is the most common
cardiac abnormality seen in Fabry disease (FD). Since myocardial
fibrosis is one of the histological hallmarks of FD cardiomyopa-
thy the assessment of the collagen turnover biomarkers is
paramount.
Methods: FD patients with left ventricle hypertrophy and age- and
sex-matched controls were studied. All patients and controls
underwent echocardiography and markers of collagen type I and
III synthesis and degradation were measured. Since type I colla-
gen is a major component of bone, bone-specific alkaline phos-
phatase (b-AP) and tartarate resistant acid phosphatase 5b
(TRAP5b) were also assessed.
Results: Ten patients and ten controls were evaluated. Levels of
propeptide of type I procollagen (PICP) were significantly higher
in FD patients (p=0.015) as also the PICP:b-AP ratio (p=0.002).
The PICP to C-terminal telopeptide of type I collagen ratio
(balance between collagen synthesis and degradation) was non-
significantly increased in FD (p= 0.258) and the matrix
metalloproteinase-2 (MMP-2) was significantly lower in FD (p=
0.028).
Conclusion: Collagen type I synthesis is increased in FD cardiomyopathy
and there is a statistical trend for the synthesis to prevail over degradation,
related to the inhibition of the MMP. As in hypertrophic cardiomyopathy
this profibrotic state is likely to be critical in FD cardiomyopathy.
Conflict of Interest declared.
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Background and objectives: In Fabry disease (FD) nephropathy storage
occurs in all renal cells (endothelial, glomerular, interstitial and tubular
cells). These histologic findings can occur with minimal or no alterations
on standard renal tests, so alternative markers of glomerular and tubular
dysfunction are crucial.
Methods: FD patients with chronic kidney disease and age- and sex-
matched controls were studied. All patients and controls underwent
kidney function evaluation (glomerular filtration rate [GFR] and albu-
minuria) and markers of glomerular (transferrinuria and collagen type IV)
and tubular (α1-microglobulin, N-acetyl-glucosaminidase and alanine
aminopeptidase) damage were measured.
Results: Ten patients and ten controls were evaluated. All the patients had
GFR<60 ml/min/1.73 m2 and 9 had albuminuria>30 mg/g creatinine.
Markers of glomerular damage were significantly higher in FD patients
(transferrinuria p=0.001; collagen type IV p=0.001). A similar result was
achieved for markers of tubular injury (α1-microglobulin p=0.006; N-
acetyl-glucosaminidase p=0.001; alanine aminopeptidase p=0.005).
Conclusion: The kidney damage in FD affects the glomeruli and the
tubules. This is the first evaluation of tubular dysfunction markers in
FD. These results suggests further study of these markers which have
shown promise in the early detection of nephropathy in other diseases
such as diabetes, so should also be pursued in FD.
Conflict of Interest declared.
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Clinical profile of females with Anderson-Fabry disease
in a Brazilian community
Curiati M A1, Mendes C S C1, Rand M H1, Kyosen S O1, Aranda C S1,
Garrote J1, Rosa M F G2, Martins A M1
1CREIM, Universidade Federal de São Paulo, São Paulo, Brazil,
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Background and objectives: Anderson-Fabry Disease (AFD) females
were thought to be asymptomatic or to develop only minor manifesta-
tions. However several studies reported that heterozygous females do
develop substantial symptoms.We aim to describe the clinical findings in
female patients carrying a null mutation.
Patients andMethods: We analyzed the clinical profile in 53 AFD female
patients with a severe phenotype.
Results: The patients, median age of 30 y (7y-68y), showed early symp-
toms: 74 % presented acroparesthesia, median age 10y (4y - 51y).
Hypohidrosis was present in 72 %, angiokeratomes in 23 %, depression
in 45 %. Heart MRI was performed in 43 patients: 51 % normal, 49 %
abnormal. Brain MRI was performed in 41 patients: 51 % normal, 49 %
abnormal. Proteinuria in 64 %. Mutation analysis showed 35 % of
c.1095delT, 35 % c.365del7, 21 % p. W47X, 4 % p. W004X and 4 %
unknown.
Discussion/Conclusion: All mutations found are expected to cause a
severe phenotype (null mutations). Our female patients showed early
symptoms of the disease, most frequently acroparesthesia and proteinuria.
They also showed high incidence of cardiac and neurologic
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tein. We found homozygote c.409 T>C mutation in SMPD1 gene
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could be thought to be a manifestation of NPD-B due to pulmo-
nary infections; in the case of positive inflammatory markers
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metalloproteinase-2 (MMP-2) was significantly lower in FD (p=
0.028).
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related to the inhibition of the MMP. As in hypertrophic cardiomyopathy
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1
Cardiac assessment in Egyptian type 3 Gaucher disease and report
of calciﬁcations in homozygous L444P mutation
Magy Abdelwahab, Aya Fattouh, Hala Hamza, Doaa Abdelaziz, Cairo
University Pediatric Hospital, Cairo, Egypt
Cardiac involvement in Gaucher disease is rare, consisting of
constrictive pericarditis, pericardial calciﬁcation, restrictive cardiomy-
opathy, pulmonary hypertension and diffuse inﬁltration of the
myocardium by Gaucher cells. Cardiac valvular and aortic arch
calciﬁcations represent a life threatening presentation of the homozy-
gous D409HGaucher variant. However aortic ﬁbrosis has been reported
in a Croatian GD1 adult homozygous for G377S mutation. Sudden
unexplained death has been recently reported in our Egyptian type 3
GD (GD3) cohort with no deﬁned pathogenesis to explain it. So the
cardiac status of 30 GD3 (22 L4444P/L444P, 4 D409H /D409H, 4
unknown ) patients was assessed. 4 patients had cardiac symptoms, 9
had a history of sudden unexplained death of a GD3 familymember and
17 GD3 children were asymptomatic. Baseline assessment included
clinical evaluation, ECG, echocardiography (2D, M-mode), tissue
Doppler andmultislice CT scan (MSCT) to exclude coronary calciﬁcation
if indicated. Our cohorts’ current age ranged from 3.5 to 22 years; 16
males and14 females. All received ERT for 2-17 years. Patients’ ECG’s
were normal and none (deceased or their siblings) had an underlying
arrhythmia and/or ischemic changes. Echocardiography showed ab-
normalities in 50% of the GD3 screened patients; aortic stenosis and
regurge in 3 patients, mitral regurge and pulmonary hypertension each
in 4 patients. Dilated and hypertrophic cardiomyopathy, pericardial
effusion, subclinical left ventricle impaired relaxation, and coarctation
of the aorta were each reported in one GD3 patient. 7 patients
(3 D409H/D409H, 4 L444P/L444P) had valvular and intracardiac
calciﬁcations including the aortic root and 3 had ectasia of the coronaries
on MSCT with normal lipid proﬁle. Homozygous L444P patients had
severe phenotype. 7/30 died [2 D409H/D409H, one unexplained and
1 post-operatively; 5L444P/L444P, 3 unexplained,1 of stridor and 1 of
cardiomyopathy]. This is the ﬁrst report of aortic calciﬁcations in
homozygous L444P GD patients, the youngest aged 3 years.
doi:10.1016/j.ymgme.2016.11.010
2
MicroRNAs in Fabry disease: role as biomarkers and a possible
pathophysiological pathway
Patricio Aguiara, Marina C Costab, Olga Azevedoc, Manuela Fiúzaa,
Jacira Marinod, José Luís Ducla Soaresa, Derralynn Hughesd,
Francisco J Enguitab, aCentro Hospitalar Lisboa Norte, Lisbon,
Portugal, bInstituto de Medicina Molecular - Lisbon Medicine Faculty,
Lisbon, Portugal, cHospital Senhora da Oliveira, Guimarães, Portugal,
dRoyal Free London NHS Foundation Trust and University College
London, London, United Kingdom
Fibrosis is a key feature of Fabry disease (FD) and a major
determinant of enzyme replacement therapy response, with better
outcomes in patients without cardiac ﬁbrosis or advanced nephrop-
athy. Thus, accurate biomarkers for early prediction of activation of
ﬁbrotic pathways are crucial. MicroRNAs (miRNAs) are short
noncoding RNAs, able to regulate gene expression at the post-
transcriptional levels and have been identiﬁed as key players in
organ ﬁbrosis. Thus, screening for differentially expressed circulating
microRNAs in FD is paramount to test their application as
biomarkers. A complete miRNAnome qPCR panel containing 752
miRNAs was used to quantify serum miRNAs in FD patients and
controls. FD patients were divided by subgroups: classic phenotype;
predominant cardiac involvement; predominant renal involvement.
12 FD patients (4 in each subgroup; 58,3% males, mean age 53,3±
11,2years, all on ERT) and 4 controls were evaluated. From the entire
panel, 34 miRNAs were signiﬁcantly differentially expressed be-
tween FD patients and controls, remarkably all down-regulated. This
signiﬁcant down-regulation was found for 19 miRNAs in the three
subgroups; 4 miRNAs were only differentially expressed in “cardiac”
group, the same for “renal” group; none miRNA was exclusively
down-regulated in the “classic” group. Most of the identiﬁed miRNAs
have been implied in the regulation of known proﬁbrotic pathways
(eg, TGF-β, MMP-9 and aldosterone). MiRNAs may play a key role in
the regulation of the proﬁbrotic state in FD and might provide
attractive candidates as biomarkers to the identiﬁcation of patients
at increased risk of ﬁbrosis development and progression of FD,
being evaluated in a larger cohort. Moreover, in the setting of
miRNAs down-regulation, we can hypothesise impaired exocytosis of
the miRNAs (due to disruption of the Golgi / endosomal / lysosomal
trafﬁcking in an environment of lysosomal dysfunction) as an
alternative pathophysiological pathway in FD.
doi:10.1016/j.ymgme.2016.11.011
3
Increase synthesis of collagen type I: an early event in Fabry
cardiomyopathy. New biomarkers?
Patrício Aguiara, Olga Azevedob, Rui Pintoc, Jacira Marinod, Carlos
Cardosoc, José Luís Ducla Soaresa, Derralynn Hughesd, aCentro
Hospitalar Lisboa Norte, Lisbon, Portugal, bHospital Senhora da Oliveira,
1096-7192/$ – see front matter
Molecular Genetics and Metabolism 120 (2016) S17–S145
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Molecular Genetics and Metabolism
j ourna l homepage: www.e lsev ie r.com/ locate /ymgme
	
Guimarães, Portugal, cDr. Joaquim Chaves, Laboratório de Análises
Clínicas, Miraﬂores, Portugal, dRoyal Free London NHS Foundation Trust
and University College London, London, United Kingdom
Cardiovascular disease is the main cause of death in Fabry disease
(FD) and a major determinant of overall disease prognosis, with
worst outcomes in patients with myocardial ﬁbrosis. Currently, late
gadolinium enhancement (LGE) is the gold standard for evaluation of
replacement myocardial ﬁbrosis. However, this is an end stage /
irreversible event, thus identiﬁcation of biomarkers of earlier diffuse
ﬁbrosis or increased collagen deposition is paramount. Type I
collagen synthesis and degradation biomarkers (carboxy-terminal
propeptide of procollagen type I [PICP], carboxy-terminal telopeptide
of type I collagen and matrix metalloproteinases [MMP] 1 and 2), as
well as markers of bone synthesis and degradation were evaluated
(to adjust type I collagen metabolism to bone turnover) in FD
patients and controls. FD patients were grouped by cardiomyopathy
severity: 1) normal echocardiogram; 2) tissue Doppler abnormalities
in echocardiogram; 3) left ventricular (LV) hypertrophy in echocar-
diogram. 60 FD patients (20 in each group; 38,3% males, mean age
50,2±14,7years, 65,0% on ERT) and 20 controls (age- and sex-
matched with group 1) were recruited. A signiﬁcant increase of PICP
and a signiﬁcant decrease in MMPs was observed in FD patients,
even in the group 1 for the former biomarker. There was a signiﬁcant
correlation between LV mass and PICP (β=0.413, p=0.001) or
MMP-1 (β=-0.339, p=0.01). PICP (adjusted for bone turnover) was
the better predictor of LV mass in a multivariate regression model
and its diagnostic accuracy to predict LGE was also signiﬁcant.
Collagen type I synthesis is increased in FD cardiomyopathy (even in
the earlier stages of the disease) and this proﬁbrotic state is a good
predictor and is likely to be critical to the development of overt LV
hypertrophy. Moreover, inhibition of enzymes involved in collagen
type I cleavage seems to be a crucial pathophysiological link in
myocardial collagen deposition.
doi:10.1016/j.ymgme.2016.11.012
4
Characterization of a secondary deﬁciency of neuraminidase
activity in a unique ovine model of GM1 gangliosidosis
Amelia Ahern-Rindell, Alexandra Quackenbush, Sara McCrohan,
University of Portland, Portland, OR, United States
Ongoing characterization of an ovine lysosomal disease with
dual deﬁciencies of beta-galactosidase and alpha-neuraminidase
activities has provided additional evidence to support the hypoth-
esis that this sheep model is a variant of GM1 gangliosidosis (GM1).
Mutations in the GLB1 gene, which codes for beta-galactosidase,
have been identiﬁed including a missence mutation we reported
on in this dual deﬁciency sheep model. The amino acid substitution
is most likely the primary cause for the profound deﬁciency of beta-
galactosidase activity as a result of its altered protein structure
and possible premature degradation. Our explanation for the less
severe, secondary deﬁciency of alpha-neuraminidase activity is
based on the fact that these two hydrolases interact with one
another as a part of the Lysosomal Multienzyme Complex (LMC).
We proposed that the structurally altered beta-galactosidase
interferes with normal formation of the LMC, which indirectly
affects the alpha-neuraminidase activity. The neuraminidase pro-
tein is coded for by the NEU1 gene and mutations in this gene
results in another lysosomal disease known as sialidosis. We believe
it is highly unlikely that our affected sheep have two separate
disease-causing mutations, one in each gene. To verify that there is
no mutation in the coding region of the NEU1 gene, we isolated
genomic DNA from normal and affected sheep and performed
PCR ampliﬁcation of the exonic regions. No signiﬁcant differences
were found as a result of a comparison between the affected sheep
DNA sequence and that of the normal sheep, and the reference
sequence of NEU1 in GenBank. We also conducted assays on ﬁbro-
blasts from affected sheep cultured in the presence and absence of
the protease inhibitor MG132. We found an increase in alpha-
neuraminidase activity in the presence of the inhibitor. We con-
clude that the structurally altered beta-galactosidase leads to the
malformed LMC that indirectly causes premature degradation of
alpha-neuraminidase.
doi:10.1016/j.ymgme.2016.11.013
5
Neurocognitive and behavioral longitudinal trajectory of
Hurler-Scheie syndrome patients with L238Q mutation
Alia Ahmed, Elsa Shapiro, Kyle Rudser, Chester Whitley, University of
Minnesota, Minneapolis, MN, United States
A cross sectional study of the medical, cognitive, and psychiatric
outcomes of patients affected with Hurler-Scheie syndrome with
a heterozygous mutation of L238Q were previously published
[PMC3939822]. This study extends prior work to investigate how
the outcomes change over time and affect their life adjustment in
comparison to non-L238Q Hurler-Scheie syndrome patients. Among
6 patients with a L238Q mutation, 4 were paired with a nonsense, 1
paired with a deletion, and 1 paired with a splice site mutation.
This L238Q group was compared to 6 patients with Hurler-Scheie
syndrome matched in age range. For the comparison group, 3
patients had a missense paired with nonsense mutation, 2 patients
with missense paired with missense, and 1 patient with nonsense
paired with splice site. To measure the somatic disease burden the
Physical Symptom Score (PSS) was used [PMID: 26303610]. We
measured FSIQ, attention, memory, adaptive function and psycho-
logical/behavioral status from 2009 to 2014. FSIQ scores increased on
average by 1.5 per year for the L238Q group and 2.0 per year in the
comparison group, but the range of FSIQ scores were uniformly
below average in the L238Q group and within the average range for
the comparison group (p ≤ 0.05). Attention and adaptive function
scores did not change signiﬁcantly over time but the range was
below average in the L238Q group and average in the comparison
group. PSS worsened with age in both groups. For psychological/
behavioral measures, parent report of anxiety worsened but scores
on depression, withdrawal, and atypicality improved, whereas self-
report of anxiety, depression and atypicality improved over time. The
L238Q mutation has a signiﬁcant impact on FSIQ, memory, attention,
adaptive functions and psychological/behavioral status. Although their
deﬁcits appear stable in their current age range, they continue to need
yearly follow up. (Support by NIH U54-NS065768, UL1TR000114, CTSI
and CNBD.)
doi:10.1016/j.ymgme.2016.11.014
6
Smallmolecule therapies for juvenile neuronal ceroid lipofuscinosis
Rebecca C Ahrens-Nicklasa, Luis Tecedora, Mark L Schultzb, Elena
Lysenkoa, Shyam Ramachandrana, Eric D Marsha, Beverly L Davidsona,
Abstracts / Molecular Genetics and Metabolism 120 (2016) S17–S145S18
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CLN3 disease is an autosomal-recessively inherited lysosomal
disease with onset during childhood. Symptoms include vision loss,
motor decline, dementia, and seizures, and impact multiple areas of
function. The Pediatric Evaluation of Disability Inventory-Computer
Adaptive Test (PEDI-CAT) was developed to assess functional
capacity in young persons (approx age 1-21 years). The PEDI-CAT
evaluates individuals across four domains of function: Daily Activi-
ties, Mobility, Social/Cognitive, and Responsibility. With domains,
items are ranked according to the difﬁculty experienced in
completing a task or skill independently: 1 = unable, 2 = hard,
3 = a little hard, 4 = easy. The major aim of the current pilot project
is to evaluate the PEDI-CAT's utility in assessing functional abilities
in CLN3 disease. The parents of ﬁve children with CLN3 disease
(3 males, 2 females) ranging in age from 9.3 to 25 years old
completed the PEDI-CAT. With the exception of the youngest subject
who participated, age-adjusted T scores across the four PEDI-CAT
domains were b10 and reﬂective of signiﬁcant limitations in
functional abilities, compared to same-age peers. PEDI-CAT Fit Scores,
reﬂecting whether responses to domain items were close to expected,
based on estimated functional level across a domain, varied from
within acceptable range to suggesting likely poor ﬁt (i.e., -2.00 and
2.00): Daily Activities, Mean Fit Score= -0.42 (range= -1.59 to 0.91);
Mobility, Mean Fit Score = -1.90 (range = -3.34 to -0.84); Social/
Cognitive, Mean Fit Score = -1.67 (range = -2.67 to -0.46);
Responsibility, Mean Fit Score = 0.36 (range = -1.05 to 1.54). These
initial data identify items that may be informative for describing
functional capacity in CLN3 disease at various ages and stages of
the disease. Further work is needed to evaluate the PEDI-CAT in
CLN3 disease, including the ability to track change in functional skills
over time.
doi:10.1016/j.ymgme.2017.12.012
4
Collagen type I synthesis biomarkers predict the progression of
Fabry disease cardiomyopathy
Patricio Aguiara, Olga Azevedob, Rui Pintoc, Jacira Marinod, Carlos
Cardosoc, Nuno Sousae, Damião Cunhae, Derralynn Hughesf, José Luís
Ducla Soaresa, aCentro Hospitalar Lisboa Norte, Lisbon, Portugal,
bHospital Senhora da Oliveira, Guimarães, Portugal, cJCS. Dr Joaquim
Chaves, Lab Análises Clínicas, Miraﬂores, Portugal, dRoyal Free London
NHS Foundation Trust and University College London, London, United
Kingdom, eLife and Health Sciences Research Institute (ICVS), School
of Medicine, University of Minho; ICVS/3Bs PT Government Associate
Laboratory, Braga, /Guimarães, Portugal, fRoyal Free London NHS
Foundation Trust and University College London, London, Portugal
Introduction: Fabry disease (FD) cardiomyopathy is characterized
by a hypertrophic phenotype, in the histological setting of cardio-
myocyte hypertrophy and myocardial ﬁbrosis; myocardial ﬁbrosis is
an irreversible event and affects the prognosis. Thus, the identiﬁca-
tion of biomarkers to predict the development of myocardial ﬁbrosis
and overt left ventricular (LV) hypertrophy is paramount.
Methods: a cohort of 60 FD patients (38,3% males, mean age
50,2±14,7years, 65,0% on ERT) was consecutively recruited and
the patients were followed for 24 months. Patients with an
increase ≥10g/m2.7 in LV mass (LVM) or an increase ≥1.5 in E/E’
average, associated with TDI abnormalities upon follow-up were
deﬁned as LVM or LV end-diastolic pressure (LVEDP) progressors,
respectively. The prognostic value of type I collagen synthesis
(carboxy-terminal propeptide of procollagen type I [PICP]) and
degradation (matrix metalloproteinase 1 [MMP-1]) biomarkers was
evaluated.
Results: during follow-up, both LVM and E/E’ ratio remained
stable, but 28,3% and 31,3% of the patients presented criteria of LVM
and LVEDP progression, respectively; there was no signiﬁcant change
in PICP and MMP-1 during follow-up. MMP-1 serum concentration at
baseline was signiﬁcantly lower in patients presenting with LVEDP
progression. Moreover, there was a signiﬁcant correlation between
PICP variation and LVM variation (ρ=0.492; p=0.001) and PICP
decreased by a median 7,6ng/mL in LVM non-progressor and
increased by a median 20,6ng/mL in LVM progressors (p=0,001);
furthermore, a patient in the forth quartile of PICP variation
presented an OR=25,0 (p=0,008) of being a LVM progressor
compared to a patient in the ﬁrst quartile of PICP variation.
Conclusion: our ﬁndings suggest that collagen type I synthesis
has good prognostic value for and is likely to be critical to the
development of overt LV hypertrophy. Moreover, inhibition of
enzymes involved in collagen type I cleavage also seems crucial to
myocardial collagen deposition and is related to the risk of progressive
diastolic dysfunction.
doi:10.1016/j.ymgme.2017.12.013
5
Tubular dysfunction biomarkers in Fabry disease: better than
albuminuria to identify patients at risk of nephropathy progression
Patricio Aguiara, Olga Azevedob, Rui Pintoc, Jacira Marinod, Carlos
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Introduction: Fabry disease (FD) nephropathy is clinically hetero-
geneous in terms rate of progression. Proteinuria/albuminuria
inﬂuence nephropathy progression, although the magnitude of this
inﬂuence is not well established, with studies showing conﬂicting
results. Therefore, the identiﬁcation of prognosis biomarkers is
paramount to the identiﬁcation of patients at increased risk of
progressive nephropathy.
Methods: in this multicentre, prospective, longitudinal and
diagnostic test study, a cohort of 78 FD patients (43,6% males, mean
age 50,1±15,1years, 69,2% on ERT) was consecutively recruited and
the patients were followed yearly, for 2 years. The accuracy of a
biomarker of tubular dysfunction (urinary N-acetyl-β-glucosaminidase
[uNAG]) in the identiﬁcation of GFR decline was compared with the
reference standard (albuminuria).
Results: during 24 months of follow-up, GFR remained stable in
the whole cohort (mean decline of -1,5ml/min/1.73m2, p=0,675),
but in 28,2% of the patients GFR declined ≥5ml/min/1.73m2(deﬁned
as progressors); during the same period, albuminuria remained
stable and there was a signiﬁcant increase in uNAG. Both albumin-
uria and uNAG were signiﬁcantly higher at baseline, comparing
GFR progressors with non-progressors. However, comparing the GFR
change according to baseline quartiles of the biomarkers, only uNAG
was consent with progressive reduction in GFR across the increasing
quartiles; for albuminuria, quartiles 1, 2 and 3 showed similar
declines in GFR, only somewhat different in quartile 4. Moreover,
only uNAG variation has a signiﬁcant inverse correlation with GFR
variation (ρ=-0.361; pb0.001, compared with ρ=-0.127; p=0.131
for albuminuria).
Conclusion: our ﬁndings, suggests that uNAG appears to outper-
form albuminuria as a prognostic biomarker, clearly identifying
patients at increased risk of progressive nephropathy. These results
support the evidence that long-term outcome of FD nephropathy
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CLN3 disease is an autosomal-recessively inherited lysosomal
disease with onset during childhood. Symptoms include vision loss,
motor decline, dementia, and seizures, and impact multiple areas of
function. The Pediatric Evaluation of Disability Inventory-Computer
Adaptive Test (PEDI-CAT) was developed to assess functional
capacity in young persons (approx age 1-21 years). The PEDI-CAT
evaluates individuals across four domains of function: Daily Activi-
ties, Mobility, Social/Cognitive, and Responsibility. With domains,
items are ranked according to the difﬁculty experienced in
completing a task or skill independently: 1 = unable, 2 = hard,
3 = a little hard, 4 = easy. The major aim of the current pilot project
is to evaluate the PEDI-CAT's utility in assessing functional abilities
in CLN3 disease. The parents of ﬁve children with CLN3 disease
(3 males, 2 females) ranging in age from 9.3 to 25 years old
completed the PEDI-CAT. With the exception of the youngest subject
who participated, age-adjusted T scores across the four PEDI-CAT
domains were b10 and reﬂective of signiﬁcant limitations in
functional abilities, compared to same-age peers. PEDI-CAT Fit Scores,
reﬂecting whether responses to domain items were close to expected,
based on estimated functional level across a domain, varied from
within acceptable range to suggesting likely poor ﬁt (i.e., -2.00 and
2.00): Daily Activities, Mean Fit Score= -0.42 (range= -1.59 to 0.91);
Mobility, Mean Fit Score = -1.90 (range = -3.34 to -0.84); Social/
Cognitive, Mean Fit Score = -1.67 (range = -2.67 to -0.46);
Responsibility, Mean Fit Score = 0.36 (range = -1.05 to 1.54). These
initial data identify items that may be informative for describing
functional capacity in CLN3 disease at various ages and stages of
the disease. Further work is needed to evaluate the PEDI-CAT in
CLN3 disease, including the ability to track change in functional skills
over time.
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Introduction: Fabry disease (FD) cardiomyopathy is characterized
by a hypertrophic phenotype, in the histological setting of cardio-
myocyte hypertrophy and myocardial ﬁbrosis; myocardial ﬁbrosis is
an irreversible event and affects the prognosis. Thus, the identiﬁca-
tion of biomarkers to predict the development of myocardial ﬁbrosis
and overt left ventricular (LV) hypertrophy is paramount.
Methods: a cohort of 60 FD patients (38,3% males, mean age
50,2±14,7years, 65,0% on ERT) was consecutively recruited and
the patients were followed for 24 months. Patients with an
increase ≥10g/m2.7 in LV mass (LVM) or an increase ≥1.5 in E/E’
average, associated with TDI abnormalities upon follow-up were
deﬁned as LVM or LV end-diastolic pressure (LVEDP) progressors,
respectively. The prognostic value of type I collagen synthesis
(carboxy-terminal propeptide of procollagen type I [PICP]) and
degradation (matrix metalloproteinase 1 [MMP-1]) biomarkers was
evaluated.
Results: during follow-up, both LVM and E/E’ ratio remained
stable, but 28,3% and 31,3% of the patients presented criteria of LVM
and LVEDP progression, respectively; there was no signiﬁcant change
in PICP and MMP-1 during follow-up. MMP-1 serum concentration at
baseline was signiﬁcantly lower in patients presenting with LVEDP
progression. Moreover, there was a signiﬁcant correlation between
PICP variation and LVM variation (ρ=0.492; p=0.001) and PICP
decreased by a median 7,6ng/mL in LVM non-progressor and
increased by a median 20,6ng/mL in LVM progressors (p=0,001);
furthermore, a patient in the forth quartile of PICP variation
presented an OR=25,0 (p=0,008) of being a LVM progressor
compared to a patient in the ﬁrst quartile of PICP variation.
Conclusion: our ﬁndings suggest that collagen type I synthesis
has good prognostic value for and is likely to be critical to the
development of overt LV hypertrophy. Moreover, inhibition of
enzymes involved in collagen type I cleavage also seems crucial to
myocardial collagen deposition and is related to the risk of progressive
diastolic dysfunction.
doi:10.1016/j.ymgme.2017.12.013
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may bemore related to the extent of the tubulointerstitial impairment
than to the severity of glomerular lesions, which is in accordance with
ﬁndings in diabetic nephropathy.
doi:10.1016/j.ymgme.2017.12.014
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A variant of GM1 gangliosidosis in a sheep model
Amelia Ahern-Rindell,University of Portland, Portland, OR, United States
In the 1980s, sheep were identiﬁed with a neurological condition
inherited as an autosomal recessive trait and appropriately classiﬁed
as a lysosomal disorder based on post-mortem pathological, his-
tological and electronmicrographic analysis. This animal model
has been studied by numerous undergraduates and myself and
conﬁrmed to be a variant of GM1 Gangliosidosis with a primary
deﬁciency of beta-galactosidase (beta-gal) (b1%) and a secondary
deﬁciency of alpha-neuraminidase (neur) (~20%). No other GM1
models have been described with this dual activity deﬁciency,
although other sheep exist with the typical sole beta-gal deﬁciency.
There is no evidence of a protective protein cathepsin A (PPCA)
deﬁciency or a DNA coding sequence variation ruling out Gal-
actosialidosis as a possible explanation that was also conﬁrmed by
somatic cell hybridization. A missence mutation has been found in
exon 6 of the affected sheep’s beta-gal gene resulting in the loss of
a cysteine residue possibly leading to the synthesis of an altered
structural beta-gal but with detectable levels of protein product
conﬁrmed by Western Blotting. We have ruled out any sequence
variation in the coding sequence of the neur gene aswell and believe it
is highly unlikely that affected sheep suffer frommultiplemutations in
separate genes. We hypothesize that the mutation identiﬁed is
disease-causing and could be responsible for the combined deﬁcien-
cies in beta-gal and neur activity because of problems with formation
of the Lysosmal Multienzyme Complex (LMC). We believe that the
altered beta-gal protein cannot complex appropriately with normal
neur and PPCA resulting in the combined beta-gal and neur activity
deﬁciencies. Based on cell culture studies utilizing galactose as a
possible chaperone for the altered beta-gal, we believe this sheep
model maybe a good candidate to use for in vivo chaperone therapy
studies because of the comparable anatomy and physiology of these
two mammalian species.
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Association of hippocampus and amygdala volumes with
neurocognitive and behavioral outcomes in patients with
Hurler-Scheie syndrome heterozygous for the L238Q mutation
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University of Minnesota, Minneapolis, MN, United States
We investigated the associations of hippocampus and amygdala
volumes with cognitive and behavioral/psychological measures in
patients with Hurler-Scheie syndrome; those with the L238Q muta-
tion were compared to age-matched (14-25 years) patients without
L238Q mutation from a cross- sectional study (ClinicalTrials.gov
NCT01870375). We hypothesized that hippocampus volumes will be
related to cognition, amygdala volumes to behavioral outcomes, and
there will be differences in hippocampus and amygdala volumes
between the L238Q and the control group. Six patients with an L238Q
mutation, 4 were paired with nonsense, 1 with a deletion, and 1 with a
splice site mutation. For the six patients in the control group, 3 patients
had a missense paired with nonsense, 2 with missense paired with
missense, and 1 with nonsense and splice site mutations. T1-weighted
images from 3T brain MRI were used for the volumetric analysis
of amygdala and hippocampus by manual tracing using BRAINS2
software. Cognitive function was measured by Wechsler Abbreviated
Scale of Intelligence (WASI) for IQ and Brief Visual Spatial Memory
Test (BVMT) to assess nonverbal memory and learning. Behavioral
outcomes were measured by the Behavior Assessment System
for Children-Parent Rating Scale and Self-Report (BASC-PRS and
BASC-SRP). The total volume of hippocampus was positively related
with BVMT (P=b0.001) but not signiﬁcantly associated with IQ in the
L238Q group (P=0.150) when comparing the slopes between the
two groups. In the control group, hippocampus was negatively related
with BVMT and not statistically signiﬁcant association with IQ. The
association between total amygdala volume and BASC scores were
not signiﬁcantly different between the groups, though PRS anxiety
and SRP depression had large estimated differences. We have found
larger hippocampus volumes were associated with higher BVMT
scores for the L238Q, and the opposite for non L238Q group. Future
analysis of longitudinal data will provide more detailed information.
(NIH U54NS065768).
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Multiple sulfatase deﬁciency (MSD) is an ultra-rare neurodegen-
erative lysosomal disorder that results from dysfunctional sulfatase
modiﬁcation. Sulfatases in the body are activated by a unique
protein, formylglycine-generating enzyme (FGE), which is encoded
by SUMF1. When FGE is absent or insufﬁcient, all 17 known human
sulfatases are affected, including dysfunction of proteins asso-
ciated with metachromatic leukodystrophy (MLD), a number of
mucopolysaccharidoses (MPS), and X-linked ichthyosis. As such,
patients demonstrate a complex and severe clinical phenotype,
which has not been fully characterized to date. In this report, we
describe two patients with distinct clinical presentations of MSD.
Also, we detail a comprehensive systems-based approach to the
management of patients with MSD, from the initial diagnostic
evaluation to unique multisystem issues and potential management
options. As there have been no natural history studies to date, the
clinical guidelines within this report are based on published studies
and consensus opinion and underscore the need for future research
on evidence-based outcomes to better treat children with multiple
sulfatase deﬁciency.
doi:10.1016/j.ymgme.2017.12.017
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